

AD _____

GRANT NUMBER DAMD17-94-J-4078

TITLE: Genomic Instability at Premalignant and Early Stages of
Breast Cancer Development

PRINCIPAL INVESTIGATOR: C. Marcelo Aldaz, M.D.

CONTRACTING ORGANIZATION: The University of Texas
M.D. Anderson Cancer Center
Houston, Texas 77030

REPORT DATE: August 1999

TYPE OF REPORT: Final

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4

1

20001013 114

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 1999	3. REPORT TYPE AND DATES COVERED Final (1 Aug 94 - 31 Jul 99)	
4. TITLE AND SUBTITLE Genomic Instability at Premalignant and Early Stages of Breast Cancer Development			5. FUNDING NUMBERS DAMD17-94-J-4078	
6. AUTHOR(S) C. Marcelo Aldaz, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Texas M.D. Anderson Cancer Center Houston, Texas 77030			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) As a continuation of our original allelotypic studies, we have determined that allelic imbalances and losses affecting the chromosome 16q arm constitute early abnormalities in breast carcinogenesis since we observed them in a significant number of preinvasive lesions. The most common region of overlapping allelic losses spans the region 16q23.3 - q24.1, observed affected in 60 - 70% of <i>in situ</i> breast lesions. Positional cloning strategies are currently being employed to clone the target genes for such anomalies. We have defined approximately 300 kb of a homozygous deletion within the region q23.3 - q24.1 of chromosome 16 in a breast cancer cell line. We have mapped to this region a large number previously reported ESTs. Several new cDNA clones were isolated and mapped. We sequenced almost 400,000 DNA base pairs from the region of interest and identified numerous putative exons. We identified and are currently characterizing a gene (WFOXID) that maps to this region. The characterization of this gene as well as other potential targets and determining their role in breast carcinogenesis could lead to development of biomarker tools of diagnostic-prognostic significance.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 171	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature

8.21.99
Date

TABLE OF CONTENTS

Front Cover	1
SF298 Report Documentation Page.....	2
Foreword.....	3
Table of Contents.....	4
Introduction	5
Body	5-15
Key Research Accomplishments	15
Reportable Outcomes	15-16
Conclusions.....	17
References.....	17-18
Appendix	
Publications	
Abstracts	

INTRODUCTION

Over the past few years, considerable progress has been accomplished in the elucidation and characterization of genes whose mutation predisposes individuals to risk of developing familial breast cancer. These genes include the recently cloned BRCA1, BRCA2, PTEN and TP53 in the case of Li-Fraumeni syndrome. However, while these genes have been shown to be frequently affected in inheritable forms of breast cancer, there is yet no conclusive evidence to suggest that these genes are also responsible for sporadic breast cancer which accounts for approximately 90-95% of the total breast cancer incidence (reviewed in 1).

Activation of oncogenes (e.g. c-myc, Cyclin D1, ERBB2) , alterations in growth factor pathways (e.g. TGF alpha, EGF, IGF and their receptors), inactivation of tumor suppressor genes (e.g. p53, Rb) and chromosomal instability are all commonly found in breast cancers. Although abundant information is available on the mentioned genomic abnormalities in sporadic breast cancer, to date no clear model of the critical events or delineation of primary abnormalities has emerged. Additionally, it is unclear which, if any, of those somatic mutations are causative of breast tumorigenesis. More likely the vast majority of genomic abnormalities described are consequence of tumor progression.

Ductal carcinoma *in situ* (DCIS) of the breast is known as a preinvasive stage of breast cancer and is probably the precursor of infiltrating breast cancer (2). Genetic alterations shown at this stage might indicate association with early events in malignancy or invasiveness. Loss of heterozygosity (LOH) at specific chromosomal loci has been considered as part of the indirect evidence for postulating the existence of possible tumor suppressor genes within those specific chromosome regions. It is known that several mechanisms can lead to the loss of alleles in tumors such as chromosomal deletions, monosomies, mitotic recombination, and unbalanced translocation. Hypothetically, the remaining allele of the tumor suppressor gene in question could be rendered inactive due to events at the gene level such as specific point mutations or other types of inactivating mutations. Usually, LOH at specific chromosome regions affects not only the putative tumor suppressor gene but also neighboring genes or genetic markers that are used as indicators to track down the minimum area of LOH.

Our original hypothesis was that a high level of chromosomal instability already exists at preinvasive stages of breast cancer development. To this end the studies described in the original application focused on early stages of breast cancer development in order to identify the earliest detectable allelic abnormalities correlating with the histological grading and subtype of the lesions. The ultimate goal was to better understand the breast carcinogenesis process and to eventually identify tools of potential diagnostic or prognostic significance.

BODY

Methodology development, DCIS and replication error phenotype studies

The best obvious source of material for the identification of the various stages of breast cancer progression is available from paraffin-embedded tissues used in routine diagnostic procedures. A first phase of this project consisted in the optimization of a comprehensive technical approach for allowing a multiparametric analysis of human breast cancer lesions from paraffin-embedded tissue

sections. Thus, numerous chromosomal loci can be analyzed from single tissue sections by means of microsatellite length polymorphism analysis. DNA samples from normal and breast cancerous tissue can be obtained from the same section by means of microdissection. This allows to correlate the allelotype of specific lesions with other markers of prognostic and diagnostic significance. The development of such technical approach was reported in a first publication (3), see attached).

As indicated in the introduction in spite of the abundance of data the relevance, role and timing of most of the genetic abnormalities observed in sporadic breast cancer are still unclear. While there is overwhelming evidence that losses of genetic material occur, inherent difficulties exist in determining the relevance of such losses to breast tumorigenesis. In most cases, the tumors analyzed were of the invasive type and/or advanced stages of progression, leading to the question whether these losses are causative factors of tumorigenesis or consequences of the general genomic instability inherent to tumors. Further, it is possible that certain losses may be selected for in the progression or clonal evolution of a tumor to a more advanced type but not necessary for the genesis of the tumor. We hypothesized that some of these questions could be addressed in part through comparative allelotyping of both noninvasive and invasive tumors.

To address the relative timing and frequency of allelic losses of commonly affected regions in breast cancer, microsatellite length polymorphism analysis was performed in a series of preinvasive ductal carcinomas (DCIS) and invasive ductal and lobular carcinomas (4, see attached). Twenty different chromosomal loci were examined in each group. As expected, frequencies of regional losses in invasive ductal carcinomas were similar to those reported by other author (reviewed in 1). However, allelotyping of DCIS samples revealed that chromosomal regions 3p, 3q, 6p, 11p, 16p, 18p, 18q, and 22q were not affected by a high frequency of loss, while analyses of these same regions of invasive tumors showed them to be affected in 10-40% of cases (4). Our findings are in agreement with those of Radford et. al. who examined 61 DCIS samples (5). Because allelic losses affecting these regions were not frequently observed at the noninvasive (DCIS) stage it can be concluded that alterations of these regions are late events in breast cancer progression. More importantly, allelic imbalances observed on chromosome arms 7p, 7q, 16q, 17p, and 17q (4), appear to be early abnormalities because they were observed frequently in DCIS samples.

Lobular carcinomas constitute approximately 10-15% of all breast cancers (2). Histologically, lobular carcinomas have a very distinctive infiltrative growth pattern and metastatic pattern (2). In addition, patients with invasive lobular carcinoma have been reported to have a higher risk of developing multifocal and contralateral breast cancer than those patients with invasive ductal carcinoma (6). To determine whether ductal and lobular carcinomas are subject to the same pattern of allelic loss, comparative allelotyping of the two subtypes was also conducted in our laboratory. Losses of chromosome arms 1p, 3q, 11q, and 18q were more prevalent for invasive ductal carcinoma than for invasive lobular carcinoma (4). However, 8p losses or imbalances were observed in 36% of invasive lobular tumors but only 14% of invasive ductal carcinomas. Interestingly, microsatellite instability was observed in almost 40% of lobular carcinomas, but only 13% of ductal carcinomas (4). This phenomenon of microsatellite instability, also known as RER+ phenotype, is identified by allele size differences between tumor and matching normal controls. First described as a characteristic of tumors from patients carrying an autosomal dominant predisposition to tumors of the colon and endometrium, microsatellite instability has been linked to defects in a group of human mismatch repair genes: hMSH2, hMLH1, hPMS1, and hPMS2 (7-9). Resultant errors in DNA repair are believed to be the cause of the observed genomic instability phenomenon. These data suggest that invasive lobular carcinomas may arise by a mechanism of carcinogenesis different

from that of ductal breast carcinomas and appear to constitute a distinct pathologic entity.

We attempted to extend those earlier observations (4) by analyzing a set of RER+ breast cancer samples for mutations in the DNA mismatch repair gene hMSH2, which as earlier indicated is the most commonly mutated gene in HNPCC kindred.

To this end paraffin embedded tissue sections were obtained from a set of nine breast cancer samples positive for microsatellite instability at multiple loci (more than 5 independent loci). Matching normal control tissues were also obtained from each patient.

Oligonucleotide primers (flanking and nested) for analysis of the 16 HMSH2 exons were synthesized according to the method described by Kolodner et al. (10).

PCR conditions and cycle sequencing were performed according to the same authors (10).

The sequence analysis of the 16 exons of the hMSH2 gene did not show evidence for germinal or somatic mutations. The hMSH2 sequence obtained in all nine RER+ breast cancer cases was normal. (Bednarek A. and Aldaz C. M., unpublished observations).

From this study we concluded that the phenomenon of microsatellite instability observed in a relative small percentage of the sporadic breast cancer cases studied appears to be independent of mutations in the prototypic and most frequently mutated DNA mismatch repair gene hMSH2. Our results are comparable to studies in RER+ sporadic colon cancer cases. Although other DNA mismatch repair genes have not been analyzed these data suggests microsatellite instability in sporadic breast cancer may be the result of a different mechanism and genes to that described in the HNPCC syndrome.

Chromosome 16 studies

As we earlier mentioned we observed that allelic imbalances and losses affecting chromosome arms 7p, 16q, 17p and 17q appear to be early abnormalities since they were observed in a significant number of DCIS lesions (4).

Due to the paucity of information and the high incidence of allelic losses affecting the long arm of chromosome 16 we decided that it was very important to redirect our efforts and focus in a more in-dept study on the identification of the putative genetic targets for the observed abnormalities. Loss of heterozygosity on chromosome 16q has already been previously reported in breast and prostate cancer with high frequency, indicating the existence of a putative tumor suppressor gene(s) locates in this chromosome arm. We observed that the most commonly affected area spanned the region from marker *D16S515* to marker *D16S504*. Within this region the most affected locus was at *D16S518*, in which LOH was observed in 20 of 26 informative cases (77%). We have estimated that the area of interest lies in subregion q23.3-q24.1. The region of highest LOH spanned approximately 2 Mb, as determined by a yeast artificial chromosome contig covering this region, reported in Chen et al. (11, see attached). Such a high frequency of LOH at a preinvasive stage of breast cancer suggests that a candidate tumor suppressor gene or genes at this location may play an important role in breast carcinogenesis.

To extend these studies we performed a chromosome 16 high resolution allelotype of a panel of human breast cancer lines in order to identify areas of hemizyosity and homozygous loss (Figure 1). As a natural and important extension of these studies we have built a contig of yeast artificial chromosome (YAC) and bacterial artificial chromosome (BAC) clones spanning the chromosome 16q region in which frequent allelic losses were detected.

In agreement with our previous findings, most breast cancer lines showed evidence of

hemizyosity affecting all or almost all the chromosome 16q arm. One breast cancer line showed a homozygous loss affecting markers from this area, indicating that a likely target gene for inactivation may reside within this region.

To extend mapping of this deleted area we built a series of new STS markers according to DNA sequences obtained from ends of BAC clones. Using a high density STS map we determined that the specific deletion is approximately 300 kb in size (Figure 2).

In studies in progress we have isolated numerous cDNA clones from a human breast epithelial library that match to this region.

In summary, we have constructed a comprehensive physical map of the region of interest, and we developed the critical resources for the positional cloning of the putative breast cancer suppressor gene.

Results

The ultimate goal of the ongoing studies is the identification and isolation of genes from chromosome 16 that can play a relevant role early in breast carcinogenesis.

We first defined a relatively small region of homozygous loss (Figure 2) located in area between markers *D16S515* and *D16S504*., that may contain this gene.

We proposed to use standard positional cloning strategies to identify and clone this putative breast cancer suppressor gene.

We characterized a panel of 23 breast cancer cell lines using STS markers as reported in Chen et al. (11). We utilized highly polymorphic markers with high heterozygosity scores (~ 0.70 or more). Given the high polymorphism of the loci investigated, the presence of large areas with lack of heterozygosity in various markers, very likely represent hemizyosity as a consequence of allelic loss. As can be observed in Figure 1, numerous breast cancer lines showed evidence of hemizyosity affecting all or almost all of the chromosome 16q arm. These results were reported (AACR Bednarek and Aldaz). These results are in strong agreement with our previous findings in preinvasive and invasive breast cancer (4, 11). In order to isolate the putative breast cancer suppressor gene residing in the area of interest we built a contig of YAC and BAC clones spanning the target region. Interestingly, we have identified one breast cancer line which showed homozygous losses affecting markers in this region (Figure 2). This indicates that the target gene is very likely contained within this region. Using new STS markers generated from BAC insert ends DNA sequences, we estimated that the homozygously deleted region is approximately 300 kb in length.

In order to better characterize the region of interest, we performed shotgun sequencing of BACs DNA spanning this region. To this end random subclones for sequencing were prepared by DNaseI digestion of the DNA from BACs; 112B17, 249B4, 286F3 and 36O22 (Research Genetics, Inc. CITB-HSP-C library) and fragments of the length approximately 1kbp were cloned into pZERO1 vector (Invitrogen).

We have sequenced so far a total of 382,765 base pairs and the largest contig length is of 96,371 bp, submitted to GeneBank nr division (NCBI, <http://www.ncbi.nlm.nih.gov>) and published under accession number AF179633 (see attached)

In order to isolate cDNAs encoded in this region we are also utilizing a solution hybrid capture method. We have isolated and characterized numerous clones from a human breast cDNA library mapping to two of the BAC clones (249B4 and 286F3) spanning the area of interest. Once the

clones were obtained after sequencing we confirmed mapping by PCR and by hybridization to the BACs DNA. We have isolated 35 cDNAs, 18 new and 17 identified to have high homology to previously known ESTs (est division of GeneBank at NCBI).

Additionally, we are also analyzing, using the BLAST algorithm, the genomic DNA sequenced (382,765 bp) from the area spanning the of homozygous deletion. We have identified additional 32 EST clusters. Using the GRAIL-1.3 algorithm (ORNL, <http://compbio.ornl.gov>), we also performed analysis on the longest contig 96,371 bp to search for putative protein coding regions, CpG islands, RNA polymerase II promoter sites and polyadenylation signal sites. We predicted 32 exons with excellent score and we have been successful to clone cDNAs for six of them.

In summary we analyzed a total of 72 different putative mRNAs mapped to BACs 112B17, 249B4, 286F3 and 36O22. Most of the analyzed cDNAs showed no good open reading frames, ORF and no exon-intron structure when aligned to genomic DNA.

Nevertheless, we identified one cDNA which had exon intron structure. This was determined from partial sequencing of a cDNA clone isolated by the hybrid capture hybridization method and additionally from BLAST identification of one EST (AI219858) which was found to form two putative exons on the genomic DNA sequence (BAC112B17).

Using primers derived from this partial sequence we isolated the whole length cDNA from a human placenta library (RapidScreen cDNA library, OriGene). Additionally, we used 3', 5' RACE on Marathon Ready cDNA library from human mammary gland (Clontech). Both strategies identified the same sequence of this putative gene. The longest clone isolated had a length of 2250bp plus polyA with a 1242bp long open reading frame. Upon further analysis of the existing databases we identified a previously reported partial cDNA sequence of this same gene, 1475 bp long spanning part of the 3' end, this gene has been tentatively defined as a putative oxidoreductase (HHCMA56). Further analysis of EST division of GeneBank returned 30 ESTs with homology to our cDNA clone.

We determined that the identified ORF encodes for a protein 414 aminoacids in length. We used Pfam analysis (<http://pfam.wustl.edu/hmmsearch.shtml>) to search for homology with known protein domains. We observed high homology to two domains; WW domain and short chain dehydrogenase domain. Thus we called this novel protein WWOXID (Figure 3).

The two WW domains are localized on the amino end of WWOXID and the short chain dehydrogenase motif in the central portion of the protein sequence (Figure 3).

Expression and mutation analysis

In order to study expression of this novel gene we performed Northern and RT-PCR analyses on normal human epithelial cells and a panel of breast cancer lines and breast tumors. We used as a probe 1554 bp long EcoRI restriction fragment of clone ORI2 covering 5'UTR and ammoniated coding region and polyA RNA as a target. The length of mRNA according to hybridization was calculated as about 2.2 kbp and correspond with length of the longest cDNA clone. Based on RT-PCR and genomic sequence analyses of the area of interest we also concluded that alternative transcripts may also exist.

As shown in Figure 4, we detected a major transcript of approximately 2.2kbp, only visible (i.e. overexpressed) in some of the breast cancer lines.

We observed much higher expression, compared to normal RNA, of WWOXID in four cancer cell lines, namely; MCF-7, ZR75-1, SKBR3, and UACC812. Hybridization to another breast

cancer cell lines, T47D, MDA-MB453, was slightly higher than to control RNA and to MDA-MB157, MDA-MB435 was on the same level as hybridization to control RNA.

To search for mutations and to map WWOXID on the genomic DNA context we performed identification of exon-intron junctions Figure 5. So far we identified five exons from the 5' end of gene plus we defined the 3' UTR. The physical map of the central region of WWOXID cDNA is currently being further characterized (Figure 5).

We also used a panel of 28 human breast cancer cell lines to search for mutation at the DNA sequence level of WWOXID. So far we have found no evidence of mutations in the first five exons and splicing sites studied from all the cell lines.

The in progress physical mapping of exons and 3'UTR on the genomic sequence show that WWOXID gene spans very likely more than 500 kbp.

Putative function of WWOXID

It is quite difficult to predict the putative role of this protein in the cell but appears to have several interesting features which make it an attractive target for potential abnormalities. The WW domains are known to bind to proline-rich sequences and are usually responsible for protein-protein interactions (12). WW domains were observed in structural, cytoskeletal proteins as well as in enzymes. Some proteins containing WW domain are well characterized. One of them, dystrophin, is found to be responsible, when mutated, for Duchenne muscular dystrophy. Mouse NEDD-4, contains 3 WW motifs, and its role is of a ubiquitin ligase which plays a central role in embryonic development and differentiation of the central nervous system. Another example is the PIN1 protein which is a prolyl isomerase involved in cell cycle regulation.

The short chain dehydrogenase domain is a common and very conserved domain found in different oxidoreductase proteins from plants, animals as well as from bacteria. Examples of oxidoreductases include retinol and steroid dehydrogenases which are enzymes participating in the metabolic processing of hormones important for cell function, cell cycle and differentiation.


On Going Studies

Chromosome 16 studies

We will continue the characterization of the area of interest of chromosome 16. This will include further studies on the potential role of WWOXID in breast cancer as well as the cloning and characterization of additional target genes of interest that might be identified within this chromosome 16 region.

DCIS studies biomarkers of progression

In collaboration with various investigators from the M.D.Anderson Cancer Center we are pursuing a multiparameter characterization of DCIS. Among the molecular/genetic biomarkers associated with progression of DCIS to invasive breast cancer, we are analyzing the incidence of allelic losses of various of the loci which we determine relevant in our first studies. To this end we are performing a retrospective case-control study of ductal carcinoma in situ with invasive cancer compared with DCIS cases-alone (i.e. with no invasive component).

**Figure 1**

High resolution allelotyping of chromosome 16 microsatellite markers in breast cancer cell lines. Markers arranged in mapping and linkage order as previously described in Chen et al. (Cancer Res. 56:5605-5609, 1996)

Dark gray blocks indicate that a single allele was observed at the corresponding locus (i.e. hemi or homozygosity), light gray areas indicates heterozygosity preserved. Blank indicates not done.

Numbers at right represent the heterozygosity scores calculated at each specific locus from analyzing this breast cancer panel.

In agreement with our previous findings, note that several breast cancer lines showed hemizygosity affecting all or most of the chromosome 16q arm.





Figure 2.

YAC and BAC contig spanning a region with observed homozygous loss in one breast cancer line. The various STSs identified and used to build this contig are shown. The represented distance between STSs is not to scale. The homozygous deletion have been defined in the region between STS markers L112 and L36.

A)



B)

WW_rsp5_WWP: domain 1 of 2, from 18 to 47: score 40.9, E = 1e-09
 ->lpsgWeeatdpsGrpiYYvNheTkttqWekP<-
 lp+gWee+t+++G + YY Nh ++tqWe+P
 query 18 LPPGWEERTTKDGWV-YYANHTEEKTQWEHP 47

WW_rsp5_WWP: domain 2 of 2, from 59 to 88: score 38.6, E = 4.4e-09
 ->lpsgWeeatdpsGrpiYYvNheTkttqWekP<-
 lp gWe+ td++G++ ++v+h++k t++ +P
 query 59 LPYGWEQETDENGQV-FFVDHINKRTTYLDP 88

adh_short: domain 1 of 1, from 125 to 330: score 89.6, E = 1.8e-24
 *->KvaLvTGassGIGlaiAkrLakeGakVvvadrneeklekGavakelk
 Kv++vTGa sGIG+++Ak +a Ga+V++a+rn +++ ++++++
 query 125 KVVVVVTGANSIGIFETAKSFALHGAHVILACRNMARA--SEAVSRIL 169

elGgndkdralaiqlDvtdeesv.aaveqaverlGrldVLVNAGgiill
 e+ k +++a++lD++ sv+ ++e+ +++ +l+vLV+NA
 query 170 EEWH--KAKVEAMTLDLALLRSVqHFAEAFKAKNVPLHVLVCNAA----- 212

rpgpfaelsrtmeedwdrvidvNltgfvlltravlplmamkkriggGrIvN
 ++ +l+ ++ + +++vN +g f+l++++ + + ++ r+++
 query 213 TFALPWSLT---KDGLTTFQVNLGHFYLVQLLQD--VLCRSAPARVIV 257

iSSvaGrke.....g.glvvgvpggSaYsASKaAvigltrsL
 +SS + r + +++ ++ + ++ + ++ +++++ aY+ SK i ++ L
 query 258 VSSESHRFTdindslgkldfsr1SpTKNDYWAMLAYNRSKLCNILFSNEL 307

AlElaphgIrVnavaP.GgvdTd<-*
 + l p+g++ nav+P+ +++ +
 query 308 HRRLSPRGVTSNAVHPgNMMYSN 330

Figure 3 A) Positions of two WW domains and short chain dehydrogenase domain in WWOXID protein. B) Homology of selected amino acid sequence from WWOXID(query line) to consensus sequences of WW domain and short chain dehydrogenase domain (top line). Capital letters in consensus line represents conserved amino acids.




Figure 4 Northern hybridization showing expression of WWOXID in immortalized normal human mammary gland epithelial cells, HME-87 and in various breast cancer cell lines. Target used was poly A RNA; as probe we used a fragment covering 5' UTR and aminoacid coding region.




Figure 5 High resolution physical map of chromosome 16q23.3-24.1 region of WWOXID gene. Length of specific BACs and position BAC293D3 are unknown. Total length of chromosome fragment between markers D16S518 and D16S516 is approximately 2Mbp. Contig of BACs 112B7, 249B4, 286F3 and 36O22 according to obtained partial sequence is approximately 400kbp long. E1, E2, E3, E4, E5 and 3'UTR represent positions of known exons and 3' untranslated region of WWOXID in BAC clones.

KEY RESEARCH ACCOMPLISHMENTS

1. Development of methodology for the analysis of allelic losses in parallel with multiple biomarkers of interest from paraffin embedded microdissected breast premalignant lesions.
2. Identification of the earliest and most common allelic losses observed at preinvasive stages of breast cancer development. (A typical hyperplasias and Ductal Carcinomas in situ).
3. Defining and comparing the allelotypic profile of invasive ductal carcinoma and invasive lobular carcinomas.
4. Determining the occurrence of microsatellite instability in a low percentage of breast carcinomas mostly of lobular type.
5. Determining that the occasionally observed microsatellite instability is not due to mutations in the hMSH2 mismatch repair gene.
6. Performing a high resolution allelotype of chromosome 16 in DCIS lesions and atypical hyperplasias.
7. Identifying and mapping a relatively small specific target area of chromosome 16 commonly lost in breast cancer lines and DCIS lesions.
8. Constructing a YAC and BAC contig spanning the region of interest for positional cloning studies.
9. Sequencing more than 380,000 base pairs of the chromosome 16 area of interest.
10. Cloning of putative target genes from the area of interest such as WWOXID.

REPORTABLE OUTCOMES

Publications:

- Aldaz, C. M., Chen, T., Sahin, A., Cunningham, J., and Bondy, M. Comparative allelotype of *in situ* and invasive human breast cancer: High frequency of microsatellite instability in lobular breast carcinomas. *Cancer Res.*, 55: 3976-3981, 1995.
- Chen, T., Dhingra, K., Sahin, A., Hortobagyi, G. N., and Aldaz, C. M. Technical approach for the study of the genetic evolution of breast cancer from paraffin embedded tissue sections. *Breast Cancer Res. and Treatment*, 39: 177-185, 1996.
- Chen, T., Sahin, A., and Aldaz, C.M. Deletion map of chromosome 16q in ductal carcinoma *in situ* of the breast: refining a putative tumor suppressor gene region. *Cancer Res.* 56: 5605-5609, 1996.

- Bednarek, A., Sahin, A., Brenner, A.J., Johnston, D.A., and Aldaz, C.M. Analysis of telomerase activity levels in breast cancer: Positive detection at the *in situ* breast carcinoma stage. *Clinical Cancer Res.* 3: 11-16, 1997.
- Brenner, A. and Aldaz, C.M. The Genetics of Sporadic Breast Cancer. *In: Etiology of Breast and Gynecological Cancer*, C.M. Aldaz, Gould, M., J. McLachlan and T.J. Slaga, (eds.) *Progress in Clinical and Biological Research*, Wiley Liss, NY Vol. 396, pp. 63-82, 1997.
- Bednarek, A.K., Chen, T., Laffin, K.J., Hawkins, K.A., Liao, Q., and Aldaz, C.M. GeneBank Accession AF179633. , GI: 5823550. Definition Homo sapiens chromosome 16 map 16Q23.3-124.1 sequence. UTMD Anderson Cancer Center, Science Park – Research Division, Smithville, TX 1999
- Charpentier, A., and Aldaz, C.M. The Molecular Basis of Breast Carcinogenesis. *In: Molecular Basis of Human Cancer: Genomic Instability and Molecular Mutation in Neoplastic Transformation.* W.B. Coleman and G.J. Tsongalis (eds.) NJ, The Humana Press Inc. in press.

Abstracts

- Chen, T., Dhingra, K., Brenner, A., Sahin, A., Sniege, N., Vogel, V., Hortobagyi, G. N., and Aldaz, C. M. Allelotype of breast carcinoma *in situ* from paraffin sections, correlation with chromosome copy number. *Proc. Amer. Assoc. Cancer Res.*, 35: 118, 1994.
- Chen, T., Sahin, A., and Aldaz, C. M. Allelotypic profile and replication error phenotype in lobular vs ductal and *in situ* breast cancers. *Proc. Amer. Assoc. Cancer Res.*, 36: 542, 1995.
- Brenner, A.J., and Aldaz, C.M. Chromosome 9p LOH and analysis of MTS1 (p16) in breast cancer. *SABCS*, 1995.
- Chen, T., Paladugu, A., Sahin, A., and Aldaz, C.M. Frequent loss of heterozygosity on chromosome 16q in “*in situ*” breast cancer. *Proc. Amer. Assoc. Cancer Res.*, 37: 3771, 1996.
- Bednarek, A., Sahin, A., and Aldaz, C.M. Telomerase in human breast cancer. *Proc. Amer. Assoc. Cancer Res.*, 37: 3855, 1996.
- Brenner, A.J., Paladugu, A., Dreyling, M.H., Olopade, O.I., Wang, H., Aldaz, C.M. Comprehensive analysis of p16^{INK4A} gene and transcripts in breast cancer. *Proc. Amer. Assoc. Cancer Res.*, 37: 4051, 1996.
- Cunningham, J.E., Wang, H., Sahin, A., Mastromarino, CL., Bondy, M.L. and Aldaz, C.M. Microsatellite instability as a predictor of second breast cancer. *Proc. Amer. Assoc. Cancer Res.*, 38: 1007, 1997.
- Bednarek, A.K. and Aldaz, C. M. Characterization of transcripts from a commonly deleted area of chromosome 16 (q23.3-q24.1) in human breast cancer. *Proc. Amer. Assoc. Cancer Res.*, 39: 872, 1998.

Personnel

C. Marcelo Aldaz, M.D.	Kendra Laffin
Andrew Bednarek, Ph.D.	Kathleen Hawkins
Taipin Chen	Hui Wang
Melissa Rodriguez	Qiao Yin Liao

CONCLUSIONS

We were able to demonstrate that chromosomal instability and allelic losses occur early in breast carcinogenesis. We observed the occurrence of such anomalies in Atypical Ductal Hyperplasias and Ductal Carcinoma in situ lesions. We defined which anomalies appear to be the earliest and which appear to be the consequence of tumor progression.

Among the abnormalities observed we determined that allelic imbalances and losses affecting the chromosome 16q arm constitute early abnormalities in breast carcinogenesis since we observed them in a significant number of preinvasive lesions. We further defined that the most common region of overlapping allelic losses spans the region 16q23.3 - q24.1, observed affected in 60 - 70% of *in situ* breast lesions. Positional cloning strategies are currently being employed to clone the target genes for such anomalies. We have defined approximately 300 kb of a homozygous deletion within the region q23.3 - q24.1 of chromosome 16 in a breast cancer cell line. We have mapped to this region a large number of previously reported ESTs. Several new cDNA clones were isolated and mapped. We sequenced almost 400,000 DNA base pairs from the region of interest and identified numerous putative exons. We identified and are currently characterizing a gene (WWOXID) that maps to this region. The characterization of this gene as well as other potential targets and determining their role in breast carcinogenesis could lead to development of biomarker tools of diagnostic-prognostic significance.

REFERENCES

1. Charpentier, A. and Aldaz, C. M. The Molecular Basis of Breast Carcinogenesis. *In*: W. B. Coleman and G. J. Tsongalis (eds.), Molecular Basis of Human Cancer: Genomic Instability and Molecular Mutation in Neoplastic Transformation. New Jersey: The Humana Press, in press.
2. Tavassoli, F. Pathology of the Breast. Norwalk, CT: Appleton & Lange, 1992.
3. Chen, T., Dhingra, K., Sahin, A., Sneige, N., Hortobagyi, G., and Aldaz, C. M. Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections. *Breast Cancer Res Treat.* 39: 177-85, 1996.
4. Aldaz, C. M., Chen, T., Sahin, A., Cunningham, J., and Bondy, M. Comparative allelotype of *in situ* and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. *Cancer Res.* 55: 3976-81, 1995.
5. Radford, D., Fair, K., Phillips, N., Ritter, J., Steinbrueck, T., Holt, M., and Donis-Keller, H. Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. *Cancer Res.* 55: 3399-3405, 1995.
6. Silverstein, M., Lewinsky, B., Waisman, J., Gierson, E., Colburn, W., Senofsky, G., and Gamagami, P. Infiltrating lobular carcinoma. It is different from infiltrating duct carcinoma? *Cancer.* 73: 1673-1677, 1994.
7. Aaltonen, L., Peltomaki, P., Leach, F., Sistonen, P., Pylkkanen, L., Mecklin, J., Jarvinen, H., Powel, I. S., Jen, J., Hamilton, S., and al, e. Clues to the pathogenesis of familial colorectal cancer. *Science.* 260: 812-816, 1993.
8. Fishel, R., Lescoe, M., Rao, M., Copeland, N., Jenkins, N., Garber, J., Kane, M., and

- Kolodner, R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. *Cell*. 75: 1027-1038, 1993.
9. Bronner, C., Baker, S., Morrison, P., Warren, G., Smith, L., Lescoe, M., Kane, M., Earabino, C., Lipford, J., Lindblom, A., P, T., Bollag, R., Godwin, A., Ward, D., Nordenskjold, M., Fishel, R., Kolodner, R., and Liskay, R. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. *Nature*. 368: 258-261, 1994.
 10. Kolodner, R., Hall, N., Lipford, J., Kane, M., Rao, M., Morrison, P., Wirth, L., and al, e. Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for MSH2 mutations. *Genomics*. 24: 516, 1994.
 11. Chen, T., Sahin, A., and Aldaz, C. Deletion map of chromosome 16q in ductal carcinoma *in situ* of the breast: refining a putative tumor suppressor gene region. *Cancer Res*. 56: 5605-5609, 1996.
 12. Lu, P. J., Zhou, X. Z., Shen, M., and Lu, K. P. Function of WW domains as phosphoserine- or phosphothreonine-binding modules . *Science*. 283: 1325-8, 1999.

APPENDIX MATERIAL

C. Marcelo Aldaz, M.D.

Final Report DAMD17-94-J-4078

Comparative Allelotype of *in Situ* and Invasive Human Breast Cancer: High Frequency of Microsatellite Instability in Lobular Breast Carcinomas¹

C. Marcelo Aldaz,² Taiping Chen, Aysegul Sahin, Joan Cunningham, and Melissa Bondy

Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Science Park, Research Division, Smithville, Texas 78957 [C. M. A., T. C.], and Departments of Pathology [A. S.] and Epidemiology [M. B., J. C.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Abstract

To better understand the timing for presentation of allelic losses in human breast carcinogenesis, we compared the allelotypic profile of 23 *in situ* ductal carcinomas with that of 29 invasive ductal carcinomas. We also compared the allelotype of the invasive ductal breast carcinomas with that of 23 invasive lobular breast carcinomas. These studies were performed by means of microsatellite length polymorphisms from microdissected paraffin sections. We observed that involvement of chromosome arms 1p, 3p, 3q, 6p, 16p, 18p, 18q, 22q, and possibly 6q and 11p appear to be late events in breast cancer progression because allelic losses or imbalances affecting these areas were observed with very low frequency at the *in situ* stage. On the other hand, allelic imbalances and losses affecting chromosome arms 7p, 16q, 17p, and 17q appear to be early abnormalities because they were observed in approximately 25-30% of ductal carcinoma *in situ* lesions. Allelic losses and imbalances affecting the 8p arm were frequently observed in invasive lobular breast carcinomas. It was also interesting that microsatellite instability, also known as replication error (RER) phenotype, was found to occur at a high frequency in invasive lobular breast carcinomas because 9 of 23 (39%) were RER+, compared with 7 of 52 (13.5%) RER+ of breast cancers with ductal differentiation ($P = 0.012$, χ^2 test). Our findings provide for the first time molecular evidence suggesting that invasive lobular breast carcinomas may arise by a different mechanism of carcinogenesis than ductal carcinomas.

Introduction

Numerous studies have focused on the role of chromosome abnormalities and gene mutations in sporadic breast cancer, but to date no clear model of the critical events or delineation of primary abnormalities has emerged. Various chromosomes or chromosome subregions have been observed to be affected by a high frequency of structural or numerical abnormalities (1). At the molecular level, several somatic mutations have also been described (reviewed in Ref. 2). Amplification or overexpression of several oncogenes, growth factors, and cyclins has been observed at various frequencies (2). Specific allelic losses were also reported at various frequencies, at various chromosome regions, including 1p34-35, 1q23-32, 3p21-25, 6q, 7q31, 11p15, 11q22-23, 13q14, 16q, 17p13, 17q, 18q23-ter and 22q (3-12). Several of these areas appear to be the sites of putative tumor suppressor genes. The tumor suppressor gene *p53* is known to be mutated in a high percentage of breast cancers (13). Despite this abundance of data, the relevance, role, and timing of most of the described genetic abnormalities in sporadic breast cancer are still unclear. It is also not known whether specific mutations play relevant roles as causative

factors or are the consequence of the general genomic instability and progression in breast tumors.

Most of the cytogenetic and molecular information on breast cancer has been obtained by analysis of advanced invasive carcinomas and metastases. In addition, very few studies have discriminated between the different histological types of breast cancer. We therefore focused this study on relatively early stages of breast cancer progression by analyzing preinvasive lesions (DCIS³), as well as comparing the allelotype of the two major histological subtypes of invasive carcinomas (*i.e.*, ductal and lobular).

These studies were performed by means of microsatellite length polymorphism analysis of paraffin-embedded tissue sections with simple sequence repeat markers for the chromosome subregions most commonly affected in breast cancer.

Materials and Methods

Paraffin blocks of breast tumors were randomly chosen from the archives of the Department of Pathology of The University of Texas M. D. Anderson Cancer Center. Five- to 8- μ m-thick sections were cut from the blocks. The basic technical approach has been described previously (14). Briefly, normal and tumor samples were obtained from different areas of the same section by means of microdissection. After deparaffinization (three washes with xylene for 30 min each), the samples were rehydrated in decreasing concentration of alcohol. DNA was extracted by incubating each sample in 200 μ l of Instagene chelex matrix solution (Bio-Rad, Hercules, CA) containing 60 μ g of proteinase K in a shaking incubator at 37°C overnight. Then, the samples were boiled for 10 min, vortexed, and centrifuged at about 7000 \times g for 5 min. Centrifugation produced 150 μ l of supernatant, of which 2-10 μ l was used for PCR amplification, depending on the number of cells in the sample. Before PCR, the forward primer was end labeled with T4 polynucleotide kinase (Promega Biotech, Madison, WI) and 6000 Ci/mmol [γ -³²P]dATP (DuPont New England Nuclear, Boston, MA). PCR was performed in a 20- μ l reaction volume including 150 μ M each dNTP, 1 unit of Taq polymerase and 1 \times Taq buffer (Promega), MgCl₂, 1 pmol of labeled primer, and 2.5 pmol of unlabeled forward and reverse primers. A "hot-start" procedure was used in which the template and primers were heated in an initial denaturation step of 5 min at 96°C, and cooled to 80°C when the remaining reaction constituents were added, followed by 30-35 cycles at 94°C for 40 s, 55°C for 30 s, and a final elongation step of 72°C for 5 min. The products were electrophoresed on 7% polyacrylamide sequencing gels at 90 W constant power for 2-3 h. The gels were dried at 65-70°C for 1-2 h and exposed to X-ray film for 4 h to overnight. For certain primer sets, the amplification conditions were further optimized by adjusting the MgCl₂ concentration in the reaction buffer. The primers used (Research Genetics, Huntsville, AL) are described in Table 1.

The sample was considered to have partial loss of heterozygosity, or allelic imbalance, if the signal intensity of one allele was diminished by approximately one-half or more of its normal intensity (*i.e.*, in normal tissue) in relation to the remaining allele. Complete loss of heterozygosity was defined as a decrease of 90% or more in the signal intensity of one allele relative to the other.

Received 6/9/95; accepted 8/4/95.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by United States Army Breast Cancer Program Grant DAMD 17-94-J-4078 (C. M. A.) and in part by NIH Grant R01 CA59967 (C. M. A.) and a University Cancer Foundation matching supplement.

² To whom requests for reprints should be addressed, at University of Texas M. D. Anderson Cancer Center, Department of Carcinogenesis, P.O. Box 389, Smithville, TX 78957.

³ The abbreviations used are: DCIS, ductal carcinoma *in situ*; RER+, replication error positive; IDC, invasive ductal carcinoma; ILCA, invasive lobular carcinoma.

Table 1 Frequency of allelic losses or imbalances in breast tumors by histology

Marker	Location	No. of tumors affected/no. of informative loci (%)			
		DCIS	IDCA	P value ^a	ILCA
D1S228	1p36-34	1/15 (7)	6/19 (32)	0.07	2/16 (12)
D1S213	1q31-32	3/20 (15)	7/23 (30)	NS	4/18 (22)
D3S1298	3p24.2-22	0/19 (0)	5/23 (22)	0.03	4/17 (24)
D3S1309	3q21.3-25.2	0/11 (0)	4/16 (25)	0.07	1/13 (8)
D6S276	6p22.3-21.3	0/11 (0)	3/10 (30)	0.05	4/10 (40)
D6S255	6q25.2	1/12 (8)	5/19 (26)	NS	4/13 (31)
D7S481	7pter-p15	4/12 (33)	5/16 (31)	NS	5/16 (31)
D7S550	7q36-qter	3/15 (20)	3/14 (21)	NS	1/13 (8)
D8S264	8p21-pter	1/15 (7)	2/14 (14)	NS	5/14 (36)
D8S256	8q24.13-qter	2/12 (17)	1/8 (13)	NS	0/9 (0)
HBB	11p15.4	0/12 (0)	2/14 (14)	NS	3/12 (25)
INT2(FGF3)	11q13.3	2/17 (12)	7/24 (29)	NS	2/16 (13)
D13S155	13q14.3-21.2	2/13 (15)	3/10 (30)	NS	2/8 (25)
D16S407	16p13.13	0/15 (0)	8/20 (40)	0.005	7/16 (44)
D16S413	16q24.3	5/20 (25)	9/21 (43)	NS	6/15 (40)
D17S513	17p13	4/14 (29)	8/14 (57)	NS	6/16 (38)
D17S579	17q12-21.3	6/21 (29)	6/26 (23)	NS	9/16 (56)
D18S59	18pter-p11.22	0/14 (0)	3/13 (23)	0.06	6/15 (40)
D18S51	18q21.33	1/13 (8)	10/23 (44)	0.025	2/12 (17)
D22S283	22q12-13	0/14 (0)	5/14 (36)	0.01	6/17 (35)

^a χ^2 test, 1 df, IDCA versus DCIS. NS, not significant.

Results and Discussion

DCIS and IDCA Allelotypes. One goal of this study was to determine which of the chromosome areas most commonly affected by allelic losses or imbalances in breast cancer were involved in the preinvasive stages of breast carcinogenesis. To that end we focused on the chromosome subregions reported to be affected in previous studies (2-12). We selected a panel of representative microsatellite markers mapping to those specific areas (Table 1). It is important to note that allelic losses and in particular allelic imbalances at specific loci do not necessarily imply the presence of a tumor suppressor gene in that area. Duplication of specific chromosome arms can also lead to an allelic imbalance. We view microsatellite length polymorphism analysis as a tool for measuring the general level of genomic instability at specific stages of tumor progression and also for identifying the chromosome arms affected at specific stages of progression. We analyzed with this approach a total of 75 breast cancer samples (23 DCISs, 29 IDCAs, and 23 ILCAs) at 20 different loci. The results obtained from the analysis of invasive ductal carcinomas validates the general approach because we observed similar frequencies of allelic losses to those reported previously (Refs. 2-12; Table 1; Fig. 1). We compared the incidence of allelic losses and imbalances in the DCISs and IDCAs to determine which chromosomal areas are already altered at the carcinoma *in situ* stage and which abnormalities are later events in ductal breast carcinogenesis. Seventeen of the 23 DCIS lesions (74%) had loss or imbalance of at least one locus (*i.e.*, only six of the tumors did not show any abnormality). The results are summarized in Fig. 1 and Table 1. No allelic losses were observed in any DCIS tumor affecting markers from chromosome arms 3p, 3q, 6p, 11p, 16p, 18p, 22q, and low frequency (5-15% of informative cases) for markers from arms 1p, 1q, 6q, 8p, 8q, 11q, 13q, and 18q. From Fig. 1 we can conclude that alterations in chromosome arms 1p, 3p, 3q, 6p, 16p, 18p, 18q, 22q, and possibly 6q and 11p appear to be late events in breast cancer progression because allelic losses or imbalances affecting these areas were not frequently observed at the DCIS stage. We can also conclude that allelic losses or imbalances affecting chromosome arms 16q, 17p, and 17q appear to be early abnormalities because they were observed in approximately 25-30% of DCIS. It was interesting that we also observed a considerable incidence of allelic imbalance affecting marker D7S481, which is on the short arm of chromosome 7, both in DCIS and invasive breast carcinomas (Fig. 1 and Table 1). This chromosome area was not reported previously to be frequently deleted

in breast cancer. However, as mentioned previously, some of the imbalances observed could be the consequence of overrepresentation of chromosome 7p. Representative allelic losses and imbalances affecting the 16q marker D16S413 are shown in Fig. 2A. Loss of alleles on 16q in invasive breast cancer has been reported by several groups (12, 15-17). At least two different regions on 16q have been reported to be involved in allelic loss and to possibly contain tumor suppressor genes (16, 17). Our findings also agree with those of previous cytogenetic studies that also implicated 16q as a possible site for primary chromosomal rearrangements in breast cancer (18, 19).

To our knowledge, this is the first report of a thorough allelotypic analysis of DCIS lesions. Previous reports have focused on the analysis of allelic losses on specific chromosome arms such as 17p (20) and more recently 11q (21). In agreement with the first of those reports (20), we observed 17p losses at the DCIS stage (Ref. 14, Fig. 1). On the other hand, we did not find a high incidence of losses at the DCIS stage (Fig. 1) affecting the INT2 locus on 11q, as reported previously (21). This discrepancy probably is due to the fact that the study of Zhuang *et al.* (21) was performed on microdissected carcinoma *in situ* component of invasive tumors, whereas our study was performed on pure DCIS tumors with no invasive components.

Because DCIS lesions are a heterogeneous group in which the architectural pattern, nuclear grade, and presence of necrosis are thought to be prognostically important (22), the lesions we studied were subclassified according to the presence or absence of necrosis and nuclear grade. They were classified by a nuclear grading system into two groups: high-grade and non-high-grade DCIS. High-grade applied to poorly differentiated tumors and non-high-grade to moderate-to-well differentiated lesions. We also established an index of allelic loss or imbalance for each tumor in which the number of allelic losses or imbalances per tumor was divided by the number of informative loci per tumor. There was no association between the presence or absence of necrosis and the allelic loss index. However, a possible association was observed between allelic imbalance index




Fig. 1. A, comparative allelotyping of breast DCIS ($n = 23$) versus IDCAs ($n = 29$). B, comparative allelotyping of IDCAs ($n = 29$) with that of ILCAs ($n = 23$).




Fig. 2. A, representative microsatellite length polymorphism analysis of marker *D16S413* of paired normal (N) and breast tumor (T) samples obtained from microdissected paraffin-embedded tissue sections. Allelic loss or imbalance was frequently observed affecting this microsatellite marker. Samples 16, 27, 29, and 78 are from IDCAs, and samples 58 and 59 are from DCIS lesions. B, various representative breast cancer samples with RER+ phenotype (microsatellite instability). Note the abnormalities in allele size (arrows) in samples from the same tumors at different chromosome loci. Sample 65 is from a DCIS, sample 39 is from an IDCA and the rest of the samples are from representative invasive lobular carcinomas. Marker *D18S51*, the only tetranucleotide repeat of the panel used, was frequently affected.

and nuclear grade; lesions classified as non-high-grade (moderate and well differentiated lesions) had overall the lowest indices, with a few exceptions. All six DCIS cases without allelic abnormalities were classified as non-high nuclear grade. All the high-grade DCISs (poorly differentiated tumors) had indices higher than 0.10 (i.e., they had loss or imbalance in at least 10% of the informative markers analyzed). The mean allelic imbalance index for the high nuclear grade DCIS tumors ($n = 14$) was $0.175 (\pm 0.06)$ and for the non-high grade lesions ($n = 9$) $0.095 (\pm 0.12)$. Although this putative correlation did not reach statistical significance, probably due to the sample size, it appears that there is a tendency for association between high nuclear grade and higher frequency of allelic losses and imbalances. This is in agreement with previous

histopathological studies that indicated that high nuclear grade appears to identify subsets of DCIS with worse prognosis (22).

ILCA Allelotype and Microsatellite Instability. We also compared the allelotypic profiles of invasive ductal carcinomas with ILCAs. "Ductal" and "lobular" do not denote a different site of origin; in fact, it has been shown that most of both types of tumors originate in the terminal duct lobular unit (23). However, there are distinct morphological differences between the two histological types. Approximately 10–15% of all breast cancers are ILCA (23). Histologically, lobular carcinomas have a distinctive infiltrative growth pattern with characteristic cytological features (23). As recently reviewed by Silverstein *et al.* (24), reports on the prognosis of ILCAs vary considerably. Because characteristically these tumors show diffuse

Table 2 Analysis of breast tumors with microsatellite instability by histology

Histology	RER+ tumors/total tumors
Ductal carcinoma <i>in situ</i>	3/23 (13 %)
Invasive ductal carcinoma	4/29 ^a (14%) 7/52 ^b (13%)
Invasive lobular carcinoma	9/23 ^c (39%)

a versus c; $P = 0.036$, χ^2 test. b versus c; $P = 0.012$, χ^2 test.

growth pattern without a prominent mass, they are more difficult to detect and diagnose. It is interesting that patients with ILCAs were reported to have statistically significantly higher risk of subsequent development of contralateral breast carcinoma (24). It has also been observed that the metastatic pattern of infiltrating lobular carcinomas differs from that of invasive ductal carcinomas (25). In our comparative allelotyping of invasive ductal *versus* invasive lobular carcinomas, we observed that allelic losses and imbalances affecting chromosome arms 1p, 3q, 11q, and 18q were more frequent in invasive ductal than in invasive lobular breast cancers (Fig. 1). On the other hand, 8p losses or imbalances were observed in 36% of invasive lobular tumors but in only 14% of invasive ductal tumors (Fig. 1). However, these differences between the two tumor types are not statistically significant at the 0.05 level, and a larger sample is necessary to conclusively identify specific anomalies.

Nevertheless, in the course of the allelotyping studies we observed that numerous lobular tumor samples showed frequent abnormalities in the allele size migration in polyacrylamide gels when compared with the matched normal controls (Fig. 2B). Abnormalities in size of simple sequence nucleotide repeats is a phenomenon described as microsatellite instability (26). This phenomenon has been described as a characteristic of tumors from patients carrying the autosomal dominant predisposition to tumors of the colon and endometrium, known as hereditary nonpolyposis colon cancer (26). These studies led to the identification of a group of human DNA mismatch repair genes as the cause of such general genomic instability phenomenon. Germline mutations in either the *Escherichia coli* *mutS* homologue *hMSH2* or the *mutL* homologues *hMLH1*, *hPMS1*, and *hPMS2* have been found in different subsets of hereditary nonpolyposis colon cancer kindreds (27, 28). Microsatellite instability, also known as RER phenotype, has also been reported to occur at various frequencies in various sporadic neoplasias other than colon cancer, such as cancers of the endometrium (29), stomach (30), esophagus (31), bladder (32), and other

tissues. Yee *et al.* (33) reported microsatellite instability in 20% of breast cancers. In some other studies, however, a very low frequency of microsatellite instability was detected in breast cancer (34, 35). These discrepancies may be due to the number of loci and the type of simple sequence repeats assayed. For instance, it has been suggested that tetranucleotide repeats are more sensitive to RERs than are dinucleotide repeats (36). Recently, Glebov *et al.* (37) observed that individuals with a family history of breast cancer and with *p53* mutations had a higher frequency of abnormalities of chromosome 17 loci.

In our study of unselected breast cancer cases and mostly dinucleotide repeat markers, we observed the RER+ phenotype in 16 of the 75 breast cancer samples (21%). This figure is similar to that reported by Yee *et al.* (33). It was interesting, however, that when analyzed by histological subtype, only 13% (7 of 52 tumors) of ductal tumors (DCIS plus invasive ductal tumors) showed the RER+ phenotype, in contrast to 39% (9 of 23) of infiltrating lobular breast carcinomas (Table 2). This difference is statistically significant by χ^2 analysis ($P = 0.012$). Furthermore, if we exclusively compare invasive ductal carcinomas with invasive lobular carcinomas, the difference is still significant ($P = 0.036$). To address whether the observed microsatellite instability could be simply the consequence of a more aggressive tumor phenotype, we plotted the allelic loss index for the DCISs and the invasive ductal and lobular tumors, identifying those samples that were RER+ (data not shown). We observed that the lobular breast carcinomas do not appear to represent a more advanced tumor stage because overall they had a similar level of allelic losses as the invasive ductal tumors. In addition, some tumors with very few losses (low indices) were already RER+, including three at the DCIS stage.

Our data suggest that invasive lobular breast carcinomas appear to arise by a mechanism of carcinogenesis different from that of ductal breast carcinomas and may constitute a possible different pathological entity. These findings also support previous observations of different clinical behaviors of lobular breast tumors and ductal tumors (23–25). As mentioned earlier, the diagnosis of lobular breast carcinoma has been associated with a higher risk for development of multifocal or subsequent contralateral breast cancer (23, 24). The possibility exists that some patients that develop lobular breast tumors could harbor or develop mutations in any of the DNA mismatch repairs genes in the mammary epithelium, thus producing a field defect and constituting a

Table 3 Breast cancer patients with microsatellite instability in their tumors

Patient	No. of Loci Affected	Histology	Age	Other cancer ^a	No. of relatives with cancer			
					FDR ^b		SDR	
					Breast	Other	Breast	Other
66	1	Ductal	54		0	2	0	1
5	1	Ductal	43		0	0	2	1
77	1	Ductal	63	Melanoma	0	1	0	2
8	1	Lobular	66	Breast	0	1	0	3
75	1	Lobular	46		0	0	0	0
65	2	Ductal	29		0	0	1	0
37	2	Ductal	66		2	0	1	0
80	3	Lobular	51	Breast, cervix	0	2	0	1
83	3	Lobular	63		0	1	0	2
24	>3	Ductal	49		0	1	1	4
39	>3	Ductal	52		0	0	1	1
50	>3	Lobular	71	Endometrium	0	0	1	3
51	>3	Lobular	73	Breast, endometrium	0	1	0	1
53	>3	Lobular	69	Breast	1	1	0	1
54	>3	Lobular	76		0	2	0	0
81	>3	Lobular	52		1	0	1	2

^a Other neoplasia in the same patient.

^b FDR, first-degree relatives (mother, father, siblings, children); SDR, second-degree relatives (aunts, uncles, grandparents, grandchildren).

facilitating event for the development of secondary mutations leading to tumor development.

Liu *et al.* (38) observed that only 1 of 10 patients with RER+ sporadic colorectal cancers had a detectable germline mutation in any of the known DNA mismatch repair genes, and most of the mutations found in the sporadic cases were somatic (38). It is important to analyze the role of microsatellite instability in breast cancer in light of the findings of Glebov *et al.* (37), who reported an association between microsatellite instability and familial history of breast cancer. The samples we used, however, were obtained at random from pathology files, and detailed information on familial history of breast cancer was not available for most of the cases, so we cannot evaluate in detail at this point the association between microsatellite instability and family history. Nevertheless, to at least partially address this point, we conducted telephone interviews with the patients (or their next of kin) who had breast tumors with the RER+ phenotype. We obtained detailed family histories on all first- and second-degree relatives (Table 3). Most of the breast cancers observed in family members, however, were among older relatives, suggesting that these are probably sporadic breast cancers. It was interesting that four of the nine patients with lobular breast cancer and the RER+ phenotype had, previously or synchronously, another breast cancer. In addition, three of these four cases were among those with multiple affected chromosomal loci. On the basis of our observations, we speculate that detection of microsatellite instability has the potential to be useful in identifying patients at risk of developing second breast cancers. However, these are only observations, and these findings will certainly be substantiated with a larger data set.

In summary, in this report we identified for the first time the chromosome arms most frequently affected by losses and imbalances at preinvasive stages of breast carcinogenesis and those allelic losses involved in more advanced stages of progression. In the course of these studies, we also observed that microsatellite instability was much more frequent in infiltrating lobular breast cancers than in ductal breast tumors. Our findings suggest that infiltrating lobular breast carcinoma is a different entity from ductal carcinoma and may arise by a different mechanism of carcinogenesis.

Acknowledgments

We thank Estelle Kastleman and Phyllis Adatto for conducting most of the telephone interviews for family history information, Judy Ing for artwork, and Michelle Gardiner for secretarial assistance.

References

- Thompson, F., Emerson, J., Dalton, W., Yang, J.-M., McGee, D., Villar, H., Knox, S., Massey, K., Weinstein, R., Bhattacharyya, A., and Trent, J. Clonal chromosome abnormalities in human breast carcinomas. I. Twenty-eight cases with primary disease. *Genes Chromosomes & Cancer*, 7: 185-193, 1993.
- Devilee, P., and Cornelisse, C. J. Somatic genetic changes in human breast cancer. *Biochim. Biophys. Acta*, 1198: 113-130, 1994.
- Genuardi, M., Tshira, H., Anderson, D. E., and Saunders, G. F. Distal deletion of chromosome 1p in ductal carcinoma of the breast. *Am. J. Hum. Genet.*, 45: 73-82, 1992.
- Chen, L. C., Dollbaum, C., and Smith, H. S. Loss of heterozygosity on chromosome 1q in human breast cancer. *Proc. Natl. Acad. Sci. USA*, 86: 7204-7207, 1989.
- Ali, I. U., Lidereau, R., and Callahan, R. Presence of two members of *c-erbA* receptor gene family (*c-erbA* and *c-erbA2*) in smallest region of somatic homozygosity on chromosome 3p21-25 in human breast carcinoma. *J. Natl. Cancer Inst.*, 81: 1815-1920, 1989.
- Deville, P., van Vliet, M., van Sloun, P., Dijkshoorn, K., Hermans, J., Pearson, P., and Cornelisse, C. Alleloypotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. *Oncogene*, 6: 1705-1711, 1991.
- Bieche, I., Champeme, M. H., Matifas, F., Hacene, K., Callahan, R., and Lidereau, R. Loss of heterozygosity in chromosome 7q and aggressive primary breast cancer. *Lancet*, 339: 137-143, 1992.
- Ali, I., Lidereau, R., Theillet, C., and Callahan, R. Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. *Science (Washington DC)*, 238: 185-188, 1987.
- Carter, S. L., Negrini, M., Baffa, R., Gillum, D. R., Rosenberg, A. L., Schwartz, G. F., and Croce, C. M. Loss of heterozygosity at 11q22-q23 in breast cancer. *Cancer Res.*, 54: 6270-6274, 1994.
- Lundberg, C., Skoog, L., Cavenee, W. K., and Nordenskjold, M. Loss of heterozygosity in human ductal breast tumors indicates a recessive mutation on chromosome 13. *Proc. Natl. Acad. Sci. USA*, 84: 2372-2376, 1987.
- Cropp, C. S., Lidereau, R., Campbell, G., Champeme, M. H., and Callahan, R. Loss of heterozygosity on chromosome 17 and 18 in breast carcinoma: two additional regions identified. *Proc. Natl. Acad. Sci. USA*, 87: 7737-7741, 1990.
- Sato, T., Tanigani, A., Yamakawa, K., Akiyama, F., Kasumi, F., Sakamoto, G., and Najamura, Y. Alleloypotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. *Cancer Res.*, 50: 7184-7189, 1990.
- Runnebaum, I. B., Nagarajan, J., Bowman, Soto, D., and Sukumar, S. Mutations in *p53* as potential molecular markers for human breast cancer. *Proc. Natl. Acad. Sci. USA*, 88: 10657-10661, 1991.
- Chen, T., Dhir, K., Sahin, A., Hortobagyi, G. N., and Aldaz, C. M. Technical approach for the study of the genetic evolution of breast cancer from paraffin embedded tissue sections. *Breast Cancer Res. Treat.*, in press, 1995.
- Lindblom, A., Rotstein, S., Skoog, L., Nordenskjold, M., and Larsson, C. Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases. *Cancer Res.*, 53: 3707-3711, 1993.
- Cleton-Jansen, A. M., Moerland, E. W., Kuipers-Dijkshoorn, N. J., Callen, D. F., Sutherland, G. R., Hansen, B., Devilee, P., and Cornelisse, C. J. At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. *Genes Chromosomes & Cancer*, 9: 101-107, 1994.
- Tsuda, H., Callen, D. F., Fukutomi, T., Nakamura, Y., and Hirohashi, S. Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread. *Cancer Res.*, 54: 513-517, 1994.
- Dutrillaux, B., Gerbault-Seureau, M., and Zafrani, B. Characterization of chromosomal anomalies in human breast cancer. A comparison of 30 paradiplod cases with few chromosome changes. *Cancer Genet. Cytogenet.*, 49: 203-217, 1990.
- Pandis, N., Heim, S., Bardi, G., Idvall, I., Mandahl, N., and Mitelman, N. Whole-arm t(1;16) and i(1q) as sole anomalies identify gain of 1q as a primary chromosomal abnormality in breast cancer. *Genes Chromosomes & Cancer*, 5: 235-238, 1992.
- Radford, D. M., Fair, K., Thompson, A. M., Ritter, J. H., Holt, M., Steinbrueck, T., Wallace, M., Wells Jr., S. A., and Donis-Keller, H. R. Allelic loss on chromosome 17 in ductal carcinoma *in situ* of the breast. *Cancer Res.*, 53: 2947-2950, 1993.
- Zhuang, Z., Merino, M. J., Chuaqui, R., Liotta, L. A., and Emmert-Buck, M. R. Identical allelic loss on chromosome 11q13 in microdissected *in situ* and invasive human breast cancer. *Cancer Res.*, 55: 467-471, 1995.
- Lagios, M. D., Margolin, F. R., Westdahl, P. R., and Rose, M. R. Mammographically detected ductal carcinoma *in situ*. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. *Cancer (Phila.)*, 63: 618-624, 1989.
- Tavassoli, F. A. *Pathology of the Breast*, Norwalk, CT: Appleton & Lange, 1992.
- Silverstein, M. J., Lewinsky, B. S., Waisman, J. R., Gierson, E. D., Colburn, W. J., Senofsky, G. M., and Gamagami, P. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? *Cancer (Phila.)*, 73: 1673-1677, 1994.
- Harris, M., Howell, A., Chrissohou, M., Swindell, R. I. C., Hudson, M., and Sellwood, R. A. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. *Br. J. Cancer*, 50: 23-30, 1984.
- Aaltonen, L. A., Peltomäki, P., Leach, F. S., Sistonen, P., Pylkänen, L., Mecklin, J.-P., Järvinen, H., Powell, S. M., Jen, J., Hamilton, S. R., Petersen, G. M., Kinzler, K. W., Vogelstein, B., and de la Chapelle, A. Clues to the pathogenesis of familial colorectal cancer. *Science (Washington DC)*, 260: 812-816, 1993.
- Fishel, R., Lescoe, M. K., Rao, M. R. S., Copeland, N. G., Jenkins, N. A., Garber, J., Kane, M., and Kolodner, R. The human mutator gene homolog *MSH2* and its association with hereditary nonpolyposis colon cancer. *Cell*, 75: 1027-1038, 1993.
- Bronner, C. E., Baker, S. M., Morrison, P. T., Warren, G., Smith, L. G., Lescoe, M. K., Kane, M., Earabino, C., Lipford, J., Lindblom, A., Tannergard, P., Bollag, R. J., Godwin, A. R., Ward, D. C., Nordenskjold, M., Fishel, R., Kolodner, R., and Liskay, R. M. Mutation in the DNA mismatch repair gene homologue *hMLH1* is associated with hereditary non-polyposis colon cancer. *Nature (Lond.)*, 368: 258-261, 1994.
- Risinger, J. I., Berchuck, A., Kohler, M. F., Watson, P., Lynch, H. T., and Boyd, J. Genetic instability of microsatellites in endometrial carcinoma. *Cancer Res.*, 53: 5100-5103, 1993.
- Han, H.-J., Yanagisawa, A., Kato, Y., Park, J.-G., and Nakamura, Y. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. *Cancer Res.*, 53: 5087-5089, 1993.
- Meltzer, S. J., Yin, J., Manin, B., Rhyu, M.-G., Cottrell, J., Hudson, E., Redd, J. L., Krasna, M. J., Abraham, J. M., and Reid, B. J. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. *Cancer Res.*, 54: 3379-3382, 1994.
- Gonzalez-Zulueta, M., Ruppert, J. M., Tokino, K., Tsai, Y. C., Spruck III, C. H., Miyao, N., Nichols, P. W., Hermann, G. G., Horn, T., Steven, K., Summerhayes, I. C., Sidransky, D., and Jones, P. A. Microsatellite instability in bladder cancer. *Cancer Res.*, 53: 5620-5623, 1993.
- Yee, C. J., Roodi, N., Verrier, C. S., and Parl, F. F. Microsatellite instability and loss of heterozygosity in breast cancer. *Cancer Res.*, 54: 1641-1644, 1994.
- Wooster, R., Cleton-Jansen, A. M., Collins, N., Mangion, J., Cornelis, R. S., Cooper,

- C. S., Gusterson, B. A., Ponder, B. A., von Deimling, A., Wiestler, O. D., Cornelisse, C. J., Devilee, P., and Stratton, M. R. Instability of short tandem repeats (microsatellites) in human cancers. *Nature Genet.*, 6: 152-156, 1994.
35. Lothe, R. A., Peltomäki, P., Meling, G. I., Aaltonen, L. A., Nyström-Lahti, M., Pylkkänen, L., Heimdal, K., Andersen, T. I., Møller, P., Rognum, T. O., Fossa, S. D., Haldorsen, T., Langmark, F., Brøgger, A., de la Chapelle, A., and Borresen, A-L. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. *Cancer Res.*, 53: 5849-5852, 1993.
36. Mao, L., Lee, D. J., Tockman, M. S., Erozan, Y. S., Askin, F., and Sidransky, D. Microsatellite alterations as clonal markers for the detection of human cancer. *Proc. Natl. Acad. Sci. USA*, 91: 9871-9875, 1994.
37. Gleibov, O. K., McKenzie, K. E., White, C. A., and Sukumar, S. Frequent *p53* gene mutations and novel alleles in familial breast cancer. *Cancer Res.*, 54: 3703-3709, 1994.
38. Liu, B., Nicolaides, N. C., Markowitz, S., Willson, J. K. V., Parsons, R. E., Jen, J., Papadopolous, N., Peltomäki, P., Chapelle, A., Hamilton, S. R., Kinzler, K. W., and Vogelstein, B. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. *Nature Genet.*, 9: 48-55, 1995.

Report

Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections

Taiping Chen,¹ Kapil Dhingra,² Aysegul Sahin,³ Nour Sneige,³ Gabriel Hortobagyi² and C. Marcelo Aldaz¹

¹ Department of Carcinogenesis, Science Park – Research Division; ² Department of Medical Oncology;

³ Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA

Key words: breast cancer, allelotype, *in situ* hybridization, paraffin sections

Summary

We have optimized a technique that allows the study of numerous chromosomal loci ($n = 20\text{--}50$) from single paraffin-embedded tissue sections by microsatellite length polymorphism analysis. DNA samples from normal and breast cancerous tissue can be obtained from the same section by means of microdissection. This technique was further improved by subjecting DNA to several cycles of amplification with a degenerate (universal) primer and then with specific microsatellite primers. This amplified DNA was also used to screen for mutations in the p53 gene by means of PCR-SSCP. In addition adjacent tissue sections were used to assess specific chromosome copy number by interphase cytogenetic analyses (chromosome *in situ* hybridization) and to analyze expression of specific genes such as p53 and ERBB2. As an example of the use of our approach we performed a detailed chromosome 17 allelotypic analysis in 22 breast tumors (5 ductal carcinomas *in situ*, 13 invasive ductal carcinomas, and 4 invasive lobular carcinomas). We detected mutations in the p53 gene by PCR-SSCP in 36% of the samples. Samples with significant levels of p53 protein accumulation detected by immunohistochemistry were also positive for mobility shifts in the SSCP analysis. We observed that chromosome 17 allelic losses and imbalance occurred at as early a stage as ductal carcinoma *in situ* (DCIS). Although in some cases we observed allelic losses or imbalance affecting the 17p13 region, close to the p53 locus, several of the tumors showed dissociation between such loss or imbalance and p53 mutation. Lobular carcinomas were predominantly disomic for chromosome 17 in contrast with ductal tumors, which often showed polysomy for chromosome 17. This comprehensive approach correlating the tumor subtype, its allelotype, with specific chromosome copy number and specific gene mutations and expression in preinvasive or early invasive breast cancer lesions will potentially provide information of relevance for a better understanding of the multistep mechanisms of breast carcinogenesis.

Introduction

Numerous somatic mutations affecting various genes and chromosome regions have been described in human breast cancer. However, the rele-

vance and role in sporadic breast cancer of most of these abnormalities is still unclear [1–3]. It is very important to determine whether some of these anomalies are cause or effect of tumor progression [2]. Thus, there is a need for studies addressing the

sequentiality and timing of the various genomic abnormalities from the putative breast premalignant lesions to the most aggressive malignant phenotypes. The best obvious source of material for the identification of the various stages of progression is available from paraffin-embedded tissues used in routine diagnostic procedures.

In this report we describe the optimization of a comprehensive technical approach for a multiparametric analysis of human breast cancer lesions from paraffin-embedded tissue sections. By analyzing preinvasive and early invasive breast cancer lesions, this approach allows determination of the timing of presentation of several of the most common genomic abnormalities. The techniques described here allow the analysis of normal and pathological template DNA from microscopic lesions. Our approach is based on the use of microsatellite chromosome markers (simple sequence repeats or SSRs) for tissue allelotyping [4]. SSRs became tools of common use in the analysis of genetic abnormalities in carcinogenesis [5, 6]. The frequent polymorphism in their length among different individuals makes SSRs particularly valuable for the detection of allelic losses or imbalance affecting specific chromosome areas. They also allow the identification of tumors that may be generated due to errors in DNA mismatch repair and characterized by a general microsatellite instability [7].

Interphase cytogenetics chromosomal *in situ* hybridization, or CISH, is another recently developed technique being used extensively for the study of genomic abnormalities in solid tumors [8, 9]. This technique can also be applied to paraffin-embedded tissue sections [10–12]. CISH allows evaluation of the degree of intratumor clonal heterogeneity and eventually identification of tumor subpopulations on microscopic lesions [12]. The optimization of micromolecular techniques such as SSR analysis of chromosomal loci from paraffin-embedded sections, coupled with other techniques in current use such as interphase cytogenetics and conventional immunohistochemistry, will allow valuable retrospective studies of archival tissues to be done.

Materials and methods

Microsatellite analysis

Five- to eight-micron-thick sections were cut from paraffin-embedded tissue blocks. Tissue microdissection was done on paraffin-embedded sections by drawing the silhouette of the area of interest on an H&E-stained slide and overlapping with the unstained specimen or by deparaffinizing first, staining with toluidine blue, and then microdissecting. Normal and tumor samples can be obtained from different areas of the same section or alternatively samples for normal DNA can be obtained from additional paraffin blocks from unaffected tissues (e.g. lymph nodes). After deparaffinizing (3X xylene/30 min), samples were rehydrated in decreasing alcohol gradients. DNA was extracted by incubating in 200 μ l Instagene chelex matrix solution (BioRad) containing 60 μ g of proteinase K. Incubations were carried out in a shaking incubator at 37° C overnight. After proteinase K digestion, samples were boiled for 10 min, vortexed, and centrifuged at > 7,000 G for 5 minutes. After centrifugation, 150 μ l of usable volume was produced: of this, 2–10 μ l were used for PCR amplification, depending upon the cellularity of each sample. Prior to PCR reactions, the forward primer was end labeled with T4 polynucleotide kinase (Promega) and 6,000 Ci/mmol [γ -³²P] = dATP (NEN). PCR reactions were performed in a 20 μ l reaction volume 150 μ M each dNTP, 1 u Taq polymerase, 1 X Taq buffer (Promega), –2mM MgCl₂, 1 pmol labeled primer and 2.5 pmol unlabeled forward and reverse primers.

In a 'hot start' procedure template and primers were heated to 96° C and denatured for 5 min. The remaining reaction constituents were added later at 80° C. The DNA was then subjected to 30–35 cycles of 40 sec at 94° C and 30 sec at 55° C, and a final elongation step of 5 min at 72° C. Products were electrophoresed on a 7% polyacrylamide sequencing gel at 90 w constant power for 2–4 hr. Gels were dried at 65–70° C for 1–2 hr and exposed to X-ray film from 4 hr to overnight. For certain primer sets, the amplification conditions were further optimized by titrating the MgCl₂ concentration in the

reaction buffer. In some cases it may be necessary to use higher annealing temperatures (60° C or 65° C). Primers used were: D17S513 [13], D17S579 [14], MPO [15], D17S784, D17S849 [16], and D17S520 (J. Weber, unpublished data).

An alternative approach was used to analyze extremely small lesions or to generate additional template DNA. This approach was based on the use of a degenerate universal primer (DOP-PCR), as described by Telenius *et al.* [17]. To this end a 1–2 µl sample from the original 150 µl template-containing solution was obtained. This sample was used as template for one round of PCR amplification with the universal degenerate primer 5'-CCGACTC-GAGNNNNNNATCTGG-3' [17]. The reaction mixture contains a template DNA sample, 1.5 µM universal primer, 200 µM each dNTP, 2 mM MgCl₂, 50 mM KCl, 10 mM Tris-HCl, pH 8.4, 0.1 mg/ml gelatin, and 2.5 U Taq polymerase in a 50 µl reaction volume.

For this alternative approach, reaction mixtures were subjected to one cycle of 4 min at 93° C; 8 cycles of 1 min at 94° C, 1 min at 30° C, and 3 min at 72° C; 28 cycles of 1 min at 94° C, 1 min at 56° C, and 3 min at 72° C, and a final extension at 72° C for 10 min. The resulting PCR product was then used as the template (1 µl) for a second PCR using either the specific microsatellite primers as described above or the specific p53 exon primers for PCR-SSCP analysis.

PCR-SSCP analysis

PCR-SSCP analysis of exons 5–8 of the p53 gene was performed using a commercially available human p53 amplicon panel (Clontech Lab. Inc.) [18]. Each PCR was done in a 20 µl volume containing 3 pmol of each primer at a 1:3 labeled/unlabeled ratio (both primers were previously end labeled with γ -³²P), 300 µM dNTPs, 10 mM Tris-Cl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.01% (weight/volume) gelatin, and 1.0 U Taq DNA polymerase. Samples were overlaid with 25 µl of mineral oil and then amplified in 35 cycles of 1 min at 94° C, 1 min and 40 sec at 66° C, and 1 min at 72° C for extension. The reaction mixture was then mixed 1:1 with a solution con-

taining 20 mM EDTA, 95% formamide, 0.05% bromophenol blue, and 0.05% xylene cyanol. Samples were heated at 95° C for 5 min, chilled on ice, and immediately loaded onto a 6% acrylamide/Tris-borate-EDTA gel containing 6% glycerol (volume/volume). Gels were run at 10 W (0.5 W/cm) for 3–4 hr at room temperature. Autoradiography was performed overnight at room temperature without intensifying screens. Genomic DNAs from control samples containing known wild-type and mutant p53 alleles were processed in parallel in every assay.

Chromosomal in situ hybridization

The methodology for interphase cytogenetic analysis has been previously described [12]. Briefly, sections from breast tumor tissue were dewaxed in xylene, dehydrated in graded alcohol, baked at 80° C for 1 h, and treated with 0.4% pepsin (Sigma, St. Louis, MO) in 0.2 N HCl for 30–55 min. Following denaturation at 94° C for 4 min, hybridization was carried out overnight in 60% formamide, 2X SSC containing 5% dextran sulphate, 1 mg/ml salmon sperm DNA, and 0.8–1.0 ng/µl probe. After hybridization, the slides were washed in 50% formamide in 2X SSC (pH 7.0) at room temperature and then washed in 0.1X SSC at 37° C. The hybridization signal was detected by the immunoperoxidase technique using the Vectastain ABC kit (Vector) and diaminobenzidine (DAB) as the chromogen substrate, as previously described [12]. Signals were quantitated as previously described [19]. The number of signal spots on a minimum of 100 nuclei in a given area was counted using previously described criteria [19]. A minimum of five randomly chosen areas were counted on each slide from each cell block. The CI was calculated by dividing the total number of signal spots by the number of nuclei counted. In brief, the chromosome index (CI) was calculated for defined histological regions by dividing the total number of signal spots by the total number of nuclei counted. For disomic cells, the CI for any given chromosome in our experience is 1.0. To account for minor technical differences in hybridization efficiency from one experiment to the next and from one region to another, a CI of ≥ 1.20




Fig. 1. Multiparameter analysis of breast cancer from paraffin sections to determine genotype phenotype correlations. A) DNA from normal (N) and tumor (T) areas of paraffin-embedded sections is obtained with the aid of microdissection. Normal DNA can also be obtained from a separate histological section of normal tissues from the same patient, e.g. unaffected lymph node. After microdissection of the area of interest the material is collected, purified and digested. PCR is performed using primers flanking specific microsatellite markers (SSRs). B) at right is shown the alternative protocol for extremely small samples using a few cycles of amplification with a universal primer mixture [17]. This DNA can also be used to screen for mutations such as in p53. Adjacent sections are used for interphase cytogenetics and immunohistochemistry.

was considered to represent polysomy and a CI of ≤ 0.80 monosomy.

When permitted by the size of the lesion, tumors were also analyzed by routine DNA flow cytometry to determine DNA index (DI).

Immunohistochemistry

p53 protein accumulation was analyzed by the avidin-biotin-peroxidase complex method using the D01 antibody (Oncogene Science), which detects

both mutant and wild-type p53 protein. Results were expressed as the approximate percentage of positive cells in random microscopic fields of observation. ERBB2 expression was detected with a commercially available antibody (Oncogene Science).

Results and discussion

We have developed a technique to analyze multiple chromosomal loci from single, microdissected, par-

affin-embedded sections. This involves PCR-mediated analysis of microsatellite length polymorphisms. Similar approaches were also recently developed by other laboratories [20]. We are now using the techniques described here to allelotype small preinvasive and invasive breast cancer lesions and then correlate the allelotypes with other tumor markers as well as cytogenetic changes such as numerical abnormalities of specific chromosomes (Fig. 1). To overcome the potential problem of normal DNA contribution from stromal or inflammatory cells, we microdissected areas of interest from each tissue section. From 5–8 μ m tissue sections, we obtained enough template DNA to perform approximately 20–50 PCR reactions, which allowed the analysis of as many different chromosomal loci (Fig. 1A). The number of reactions depends on the size of the original sample, and certain primer sets require higher levels of template DNA. Thus, this general strategy was further improved by modifying a previously described DOP-PCR technique [17] to allow the analysis of even smaller samples and the gathering of larger amounts of template DNA. This facilitated the analysis of more chromosomal loci as well as the screening of specific gene mutations by PCR-SSCP. We obtained a minimum sample (1–2 μ l) from the original template-DNA-containing solution by this alternative approach (Fig. 1B). This sample was subjected to a few cycles of PCR amplification with a universal degenerate primer, as described by Telenius *et al.* [17]. The resulting amplified products were used as template for amplification with the specific microsatellite flanking primers or the gene-specific primers (e.g. p53 amplimer panel). Figure 2 compares both of the methods described above. The allelic loss affecting marker D17S579 (upper allele) could be detected equally well by the direct technique (Fig. 2A) and the universal primer technique (Fig. 2B). This indicates that the proportionality of the alleles is preserved even after several cycles of whole genome amplification with a universal primer. This was further demonstrated by mixing at variable proportions two DNA samples, each homozygous for a different allele of marker D17S513, and comparing the sensitivity of both techniques, the direct approach and the universal primer method (Figs 2C and D,




Fig. 2. Comparison of both techniques as shown in Fig. 1. A) Direct analysis of the D17S579 marker in patient 1, with loss of the upper allele in the tumor (T1) and in the corresponding metastasis (M1). At right B) is shown the analysis of the same D17S579 marker by the universal primer approach (Fig. 1B). As seen, the loss of the upper allele of this marker in T1 and M1 is preserved and detected using the universal primer approach.

Comparative analysis of mixtures of two alleles of D17S513 by using the direct method in C and the universal primer approach in D. Two DNA samples homozygous for D17S513 were mixed at various proportions prior to PCR, the percentage in the mixture of the sample with the smaller allele is shown at the bottom of each figure, see text for details.

respectively). The two samples with similar DNA concentrations were obtained from tissue sections were mixed at various proportions as indicated (Figs 2C, D) and were subjected to amplification using the direct approach (Fig. 2C). A 1 μ l sample of the original mixtures was diluted in a 49 μ l reaction volume for PCR amplification using the universal primer. Finally a 1 μ l sample of this last reaction was used to amplify using the specific primer set for D17S513 (Fig. 2D). As can be observed both approaches yielded comparable results confirming that the universal primer method can detect alterations in the proportionality of the different alleles.




Fig. 3. Representative autoradiographs of multiple normal (N) and breast tumor (T) samples obtained from paraffin-embedded tissues demonstrating the analysis of chromosome 17 loci. In panels A and B note LOH in samples T5, T11, and T20. In panel C, note the generation of a novel allele (arrow) in the tumor T24; we observed the same phenomenon with other markers in this patient (microsatellite instability). PCR-amplified microsatellites with one primer end labeled were separated on a 7% polyacrylamide sequencing gel.




Fig. 4. Schematic representative summary of chromosome 17 allelotype and p53 mutation analysis of various breast cancer samples previously analyzed by means of microsatellite polymorphism in paraffin sections. Open circles, no LOH; closed circles, LOH or allelic imbalance; -, noninformative. p53 mutations were detected by PCR-SSCP analysis.

Figure 3 shows a representative analysis of multiple loci from the q and p arms of human chromosome 17 in various invasive and *in situ* breast carcinomas by the direct technique. Figure 4 shows the results of our detailed chromosome 17 analysis of 22 breast tumors (5 ductal carcinomas *in situ*, 13 invasive ductal carcinomas, and 4 invasive lobular carcinomas).

We also evaluated the sensitivity of the universal primer technique in detecting specific gene mutations. In this case we analyzed the same 22 tumors for p53 gene mutations by PCR-SSCP assay. We used 5 ng samples of template DNA from normal human DNA as negative controls and 5 ng samples from cell lines with known mutations in each of the p53 exons as positive control (e.g. Colo-320 for exon 7, BT-474 for exon 8). The control and tumor samples were first subjected to universal primer amplification as described in Methods. A 1–2 μ l sample of the resulting products was then subjected to a second PCR using the end-labeled p53 exon-specific primers. After a final denaturation, the

PCR products were separated on a 6% polyacrylamide gel under nondenaturing conditions. Representative results are shown in Fig. 5. Of the 22 tumors analyzed for mutations in p53 exons 5–8, we detected mobility shifts in 8 (36%) samples: 2 ductal carcinomas *in situ*, 4 invasive ductal carcinomas, and 1 lobular carcinoma (Fig. 4 lower panel).

Adjacent sections from 14 of the tissue blocks were also analyzed for chromosome 17 copy number by interphase cytogenetics CISH and expression of p53 and ERBB2 by immunohistochemistry. The results of these studies are shown in Table 1. Based on the data shown in Fig. 4 and Table 1, we concluded that allelic losses and imbalance already were occurring at the carcinoma *in situ* stage, as previously reported [21]. In several cases we observed allelic losses or imbalance affecting the 17p13 region, close to the p53 locus, but in several other tumors this event and p53 mutations were dissociated as observed by other authors [22]. However, tumors showing significant levels of p53 protein accumulation such as tumors 7, 10, and 19 also showed mobility shifts in the p53 PCR-SSCP assay. We also observed only a modest number of losses involving the 17q21–22 region, lower than previously reported by others [5].

The results also show that interphase cytogenetic analysis supplements the information gained from ploidy analysis by DNA flow cytometry alone. In many cases where flow cytometry could not be performed because the lesions were too small for gross observation, CISH techniques allowed the copy numbers of specific chromosomes to be estimated (e.g. tumors 5, 10, 16, 19, and 24). Furthermore, difference in copy number of chromosomes between adjacent but phenotypically distinct regions could be determined: e.g. tumor 10, the *in situ* component was polysomic (CI 1.66) for chromosome 17, but the invasive component was disomic (CI 1.10).

In summary, we have developed and applied a methodology for analyzing large numbers of chromosomal loci from single paraffin-embedded sections of small preinvasive and invasive breast cancer lesions. The basic technique involves tissue microdissection and microsatellite length polymorphism analysis. We have further improved this approach conducting a first round of DNA PCR




Fig. 5. Representative PCR-SSCP analysis of p53 exons 6 and 7 from a DNA template obtained from paraffin-embedded breast cancer tissues using the universal primer method. WT; wild type, M; positive control DNA for mutation in the corresponding exon. Note the clear shift in band mobility in some of the positive samples as indicated by arrows.

amplification with a degenerate universal primer for total genome amplification and then with specific microsatellite primers. We observed that the DNA so obtained preserved the proportionality of the different alleles as found in the original sample. We also determined that DNA obtained from the same lesions and amplified with the universal primer could be used to screen for specific gene mutations such as in p53. In addition, tissue sections adjacent to those used for the micromolecular analysis were successfully used to assess specific chromosome copy number by interphase cytogenetic analysis (CISH) and to analyze the expression of specific genes by immunohistochemistry.

This type of comprehensive approach using archival paraffin-embedded tissues will allow correlation of genetic changes (at both the chromosomal and molecular levels) with their phenotypic consequences in the same preinvasive and invasive lesions. Such an approach will also allow us to dissect the specific events involved in the multistep process of breast carcinogenesis.

Table 1. Analysis of multiple genotype and phenotype characteristics from breast cancer paraffin sections

Sample	Pathology ^a	Nuclear grade ^c	LOH or imbalance ^d		p53 mutation ^e	p53 accumulation ^f	c-erb B-2 expression ^g	DNA index ^h	Chromosome 17 CI ⁱ
			17p	17q					
4	IDC	I	○	ni	+(E6)	nd	nd	1.99	0.86
5	IDC	I	(2) ●	(1) ●	–	–	–	nd	0.91
10	IDC/DCIS	II	○	○	+(E7)	5%	–	nd	IDC 1.10; DCIS 1.66
16	IDC	I	(2) ●	○	–	5%	–	nd	1.60
7	DCIS ^b	II	ni	(2) ●	–	–	–	1.0	1.09
11	DCIS	I	(1) ●	○	–	–	+	2.22	2.24
12	DCIS	I	○	○	–	–	+	1.36	nd
13	DCIS	I	○	(1) ●	+(E7)	50%	+	1.13	1.19
19	DCIS	II	(1) ●	○	+(E8)	20%	–	nd	1.93
24	DCIS	II	MI ^j	MI ^j	nd	–	–	nd	nd
8	ILC	III	(2) ●	(1) ●	–	1%	–	1.16	1.12
9	ILC	II	(1) ●	○	–	1%	–	1.0	1.05
15	ILC	II	○	(1) ●	–	–	–	0.93	1.02
20	ILC/LCIS	II	(2) ●	○	+(E8)	nd	–	1.65	1.21

^a Abbreviations: IDC, invasive ductal carcinoma; DCIS, ductal carcinoma *in situ*; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma *in situ*.

^b All DCIS lesions were comedo DCIS with the exception of Sample # 7 which is a non-comedo lesion.

^c According to Black's nuclear grading system in which I = poorly differentiated, II = moderately differentiated and III = well differentiated.

^d According to microsatellite analysis. ●, loss or allelic imbalance, in parenthesis number of markers affected per arm; ○, no loss; ni, non informative.

^e Exon affected, as determined by PCR-SSCP; shown in parentheses.

^f Determined by immunohistochemistry using an antibody that recognizes both wild-type and mutant p53 protein. –, negative for accumulation; +, accumulation expressed as approximate percentage of positive cells; nd, not determined.

^g Determined by immunohistochemistry.

^h Determined by DNA flow cytometry from fresh specimens.

ⁱ Determined by chromosomal *in situ* hybridization with chromosome 17 centromeric probe.

^j MI, microsatellite instability.

Acknowledgements

Supported by U.S. Army Award DAMD 17-94J-4078 and NIH grant P20 CA58186. We thank John Riley and Judy Ing for artwork and Michelle Gardiner for secretarial assistance.

References

- Callahan R, Campbell G: Mutations in human breast cancer: an overview. *J Natl Cancer Inst* 81: 1780–1786, 1989
- McGuire WL, Naylor SL: Loss of heterozygosity in breast cancer: cause or effect? *J Natl Cancer Inst* 81: 1764–1765, 1989
- Chen L-C, Kurisu W, Ljung BM, Goldman ES, Moore II D, Smith HS: Heterogeneity for allelic loss in human breast cancer. *J Natl Cancer Inst* 84: 506–510, 1992
- Weber JL, May PE: Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. *Am J Hum Genet* 44: 388–396, 1989
- Futreal PA, Söderkvist P, Marks JR, Iglehart JD, Cochran C, Barrett JC, Wiseman RW: Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. *Cancer Res* 52: 2624–2627, 1992
- Jones MH, Nakamura Y: Deletion mapping of chromosome 3p in female genital tract malignancies using microsatellite polymorphism. *Oncogene* 7: 1631–1634, 1992

7. Aaltonen LA, Peltomäki P, Leach FS, Sjösten P, Pylkkänen L, Mecklin J-P, Järvinen H, Powell SM, Jen J, Hamilton SR, Petersen GM, Kinzler KW, Vogelstein B, de la Chappelle A: Clues to the pathogenesis of familial colorectal cancer. *Science* 260: 812-816, 1993
8. Hopman AHN, Moesker O, Smeets AWGB, Pauwels RP, Vooijs GP, Ramaekers FC: Numerical chromosome 1, 7, 9 and 11 aberrations in bladder cancer detected by *in situ* hybridization. *Cancer Res* 51: 644-651, 1991
9. Devilee P, Thierry RF, Kiebits T, Kolluri R, Hopman AHN, Willard HF, Pearson PL, Cornelisse CJ: Detection of chromosome aneuploidy in interphase nuclei from human primary breast tumors using chromosome-specific repetitive DNA probes. *Cancer Res* 58: 5825-5830, 1988
10. Emmerich P, Jauch A, Hofmann M-C, Cremer T, Walt H: Interphase cytogenetics in paraffin embedded sections from human testicular germ cell tumor xenografts and in corresponding cultured cells. *Laboratory Investigation* 61: 235-242, 1989
11. Walt H, Emmerich P, Cremer T, Hofmann M-C, Bannwart F: Supernumerary chromosome 1 in interphase nuclei of atypical germ cells in paraffin-embedded human seminiferous tubules. *Laboratory Investigation* 61: 527-531, 1989
12. Dhingra K, Sahin A, Supak J, Kin SY, Hortobagyi G, Hittelman WN: Chromosome *in situ* hybridization on formalin-fixed mammary tissue using non-isotopic, non-fluorescent probes: technical considerations and biological implications. *Breast Cancer Res and Treatment* 23: 201-210, 1992
13. Oliphant AR, Wright EC, Swensen J, Gruis NA, Goldgar D, Skolnick MH: Dinucleotide repeat polymorphism at the D17S513 locus. *Nucleic Acids Res* 19: 4794, 1991
14. Hall JM, Friedman L, Guenther C, Lee MK, Weber JL, Black DM, King MC: Closing in on a breast cancer gene on chromosome 17q. *Am J Hum Genet* 50: 1235-1242, 1992
15. Polymeropoulos MH, Xiao H, Rath DS, Merrill CR: Dinucleotide repeat polymorphism at the human gene of the light and heavy chains of myeloperoxidase glycoprotein (MPO). *Nucleic Acids Res* 19: 1961, 1991
16. Weissenbach J, Gyapay G, Dib C, Vignal A, Morissette J, Millasseau P, Vaysseix G, Lathrop M: A second-generation linkage map of the human genome. *Nature* 359: 794-801, 1992
17. Telenius H, Carter NP, Bebb CE, Nordenskjöld M, Ponder BA, Tunnacliffe A: Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. *Genomics* 13: 718-725, 1992
18. Orita M, Iwahana H, Kanazawa H, Hayashi K, Seklye T: Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphism. *Proc Natl Acad Sci USA* 86: 2766-2770, 1989
19. Dhingra K, Sneige N, Pandita TK, Johnston DA, Lee JS, Emami K, Hortobagyi GN, Hittelman WN: Quantitative analysis of chromosome *in situ* hybridization signal in paraffin-embedded tissue sections. *Cytometry* 16: 100-112, 1994
20. O'Connell P, Pekkeli V, Fuqua S, Osborne CK, Allred DC: Molecular genetic studies of early breast cancer evolution. *Breast Cancer Research Treatment* 32: 5-12, 1994
21. Radford DM, Fair K, Thompson AM, Ritter JH, Holt M, Steinbrueck T, Wallace M, Wells SA, Donis-Keller HR: Allelic loss on chromosome 17 in ductal carcinoma *in situ* of the breast. *Cancer Res* 53: 2947-2950, 1993
22. Deng G, Chen L-C, Schott DR, Thor A, Bhargava V, Ljung B-M, Chew K, Smith HS: Loss of heterozygosity and *p53* gene mutations in breast cancer. *Cancer Research* 54: 499-505, 1994

Deletion Map of Chromosome 16q in Ductal Carcinoma *in Situ* of the Breast: Refining a Putative Tumor Suppressor Gene Region¹

Taiping Chen, Aysegul Sahin, and C. Marcelo Aldaz²

Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas 78957 [T. C., C. M. A.], and Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [A. S.]

Abstract

Allelic losses or imbalances affecting chromosome arm 16q appear to be early genomic abnormalities in breast carcinogenesis, because they were observed in a significant number of breast ductal carcinoma *in situ* lesions in our previous study (Aldaz *et al.*, Cancer Res., 55: 3976-3981, 1995). To define the minimum region of loss of heterozygosity (LOH), we generated a high-resolution allelotype of 35 ductal carcinoma *in situ* cases and completed a deletion map of chromosome 16q by means of paraffin-embedded tissue microdissection and PCR microsatellite analysis of 22 markers. We observed a strikingly high frequency of LOH in 16q, with 31 of 35 tumors (89%) affected. We identified three distinctive areas with high LOH. Two areas were described previously and correspond to 16q21 and 16q24.2-qter. The third and most commonly affected area spanned the region from marker D16S515 to marker D16S504. The most affected locus was at D16S518, in which LOH was observed in 20 of 26 informative cases (77%), and we estimate that it lies in subregion q23.3-q24.1. The region of highest LOH spanned approximately 2-3 Mb, as determined by a yeast artificial chromosome contig reported to cover this region. Such a high frequency of LOH at a preinvasive stage of breast cancer suggests that a candidate tumor suppressor gene or genes at this location may play an important role in breast carcinogenesis.

Introduction

Breast cancer is the most common cancer among women, accounting for approximately 46,000 deaths in the United States each year (1). Numerous studies have focused on the identification and analysis of specific gene mutations and chromosome abnormalities in sporadic breast cancer, but to date no clear model of the critical events or delineation of primary abnormalities has emerged (2). DCIS³ of the breast is known to be a preinvasive stage of breast cancer and is probably the precursor of infiltrating breast cancer (3). Thus, genetic alterations shown at this stage might indicate association with early events in malignancy or invasiveness.

LOH at specific chromosomal loci has been considered part of the indirect evidence for postulating the existence of possible tumor suppressor genes within those specific chromosome regions. It is known that several mechanisms, such as chromosomal deletions, monosomy, mitotic recombination, and unbalanced translocation, can lead to the loss of alleles in tumors (4). Hypothetically, the remaining allele of the tumor suppressor gene in question could be rendered inactive by events occurring at the gene level, such as specific point mutations or other types of inactivating mutations. Usually, LOH at

specific chromosome regions affects not only the putative tumor suppressor gene but also neighboring genes or genetic markers that are used as indicators to track down the minimum area of LOH.

In a previous report, we described the development of a technical approach that allowed us to generate LOH analyses (allelotypes) from paraffin-embedded tissue samples (5). The basic technique involves tissue microdissection and microsatellite length polymorphism analysis. Using this micromolecular approach, we compared the allelotypes of *in situ* and invasive breast cancer lesions (6). We observed that specific chromosome arms are more frequently affected by allelic losses and imbalances at preinvasive stages of breast cancer. In particular, allelic losses affecting chromosome 16q, as well as chromosomes 17p, 17q, and 7, appear to be early genomic abnormalities because they were observed in a significant number of DCIS lesions (6).

LOH on chromosome 16q at various frequencies has been widely reported in breast (7-10), prostate (11), hepatoblastoma (12), and Wilms' tumors (13). In particular, two regions on chromosome 16q have been revealed to have a very high frequency of LOH in breast cancer; one maps to region 16q22.1 and the other to 16q24.2-qter (8-10).

In the study reported here, we extended our previous observations (6) using PCR microsatellite-length polymorphism analysis and precise tissue microdissection of paraffin-embedded tumor samples to generate a high-resolution deletion map of chromosome 16q in breast DCIS. We were able to identify a region of approximately 2-3 Mb as the location of a putative tumor suppressor gene of possible relevance in the development of breast cancer.

Materials and Methods

Tumor Samples. DCIS samples were obtained from paraffin-embedded tissue blocks from the archives of the Department of Pathology of The University of Texas M. D. Anderson Cancer Center. A total of 35 cases of tumors collected and diagnosed as pure breast DCIS by our collaborating pathologist (A. S.) was analyzed. DCIS samples were classified by nuclear grade and by the presence (comedo) or absence of necrosis. Twelve tumors were classified as poorly differentiated with high nuclear grade; the remaining 23 samples were classified as moderate and well differentiated with lower nuclear grades (moderate and low nuclear grades). Twenty-one of the samples showed evidence of necrosis; the remaining 14 showed no necrosis. We did not include any DCIS with infiltrating components.

Paraffin-embedded Tissue Microdissection. The basic technical approach has been described previously (5). Minor modifications were introduced to improve the efficiency of microdissection. Briefly, one to three 5-8- μ m-thick paraffin sections were stained and microdissected. Using companion H&E-stained slides as a reference, tumor cells were microdissected using a fine-point surgical blade (No. 11) under an inverted microscope. The edges of tumor area and stroma were cleared of debris using the same blade and blown with a stream of compressed air. A new blade was then used to dissect normal tissue the same way.

DNA Preparation. Samples were rehydrated, and DNA was extracted by incubating in 200- μ l Instagene chelex matrix solution (Bio-Rad) containing 60

Received 9/9/96; accepted 10/29/96.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by United States Army Breast Cancer Program Grant DAMD 17-94-J-4078.

² To whom requests for reprints should be addressed, at Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Science Park-Research Division, P. O. Box 389, Smithville, Texas 78957. Phone: (512) 237-2403; Fax: (512) 237-2475.

³ The abbreviations used are: DCIS, ductal carcinoma *in situ*; LOH, loss of heterozygosity; YAC, yeast artificial chromosome.

μg of proteinase K in a shaking incubator at 37°C overnight. After proteinase K digestion, samples were boiled for 10 min, vortexed, and centrifuged at $>7000 \times g$ for 5 min. Aliquots of the supernatant ($5 \mu\text{l}$ each) were used for PCR amplification.

PCR Microsatellite Analysis. The primers for highly polymorphic human microsatellite repeats listed in Table 1 were purchased from Research Genetics (Huntsville, AL). Before PCR reactions, the forward primer was end labeled using T4 polynucleotide kinase (Promega) and $[\gamma\text{-}^{32}\text{P}]\text{ATP}$ (DuPont New England Nuclear). Each PCR reaction was performed in a $20\text{-}\mu\text{l}$ reaction volume containing $150 \mu\text{M}$ each dNTP, 1 unit of Taq polymerase (Promega), $1 \times$ Taq buffer (Promega), 1.5 mM MgCl_2 , 1 pmol-labeled primer, and 2.5 pmol of unlabeled forward and reverse primers. A hot-start procedure was used in which template and primers were denatured at 96°C for 5 min. Afterward, the remaining reaction constituents were added for 35–40 cycles at 94°C for 40 s, 55°C for 30 s, and 72°C for 30 s, and a final elongation step at 72°C for 5 min. Products were electrophoresed on 7% polyacrylamide sequencing gels at 90 W of constant power for 2–3 h. Gels were dried at $65\text{--}70^\circ\text{C}$ for 1–2 h and exposed to X-ray film from 4 h to overnight. As necessary, for certain primer sets, the amplification conditions were further optimized by adjusting the MgCl_2 concentration in the reaction buffer.

The sample was considered to have partial LOH, or allelic imbalance, if the normal signal intensity of one allele was diminished by approximately half or more in relation to the remaining allele. Complete LOH was defined as a decrease of 90% or more in the signal intensity of one allele relative to the other. YAC clones spanning the region of interest were purchased from Research Genetics.

Results

Microdissection of Paraffin-embedded Ductal Carcinoma *in Situ*. To optimize the microdissection of tumor and normal samples, the sections were stained before dissection. In this way, exact areas of tumor and normal tissue could be dissected from the same slide. Fig. 1 shows three foci of DCIS (case 59) before (A) and after (B) microdissection. For each slide, separate blades were used to dissect tumor and normal samples, and a stream of compressed air was used to clear away debris before dissecting the normal tissue. Using this approach, we generated from a single slide relatively pure tumor and normal genomic DNA pools that could serve as templates for approximately 20–30 PCR reactions.

Allelic Loss and Deletion Map on Chromosome 16q. We analyzed a total of 35 breast DCIS cases for LOH using a panel of 22




Fig. 1. Representative microdissection of a DCIS sample from paraffin-embedded tissue section. A, before microdissection; note the three central structures (arrows). B, same area after microdissection (arrows).

microsatellite markers as summarized in Table 1 and Fig. 2. Thirty-one of these samples (89%) showed LOH, or allelic imbalance, in at least one or more chromosome 16 loci. Fig. 2 schematically displays the chromosome 16 allelotype of the individual DCIS tumors. We observed no correlation between the occurrence or pattern of LOH and the histopathological classification. (*i.e.*, DCIS samples with or

Table 1 Chromosome 16 LOH in ductal carcinoma *in situ* of the breast

Locus	Cumulative linkage map distance (cM) ^a	Cytogenetic location ^b	No. of cases	Tumors with LOH/Informative cases	% LOH
D16S407	47	p13.13	34	2/33	6
D16S420		p12.3	31	3/24	13
D16S285		q12.1	34	4/24	17
D16S261		q12.1	34	6/20	30
D16S390	89	q12.2	32	5/23	22
D16S533		q21	33	7/23	30
D16S400		q21	32	7/11	64
D16S503		q21	28	10/21	48
D16S398	92	q22.1	34	13/28	46
D16S421		q22.1	32	12/22	55
D16S512		q22.1	33	9/21	43
D16S260		q22.2	29	8/16	50
D16S395	100	q23.1–q23.2	35	14/26	54
D16S515		q22.3–q23.1	33	13/23	57
D16S518		q23.1–q24.2	33	20/26	77
D16S516		q24.1	30	14/21	67
D16S504	109	q24.1	32	15/20	75
D16S507		q23.2	35	7/19	37
D16S393		q24.1	32	10/23	43
D16S422		q24.2	29	10/21	48
D16S402	120	q24.2	32	14/19	74
D16S413		q24.3	35	10/27	37

^a According to Genethon Linkage Map (March 1996).

^b According to GDB (August 1996).




Fig. 2. Schematic representation of chromosome 16q allelotyping in breast DCIS. Numbers at the top of the figure represent each individual tumor. ■, LOH; □, allelic imbalance; □, no LOH; NI, noninformative locus; S, shift in allele size.

without necrosis and with high or low nuclear grades showed LOH at multiple loci in chromosome 16q.) As can be observed, approximately one-third of the cases displayed large terminal deletions or recombinations involving most or all of the whole chromosome 16 q arm (Fig. 2). The remaining two-thirds of LOH appeared to be the result of mostly interstitial deletions or more complex recombination events. By overlapping the LOH pattern of the various tumors, we could determine that the region between markers *D16S515* and *D16S504* (box in Fig. 2) was the most commonly affected area. Fig. 3 shows representative autoradiographs demonstrating allelic losses in tumor-derived DNA between 16q21 and 16q24. Clear patterns of allelic losses, as shown, were observed throughout the experiment.

Table 1 summarizes the information gathered on the 22 loci studied. Loci are displayed in linear order according to the integrated chromosome 16 physical and genetic map (14). Three distinct regions were observed to have a very high percentage (~70% or above) of allelic losses among informative DCIS samples. The main region extended approximately from 16q23.1 to 16q24.1, which spans the area including markers *D16S515* (57% frequency of LOH), *D16S518* with losses in 20 of 26 informative DCIS samples (77%), *D16S516* (67%), and *D16S504* (75%). The two other areas of high LOH were 16q24.2, including the *D16S402* locus with a 74% LOH (14 of 19 informative cases), and 16q21, including *D16S400* (64% LOH; 7 of 11 informative cases). Other loci in the p arm and in the q arm more proximal to the centromere showed a much lower frequency of involvement.

As indicated, *D16S518* was the most commonly affected locus in the chromosome 16q arm. To estimate the approximate physical size of the region with the highest frequency of overlapping deletion, the region of interest was compared with a partial YAC contig that reportedly spans this area (Fig. 4; Ref. 14). We confirmed the location of the microsatellite markers *D16S518*, *D16S516*, and *D16S504* to YAC clones 933h2 and 972d3 as shown. This area appears to span approximately 2–3 Mb, and is very likely located within chromosome bands 16q23.3–q24.1.

Discussion

DCIS was always suspected to be the most probable precursor to invasive carcinoma (3). Page and Dupont (3) found a greatly increased risk of subsequent invasive breast cancer in women with a history of DCIS positive biopsy. Recently, several laboratories have provided molecular evidence that further substantiates the model of progression from DCIS to invasive breast cancer (15–17). Nevertheless, we still know very little about the role of specific genetic abnormalities at preinvasive stages of breast cancer development. We have recently demonstrated that specific chromosome arms are more frequently affected by allelic losses at the DCIS stage (6). On the basis of these results, we postulated that these genetic alterations in DCIS are early events and may play an important role in the genesis of invasive breast cancer. In that study, we observed that marker *D16S413* located on telomeric band 16q24.3 was significantly affected by allelic losses when compared with other loci. This prompted us to extend our analysis on the q arm of chromosome 16 by generating a high-resolution allelotyping of this chromosome arm.

Chromosome 16q has been suggested as a site for the occurrence of primary cytogenetic structural abnormalities in the development of breast cancer (18, 19). In particular, 16q was shown to participate systematically in nonrandom translocations with chromosome 1 and to have frequent deletions (2). Furthermore, breast cancer allelotypic studies have systematically shown the common occurrence of allelic losses affecting the chromosome 16q arm. In addition to our observations (6), other investigators have also reported the occurrence of frequent allelic losses affecting chromosome 16q in DCIS (9, 20).

It has been suggested that more than one putative tumor suppressor locus of interest in breast cancer may reside in 16q. At least two regions of chromosome 16q have been reported previously to have consistent LOH: 16q21 and 16q24.2–qter (2, 8–10). Here, we report that 31 of 35 DCIS tumors (89%) showed allelic losses in one or more loci of the long arm of chromosome 16. This is a very high incidence when compared with approximately 50% or lower frequency of LOH seen in other studies of invasive breast carcinomas (8–10). We can




Fig. 3. Representative autoradiographs demonstrating LOH and allelic imbalance at various chromosome 16q loci as indicated. *N*, normal tissue; *T*, tumor (DCIS) tissue.

explain this difference by our use of very precise tissue microdissection in our study, which improved the separation of tumor DNA from normal stromal contaminants. This is particularly important when dealing with small islands of tumor cells such as in DCIS. In addition, in our study we used highly polymorphic microsatellite markers that provide a high number of informative samples.

In our analysis of DCIS lesions, we identified three distinct regions with a very high percentage (~70% or above) of allelic losses among informative DCIS samples. Two of them agree with previously described areas: 16q21 at locus *D16S400* and 16q24.2 at locus *D16S402*. However, the region with the highest incidence of LOH observed in our study spanned the region between markers *D16S515* and *D16S504* (see Table 1). Within this region, the *D16S518* locus was the most frequently affected, with 20 of 26 DCIS tumors (77%) at this site showing LOH.

These observations strongly suggest that a putative tumor suppressor

gene or genes may be harbored at or near this locus. Furthermore, the incidence of allelic loss at *D16S518* could potentially be higher, because a few tumors that preserved heterozygosity at this locus also showed losses of flanking markers (e.g., tumors 58 and 102). This could be due to homozygous deletions affecting this region, changes that are very difficult to judge because of the nature of the PCR-mediated approach we used.

On the basis of a partial YAC contig reported to span the region of interest (14), we were able to estimate that the minimum region with the highest frequency of LOH is no larger than 2–3 Mb (Fig. 4). Furthermore, based on the cytogenetic location of markers *D16S516* and *D16S504* and the distance to *D16S518*, this area should be contained within bands 16q23.3–q24.1. This region appears different from another more distal area of frequent LOH at locus *D16S402* in band 16q24.2. This observation is substantiated by the fact that both areas are 17 cM apart based on the Genethon Linkage Map (March 1996) and several megabases away based on the comprehensive chromosome 16 physical and genetic map (14).

It will be particularly important now to analyze other, less advanced hyperplastic breast lesions for the occurrence of allelic losses in the chromosome regions identified in this report. This analysis will be useful in improving our understanding of breast carcinogenesis and may help in the identification of markers with diagnostic-prognostic significance.

In summary, this study has shown that chromosome 16q is highly affected by allelic losses in breast DCIS. We refined the location of the minimal deleted region that we found most commonly affected at 16q23.3–q24.1, locus *D16S518*, a locus that to our knowledge was not reported previously. These data indicate the existence of a putative




Fig. 4. Minimum area of highest LOH and partial YAC contig spanning the region as reported by Hudson *et al.* (14). Numbers in parentheses indicate percentage of LOH at the indicated marker.

tumor suppressor gene or genes, most probably located within a 2–3-Mb region. Two other regions of interest for LOH are located at 16q24.2 and possibly at 16q21. Such a high frequency of LOH at a preinvasive stage of breast cancer suggests that a candidate tumor suppressor gene or genes at the 16q23.3–q24.1 location may play an important role in breast carcinogenesis. Further studies are necessary to identify the gene or genes of interest.

References

1. Marshall, E. Search for a killer: focus shifts from fat to hormones. *Science* (Washington DC), 259: 618–621, 1993.
2. Devilee, P., and Cornelisse, C. J. Somatic genetic changes in human breast cancer. *Biochem. Biophys. Acta*, 1198: 113–130, 1994.
3. Page, D. L., and Dupont, W. D. Anatomic markers of human premalignancy and risk of breast cancer. *Cancer* (Phila.), 66: 1326–1335, 1990.
4. Cavenee, W. K., Koufos, A., and Hansen, M. F. Recessive mutant genes predisposing to human cancer. *Mutat. Res.*, 168: 3–14, 1986.
5. Chen, T., Dhingra, K., Sahin, A., Sneige, N., Hortobagyi, G., and Aldaz, C. M. Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections. *Breast Cancer Res. Treat.*, 39: 177–185, 1996.
6. Aldaz, C. M., Chen, T., Sahin, A., Cunningham, J., and Bondy, M. Comparative allelotype of *in situ* and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. *Cancer Res.*, 55: 3976–3981, 1995.
7. Lindblom, A., Rotstein, S., Skoog, L., Nordenskjöld, M., and Larsson, C. Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases. *Cancer Res.*, 53: 3703–3711, 1993.
8. Sato, T., Tanigami, A., Yamakawa, K., Akiyama, F., Kasumi, F., Sakamoto, G., and Nakamura, Y. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. *Cancer Res.*, 50: 7184–7189, 1990.
9. Tsuda, H., Callen, D. F., Fukutomi, T., Nakamura, Y., and Hirohashi, S. Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancer irrespectively of differences in phenotype and extent of spread. *Cancer Res.*, 54: 513–517, 1994.
10. Cleton-Jansen, A. M., Moerland, E. W., Kuipers-Dijkshoorn, N. J., Callen, D. F., Sutherland, G. R., Hansen, B., Devilee, P., and Cornelisse, C. J. At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. *Genes Chromosomes & Cancer*, 9: 101–107, 1994.
11. Carter, B. S., Ewing, C. M., Ward, W. S., Treiger, B. F., Aalders, T. W., Schalken, J. K., Epstein, J. I., and Isaacs, W. B. Allelic loss of chromosomes 16q and 10q in human prostate cancer. *Proc. Natl. Acad. Sci. USA*, 87: 8751–8755, 1990.
12. Nishida, N., Fukuda, Y., Kokuryu, H., Sadamoto, T., Isowa, G., Honda, K., Yamaoka, Y., Ikenaga, M., Imura, H., and Ishizaki, K. Accumulation of allelic loss on arms of chromosomes 13q, 16q, and 17p in the advanced stages of human hepatocellular carcinoma. *Int. J. Cancer*, 51: 862–868, 1992.
13. Maw, M. A., Grundy, P. E., Millow, L. J., Eccles, M. R., Dunn, R. S., Smith, P. J., Feinberg, A. P., Law, D. J., Paterson, M. C., Telzerow, P. E., Callen, D. F., Thompson, A. D., Richards, R. I., and Reeve, A. E. A third Wilms' tumor locus on chromosome 16q. *Cancer Res.*, 52: 3094–3098, 1992.
14. Hudson, T. J., Stein, L. D., and Gerety, S. S., Ma, J., Castle, A. B., Silva, J., Slonim, D. K., Baptista, R., Kruglyak, L., Xy, S.-H., Hu, X., Colbert, A. M. E., Rosenberg, C., Reeve-Daly, M. P., Rozen, S., Hui, L., Wu, X., Vestergaard, C., Wilson, K. M., Bae, J. S., Maitra, S., Ganiatsas, S., Evans, C. A., DeAngelis, M. M., Ingalls, K. A., Nahf, R. W., Horton, L. T., Jr., Anderson, M. O., Collymore, A. J., Ye, W., Kouyoumjian, V., Zemsteva, I. S., Tam, J., Devine, R., Courtney, D. F., Renaud, M. T., Nguyen, H., O'Connor, T. J., Fizames, C., Fauré, S., Gyapay, G., Dib, C., Morissette, J., Orlin, J. B., Birren, B. W., Goodman, N., Weissenbach, J., Hawkins, T. L., Foote, S., Page, D. C., and Lander, E. S. An STS-based map of the human genome. *Science* (Washington DC), 270: 1945–1954, 1995.
15. Zhuang, Z., Merino, M. J., Chuaqui, R., Liotta, L. A., and Emmert-Buck, M. R. Identical allelic loss on chromosome 11q13 in microdissected *in situ* and invasive human breast cancer. *Cancer Res.*, 55: 467–471, 1995.
16. O'Connell, P., Pekkel, V., Fuqua, S., Osborne, C. K., and Allred, D. C. Molecular genetics studies of early breast cancer evolution. *Breast Cancer Res. Treat.*, 32: 5–12, 1994.
17. Radford, D. M., Phillips, N. J., Fair, K. L., Ritter, J. H., Holt, M., and Donis-Keller, H. Allelic loss and the progression of breast cancer. *Cancer Res.*, 55: 5180–5183, 1995.
18. Dutrillaux, B., Gerbault-Seureau, M., and Zafrani, B. Characterization of chromosomal anomalies in human breast cancer: comparison of 30 paradiplod cases with few chromosome changes. *Cancer Genet. Cytogenet.*, 49: 203–217, 1990.
19. Pandis, N., Heim, S., Bardi, G., Idvall, I., Mandahl, N., and Mitelman, F. Whole-arm t(1;16) and i(1q) as sole anomalies identify gain of 1q as a primary chromosomal abnormality in breast cancer. *Genes Chromosomes & Cancer*, 5: 235–238, 1992.
20. Radford, D. M., Fair, K. L., Phillips, N. J., Ritter, J. H., Steinbrueck, T., Holt, M. S., and Donis-Keller, H. Allelotyping of ductal carcinoma *in situ* of the breast: deletion of loci on 8p, 13q, 16q, 17p, and 17q. *Cancer Res.*, 55: 3399–3405, 1995.

Advances in Brief

Analysis of Telomerase Activity Levels in Breast Cancer: Positive Detection at the *in Situ* Breast Carcinoma Stage¹

Andrzej K. Bednarek, Aysegül Sahin,
Andrew J. Brenner, Dennis A. Johnston,
and C. Marcelo Aldaz²

Department of Carcinogenesis, University of Texas M. D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas 78957 [A. K. B., A. J. B., C. M. A.], and Departments of Pathology [A. S.] and Biomathematics [D. A. J.], University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Abstract

Telomerase activity has been implicated to be associated with most human malignant tumors, including breast cancer. To evaluate possible associations with well-known prognostic factors in breast cancer, we performed a semi-quantitative analysis of telomerase activity levels using the very sensitive PCR-mediated telomeric repeat amplification protocol. Telomerase activity was detected in 99 of 104 breast cancer samples analyzed (95.2%), whereas no activity was detected in 10 of 10 adjacent nonmalignant breast tissues. Analysis of five breast fibroadenoma samples revealed telomerase activity in one (20%). In contrast to previous observations, we observed that 100% of stage I breast tumors were positive for telomerase activity. More interestingly, we detected telomerase activity in six of six ductal carcinoma *in situ* samples (*i.e.*, stage 0). In our semiquantitative analysis of levels of enzymatic activity, we found no statistically significant correlation at the $P < 0.05$ level between telomerase levels and lymph node metastasis status, estrogen and progesterone receptor status, tumor size, S-phase fraction, and ploidy. The only statistically significant correlation was found with patient age ($\rho = -0.3$; $P = 0.03$). We observed no statistically significant difference in the telomerase activity levels of early tumors (stages 0 and I) versus more advanced lesions (stages II to IV). Nevertheless, stage IV tumors displayed a tendency for higher telomerase activity levels. In summary, no clear association was observed between telomerase levels and known breast cancer prognostic indicators. However, telomerase detection by the telomeric repeat amplification protocol method, due to its high sensitivity, may be of value in early breast cancer diagnosis and detection, because our data indicate that

telomerase reactivation appears to constitute a relatively early event in breast carcinogenesis.

Introduction

The specialized synthesis of telomeric repeats, TTAGGG in vertebrates, was demonstrated to be performed by the ribonucleoprotein telomerase using its RNA component as a template (1-3). It has been postulated that telomerase activity is associated with acquisition of an immortal phenotype *in vitro*, and it was shown that most immortal cell lines express this enzyme (reviewed in Ref. 4). Using a very sensitive PCR-based TRAP assay,³ it has been demonstrated that most human adult somatic tissues do not show evidence of active telomerase (5). Activity of this enzyme, however, has been observed in germline cells, bone marrow, activated peripheral blood lymphocytes, and possibly stem cells (reviewed in Ref. 4). Interestingly, telomerase activity was detected in numerous human cancer types, suggesting that tumor cells may need reactivation of this enzyme to remain viable (4, 6-14).

Breast cancer is one of the tumor types in which telomerase activity has been demonstrated (12). Furthermore, it has been suggested recently that telomerase detection could have prognostic implications in breast cancer (5, 12). Exactly when in the process of breast carcinogenesis reactivation of telomerase occurs remains to be determined.

Although numerous somatic mutations affecting various genes have been described in sporadic breast cancer, it still remains to be determined which anomalies could be considered causative of breast carcinogenesis. Certain specific aberrations, such as ERBB2 or EGFR amplification and overexpression and P53 mutation, have been postulated and explored as of possible aid in determining breast cancer prognosis (15-18).

In this report, we analyze possible associations of telomerase with well-known prognostic factors in breast cancer to further evaluate whether telomerase detection and quantification could have potential impact on breast cancer prognosis.

Materials and Methods

Unselected breast cancer samples were obtained from the Cooperative Human Tissue Network (about one-half of the samples) and from the Department of Pathology, University of Texas M. D. Anderson Cancer Center. Breast cancer samples and adjacent nonmalignant breast tissues were obtained from 104 patients, frozen, and stored at -80°C until use. We also analyzed a group of five breast fibroadenomas obtained from Cooperative Human Tissue Network. For most of the breast cancer samples, information about estrogen and progesterone

Received 7/10/96; revised 10/9/96; accepted 10/23/96.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported in part by Department of Defense Breast Cancer U. S. Army Grant DAMD17-94-J-4078 (to C. M. A.).

² To whom requests for reprints should be addressed. Phone: (512) 237-2403; Fax: (512) 237-2475.

³ The abbreviations used are: TRAP, telomeric repeat amplification protocol; ITAS, internal telomerase assay standard; DCIS, ductal carcinoma *in situ*.

receptor status, lymph node metastasis status, S-phase, ploidy, tumor stage, and age of patients were available. Tumor staging was performed according to the guidelines of the American Joint Committee on Cancer (19).

The TRAP assay allows the detection of *in vitro* telomerase products (5, 20). We used a modified version of this assay. In brief, telomerase adds TTAGGG repeats to the 3' end of TS primer (5'-AATCCGTCGAGCAGAGTT-3'; Refs. 5 and 21). The number and amount of the repeats added is dependent upon telomerase activity. In a second step, telomerase products are amplified using the CX primer (5'-CCCTTACCCTTACCCTTACCCTAA-3') and Taq DNA polymerase. As positive control, a cell extract from a sample with known telomerase activity (a rat mammary tumor line) was used. As negative control, lysis buffer was substituted for cell extract (20). To compare the level of telomerase activity in different tumor samples, we used a semiquantitative analysis based on the use of an internal standard (ITAS), which amplifies from the same primers (22). This internal standard, which consists of a 150-bp DNA product, allows identification of false-negative tumor samples that could contain Taq polymerase inhibitors.

Cell extracts were obtained from 10–50-mg samples of the tumors, and telomerase assay was performed according to a method described previously (5, 20), with minor modifications (22, 23). In a standard procedure, we used 2 μ l of tissue extract (protein concentration, 0.5 μ g/ μ l) per assay. The CX primer, ITAS, and Taq DNA polymerase (7 units/assay) were added to each sample at a "hot start" after 5 min incubation at 90°C. Because telomerase has an RNA component, 5 μ l of the tumor cell extract from the same samples and the positive cell extract were incubated with 1 μ l of RNase A (1 mg/ml) as an additional experimental control.

Aliquots (10 μ l) of the PCR mixture were analyzed on 8% nondenaturing, 0.4-mm acrylamide gels (20 \times 40 cm) run in 0.5 \times TBE buffer until the xylene cyanol had migrated 17 cm from the origin. The gels were then dried and exposed for 20 h to hyperfilm MP films (Amersham Corp., Arlington Heights, IL). Following autoradiography, each gel was analyzed after overnight exposure using a Molecular Dynamics PhosphorImager (Sunnyvale, CA). This scan was used to perform the measurements of the telomerase ladder amplification intensity. Thus, area integration of all peaks (except the first band from the bottom) were normalized to the signal from the internal standard and then, after background subtraction, expressed as relative to the positive control signal that was run with each experiment. The first band from the bottom was not included, because it usually incorporates background from primer-dimer formation (8, 13). The method described is only semiquantitative, but it is sufficient for the comparative analysis of the tumors relative to the same positive-control cell extract.

Analysis of the levels of telomerase activity and other clinico-pathological characteristics was performed using non-parametric Spearman rank correlation and *t* test.

Results and Discussion

To confirm the linearity of the TRAP assay, we performed a dilution experiment of the telomerase-positive breast cancer cell line MDA-MB-157 (Fig. 1). The activity of the telomerase




Fig. 1 Quantification of telomerase activity from breast cancer cell line MDA-MB-157. The activity level was calculated by summation of integrated areas of the telomerase ladder and normalized to internal standard (ITAS). After background subtraction, levels were expressed as relative to a 100-cell equivalent sample. The solid line was computer fitted according to a calculated algorithm.

ladder was normalized to that of the internal standard (ITAS; Ref. 22), expressing the results relative to the activity found in the 100-cell equivalent sample. Linearity of activity with cell number was observed (Fig. 1), in agreement with observations published previously (22).

Telomerase activity was then analyzed and detected in 99 of the 104 breast cancer samples (95%). It was undetectable in 10 of 10 adjacent nonmalignant breast samples (Fig. 2). As expected, the enzymatic activity detected is abolished if samples are pretreated with RNase A (Fig. 2).

Interestingly, we detected telomerase activity in six of six DCIS samples analyzed (Fig. 3A; stage 0 in Fig. 4A). Four of these DCIS samples were classified as high nuclear grade and showed high telomerase activity, whereas the two samples classified as low nuclear grade showed very weak telomerase activity (Fig. 3A). These findings suggest that the reactivation of telomerase activity occurs relative early in breast carcinogenesis. We also analyzed a small group of breast fibroadenomas for telomerase activity and observed one positive tumor of five tested (20%).

Several clinical, histological, and biological indicators of prognosis are commonly used to determine the therapeutic management of breast cancer patients. Marker combinations are usually more accurate than single markers (18, 24). A major goal of our study was to evaluate the role of telomerase detection as a possible additional prognostic indicator. Our overall incidence of telomerase-positive breast cancer samples (95.2%) is similar to that reported previously by Hiyama *et al.* (Ref. 12; 93%). However, whereas Hiyama *et al.* (12) found 68% of stage I breast carcinomas to be positive for telomerase activity, we found 100% of the 17 stage I breast carcinomas to be positive. The few tumors negative for telomerase activity were found to be advanced-stage (II and III) rather than early-stage tumors, as can be observed in Fig. 4A, in which breast cancer samples are grouped by tumor stage. Furthermore, we did not find any correlation between the very few tumors (five samples) found to

Fig. 2 TRAP assay from human breast cancers (T) and matching adjacent nonmalignant tissues (N) with internal standard (ITAS). To show assay specificity, tumor samples were RNase A pretreated (+RNase A).





Fig. 3 Detection of telomerase activity in human breast cancers. A, telomerase activity in DCIS (LG, low nuclear grade; HG, high nuclear grade). B, activity in lymph node metastasis negative (LN-) and positive (LN+) tumors. Note that lymph node-negative tumors have the same activity levels as lymph node-positive tumors (ITAS, internal standard).



be negative for telomerase activity and any of the known prognostic indicators.

In our semiquantitative analysis of levels of enzymatic activity, we found no statistically significant correlation at the $P < 0.05$ level between telomerase levels and tumor size, lymph node metastasis, estrogen and progesterone receptor status, S-phase fraction, and ploidy, (Fig. 4 and Table 1). Axillary lymph node status is generally accepted as one of the

best prognostic indicators for breast cancer recurrence (24). We observed as much telomerase activity in lymph node-negative tumors as in tumors positive for lymph node metastasis (Fig. 4E). Interestingly, we only found statistically significant correlation with patient age (Fig. 4C; Table 1). It appears that levels of telomerase activity are higher in tumors from younger patients. However, although $P = 0.03$, the Spearman rank correlation analysis indicates that since the




Fig. 4 Comparison of relative telomerase activity levels to prognostic indicators in breast cancer.

rho value is -0.3 (Table 1); approximately only 9% of the variability in telomerase levels is explained by age. As mentioned earlier, we observed that all stage 0 and stage I tumors express telomerase activity. We did not observe a statistically

significant difference in telomerase activity levels of early tumors (stages 0 and I) versus more advanced lesions (Fig. 4A and Table 1). However, as can be observed in Fig. 4A and Table 1, stage IV tumors appear to show a tendency for

Table 1 Statistical analysis of telomerase activity levels

	Age	Ploidy	Size	S-phase
rho (Spearman rank correlation)	-0.3	0.02	0.06	0.1
P	0.03	0.88	0.56	0.39
Comparison of breast tumor status ^a				P(t-test)
ER+ (318 ± 67) versus ER- (333 ± 91)				0.9
PR+ (276 ± 60) versus PR- (405 ± 101)				0.2
ER+/PR+ (277 ± 68) versus ER-/PR- (345 ± 111)				0.6
LN+ (319 ± 49) versus LN- (371 ± 113)				0.7
Stages 0 and I (249 ± 52) versus II-IV (367 ± 70)				0.4
Stages 0-IIIb (290 ± 45) versus IV (1083 ± 623)				0.001

^a ER+ and ER-, estrogen receptor positive and negative, respectively; PR+ and PR-, progesterone positive and negative, respectively; LN, lymph node. Values in parentheses represent mean ± SE. The analysis was performed using StatView 4.0 (Abacus Concepts).

higher telomerase levels. The small number of stage IV tumors precludes further speculation on this observation.

Although patient follow-up was not analyzed in our study, the lack of a clear association between telomerase activity levels and proven prognostic indicators in breast cancer indicates that analysis of the levels of this enzyme by means of the PCR-mediated TRAP assay in human breast cancer may have limited value as a prognostic tool. This appears in contrast to preliminary observations by another laboratory (25). It is unclear at this point whether the hypothesis that a worse prognosis should correlate with higher telomerase levels is incorrect, or alternatively that the lack of correlation observed is the result of the methodological approach. It is then possible that future development of non-PCR-mediated methodologies for measurement of telomerase activity may be better suited for studies of prognosis. On the other hand, because we detected telomerase activity at preinvasive stages of breast cancer, the highly sensitive TRAP assay may be of value in early breast cancer detection and diagnosis, as recently suggested by Hiyama *et al.* (26). Our findings are in agreement with observations of other neoplasias in which telomerase activity was detected at preinvasive stages of tumor development (13, 14). For instance, telomerase activity has been demonstrated in premalignant prostatic hyperplasias (13), and recently telomerase activity has been also observed in colon adenomas (14). We have also reported a significant increase in telomerase activity at premalignant stages using a mouse multistage carcinogenesis model (23).

As mentioned previously, we also observed that one of five breast fibroadenomas analyzed showed telomerase activity. This incidence appears lower than that reported previously (45%; Ref. 12). Despite the difference in incidence, both studies indicate that some breast fibroadenomas show reactivation of telomerase. It is unclear at this point the putative role for telomerase reactivation in this benign neoplasia.

In summary, telomerase activity was observed in almost all breast cancer samples, regardless of tumor stage. No telomerase activity was detected in the normal breast samples tested, and telomerase activity was detected in 20% of fibroadenomas. No correlation was found between telomerase detection or level of activity and known breast cancer prognostic indicators, which appears to limit the potential value of evaluating the level of this putative biomarker in managing patients with invasive breast cancer. Nevertheless, the final conclusion on this issue will only

be resolved after considering the correlation between patient outcome and telomerase levels. Probably the most important conclusion from our study is that telomerase reactivation appears to be an early event in breast carcinogenesis. This factor highlights the potential for using telomerase detection as a possible aid in early tumor detection.

Acknowledgments

We thank Dr. Jerry Shay for the ITAS standard samples.

Note Added in Proof

While this manuscript was being reviewed, Sugino *et al.* reported similar conclusions on the potential value of telomerase detection as an early diagnostic marker in breast cancer rather than as a prognostic indicator (Sugino, T., Yoshida, K., Bolodeoku, J., Tahara, H., Buley, I., Manek, S., Wells, C., Goodison, S., Ide, T., Suzuki, T., Tahara, E., and Tarin, D. Telomerase activity in human breast cancer and benign breast lesions: diagnostic applications in clinical specimens, including fine needle aspirates. *Int. J. Cancer*, 69: 301-306, 1996).

References

- Greider, C. W., and Blackburn, E. H. The telomere terminal transferase of tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. *Cell*, 51: 887-898, 1987.
- Morin, G. B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. *Cell*, 59: 521-529, 1989.
- Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Ailion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., Le, S., West, M. D., Harley, C. B., Andrews, W. H., Greider, C. W., and Villeponteau, B. The RNA component of human telomerase. *Science* (Washington DC), 269: 1236-1241, 1995.
- Holt, S. E., Shay, J. W., and Wright, W. E. Refining the telomere-telomerase hypothesis of aging and cancer. *Nat. Biotechnol.*, 14: 836-839, 1996.
- Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. Specific association of human telomerase activity with immortal cells and cancer. *Science* (Washington DC), 266: 2011-2015, 1994.
- Counter, C. M., Hirte, H. W., Bacchetti, S., and Harley, C. B. Telomerase activity in human ovarian carcinoma. *Proc. Natl. Acad. Sci. USA*, 91: 2900-2904, 1994.
- Hiyama, E., Yokoyama, T., Tatsumoto, N., Hiyama, K., Imamura, Y., Murakami, Y., Kodama, T., Piatyszek, M. A., Shay, J. W., and

- Matsuura, Y. Telomerase activity in gastric cancer. *Cancer Res.*, 55: 3258–3262, 1995.
8. Chadeneau, C., Hay, K., Hirte, H. W., Gallinger, S., and Bacchetti, S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. *Cancer Res.*, 55: 2533–2536, 1995.
9. Hiyama, E., Hiyama, K., Yokoyama, T., Matsuura, Y., Piatyszek, M. A., and Shay, J. W. Correlating telomerase activity levels with human neuroblastoma outcomes. *Nat. Med.*, 1: 249–257, 1995.
10. Hiyama, K., Hiyama, E., Ishioka, S., Yamakido, M., Inai, K., Gazdar, A. F., Piatyszek, M. A., and Shay, J. W. Telomerase activity in small-cell and non-small-cell lung cancers. *J. Natl. Cancer Inst.*, 87: 859–902, 1995.
11. Avilion, A. A., Piatyszek, M. A., Gupta, J., Shay, J. W., Bacchetti, S., and Greider, C. W. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. *Cancer Res.*, 56: 645–650, 1996.
12. Hiyama, E., Gollahon, L., Kataoka, T., Kuroi, K., Yokoyama, T., Gazdar, A. F., Hiyama, K., Piatyszek, M. A., and Shay, J. W. Telomerase activity in human breast tumors. *J. Natl. Cancer Inst.*, 88: 116–122, 1996.
13. Sommerfeld, H.-J., Meeker, A. K., Piatyszek, M. A., Bova, G. S., and Shay, J. W. Telomerase activity: a prevalent marker of malignant human prostate tissue. *Cancer Res.*, 56: 218–222, 1996.
14. Tahara, H., Endo, H., Maeda, S., Nakanishi, T., Nagai, N., Ide, T., and Tahara, E. Telomerase activity in various precancerous and cancer tissues. *Proc. Am. Assoc. Cancer Res.*, 37: 559, 1996.
15. Caleffi, M., Teague, M. W., Jensen, R. A., Vnencak-Jones, C. L., Dupont, W. D., and Parl, F. F. *p53* gene mutations and steroid receptor status in breast cancer. *Cancer (Phila.)*, 73: 2147–2156, 1994.
16. Ravdin, P. M., and Chamness, G. C. The *c-erbB-2* proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers—a review. *Gene (Amst.)*, 159: 19–27, 1995.
17. Nakopoulou, L. L., and Alexiadou, A. Prognostic significance of the co-expression of *p53* and *c-erbB-2* proteins in breast cancer. *J. Pathol.*, 179: 31–38, 1996.
18. Scholl, S., Bieche, I., Pallud, C., Champeme, M. H., Beuvon, F., and Hacene, K. Relevance of multiple biological parameters in breast cancer prognosis. *Breast*, 5: 21–30, 1996.
19. Beahrs, O. H., Henson, D. E., Hutter, R. V. P., and Kennedy, B. J. (eds.). American Joint Committee on Cancer. Manual for Staging of Cancer, Ed. 4. Philadelphia: J. B. Lippincott Co., 1992.
20. Piatyszek, M. A., Kim, N. W., Weinrich, S. L., Hiyama, K., Hiyama, E., Wright, W. E., and Shay, J. W. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). *Methods Cell Sci.*, 17: 1–15, 1995.
21. Morin, G. B. Recognition of a chromosome truncation site associated with α -thalassaemia by human telomerase. *Nature (Lond.)* 353: 454–456, 1991.
22. Wright, W. E., Shay, J. W., and Piatyszek, M. A. Modifications of a telomeric repeat amplification protocol (TRAP) results in increased reliability, linearity and sensitivity. *Nucleic Acids Res.*, 23: 3794–3795, 1995.
23. Bednarek, A., Budunova, I., Slaga, T. J., and Aldaz, C. M. Increased telomerase activity in mouse skin premalignant progression. *Cancer Res.*, 55: 4566–4569, 1995.
24. Donegan, W. L. Prognostic factors: stage and receptor status in breast cancer. *Cancer (Phila.) (Suppl.)*, 70: 1755–1764, 1992.
25. Kim, N. W., Levitt, D., Huang, G., Wu, F., Osborne, K., and Clark, G. Correlation of telomerase with prognostic indicators of breast cancer. *Proc. Am. Assoc. Cancer Res.*, 37: 562, 1996.
26. Hiyama, E., Gollahon, L., Kataoka, T., Kuroi, K., Yokoyama, T., Gazdar, A. F., Hiyama, K., Piatyszek, M. A., and Shay, J. W. Telomerase activity in human breast tumors. *J. Natl. Cancer Inst.*, 88: 839–840, 1996.

**PROGRESS IN CLINICAL
AND BIOLOGICAL RESEARCH
VOLUME 396**

**ETIOLOGY OF BREAST
AND GYNECOLOGICAL
CANCERS**

Editors: C. Marcelo Aldaz
Michael N. Gould
John McLachlan
Thomas J. Slaga

 **WILEY-LISS**

ETIOLOGY OF BREAST AND GYNECOLOGICAL CANCERS

Proceedings of the Ninth International Conference on Carcinogenesis and Risk
Assessment, Held in Austin, Texas, November 29 – December 2, 1995

Editors

C. Marcelo Aldaz

University of Texas
M.D. Anderson Cancer Center
Science Park - Research Division
Smithville, Texas

Michael N. Gould

Comprehensive Cancer Center
University of Wisconsin
Madison, Wisconsin

John McLachlan

Department of Pharmacology
Center for Bioenvironmental Research
Tulane University
New Orleans, Louisiana

Thomas J. Slaga

University of Texas
M.D. Anderson Cancer Center
Science Park - Research Division
Smithville, Texas



WILEY-LISS

A JOHN WILEY & SONS, INC., PUBLICATION
New York • Chichester • Weinheim • Brisbane • Singapore • Toronto

THE GENETICS OF SPORADIC BREAST CANCER

Andrew J. Brenner and C. Marcelo Aldaz

Department of Carcinogenesis, University of Texas M.D. Anderson Cancer
Center, Science Park-Research Division, Smithville, Texas 78957

INTRODUCTION

Breast cancer which affects as many as one in eight women, is the most common malignancy of women in the industrialized countries of the Western hemisphere (Feuer, 1993; Boring, 1994). To expedite the development of new treatment strategies, increased emphasis has been placed on understanding the cellular and molecular events that lead to malignancies of the breast. Over the past few years, numerous advances have been made in the elucidation and characterization of genes whose mutation predisposes individuals to risk of developing familial breast cancer. These genes include the recently cloned *BRCA1* and *BRCA2* (Miki et al., 1994; Wooster et al., 1995). However, while these genes have been shown to be frequently affected in inheritable forms of breast cancer, there is yet no conclusive evidence to suggest that these genes are also responsible for sporadic breast cancer which accounts for approximately 90% of breast cancer cases. To provide insight into the aberrations responsible for the genesis of sporadic breast cancer, ongoing work is attempting to identify genomic regions frequently affected. In this chapter, we will focus on the known somatic genetic aberrations of sporadic breast cancer.

CYTOGENETICS OF BREAST CANCER

Numerous attempts have been made toward characterization of aberrations at the chromosomal level in breast cancer. However, as is the case with other solid tumors of epithelial origin, it has been difficult to discern any characteristic primary cytogenetic changes among the large number of apparently random alterations. This is due to the inherent difficulties in obtaining high-quality metaphases from solid tumors as well as their characteristic clonal heterogeneity. In addition, of the tumors that have been karyotyped, the vast majority are of the more advanced invasive stages, since the less advanced "in situ" carcinomas tend to be much smaller, thereby making it even more difficult to obtain high-quality metaphase cells. Nevertheless, several genetic changes with a relatively higher prevalence have been identified. Overall, the most frequent tend to be numerical alterations

of whole chromosome copy number including trisomies of 7 and 18 and monosomies of 6, 8, 11, 13, 16, 17, 22, and X (reviewed by Devilee and Cornelisse, 1994). The most common aberrations in near-diploid tumors without metastases are loss of chromosomes 17 and 19, trisomy of chromosome 7, and overrepresentation of 1q, 3q, and 6p (Thompson et al., 1993). Structural alterations include terminal deletions and unbalanced nonreciprocal translocations, most frequently involving chromosomes 1, 6, and 16q. Breakpoints of structural abnormalities cluster to several segments, including 1p22-q11, 3p11, 6p11-13, 7p11-q11, 8p11-q11, 16q, and 19q13 (Thompson et al., 1993). Tumors from patients with metastatic breast carcinoma display a different pattern of abnormalities with structural alterations and numerous numerical alterations affecting various chromosomes (Trent et al., 1993).

A recently developed technique, comparative genomic hybridization (CGH), allows analyses of chromosome copy number abnormalities involving segments of at least 10 Mb (Kallioniemi et al., 1992A). Since CGH involves hybridizing differentially labeled genomic DNA from a tumor and a normal cell population to the same normal metaphase, it circumvents some of the difficulties encountered in conventional karyotyping. Through such analyses, nearly every tumor analyzed revealed increased or decreased DNA sequence copy number (Kallioniemi et al., 1994). The most common regions of increased copy number in breast cancer as determined by CGH include 1q, 8q, 17q22-24, and 20q13. Increased copy number at 17q was previously determined through gene fluorescence *in situ* hybridization (FISH) analysis to be 50 to 100-fold amplification of *ERBB2* (Kallioniemi et al., 1992B), a gene known to be overexpressed and amplified in a considerable percentage of breast cancers. Amplifications at region 8q would analogously be *MYC*, another gene known to be overexpressed in some breast cancers (Shiu, Watson, and Dubik, 1993). No candidate gene has yet been identified for region 20q13 amplification. Regions of decreased DNA copy number were also observed and include 3p, 6q, 8p, 11p, 12q, 13q, and 17p (Gray et al., 1994). For some of these regional losses, candidate genes exist that may be the target of deletion in the progression to a malignant phenotype (Table 1). More specifically, both *RB1* (13q) and *TP53* (17p) have been shown extensively to undergo deletion in a significant fraction of breast cancers (Cox, Chen, and Lee, 1994). Interestingly, when both loss and gain of DNA copy number as determined by CGH were compared with survival data in a series of node negative breast tumors, only copy number losses were significant for recurrence and for overall survival (Isola et al., 1995). However, as is the case with conventional cytogenetics, CGH has yet to reveal any characteristic abnormalities that occur in the majority of breast tumors and which abnormalities if any, could be considered "primary".

ONCOGENES

The proto-oncogenes encode proteins involved in a cascade of events leading to growth in response to mitogenic factors. Alteration in the normal function of proto-oncogenes, through mutation or increased expression can result in a constant growth stimulus and a constitutive mitogenic response. Aberration of a single allele of an oncogene can be sufficient to lead to altered signal and as such is dominant. In human solid tumors, the most common aberration affecting oncogenes appears to be gene amplification.

Genetic Region	Cytogenetic ¹ Finding	CGH ² Finding	Invasive ³ LOH (%)	DCIS ³ LOH (%)	Possible Targets
1p	-1p		32	8	
1q	+1q	+1q	30	16	
3p		-3p	22	0	
3q			25	0	
4p	-4p		2 ¹	0 [†]	
5p			18 ¹	0 [†]	
5q			13 ¹	0 [†]	
6p	-6	+6p	30	0	
6q	-6, -6q	-6q, +6q	26	8	
7p	+7	+7p	32	32	
7q	+7		25	24	
8p	-8, -8p	-8p	18	10	
8q	-8, +8q	+8q	20	22	<i>MYC</i>
9p	-9p		58	30	<i>p16^{INK4a}</i>
9q			24 ¹	0 [†]	
10p			11 ¹	0 [†]	
10q			15 ¹	0 [†]	
11p	-11, -11p	-11p	28	0	
11q	-11, -11q	+11q	30	12	<i>CCND1</i>
12p			8 ¹	0 [†]	
12q		+12q	4 ¹	0 [†]	
13q	-13	-13q	30	18	<i>RB1, BRCA2, Brush</i>
16p	-16		40	0	
16q	-16, -16q		48	27	<i>CDH1?</i>
17p	-17, -17p	-17p	57	33	<i>TP53</i>
17q	-17	+17q	36	31	<i>BRCA1, NME1, ERBB2</i>
18p			25	0	
18q			48	12	
19p			18 ¹	0 [†]	
19q		+19q	14 ¹	0 [†]	
20q		+20q13	17 ¹	6 [†]	
21q			17 ¹	5 [†]	
22q	-22		36	0	
Xp	-X		22 ¹		
Xq	-X		8 ¹		

Table 1. Summary of genetic aberrations affecting sporadic breast cancer (¹ Devilee and Cornelisse [1994], Thompson et. al. [1993]; ² Gray et. al. [1994]; ³ Aldaz et. al. [1995]; [†] Radford et. al. [1995]).

Current data suggests of the numerous oncogenes described to date, that only a few may have a role in breast tumorigenesis. Of these, *ERBB2* remains the oncogene most studied in breast cancer. Also known as *HER2* or *neu*, *ERBB2* encodes a tyrosine kinase growth factor receptor with high homology to epidermal growth factor receptor (43% in the extracellular domain and 82% in the tyrosine kinase domain; Coussens et al., 1985; Jardines et al., 1993). However, while these two receptors share homology, their ligand specificity is distinct since neither epidermal growth factor nor transforming growth factor- α bind *ERBB2*. Activation or overexpression of *ERBB2* in transgenic mice results in the genesis of mammary tumors (Brouhard et al., 1989; Muller et al., 1988). As mentioned previously, FISH analysis has shown that *ERBB2* is amplified. Prior analysis by other means had shown amplification of *ERBB2* in 25-30% of breast cancers with concomitant overexpression, implicating its involvement in breast tumorigenesis (Berger et al., 1988; Zhou et al., 1987). Early studies reported a prognostic value of *ERBB2* overexpression in node-negative breast cancer. However, more recent studies using larger data sets do not support these early observations and question the prognostic role for *ERBB2* expression in node-positive breast cancer. Expression of *ERBB2* may have value in predicting response to specific therapies, but additional studies are needed to confirm these preliminary findings (reviewed by Ravdin and Chamness, 1995).

Similar to *ERBB2*, the *MYC* gene has been shown to be amplified in approximately 25% of breast carcinomas. Although the functions of *Myc* are not yet clearly understood, *c-Myc* has been shown to heterodimerize with Max (*c-Myc*-associated protein X), positively and negatively regulating the expression of various genes in apoptosis and cell cycle progression (Ryan and Birnie, 1996). Overexpression of *c-Myc* in transgenic mice results in mammary tumors (Muller et al., 1988), and amplification of *c-Myc* has been associated with high grade tumors in humans (Varley et al., 1987). However, when lymph node metastases from patients whose primary tumor showed amplification are examined, the metastatic cells do not show amplification, suggesting that amplification occurs before invasion and is not a prerequisite for a metastatic phenotype (Shiu et al., 1993). Of additional interest, *c-Myc* expression is modulated by the presence of estrogen in estrogen-responsive cell lines, and constitutively high *c-Myc* expression is observed in hormone-dependent lines, probably because of increased stability of the transcript (Shiu et al., 1993).

Chromosome region 11q13 has also been reported to be amplified in 15-20% of breast cancers (Lammie and Peters, 1991). The cyclin D1 (*CCND1*) gene, located in the region, is thought to be the target of such amplification. Cyclin D1 is a direct regulator of the cell cycle and is overexpressed in 45% of breast carcinomas, most of which are both estrogen and progesterone receptor positive (Gillet et al., 1994; Bartkova et al., 1994). Studies show that transgenic mice homozygously null for *CCND1* fail to undergo proliferative changes of the mammary epithelium associated with pregnancy, thereby indicating a role for *CCND1* in steroid-induced proliferation of the mammary epithelium (Sicinski et al., 1995). Transgenic mice overexpressing *CCND1* have been shown to develop mammary carcinomas (Wang et al., 1994). Analysis of *CCND1* expression by mRNA *in situ* hybridization has shown a dramatic increase of *CCND1* expression in 76% of low grade carcinoma *in situ*, further suggesting a role for *CCND1* in the tumorigenesis of the breast (Weinstat-Saslow et al., 1995).

TUMOR SUPPRESSORS AND LOSS OF HETEROZYGOSITY

Although the first tumor suppressor gene, *RBI*, was not identified until 1987, the existence of a genetic element with growth suppressive properties had been shown nearly two decades earlier. When Harris et al. fused normal mouse fibroblasts with highly malignant tumor cells, the resultant hybrids lost all tumorigenic capacity (Harris et al, 1969). Further, passage *in vitro* resulted in segregants that reverted to malignant phenotype upon loss of chromosomes (Harris et al., 1969; Klein et al., 1971). Two years later, Knudson, on the basis of statistical analysis of clinical observations, was the first to suggest retinoblastoma was a cancer caused by two mutational events (Knudson, 1971). In the hereditary form, one mutation was germinal; thus only a single additional somatic mutation was required. This results in early onset and a tendency toward bilateral tumorigenesis. In the sporadic form, both mutations are somatic, resulting in a tendency toward unilaterally and late onset. Comings later suggested that these two mutational events could occur within separate alleles of a regulatory gene (Comings, 1973). Indeed, cytogenetic analysis of retinoblastoma revealed characteristic deletions of the long arm of chromosome 13. Subsequent analysis of this region led to the identification of *RBI* and elucidation of aberrant transcripts encoded from the remaining allele (reviewed by Goodrich and Lee, 1993). Hence, a precedent emerged where inactivation of one allele of a tumor suppressor is accomplished by mutation, leading to the eventual deletion of the remaining normal allele through chromosomal aberrations and loss of heterozygosity (LOH) is thereby observed in the suppressor locus. This precedent is now considered the convention for suppressor inactivation and similar observations have been made for several other suppressive genes (e.g., *APC*, *DCC*, *VHL*, *TP53*; reviewed by Cox, Chen, and Lee, 1994). Further, LOH is considered indirect evidence for the existence of a suppressor gene within the affected region.

Allelotype of Breast Cancer

Because the mechanisms by which loss of heterozygosity occurs tend to involve large segments of DNA, it is possible to utilize the neighboring genes or known noncoding sequences as indicators to identify deleted regions harboring putative suppressor genes whose loss may be important in the genesis of the tumor. One such genetic marker is naturally occurring simple sequence length polymorphisms (SSLPs). SSLPs consist mainly of dinucleotide repeats, primarily (CA)_n, which are repeated in tandem at variable number (n) interspersed throughout the genome. To date, more than 5,000 such SSLPs with length polymorphisms of approximately 10-60 repeats, termed polymorphic microsatellites, have been identified (Dib et al., 1996; Litt and Luty, 1989). These polymorphic microsatellites have a mean heterozygosity of 70% at an average interval size of 1.6 cM. Through known linkage maps and comparison to physical maps, it is possible to select highly polymorphic microsatellites at any position within the genome. Further, through PCR amplification of these microsatellites and comparison with normal DNA from the same patient, it is possible to generate a comprehensive map of allelic imbalances (allelotype) occurring in a neoplasm (Weber and May, 1989).

Allelotyping of breast cancer has been reported in numerous studies, and numerous regions of allelic imbalance have been described using microsatellites as well as the older

restriction fragment length polymorphism analysis. As reviewed by Devilee and Cornelisse, compilation of data from more than 30 studies reveals a consensus of imbalances affecting more than 11 chromosome arms at a frequency of more than 25% (Table 1). Chromosome arms 1p, 1q, 3p, 6q, 8p, 11p, 13q, 17q, 18q, and 22q were affected at a frequency of 25-40%, whereas chromosome arms 16q and 17p were affected in more than 50% of tumors (Devilee and Cornelisse, 1994). In addition, chromosome arm 9p, which was not evaluated in these studies most likely because of lack of previous cytogenetic data implicating it, has recently been shown by our laboratory to be affected in 58% of breast carcinomas (Brenner and Aldaz, 1995). The loss of generic material in many of these regions has been corroborated by either CGH or classic cytogenetic data (Devilee and Cornelisse, 1994; Trent et al 1993). Further, some of these regions are known to harbor tumor suppressive genes whose loss has been demonstrated through a variety of techniques, including Southern blot analysis and FISH using gene-specific single-copy probes (Cox, Chen, and Lee, 1994).

While there is overwhelming evidence that these genetic losses occur, inherent difficulties exist in determining the relevance of such losses to breast tumorigenesis. In most cases, the tumors analyzed were of the invasive type and/or advanced stages of progression, leading to the question whether these losses are causative factors of tumorigenesis or consequences of the general genomic instability inherent to tumors. Further, it is possible that certain losses may be selected for in the progression or clonal evolution of a tumor to a more advanced type but not necessary for the genesis of the tumor. Some of these questions could be addressed in part through comparative allelotyping of both noninvasive and invasive tumors.

To address the relative timing and frequency of allelic losses of commonly affected regions in breast cancer, microsatellite length polymorphism analysis was performed in a series of preinvasive ductal carcinomas (DCIS) and invasive ductal and lobular carcinomas (Aldaz et al, 1995). Twenty different loci were examined in each group. As expected, frequencies of regional losses in invasive ductal carcinomas were similar to those in the aforementioned compilation by Devilee and Cornelisse of analyses from more than 30 studies. However, allelotyping of DCIS samples revealed that chromosomal regions 3p, 3q, 6p, 11p, 16p, 18p, 18q, and 22q were not affected by a high frequency of loss, while analyses of these same regions of invasive tumors showed them to be affected in 10-40% of cases (Aldaz et al., 1995). Our findings are in agreement with those of Radford et. al. who examined 61 DCIS samples (Radford et al, 1995). Because allelic losses affecting these regions were not frequently observed at the noninvasive (DCIS) stage it can be concluded that alterations of these regions are late events in breast cancer progression. More importantly, allelic imbalances observed on chromosome arms 7p, 7q, 16q, 17p, and 17q (Aldaz et al., 1995), as well as 9p as reported by others (Fujii et al., 1996), appear to be early abnormalities because they occur in approximately one third of DCIS samples.

Lobular carcinomas constitute approximately 10-15% of all breast cancers (Tavassoli, 1992). Histologically, lobular carcinomas have a very distinctive infiltrative growth pattern and metastatic pattern (Tavassoli, 1992). In addition, patients with invasive lobular carcinoma have been reported to have a higher risk of developing multifocal and contralateral breast cancer than those patients with invasive ductal carcinoma (Silverstein et al., 1994). To determine whether ductal and lobular carcinomas are subject to the same pattern of allelic loss, comparative allelotyping of the two subtypes was also conducted in

our laboratory. Losses of chromosome arms 1p, 3q, 11q, and 18q were more prevalent for invasive ductal carcinoma than for invasive lobular carcinoma (Aldaz et al., 1995). However, 8p losses or imbalances were observed in 36% of invasive lobular tumors but only 14% of invasive ductal carcinomas. Interestingly, microsatellite instability was observed in almost 40% of lobular carcinomas, but only 13% of ductal carcinomas (Aldaz et al., 1995). This phenomenon of microsatellite instability, also known as RER+ phenotype, is identified by allele size differences between tumor and matching normal controls. First described as a characteristic of tumors from patients carrying an autosomal dominant predisposition to tumors of the colon and endometrium, microsatellite instability has been linked to defects in a group of human mismatch repair genes: *hMSH2*, *hMLH1*, *hPMS1*, and *hPMS2* (Aaltonen et al., 1993; Fischel et al., 1993; Bronner et al., 1994). Resultant errors in DNA repair are believed to be the cause of the observed genomic instability phenomenon. These data suggest that invasive lobular carcinomas may arise by a mechanism of carcinogenesis different from that of ductal breast carcinomas and appear to constitute a distinct pathologic entity.

Targets of Allelic Loss

Chromosome arm 17p, as previously discussed, is subject to allelic loss in more than 50% of invasive ductal carcinomas, and approximately 30% of noninvasive ductal carcinomas (Radford et al., 1993; Aldaz et al., 1995; Radford et al., 1995). This high frequency of allelic loss suggests that a tumor suppressor of relevance to breast tumorigenesis resides in this region. Indeed, tumor suppressor *p53* is located in this chromosome arm and is known to harbor somatic mutation in 25 to 45% of primary breast carcinomas (Osborne et al., 1991). In addition, germline *p53* mutations have been detected and shown to be causative in families with Li-Fraumeni cancer predisposition syndrome (Malkin et al., 1990; Srivastava et al., 1990). Breast cancer is one of the neoplasms affecting patients with this syndrome. In tumors from patients with Li-Fraumeni syndrome, loss of the wild-type allele is observed with retention of the mutant *p53* allele. Functional studies of cells with mutant *p53* indicate a change of phenotypes, including cellular immortalization, loss of growth suppression, and fourfold increase in protein half-life which leads to *p53* accumulation. Accumulation of *p53* protein, observed by immunohistochemical analysis in roughly 30-50% of sporadic breast carcinomas, was proposed to be an indicator of higher risk of recurrence in patients with tumors positive for *p53* expression (reviewed by Ozbun and Butel, 1995). It is possible that early in breast tumor development, *p53* inactivation through mutation and LOH may be intrinsically linked to the development of subsequent further genomic instability as suggested by findings in experimental model of carcinogenesis (Donehower et al., 1995).

Although *p53* is the most likely candidate for allelic loss on 17p, other reports indicate that there may exist another distinct locus that may be a target of allelic loss. In an analysis of 141 breast tumors, Cornelis et al. observed a strong association between *p53* mutation and allelic loss of the *p53* locus (Cornelis et al., 1994). However, in cases where *p53* mutation was not observed, allelic loss of distal region 17p13.3 was always observed, sometimes without *p53* allele loss. Similar findings of distal deletion of 17p were also observed in DCIS (Radford et al., 1995). While these findings support the existence of a

second gene as target of allelic loss, further studies are needed to address this issue.

The long arm of chromosome 17, also frequently affected by allelic imbalance in both familial and sporadic breast cancers, has recently been subjected to extensive analysis because 17q has been linked to familial breast cancer (Hall et al., 1990). As a result, the *BRCA1* gene was isolated by positional cloning and mutations found to cosegregate with the predisposing haplotype in affected kindreds (Miki et al., 1994). However, when sporadic breast tumors with allelic loss of 17q were examined for *BRCA1* coding sequence alterations, only about 10% of those with LOH revealed any change of sequence, and those mutations were found to be germinal (Futreal et al., 1994). Cellular mislocalization of the *BRCA1* protein has since been reported in sporadic breast tumors, although other groups have not been able to confirm these results (Chen et al., 1995). It remains to be determined what role, if any, *BRCA1* plays in sporadic breast cancer. Another known suppressive gene localized in this region, nm23 or *NME1*, has been shown to undergo allelic loss in as much as 60% of breast carcinomas (Leone et al., 1991). However, analysis of *NME1* has not revealed evidence of mutations (Cropp et al., 1994). An additional possible explanation for allele loss is the existence of a yet-unidentified gene within this region as the target of allelic loss.

Loss of the *RBI* region 13q14 has been reported for numerous neoplasms including small cell lung carcinoma, bladder carcinoma, osteosarcoma, and breast carcinoma (reviewed by Cox, Chen and Lee, 1994). These losses appear to be relatively early losses in some tumors since 15-20% of tumors at the DCIS stage reveal allelic loss of 13q (Aldaz et al., 1995; Radford et al., 1995). However, when allelic loss and expression are examined in the same breast tumors, no correlation between the two is observed, suggesting that Rb inactivation is not acquired by allelic loss and that another gene may be the target of such inactivation (Borg et al., 1992). More recently, linkage analysis of high-risk breast cancer families localized a second breast cancer susceptibility locus, *BRCA2*, to chromosome 13q12-13 (Wooster et al., 1994). This suggested that the *BRCA2* gene may be involved in sporadic breast cancer as well. However, similar to the findings with *BRCA1* on 17q, when sporadic breast tumors were analyzed for mutation of *BRCA2*, mutations were infrequent, indicating that *BRCA2* is not the gene being targeted by loss (Miki et al., 1996; Teng et al., 1996; Lancaster et al., 1996). Brush-1 is another gene that has been mapped to 13q12-13, proximal to *RBI*. Analysis of Brush-1 expression indicated it to be low to absent in 6 of 13 breast cancer lines and decreased in four of four tumors showing LOH of 13q12-13 (Schott et al., 1994). However, no sequence analysis has yet been reported, and the question of whether decreased expression of Brush-1 results from allelic loss involving large regions of another gene has yet to be addressed.

Chromosomal region 9p21, as previously discussed, has been shown to be affected by allelic loss in 58% of invasive ductal carcinomas and 30% of DCIS, suggesting it may be involved in breast tumorigenesis (Brenner and Aldaz, 1995; Fujii et al., 1996). Previously, the *p16^{INK4a}/MTS1/CDKN2* tumor suppressor gene has been identified within this region by positional cloning and shown to be affected in 60% of breast carcinoma lines (Kamb et al., 1994). However, when primary breast tumors were analyzed in our laboratory for mutation of the *CDKN2* coding region, few mutations were found (Brenner and Aldaz, 1995). More recent analysis, including FISH determination of gene copy number, methylation of the 5' region, and analysis of expression, indicate that *p16* is indeed affected in 40 - 60% of breast tumors (Brenner et al., 1996). This observation of inactivation substantiates a role

for *p16* inactivation in the tumorigenesis of the breast and as a target of 9p allelic loss.

Chromosome 16q has been suggested as a site for the occurrence of primary cytogenetic structural abnormalities in the development of breast cancer (Dutrillaux, Gerbault-Seureau, and Zafrani, 1990; Pandis et al., 1992). In particular the long arm of chromosome 16 was shown to systematically participate in nonrandom translocations with chromosome 1 and 16q deletions were also frequently observed. Breast cancer allelotypic studies have also systematically shown the common occurrence of allelic losses affecting the long arm of chromosome 16 (Sato et al., 1990; Tsuda et al., 1994; Cleton-Jansen et al., 1994). In addition to our observations (Aldaz et al., 1995), other investigators have also reported the occurrence of frequent allelic losses affecting chromosome 16q in DCIS (Tsuda et al., 1994; Radford et al., 1995).

It has been suggested that probably more than one putative tumor suppressor locus of interest in breast cancer resides in 16q. At least two regions of chromosome 16q have consistently been previously reported to show LOH: 16q21 and 16q24.2-qter (Tsuda et al., 1994; Cleton-Jansen et al., 1994; Sato et al., 1990). Very recently, by performing a high-resolution allelotype of chromosome 16 in DCIS lesions, we have identified three distinct regions with a very high incidence (about 70% or more) of allelic losses among informative DCIS samples (Chen et al., 1996). Two of the regions agree with previously described areas: 16q21 at locus D16S400 and 16q24.2 at locus D16S402. However, the region with the highest incidence of LOH observed in our study lies between markers D16S515 and D16S516 (Figure 1). Within this region the D16S518 locus was the most frequently affected: 20 of 26 DCIS tumors (77%) showed LOH at this locus. These observations strongly suggest that a putative tumor suppressor gene(s) may possible be harbored at or in the vicinity of this locus. On the basis of a YAC contig spanning the region of interest, we can estimate that the minimum region with the highest frequency of LOH is no larger than 2-3 Mb. (Chen et al., 1996). Furthermore, on the basis of the cytogenetic location of markers D16S504 and D16S516 and the distance to D16S518, this area should be contained within bands 16q23.3-q24.1. This region appears different from another area of frequent LOH more distally located at locus D16S402 in band 16q24.2. Both areas are 17 cM apart according to the Genethon Linkage Map (March 1996) and several megabases away according to a comprehensive chromosome 16 physical and genetic map. Further studies are necessary to identify the target gene(s).

It will be particularly important to analyze for the occurrence of allelic losses at the mentioned chromosome 16 regions in other less advanced hyperplastic breast lesions. This analysis will be useful in our understanding of breast carcinogenesis and may help in the identification of markers with diagnostic or prognostic significance.




Figure 1. Chromosome arm 16q allelic loss in preinvasive breast carcinomas.

CELL CYCLE IN BREAST CANCER

Normal cell division in eukaryotes proceeds through an orderly cascade of events manifested as a cell cycle. The machinery responsible for such progress includes a hierarchy of proteins and complexes each exerting an effect on the next. At the top of this hierarchy are the cyclin subunits, whose expression and stability oscillate in a phase-dependent manner. Further, the expression of certain cyclin genes can be upregulated by different mitogenic stimuli, for example, the upregulation of cyclin D1 by estrogen (Altucci et al., 1996). Each of these cyclins can associate in a non-promiscuous manner with specific cyclin-dependent kinases (CDKs). When bound, the cyclins result in activation of CDK activity. However, these cyclins are in competition with CDK inhibitors, which have the ability to displace the cyclin and form an inactive complex with the CDKs. When CDKs are active, they phosphorylate, and hence inactivate, other proteins with transcription-repressing activity (Reviewed by Sherr et al., 1994).

Of the restriction points, G1 to S is best characterized in breast cancer. The players involved in this restriction point include cyclins D1-D3; CDKs 4 and 6, the inhibitors of those CDKs *p15*, *p16*, and *p18*; and the substrate of the CDKs, the *Rb* protein (Figure 2). Collectively, these proteins are known elements responsible for regulation of progression through G1, and loss of function or dysregulation of expression of an individual protein can lead to loss of cell cycle regulation and proliferation. Of these proteins, the *Rb* protein, cyclin D1, and *p16* have all been observed to be affected in breast tumorigenesis. As previously mentioned, cyclin D1 has been shown to be both amplified in 10-20% of breast tumors and overexpressed in the majority of breast tumors (Gillet et al., 1994; Bartkova et al., 1994; Weinstat-Saslow et al., 1995). When cyclin D1 is over-abundant, it competes with *p16* for heterodimerization with the CDKs; when cyclin D1 is bound to a CDK, it positively regulates the activity of the CDK which is able to phosphorylate and inactivate *Rb*. Inactivation of *Rb* itself has been described in breast cancer, and when multiple modes of inactivation are accounted for, *Rb* is inactivated in approximately 20% of breast cancers (Borg et al., 1992; Varley et al., 1989). In addition, analyses of *Rb* and *p16* have shown an inverse relationship in expression of the two genes in the vast majority of tumor lines studied (Okamoto et al., 1994; Parry et al., 1995). This is true in breast tumor cell lines as well: in those lines retaining *Rb* expression, *p16* is deleted, mutated, or otherwise affected, and its expression is often undetectable. In contrast, those cell lines retaining *p16* expression often lack expression of *Rb*. Further, when primary breast tumors are analyzed for *p16* expression, approximately 50% show loss of expression due to homozygous deletion, methylation of the 5' region, and rarely by mutation (Brenner et al., 1996). While *CDK4* has not been extensively studied in breast cancer, other neoplasms show overexpression or mutation of the *p16* binding site (He et al., 1994; Zuo et al., 1996). Thus, it appears that mutation or disruption of either *Rb* or *p16* expression or overexpression of cyclin D1 or possibly *CDK4* is sufficient to eliminate this pathway's control of cell cycle progression. The high cumulative rate of alterations affecting these proteins in breast cancer suggests that abrogation of the G1 restriction point may be necessary for breast tumorigenesis.




Figure 2. Schematic representation of G1/S restriction point interactions.

The CDK inhibitor *p21*^{WAF1/CIP1} is known to be another negative regulator of the cell cycle. Unlike *p16*, it is known to be a universal inhibitor of CDKs thereby inducing arrest at both the G1/S and G2/M restriction points (Xiong et al., 1993). Further, *p21* also complexes with proliferating cell nuclear antigen *in vitro*, resulting in inhibition of DNA replication (Waga et al., 1994). Because *p21* gene transcription is regulated by *p53*, it has been suggested that *p53*-dependent cell cycle arrest is mediated by *p21*. Indeed, *p21* nullizygous mice fibroblasts fail to undergo G1 arrest following DNA damage although apoptosis is unaffected in these same cells (Brugarolas et al., 1995). As previously mentioned, positive *p53* gene detection has been shown in as much as half of breast carcinomas, and *p53* has been shown to be associated with *p53* mutation and a higher risk of recurrence (reviewed by Ozburn and Butel, 1995). This would suggest that an additional possible consequence of *p53* inactivation in the tumorigenesis of the breast is the abrogation of cell cycle arrest through loss of transcriptional activation of *p21*.

SUMMARY

Breast cancer is a complex disease in which numerous genetic aberrations occur. It is unclear which, if any, of these abnormalities are causative of breast tumorigenesis. However, on the basis of the currently accepted view of breast cancer as a multistep process, it is possible that specific abnormalities may be required in the progression from a normal breast epithelial cell to an invasive tumor cell. Figure 3 shows a schematic putative model of breast cancer progression based primarily on epidemiological and histopathological studies (Page and DuPont, 1992). Advances in methodology have allowed us to more precisely determine the approximate chronology of some of these aberrations and the possible roles each plays in the formation of malignancy. Simplistically, one could speculate that it is the early loss of cell cycle control in the presence of a mitogenic stimulus that allows a cell to divide unchecked. Such uncontrolled proliferation in the absence of wild type *p53* would yield a high level of genomic instability. As proliferation continues, numerous additional

chromosomal abnormalities occur, and increased tumor heterogeneity would be observed as distinct subpopulations emerge in the evolution toward a progressively more aggressive phenotype. However, much still remains to be learned to gain a full understanding of the key players behind the genetic evolution of breast cancer. Only by analyzing preinvasive and putative early stages of breast cancer will we be able to characterize the most probable sequence of genomic abnormalities.




Figure 3. Schematic putative model of breast cancer progression.

ACKNOWLEDGEMENTS

The authors wish to thank contributing colleagues Taiping Chen, Andzej Bednarek, Abhaya Paladugu, Hui Wang, and Qiao Ying Liao, and Michelle Gardiner for her secretarial assistance. This work was supported by Grants DAMD 17-94-J-4078 and DAMD 17-96-1-6252 from the U.S. Army Breast Cancer Program and NIH Grant R01 CA59967.

REFERENCES

- Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, et al (1993): Clues to the pathogenesis of familial colorectal cancer. *Science* 260:812-816.
- Aldaz CM, Chen T, Sahin A, Cunningham J, Bondy M (1995): Comparative allelotyping of *in situ* and invasive human breast cancer: High frequency of microsatellite instability in lobular breast carcinomas. *Cancer Res* 55:3976-3981.
- Altucci L, Addeo R, Cicatiello L, et al (1996): 17 β -estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. *Oncogene* 12:2315-2324.
- Bartkova J, Lukas J, Muller H, Lutzft D, Strauss M, Bartek J (1994): Cyclin D1 protein expression and function in human breast cancer. *Intl J Cancer* 57:353-361.
- Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE (1988): Correlation of C-ERBB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. *Cancer Res* 48:1238-1243.
- Borg A, Zhang Q-X, Alm P, Olsson H, Sellberg G (1992): The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression. *Cancer Res* 52:2991-2994.
- Boring CC (1994): Cancer statistics. *CA Cancer J Clin* 44:7-26.
- Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P (1989): Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/C-NEU oncogene. *Cell* 57:931-936.
- Brenner AJ, Aldaz CM (1995): Chromosome 9p allelic loss and *p16/CDKN2* in breast cancer and evidence of *p16* inactivation in immortal breast epithelial cells. *Cancer Res* 55:2892-2895.
- Brenner AJ, Paladugu A, Wang H, Olopade OI, Dreyling MH, Aldaz CM (1996): Loss of

- p16 is preferential over alternative p19 in breast cancer. *Clinical Cancer Res* (in press).
- Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabine C, Lipford J, Lindblom A, Tannergard P, Bollag RJ, Godwin AR, Ward DC, Nordenskjold M, Fishel R, Kolodner R, Liskay RM (1994): Mutation in the DNA mismatch repair gene homologue *hMLH1* is associated with hereditary non-polyposis colon cancer. *Nature* 368:258-261.
- Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ (1995): Radiation-induced cell cycle arrest compromised by p21 deficiency. *Nature*. 377(6549):552-7.
- Chen T, Sahin A, and Aldaz CM (1996): Deletion Map of Chromosome 16q in Ductal Carcinoma *In Situ* of the Breast: Refining a Putative Tumor Suppressor Gene Region. (Submitted for publication).
- Chen Y, Chen CF, Riley DJ, Allred DC, Chen PL, Von Hoff D, Osborne CK, Lee WH (1995): Aberrant subcellular localization of BRCA1 in breast cancer. *Science* 270:789-791.
- Cleton-Jansen AM, Moerland EW, Kuipers-Dijkshoorn NJ, Callen DF, Sutherland GR, Hansen B, Devilee P, Cornelisse CJ (1994): At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. *Genes, Chromos. & Cancer*, 9:101-107.
- Comings DE (1973): A general theory of carcinogenesis. *Proc Natl Acad Sci USA* 70:3324-3328.
- Cornelis RS, van Vliet M, Vos CBJ, Cleton-Jansen A-M, van de Vijver MJ, Peterse JL, Khan PM, Borresen A-L, Cornelisse CJ, Devilee P (1994): Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without *p53* mutations. *Cancer Res* 54:4200-4206.
- Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, et al (1985): Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with Neu oncogene. *Science* 230:1132-1139.
- Cropp CS, Lidereau R, Leone A, Liscia D, Cappa APM, Campbell G, Barker E, Le Doussal V, Steeg PS, Callahan R (1994): NME1 protein expression and loss of heterozygosity mutations in primary human breast tumors. *J. Natl. Cancer Inst.* 86:1167-1169.
- Cox LA, Chen G, Lee E Y-H P (1994): Tumor suppressor genes and their roles in breast cancer. *Breast Cancer Res Treat* 32:19-38.
- Devilee P, Cornelisse CJ (1994): Somatic genetic changes in human breast cancer. *Biochimica*

et Biophysica Acta 1198:113-130.

Dib C, Fauré S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gyapay G, Morissette J, Weissenbach J (1996): A comprehensive genetic map of the human genome based on 5,264 microsatellites. *Nature* 380:152-154.

Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, Fisher C, Barnes D, Peters G (1995): Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. *Cancer Let* 90:43-50.

Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, Gray J, Bradley A, Medina D, Varmus HE (1995): Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. *Genes & Development* 9(7):882-95.

Dutrillaux B, Gerbault-Seureau M, Zafrani B (1990): Characterization of chromosomal anomalies in human breast cancer. A comparison of 30 paradiplod cases with few chromosome changes. *Cancer Genet Cytogenet* 49:203-217.

Easton DF, Bishop DT, Ford D, Crockford GP (1993): Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. *Am J Hum Gene* 52:678-701.

Feuer EJ (1993): The lifetime risk of developing breast cancer. *J Natl Cancer Inst* 85:892-897.

Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R (1993): The human mutator gene homolog *MSH2* and its association with hereditary nonpolyposis colon cancer. *Cell* 75:1027-1038.

Fujii H, Marsh C, Cairns P, Sidransky D, Gabrielson E (1996): Genetic divergence in the clonal evolution of breast cancer. *Cancer Res* 56:1493-1497.

Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, et al (1994): *BRCA1* mutations in primary breast and ovarian carcinomas. *Science* 266:120-122.

Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G (1994): Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. *Cancer Res* 54:1812-1817.

Goodrich DW, Lee W-H (1993): Molecular characterization of the retinoblastoma susceptibility gene. *Biochimica et Biophysica Acta* 1155:43-61.

Gray JW, Collins C, Henderson IC, Isola J, Kallioniemi A, Kallioniemi O-P, Nakamura H,

- Pinkel D, Stokke T, Tanner M, Waldman F (1994): Molecular Cytogenetics of Human Breast Cancer. 645-652.
- Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. (1990): Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684-1689.
- Harris H, Miller OJ, Klein G, Worst P, Tachibana T (1969): Suppression of malignancy by cell fusion. Nature 223:363-368.
- He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day III RS, James CD (1994): CDK4 amplification is an alternative mechanism to *p16* gene homozygous deletion in glioma cell lines. Cancer Res 54:5804-5807.
- Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK, Waldman FM (1995): Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Path 147:905-911.
- Jardines L, Weiss M, Fowble B, Greene M (1993): neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 61:268-282.
- Kallioniemi A, Kallioniemi O-P, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW, Waldman FM (1994): Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 91:2156-2160.
- Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D (1992a): Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818-820.
- Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D, Gray JW (1992b): ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89:5321-5325.
- Kamb A, Gruis N, Weaver-Feldhaus J, Qingyun L, Harshman K, Tavtigian S, Stockert E, Day R, Johnson B, Skolnick M (1994): A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
- Klein G, Bregula U, Wiener F (1971): The analysis of malignancy by cell fusion. J Cell Sci 8:659-672.
- Knudson AG (1971): Mutation and Cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
- Lammie GA, Peters G (1991): Chromosome 11q13 abnormalities in human cancer. Cancer

Cells 3:413-420.

Lancaster JM, Wooster R, Mangion J, et al (1996): BRCA2 mutations in primary breast and ovarian cancers. *Nature Genetics* 13:238-240.

Leone A, McBride OW, Weston A, Wang MG, Anglard P, Cropp CS, Goepel JR, Lidereau R, Callahan R, Linehan WM, Rees RC, Harris CC, Liotta LA, and Steeg PS (1991): Somatic allelic deletion of *nm23* in human cancer. *Cancer Res* 51:2490-2493.

Litt M, Luty JA (1989): A hypervariable microsatellite revealed by in vitro amplification of a dinucleotide repeat within the cardiac muscle actin gene. *Am J Hum Genet* 44:397-401.

Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al (1990): Germ line *p53* mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 250:1233-1238.

Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y (1996): Mutation analysis in the BRCA2 gene in primary breast cancers. *Nature Genetics* 13:245-247.

Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, et al (1994): A strong candidate for the breast and ovarian cancer susceptibility gene *BRCA1*. *Science* 266:66-71.

Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P (1988): Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated *c-neu* oncogene. *Cell* 54:105-115.

Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC (1994): Mutations and altered expression of *p16^{INK4}* in human cancer. *Proc Natl Acad* 91:11045-11049.

Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa APM, Chiba I, Takahashi T, Nau MM, Callahan R, Minna JD (1991): Mutations in the *p53* gene in primary human breast cancers. *Cancer Res* 51:6194-6198.

Ozmun MA, Butel JS (1995): Tumor suppressor *p53* mutations and breast cancer: a critical analysis. *Adv Cancer Res* 66:71-141.

Page DL, Dupont WD (1992): Benign breast disease: indicators of increased breast cancer risk. *Cancer Detection & Prevention* 16:93-97.

Pandis N, Heim S, Bardi G, et al (1992): Whole-arm *t(1;16)* and *i(1q)* as sole anomalies identify gain of 1q as a primary chromosomal abnormality in breast cancer. *Genes Chromosomes & Cancer*, 5:235-238.

- Parry D, Bates S, Mann DJ, Peters G (1995): Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16^{INK4/MTS1} tumour suppressor product. *EMBO J* 14:503-511.
- Radford DM, Fair KL, Phillips NJ, Ritter JH, Steinbrueck T, Holt MS, Donis-Keller H (1995): Allelotyping of ductal carcinoma *in situ* of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. *Cancer Res* 55:3399-3405.
- Radford DM, Fair K, Thompson AM, Ritter JH, Holt M, Steinbrueck T, Wallace M, Wells SA Jr, Donis-Keller HR (1993): Allelic loss on a chromosome 17 in ductal carcinoma *in situ* of the breast. *Cancer Res* 53:2947-2949.
- Ravdin PM, Chamness GC (1995): The *c-erbB-2* proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. *Gene* 159:19-27.
- Ryan KM, Birnie GD (1996): Myc oncogenes: the enigmatic family. *Biochem J* 314:713-721.
- Sato T, Tanigami A, Yamakawa D, et al (1990): Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. *Cancer Res.*, 50:7184-7189.
- Schott DR, Chang JN, Deng G, Kurisu W, Kuo WL, Gray J, Smith HS (1994): A candidate tumor suppressor gene in human breast cancers. *Cancer Res* 54:1393-1396.
- Sherr CJ (1994): G1 phase progression: cycling on cue. *Cell* 79:551-555.
- Shiu RPC, Watson PH, Dubik D (1993): *c-myc* oncogene expression in estrogen-dependent and -independent breast cancer. *Clin Chem* 39:353-355.
- Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA (1995): Cyclin D1 provides a link between development and oncogenes in the retina and breast. *Cell* 82:621-630.
- Silverstein MJ, Lewinsky BS, Waisman JR, Gierson ED, Colburn WJ, Senofsky GM, Gamagami P (1994): Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? *Cancer* 73:1673-1677.
- Silverstein MJ, Lewinsky BS, Waisman JR, Gierson ED, Colburn WJ, Senofsky GM, Gamagami P (1994): Infiltrating lobular carcinoma. It is different from infiltrating duct carcinoma? *Cancer* 73:1673-1677.
- Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH (1990): Germ-line transmission of

- a mutated p53 gene in a cancer-prone family with Li-fraumeni syndrome. *Nature* 348:747-749.
- Tavassoli FA (1992): *Pathology of the Breast*, Norwalk, CT: Appleton & Lange.
- Tavtigian SV, Simard J, Rommens J, et al (1996): The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. *Nature Genetics* 12:333-337.
- Teng DH, Bogden R, Mitchell J, et al (1996): Low incidence of BRCA2 mutations in breast carcinoma and other cancers. *Nature Genetics* 13:241-244.
- Thompson F, Emerson J, Dalton W, Yang J-M, McGee D, Villar H, Knox S, Massey K, Weinstein R, Bhattacharyya A, Trent J (1993): Clonal chromosome abnormalities in human breast carcinomas I. Twenty-eight cases with primary disease. *Genes, Chromo Cancer* 7:185-193.
- Trent J, Yang J-M, Emerson J, Dalton W, McGee D, Massey K, Thompson F, Villar H (1993): Clonal chromosome abnormalities in human breast carcinomas II. Thirty-four cases with metastatic disease. *Genes, Chromo Cancer* 7:194-203.
- Tsuda H., Callen DF, Fukutomi T., Nakamura Y, Hirohashi S (1994): Allele loss on chromosome 16q24..2-qter occurs frequently in breast cancer irrespective of differences in phenotype and extent of spread. *Cancer Tes.*, 54:513-517.
- Varley JM, Armour J, Swallow JE, Jeffreys AJ, Ponder BA, T'Ang A, Fung YK, Brammar WJ, Walker RA (1989): The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. *Oncogene* 4:725-729.
- Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA (1987): Alterations to either C-ERBB-2 (NEU) or C-MYC proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. *Oncogene* 1:423-430.
- Waga S, Hannon GJ, Beach D, Stillman B (1994): The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. *Nature*. 369:574-578.
- Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV (1994): Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. *Nature* 369:669-671.
- Weber JL, May PE (1989): Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. *Am J Hum Genet* 44:388-396.
- Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS (1995): Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. *Nature Med* 1:1257-

1260.

Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, et al (1994): Localization of a breast cancer susceptibility gene, *BRCA2*, to chromosome 13q12-13. *Science* 265:2088-2090.

Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, et al (1995): Identification of the breast cancer susceptibility gene *BRCA2*. *Nature* 378:789-792.

Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993): p21 is a universal inhibitor of cyclin kinases. *Nature* 366(6456):701-704.

Yeager T, Stadler W, Belair C, Puthenveetil J, Olopade O, Reznikoff C (1995): Increased p16 levels correlate with pRb alterations in human urothelial cells. *Cancer Res* 55:493-497.

Zhou D, Battifora H, Yokota J, Yamamoto T, Cline MJ (1987): Association of multiple copies of the *c-erbB-2* oncogene with spread of breast cancer. *Cancer Res* 47:6123-6125.

Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC (1996): Germline mutations in the *p16INK4a* binding domain of CDK4 in familial melanoma. *Nature Genetics* 12:97-99.

NCBI **Entrez****Nucleotide QUERY****BLAST Entrez ?**

Other Formats:

FASTA**Graphic**

LOCUS AF179633 96371 bp DNA PRI 05-SEP-1999
DEFINITION Homo sapiens chromosome 16 map 16q23.3-q24.1 sequence.
ACCESSION AF179633
NID g5823550
VERSION AF179633.1 GI:5823550
KEYWORDS .
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 96371)
AUTHORS Bednarek,A.K., Chen,T., Laflin,K.J., Hawkins,K.A., Liao,Q. and
Aldaz,C.M.
TITLE Direct Submission
JOURNAL Submitted (23-AUG-1999) Carcinogenesis, University of Texas, M.D.
Anderson Cancer Center, Science Park-Research Division, Park Road
1C, P.O. Box 389, Smithville, TX 78957, USA
FEATURES
source Location/Qualifiers
1..96371
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="16"
/map="16q23.3-q24.1; between D16S518 and D16S516"
/clone="BAC249B4; BAC286F3; BAC112B17; BAC36O22"
/clone_lib="Research Genetics, Inc. CITB-HSP-C library"
repeat region complement(265..541)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 1099..1397
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(2501..2778)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(3376..3606)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(3729..3812)
/rpt_family="MIR"
/rpt_type=dispersed
STS 7553..7684
/db_xref="dbSTS:G22903"
repeat region complement(8121..8403)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(8601..8864)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 9337..9590
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(10106..10193)
/rpt_family="MIR"
/rpt_type=dispersed
repeat region 10503..10750
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 11491..11787
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 14683..14864
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(16507..16781)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 17333..17625
/rpt_family="Alu"

repeat region /rpt_type=dispersed
17830..18117
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 19141..19428
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 19458..19711
/rpt_family="MLT2B2"
/rpt_type=dispersed
repeat region 21308..21571
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 23421..23707
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(25091..25226)
/rpt_family="L1"
/rpt_type=dispersed
repeat region complement(25356..25608)
/rpt_family="MER7"
/rpt_type=dispersed
repeat region complement(25775..26032)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 27530..27815
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 28973..29184
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(29778..29942)
/rpt_family="MLT1"
/rpt_type=dispersed
repeat region complement(32318..32601)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(32812..33114)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 34781..34837
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 35161..35951
/rpt_family="MER42"
/rpt_type=dispersed
repeat region complement(39543..39810)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(39994..40187)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(43566..43874)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 48563..48668
/rpt_family="MIR"
/rpt_type=dispersed
repeat region 49091..49373
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 50165..50335
/rpt_family="MLT1"
/rpt_type=dispersed
repeat region complement(52299..52423)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 52862..53272
/rpt_family="MLT2B2"
/rpt_type=dispersed
repeat region complement(54582..54832)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 55726..56056
/rpt_family="MLT1"

repeat region /rpt_type=dispersed
complement(56053..56309)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 57555..57909
/rpt_family="THE1"
/rpt_type=dispersed
repeat region 58410..58622
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(59901..60181)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 60238..60516
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 61451..61721
/rpt_family="MLT1"
/rpt_type=dispersed
repeat region complement(63697..63934)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(67062..67361)
/rpt_family="Alu"
/rpt_type=dispersed
STS 68170..68305
/db_xref="dbSTS:G43876"
repeat region complement(69661..69955)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 70746..70866
/rpt_family="Alu"
/rpt_type=dispersed
STS 73190..73332
/db_xref="dbSTS:G15501"
repeat region 74482..74622
/rpt_family="MER3"
/rpt_type=dispersed
repeat region 74482..74535
/rpt_family="MER33"
/rpt_type=dispersed
repeat region complement(74584..74626)
/rpt_family="MER3"
/rpt_type=dispersed
repeat region 76820..77138
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 78678..78951
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(79491..79770)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(80909..81184)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 81261..81364
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(84469..84695)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 85302..85588
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(86554..86724)
/rpt_family="MIR"
/rpt_type=dispersed
repeat region complement(88516..88612)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 89071..89331
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement(90533..90812)

```

/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement (91380..91658)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 91963..92288
/rpt_family="Alu"
/rpt_type=dispersed
repeat region complement (92304..92499)
/rpt_family="MIR"
/rpt_type=dispersed
repeat region 93182..93265
/rpt_family="MER21"
/rpt_type=dispersed
repeat region 93490..94079
/rpt_family="MER21"
/rpt_type=dispersed
repeat region 94217..94612
/rpt_family="L1"
/rpt_type=dispersed
repeat region complement (95236..95546)
/rpt_family="Alu"
/rpt_type=dispersed
repeat region 96212..96360
/rpt_family="Alu"
/rpt_type=dispersed

```

BASE COUNT 29090 a 20438 c 19962 g 26877 t 4 others
ORIGIN

```

1 ctgaaactga aatgtcatca atccatatac actaaggaga gggacaatgg caggatgggg
61 gtgcacctgc tcggaagagg tatccacaac tcaccactca ctttaaaact ctgtggataa
121 cttcattcag aaacaaagtt aaggagagaa attgttaatg tggggtgaga gctcaaaaat
181 ttgcccagta aggacttttg ctgcattcaa atgctagaag gataaatatc ctcatcggaa
241 gctaaaatag caaggggttg tttatttttg agatagggtc tagccttgtc acccagggtg
301 gagtgcggtg acatgatatac agcttactgc aacctctacc tcctgggttc aagtgcacct
361 cctgcctcag cctcctgagt agctgggagt atagcacatg ccaccacacc cagctaattt
421 ttgtattttt agtagagatg ggatttcacc atgttggcca ggggtggtct aaactcccaa
481 cctcagggga tctacctgcg ttggcctccc aaagagctgg gattacaggg atgagccacc
541 gtgcctggac tgtcagttct tctaattcga gaagaaaatg cctatatcca taaaatcact
601 atagaaacca actgagcaga agaaccattt tggcgtagac aagccagaaa gaaaatcatt
661 gatcattcta ttacttctta agtgattaat ggtgagccaa cctatcatgt acaaatattg
721 tctatctgta tttaacacaa tggagctaag aagaatgtaa tacaaagcaa cacagatacc
781 ttacatcaag tcacaattac tcttgatctt aaagctagac agcaattgcc ttgagggttag
841 aatagaattc actcaaggatc ctggcaaatg gttggccctc cgaaattggt tgttgaatat
901 ttaattttct agtctaaatg cattggaaac ttttattctc tgattttcct tgaaaatata
961 ttttgagaga aacctgtata ttagtttcct agaagttctg gtctgcaaga aaaacttaac
1021 taaattagac taacattttt cagattttgc ctgggcagca gtaactacgt agacaaaatt
1081 ttaccagggc caggcagagt ggctcatgct tgaaccctta gcactttggg aggctgaggg
1141 acgtgaatcg cttgagccca ggagttttga gaccagcctg ggcaacatgg caaaaatcca
1201 tctgtaccaaa aaaaatacaac aacaacaaaa attgggcagg catggtggtg tgcccctgtg
1261 gtcccagctc ccttggggagg ctgaggttagg aggatcactt gcgccagga ggcaaagggt
1321 gcagtgcgac gtgactctgc caccacatgc cagcctggca acagggcgag actttgtctc
1381 aaaaaaaaaa aaaaaaagaa aaaaaattac cagaagcctt aggggaccga aagatagact
1441 cataatgaaa aaaaaaagtg cttggaaaac aggagtcagg gtcttatacc tacgtctgac
1501 ctgatctgat atcatakaca agaaggcaga gcatttctct gaatygtgaa ctgatcccaa
1561 cttagaaaca tactcccatg ttgggaaaac acattgtctt tccatttgat acagtaagtt
1621 ctttgaaacc atcttctccc aaaggtagtg ttgtcaaaaa atagtactc acacttatgt
1681 gaactctcag atggaccgcc agcaagagta catcagcaag ttcggcaagt gaattccctc
1741 accaataata aataaggagc aaaggggaatg aagatgggca ttttggctgg attocaaatg
1801 caaaaacctg cctatctacc ttcaaaatgt tgcaagattg cagtttggtt aatgttcac
1861 ttagtgtgctt taattaccgat agtgcttgac taattatttc ttgttttgta gactatttaa
1921 acagagaagg aaagcagcta tatactttcg tataccgaat gaggatttgt aactcatttt
1981 tgtaatcgca taattcccgg agggcttcat tacaaacacg aaagaaaaca ggatgctaaa
2041 agcaggtgac agtctaattt ccacaggtac gggtgaaagc attagagtga agtaatggaa
2101 aataaaaata aaaaatagcct ttagatgttt ccatctatgt aagggtgttt catgttaata
2161 agagagaaaa ctgcaaatac agcaaagata tcttcgtttg gtactggtgt cttttctgat
2221 gtctgatttg atccaacatc tctgaaataa accaccaaat agacccaggt tttcttattc
2281 acaaatgtaa gtgtttgaca agttgcatac ggtatcatca actcgtatca tgtctctgtt
2341 ttactctttt tactttatct acttttgact ataaaattctt ggtcatctaa cgccattaca
2401 ccagatttca aatgttttag aaaaatgtga ggcttaaaact aaaggataat accagagacc
2461 ctgagatttc cagactgtta ggaattactt cttcttcttc tttttttttt ttgagacaga
2521 gttttgtgtt tgttgcccag gctggagtag aatgacatga tctcagctca cggcaacctc
2581 tgctcctcaa gttcaagcga ctctcctgcc tcagcctccc aagtagctgg gattacaggg
2641 atgtgccacc atgctggctt aattttgtat ttttagtaaa gacaggggtt cccatgttg
2701 atcagactgg tctcgaactc ccgaccttag gtgatccgcc tgcctcggcc tcccaaagcg
2761 ctgggattac aggcgtgaac catcatgcc agccaggaat tccttctaag cacaacaat

```

2821 gttgcttctt ggatggaaat cagatttggg ggtcacgagg ccaaaggcca aatttttttt
2881 tttttttgag agtggacttt aagaccaggg tggatttaca tggttgggga agtgagagca
2941 gatcctgaaa aagtatgaga tgtggatttt gtccttatgg catgaagaaa ctaattggga
3001 atttgaaata agacatttga aacaacagca aacaccatct ttgacatcat gttgtcaaca
3061 tcagagggtc caccatttat caagctctta cgggtgtctca tactgagatg caatcttcac
3121 ttctctttac attgtcacia aagcctgccc ggcatgccc accagctctt ttccagatg
3181 ttgcaactga ggtctatgac cgtgaaagat gagctccttg ccctcaactt cgattttctt
3241 atctgcgttt ttctgcctta acaagtactt aggattacag aagttaattt gcttctagta
3301 aattcctcct tccctccctt cctcctttoc tcccttctct ccagatccag ggtgaagtgt
3361 agtgacacaa tgatagctca ctgcaacctt aaattcctgg gctcaaggca tctctccacc
3421 tcagcctcct gaatagctaa gactataggc atgtaccact atgacaggct tttttttttt
3481 tttttttttt tcatTTTTTT gtagagatag tattttgtca tcttgcccag gctgggtctca
3541 aactcctgga ctcaagagat catagggatt ctctgcctc agcttcttga gtttctggga
3601 ttacagccat aagcctggcc tggtaaattt caagcaagca acttcaacta cattgtcagg
3661 atagaagcca gactactggg tgttgcaagg aaaggggtct ataaaggaaa ttaaggaaata
3721 aaatgggtaa catttacaga accctcacat gcaccaaaca gtgtgctagg ttcttcatac
3781 atattatctc atgatatcct catagcaacc ctgtaaaata ggtgttaata taattatagt
3841 taacatttat taagtgccaa tgtgcttcag agattaaacc aagcctttta tatgtgttat
3901 ttcatttgat gctcccccaa gccctataaa atagttttga ttatcaatca tctcatttta
3961 gctgaagaat aaatgtaggc tttagagggt caatttgttc caaagttagt ataattactt
4021 tactcaatga caggggcagg aattgaacct aggggcctgc ctgcaaagtc tgtacttccc
4081 aatgtcatgc taggccatca ttcagcatgg tatttttatt tattgtaact cagacaagct
4141 cagtcactct cccaacgtca tgaggctagg gagttctggc tcaggattcc catccatggg
4201 ctgtctctct gaatagcatt cagcaccacc tcggaagcag gcatggctgc tcaaggaggca
4261 gggcagttgt attccgaacc ccagtggata ctactgagc cagtactagt tatgctaaaa
4321 actacaggga atgtcttgtc ttaggggatc ttctctctct gtgacgcaaa gagaaggggac
4381 ctgctagagc ctataaaaaa aaaaatcatc gacctgtaa aggcaacaaga ggggatttgc
4441 aattgaacag acctggattc caatccctc tcatccagga gtatctgttg gcgctgaagt
4501 catttagctt tttgggctgc tgggcttagc tataaaatgt atataaaact acctatgttg
4561 ctgtgtggta gagtgagttg gacattatac atccaaggat atttctagat tcatttctcc
4621 aataaatatt gtcttccacg tgctaagcct tctctaggc cctgaagtac aatagtgagc
4681 aaagagagca aaaatgctag tacttacaac cttacattct tctagagaat aggagaataa
4741 acacaaaact catgtatgtc tatgtctcta tctatgtcca catctatgtc tgtatctatg
4801 tgatataata agtgccacaa ggaatacaaa gcaggaaaag gaagagaggg tgcaaggctc
4861 agagaggcag gctgccattt tatagttagt ggtgagaaac agcttcaact agaaagtgtc
4921 agttgagcaa agccttttgg agaagaacag ctcagtgtgc tacatggaag aatactccag
4981 gcagaaggag cagcaaaagg aaagcgtctg agacaggaac acacctggga tgtctgagga
5041 acagctgaag aagaacaaga ggccagtagg tggaaaaagc tcacaggggg gaggcaggcg
5101 ggtcagaggg gggaggcagg cagggcatac agaggggttg gtgtcctact gtgacgattt
5161 tgccttttaa tcagcctgaa atgggatata aagctcttaga tggatgaaat aggaataact
5221 ttctctctt ccttctctgt ctgactaaat taacagatga aggaattgtc aaaatacaaa
5281 accttcttcc ttactgaacc cactgacctg gcagggtctg taaggaaaag aatttgtttc
5341 tagaagagct atttaaatgt cctggacctc ttcgaaaccag cagaataagg aaccagttaa
5401 cttaacaggc aaagtaataa gactatacag aggaacacaa ttttcttct ttatgcctta
5461 attttacaag gagttacaag atttctgtga ggaattcaga gtgttatctt atttttagcc
5521 ccaaactaga aagagcgttc cactgggttt gccaaagctgt taagatgaaa atatctgttt
5581 gagcacagca taatagatga ggtgtttaag gcattttctt ttagattttt ggttaatctt
5641 ctttttagtta attttctgag ataaaaatca gttataaata acctgagggt accctaactg
5701 ggctgttctg agaattggca atctttaata gccagaactt ctgcctttta gagatctcta
5761 gagaagcag tactttgaaa attatccaaa gcaaaaataag tcgaaagcat taacaaatta
5821 aagacagtgg gagagagaag aaaggggcga atgagaaact tctttgacat tcacaagaca
5881 cgagatctta cctttgaaac tcttttaaaa aaaaaaaaag aagaagagtc aagcattcac
5941 aatctatttg ttgattaaac acagagaact ggtgagtttc tgtcataaca gagtctcgga
6001 aaattcatcc tttttcacia aaggaaagga gagaaaattc cagacaaaac acccaaagtg
6061 cagaagaaag ggcattggca taagcagcca tcaactagac taaagtacaa tgggtacaat
6121 attaaaataa gaagtttttag aactgctttt aaagatagct ggcggaagaa ttaaaaaaaa
6181 aagaaaggaa aaaaacctta agtgttttcc gttgttaaaa cgtaaagcaa aatttataaa
6241 aggattataa ggtagctatg gtaagaaagt catgtaaaact agttgaaata tccagagttc
6301 ctacagacaa aaagagcagg ttggcagctg tccatctgca gtgtatatag taccatggag
6361 cctgtttata aaaataagag aggggtgggag acctaaagtg ggtataactc aaaacaaaac
6421 aaatctgtag gactagataa gggagggtga ttattcccag gtactaatag gctaaatggg
6481 atcaggagaa agaatttaga caagtttcta ctaagcaata aaagtgtgga agaaacattc
6541 ttttaaaaaa cgaatgagat gccctagaaa cctgtaagtc aataaccgtg tcaccaattg
6601 taggattatc caggacatgc agagcctaca ctgacaggcc agttgaaagg gttagacacag
6661 ttgtaatcga ctaggaaatt gccactgtgg cttagaaaaa ccaagtcttg ttatggggtt
6721 tgcttccatc tttctaagct tctataaaag gtggctgggt aaatgtaccg ggattctgac
6781 gatactcacc ttgagataag ggatatgaag agtcgggaac agaggcaaaag tgaattccat
6841 atagccaaga acagacagaa ggaaaaacag attaaatagc aatcaaaaca ctgtcctcca
6901 cttaatgaag tggactgtca aactgatttt ctattttttt gttttaatca ttctagccag
6961 gcagactaga cactcgagaa ttagagaaat actaatgttg actagacact ggaaatgtct
7021 tatatactgg gagcatcata aagcttagaga aggccttaca agcaagatgg ctgccactga
7081 gatcagcaca ctggggtttt taacagaaac ctattacttg atttactggg agtggtagaa
7141 ccctaagaaa gcggtgaaca tccaacactg aaatttgagc tggctcttcc tcagaaaggt
7201 ttcagcggct taatctcatg caatcttgca acattcctga attcaaacc atgaagtaga
7261 gagtcagccc gagacctctc tcagaatcca cagagctgct tgggcaggaa gagctagctt

7321 gttgagttgt cctgctgcaa atgaaatagt aactttctca gaagcatagg atattgaaag
7381 attccttttaa gaggccaagt cctcaaaggc atgtatgcaa cgtgaagtca tgggggcagg
7441 ccttcctgggt tccaatgcat gttttcacag gggtgtgtct ctatgcttga aggggagctc
7501 ttgggcctat ctgagggatc atttaccact tgctgttaga aagtccagtg gaaatcactt
7561 ctagtgggtga gtcttggcca aatatactcc tatgtagaag gcctgtgtag gaggttatgc
7621 ttggaacagt tgagtagatg ttctggcaac ctgtgatggc cttactaagt catgacagtc
7681 agccaaaaaa aaaaaaaaga aaaaaagaa aaaaatcttc tgggtcacaga cacagttgaa
7741 ggtgtttcaa tttttgtcca ctaccatttg ccaacatgtc ttttaagtcac ttgccatcag
7801 aatctgtagt ggagaccatc cagacatctt ttgccatgaa taacatcaag ttcttctgt
7861 ataccaggcg ctgcagttag ccctggccag gcaccacatc aggtcagac aagtcataa
7921 ttttttgaaa tcgacccagt tggaggtagc agaaccagga ctgcattcca agggagcggg
7981 acttgacagc ttttagcaact gcgtctgctt tccctccgct cctagcctct cactaccca
8041 agatcatgtc tgttcaggat gcagctctct attcaactcc ccaactcagg gcctcctttc
8101 ctggcggtc aaatggaagc tttttttttt tttttngaga cagagtctcg ctctgtcgcc
8161 catgctagag tgcagcggcg ccatctcagc tcaactgcaac cttcacctcc tgggttcaag
8221 cgattctcct ctgcagcca ctogagttag tgggattaca gacgtgtgcc accatacca
8281 gctatttttt ttttaataaa ttttagtaga gacaggggtg gtcaggctgg tttcaactc
8341 ctgacctgtg gatccgcccc ccccgccctc ccaaagtgtc gggattacag gcatgagcca
8401 ccgtgctcag ccagaacctt tctttaactt gattactgtg ggtagttaca cattttcaat
8461 cgcactcaga ctgaagtctt cagagacact aggaacctgac ctgtgattgc ccctcgctat
8521 actcccaggg actaagcaca tggcctggca aaaaaacata gccttccaaa tatctcgttt
8581 tattttacta ttttattttac tttttgaggc aggtgtcttc tgttgcccag gctggagtac
8641 agtgggtaca taacagctct ctgcagcctt gaacttccgg cctcaagcaa tcttctctct
8701 cagtctccca tagctctggg atgacaggca tgcaacatca tgcccagctg agttttaaaa
8761 aatattttat agagatgagg tgtcagttag tttcccaggc tagcctccaa ctctagccc
8821 caattaatcc tcccacctca gcctccaaaa gtgctgggat tacaaggat aagccactgt
8881 gcctggccct ccaagtattt aaaatgaatg gatattctcc aaagactaag ctgtaaatgg
8941 ctgaacaact tcaattctta ccacatctgc tagatggtaa atatttgtgc tgctatttaa
9001 aagaaaaaaa aatcagcat aaggagatag tcaacttgaa ggggtgatgac cagatctctg
9061 ataataaggag ctagtccctt cttaattcca attaggagct acacgttggg aattagtgc
9121 attcaaacct ctatctaaaa caaattttta aacttttttt atcaagcata attacatgca
9181 aaaaagcaca tacataataa gtgcacgact caaattttcc acaaaactgaa tacgcatgga
9241 gccaaagccc agatggagga agagaaaaag gactagcatt taaagaaggc ctctgggctg
9301 ggtgtggtga cttacacccg taatctcagt acttcaggag gccaaagcag gaggactgct
9361 tgaggccagg agctccagac cagcctgggc agcatagcaa gacctcatct ttacagaaac
9421 acaaagatta gccaggcatg gtgaaatata cctgtgtgcc cagatacaaa ggaggtcaac
9481 atgtggggac tgccttgacc ctggaggcca agcctgacat gagctgagat cacaccacta
9541 cactccagcc tgagcaagag agcagagacc tgtctcaaaa aaattaaaaa taaataaata
9601 aaaggggcct ctgcatgtga agtaagtgtt gatgtctcaa aaaccacca gatggcagct
9661 tcggaaggca aagaaagaga aacgcaggga gtgggtgggg aactgcctg tctatggttt
9721 tgcactctgg ctgcaagcaa atgtgaggtg agcaaaaagg tgagaaagac agtgagcatt
9781 tactgaattc ctaccatgtg ccctaaggta ttttagttaa ttatttttaa aacaaagaaa
9841 ttgaggctta gtagtattaa tgcacttggt caaggccaca gatgccaggc ctgtgtgaca
9901 ccacagcccc tttatccccc actgtaattc actgtctcat ctctcagcct ggcattttct
9961 tcttttaact ccttttgatt aaaaagatg gctattttca taataatgac gttagtaata
10021 gctttaatta taactttgtt gagtctcag tctgcaacaa gtgttttccc tacattattt
10081 ccttatgccc atctttctta tgagaaaact gagacttggg gaaattaagt aaacttttct
10141 gagctctcat agagatctca gtaatagcag agctgggatt tgaatccagg cagcctgggt
10201 ctatgggttg catctgttag catcgtctct aaaagtacat gcaattataa ccagaattcc
10261 tttataattc cgttctctta attctctcatt agaagtggaa atgaacgtct tacgtacttc
10321 aaacactggg tagaagggtt gacagaaatt ttgtgcccta gactagagat ttctctocag
10381 ttggcccttg ttgagtggca tctgagaggg tctgcaaggc cacagccaag ctctccctag
10441 ggcattgctg gccatgaaata cagatgaggg ccagaaaagg ggggccagg gtaggcctg
10501 ggggctcaca cctgtaatcc gagcgtcttg ggaggccaag gtggcggtat cacttgaggc
10561 caggagtttg agaccagcct ggccaatatg gtgaaacccc tctctactaa aaaagataca
10621 aaaaattagg tgggtatggt ggtgcctgcc tgtagtccca gctgcttggg aggttgaggc
10681 aggcagaatt ctgaaccca gaaggcagat gttgcagtga gctgagattg cactactgca
10741 ctccagcctg atccagcctg taatagccat ttctctagag cctgtcacct agtgcatttc
10801 ctagtaagcc tcaatttagg atttagattg tcaccacagc tccagagtca tccaagcgtg
10861 aactggctcc ttggagatct tgtcacctgt gtctcacagg actcatttct gaccaccag
10921 gtgcagaagc actggaaact gtggtggaca caagcttcat cgaagcctgt gccaacatt
10981 cagttatcac cctggtgctt tgcaaacatc attacaaggc ttttaatccag gcatcgagac
11041 tcaagttcac ccagtcctc tctgtccact gtgacatggt tattcagcag gttcagcagt
11101 gcatacaggt tataagaata aggacgaagc catgggggga aaaatcccc ctcttctgt
11161 cttaggacag cagcgggggt ttttaccctt gattgctca ttaaaaaaa aaaaaaaca
11221 accttcacga aagttaggaa ttactatatt caatgtagaa tgccatttgt tcatcattt
11281 gatattcaac aagtattttac tgaattgctt ctatgagcta taggggataa tttaaaaact
11341 tgttttacct cgagaaatta atttcccag aagaattaac cataagcaga gtctatgaga
11401 ccctggctat tgggacactt aagactctgg tgggtgtggt aaaccagaat caggcggaca
11461 gtttcagatt taaaggaatt gattagatta ggcgggcat ggtggctcat gcctataatc
11521 ctgacacttt ggtgaagctga ctggggcaga ctgcctaaag tcaggagttc gagacaaccc
11581 tgggcaacac ggtgaaacc cgtctctact aaaatacaaa aatttagctg ggcatggtgg
11641 catgcacctg taatcccagc tacttgggag actgaggcag gagaattgct tgaacccagg
11701 aggcagaggt tgccgtgagg caagatcgca ccaccgact ccagcctggg caacagagtg
11761 agattccgtc tccaaaaaag aaaaaaagaa ctgattacat tggtaggggt gagaagagag

11821 acaaggggag aagaggagga agaattacat atttaaaaga tcagtggagg ttttttgttt
11881 tttttttaat ctgacacaga aaaaatgagc tctgaatcct gaatcaagac attgtatcaa
11941 ttccggttat ccccatgatg gcaggtcatt caagcttgga ccttagtctt cccatctaca
12001 aaatgggaag gtcaggggag atgtccttta atggaccttg tgattctaaa gtttgaaaaa
12061 cttatgatcc ctagaatgaa aagaagtaat gtgtgtctat acatttattt agtcaaagaa
12121 actgggtcat tgtcatcaag caaaacagaa accagagtcg tgaatgtgta tcaacagaat
12181 cttgaggaag cagattacct gccatccagg atcttagggt taggagatgg aaagcaattt
12241 ccccttccct gtttgaggat tgagtcatgc cctgtcagag cacttagggc tggccttaca
12301 catggacagg tgacagacca atactttgat caatgatttg tagttgatgg aagaagtccc
12361 ctggaggact ggaagacaga tcagtggaga gactttgatc tgtgtcattc agcttccaaa
12421 acctttaagc tcacataaac atagactccc aaggcactga cgtcaatgat aaatcccatg
12481 ttctccaaat gtgtctggccc ctcagttatt tgggaaaaaa gagcccatga gtaaaaggga
12541 gataaacata cacacacaaa cttactccaa agcaaatgct gactcttctc tctgctggct
12601 tttggctctg ctaagaggct atctgggggc aagacttatt gttgtttaga aactagaaat
12661 ctacaactca gcagctcttg ctcatctaaa tcagagtggg cgatgcactg taagttaggc
12721 accactcccc acgtccacaa aaataaccgca gaatcagtaa cccatcatga caccctttcc
12781 caacgagccc atgacagtg tcaaaatcct tttcaacaca gcacttcaat cggctgtttc
12841 aattgaccag acttggttca tgaatgaat cctattttac atccttcac taaattgtta
12901 ccggtgagc tgggagggag ggctgtgtgc acttcttgcg tataaacttg tgttggtgac
12961 tgtagtccag gcaattggca aataagaata gaatccataa aaaccatttt gagtaggaaa
13021 gacaggttgc agtctggatg cttggaaaag taggcacttt ctgactgaag ataatacaca
13081 ccaactctcg gactttcctt gatcccttcc taacccttaa gtgtttcatt tccagcaggg
13141 tgacaggata gagatctgct tcagggaggc ttggacccca cccaccatag agtccacaga
13201 acatgaataa ggttgactga ggttgactaa aacgtatata caattttaat tacatatact
13261 agtgtattta aaatttcatt ctaaactaat gtaatacaaa ctaatgtaaa taaacataca
13321 gtggttatct ctgaatgata ggactacagg tgatttttat tttcttctt taaaactttg
13381 gcctttgtga ctttttacag atcgcatgca tgtgtgtgtg tgtctgtgtg tacatgggtg
13441 tgtatggacg tttgcacgca ggtgtgtttt aatggaaaaa ggggggaaaa gtgcaaattt
13501 ctaagggatg caaagacata ttaaaaatcc atgagacaat gagatagcat aaggactaga
13561 agagctgcag gtctttcctc tccctgccaga ttattaatgg tcattatttg aggggttaggg
13621 gcatgtgaat tttagacata tatagtgcag cagagcctat gaatggctca tcagcattgg
13681 ttccaacggt ccttccctct ctcaactctc agagtgcact ttgctaaact gttggacaga
13741 tagtaacaga atttgtctaa ttatacagaa tgggtgaaaa tctttctatg ttctgtaac
13801 tattggctca gtcactgat ttaatggctc tggaaattcat ttttatgac ttattaatg
13861 tgaattcac ataccatag atttaaccat tgtaaatata cagtttgatg atagatat
13921 tatccagttg tgcagccatc accacagctc tgtctagaa cattttcttg acccccaca
13981 attgccccac cctttccagg taatccctc cactcactcc cagccccagg caaccatcat
14041 tctgtttgct gtctatagag ttctatcttt tctagaaatt tcatataaat gtcacatcat
14101 actatgtggt cttttatgac cggcttctct cacttagcgt aatgtttttg aagttcatct
14161 atgttattaa aggtatgctc agttagtctc ttttcattgc tgagtgtat tccattgtgt
14221 cgatagacta cattttgttc tccattcccc agctaattgga catttgggta tttccggcgt
14281 ttggctatca tggatgatgc tgctatgaac attcatgaac aagactttgt ataagcattt
14341 attttcttcc cagtaggttc ttaggaaggg aactgctgag ccacatatgt gtgtgtttaa
14401 ctttttaagg cactggacaa ctgtttccaa attcattgta ccattttaca ttcccaccag
14461 cagtgaatga cagttctagt tcttccacat tttcacact cttgggataa taaatctttt
14521 tggttagagc taagctagta ggcatgtcat ggtctggggc tagaactcat tttacagtgg
14581 cagcgtatgag gtcagaaaag gcctcagatt ggcagtataa aaattagttc cgcaatttac
14641 agctcacagc tcaccagttg taggacttta agaaactgac ttaattagcc aggcattggt
14701 gcaggccact gcaatcccag ctactcgtga ggctgagggt ggagactctc ttgaacctgg
14761 gatgtttagt ttgcagtga ctgagattgc accaaggcac tccagcctgg gtgaaagagc
14821 aaagctccgt cttaaaaaaa aacaaaaaca cacacacaaa aaaacaaaaac acacacacat
14881 acacacacac acacacacac acacaaaatc atttaacttc tctgagtctc agattcccca
14941 tctgtcaatt ggaactcata atagctctag attatgaaga gtcaccagtt gaggtgaagat
15001 gtgtaaaaga ttgtgcctaa gttcccatct atttctggaa caaaaagtat attgataaat
15061 atgtacataa aatagaagg gatatgaaaa tagacggcgt tggatttctt ttcttctgtt
15121 aaccaagcca agatgttcac tccattttcc tttgcacct aacttcttgc actccccac
15181 tcaccagtgt gccatgaaga tgagtgcag ttttgtctgt ctcatctctc ccacttttct
15241 tgtcattgac ccacccttcc tcatcattaa ccacttttag tgagctaaga acataacaga
15301 aggcgcctct ctccaattgt gaatacttcc tcaagccttc tcttccaca aagtcagaa
15361 ggactagacc cagcctgcaa taggagcgtt tatgacaaat cacaaatttg aaacctttg
15421 gctatcatat ttatgcagc ggtggcaagg gttcatattt gaagcttcag accaaagaaa
15481 gagtttgcct ctcagccctg atgctgcagg cttggcttct gagtgggtc acctactgac
15541 cctactattt taagaaaaac tggaaaggcc agtaatttgg atatggtcct agctcaagat
15601 acattacaga ctgtcccaaa ttccctggat agcccggtggc tggaaacagt gcattcctgg
15661 tttattgcca atgtccttga tttgcgtgct ctgccattta cttagaacaa tcaggctacg
15721 ttgcaagcca gggaacaaaa aacaccgcca ggagccaaat aggtccacag gggatgcacc
15781 agtgcccttg tggccctgaa cacttaagt attttgttcc ccttccaat tcgtgtggta
15841 cattagcttt tatcgatagc tcatagcttc agcaactgtt ctctgtttta ctaacctgaa
15901 ggacagagga acaagaggt cccacacagc tgatatgcaa gaaaaaaa atagcacggg
15961 atgtcttgat cagttctgat gatttctcc cttgctacat ctctccttta atgagggagt
16021 cacaattatt gcaagttaat catgtctcag tccccagag ggagaaagag tgaaatgacc
16081 acttgaatc tgaccgtggc tccctccaag aaaatcctgg tggcacagcg aggcattcat
16141 gaaactgcgg gctctgattt atactactgc tatggagact ggcagaagga ttcttcgggtg
16201 ttttcataat acaactacta aacaaaagtt agcccaggag ctagatggga aatctatgtt
16261 atggaagaga aagagatcaa tttttctatt gctctaaaaa acttaacatt tccaactaga

```

16321 atctgcacct tggagcaatg cagtgagtct atgactcacg gatgctgtga atgctgtaac
16381 tgcttccctt tctgcgtagt atgtgatcac ctacggtttt taaaaacat tattgttaaa
16441 atcaaaacaa tcacagatat gatttgttga gtaactatca caaaggccag acacaattct
16501 tgtttatttt ttgagacgga gtttctactc tgcgccagcg tggagtgcgg tgggtgcaatc
16561 tggctcactg caaactctgc cttccgagtt caagtattc tcctgcctcc gtctcttgag
16621 taggtgggat tacaggcact tgccaccaag catggctaatt tttgtattt ttagtagaga
16681 tgggggttca ccatgttggc caggcttggg tcgaactcct gacctcaggt gatccacca
16741 cctcagcctc ccaaagtgtc gggattacag gcttgagcca cactgcacct ggccggccac
16801 acacaattcc ttgcacttta cctaccttgc ctcaattcat tctcacagca atctaaggaa
16861 ttataaattt gtattgtctat tttgtggcaa aggaaactga ggttcaggga gcatttgaaa
16921 ttgtcaaaag cctcagcaag gaagagaaag agccatgatg tgaatcaaaag tccactggag
16981 tgtaaagatt tatctatggt gttgacctct atctgccctt cacttgacgt acttctttta
17041 aggaaatcag tcatttaata agtcttgcaa gttgtcttac attatttatg agattggcaa
17101 ggaataacag agaaagtga gaagggaaaa aaataaagga agagagtaag tcaaggaaaa
17161 aaaatcagtc gcatcttaaa tcattctctt aaacatatcc atcgcaaaa catacaacct
17221 ttagcacttt aaaatgtacg gagtttattt tacatatata catatgtaat atgttaataa
17281 ggggtgttta catattaaag cattaacttt aaaaaatgga atttgaaagc caggcgcggt
17341 ggctcacgcc tgtaatccca gcactttggg aggccaaagt ggggtgatca cttgaggtca
17401 ggagttcaag accagcttgg ccaacatgtt aaaaccccaa ctctactaaa aatacaaaaa
17461 ttagccagggt gtgggtgtgc acgctgtgtg tcccagctac tcgggggggt tcgaaggag
17521 aatcgcttga acccgggagg tggatgttgc agtgagccga gttcacacca ctgcactcca
17581 gcctgggcaa tagagtgaag ctgtctcaaa aaaaaaaaaa aaaaaaaaaa aaaaggagtt
17641 ggagaaaaat agccacacag ctgtttttta ttaccaaaag tccattgttc atctgtgatg
17701 tgtcagaccc ttgtctaaca gggaaatctca gagctgggcc caatgggacc tcaacagaca
17761 cagccagaat cacatcatgg aggttatgtg cagccctgtt tcaaaaagcc aaatccaggg
17821 ctgggtgcag tggctcatgc ctataatccc agcatttttg gaggccaagg caggcggtatc
17881 tcctgatccc aggagtgtaa gatcagcctt ggcaacatgg agaaaccttg cctctacaaa
17941 aaaatacaaa acttagctgg gtgtgtgtgc agcctcctg agatcgaggg tgcagtgaac catgactgca
18001 ctgaggtggg aggatggctt gagccccagg agatcgaggg tgcagtgaac catgactgca
18061 cactgcact ccagcttggg caacagagca agattctgtc tcaaaaaaaa aaaaaaatct
18121 gtaaagtaaa aaagggctcc attctgtatt atcttcagat atccaacatc aaaaatttat
18181 aaaataattc ctgatgaatt aacctagat ttactgtatg accccgtaat tccactcca
18241 ggtaggtggt taggttaggt gtttggcttg atataaatac atatccctaa gaactggaaa
18301 taggtgttcc acaaaaaact tacacagaaa tgttcagagc agctttattt gcaatagtca
18361 aagggtaaaa acaacacaaa tgcccataca cagatgaaag gagaaaaata tttggtatat
18421 ccatacaatg caatgatatt cagccacaca aagagagatg gacatgctac aactgtggct
18481 gaacctcaaa aacacgacgc taagtggagg aggccaatca caaaaagcca tatattgtac
18541 aatagcattt ataggatgtg gacatagttt tttgagagcc atcattccaa ctactatgc
18601 ctgtgatagt ttgtttatga agcaatagaa aactagtaca gtgaccaccc attaatattt
18661 tcatttgttt gttttgcccgt ttcaacagat acccactgag cacttgtctg gtgcaggcca
18721 ctatgttggg cttcagaaaac actgagtaaa taagagactt cgtgcctgcc tgaatacatc
18781 ttatggttgg gagattcact cttaggccct tctcacaag ggagccacaa tgccgaaaga
18841 tcacgaggac tactgatggt tttgagctgt gacactaaat cagcagggac cagtgttcca
18901 ttggtgactc tctgatgaaa gacaagtacc ctcttcccag gtacaaatgg aatataatgc
18961 tgcataattt tctaagatat tctaagatat tcagggtcca ttcataaagg tccatagtta
19021 agaactcttg gcctagagat ttttgagatg actctgaaaa agaaatatac taagtagaga
19081 atgtactgag agtgtctgct cattgtttcc aagttaaaac ttacttggct ggctgggagt
19141 ggtgtgctac gccgttaatc cttagcattt gggaggccaa ggccgggtgga tcacctgagg
19201 tcaggagtgt gagcagctc tggccaacat ggtgaaaccc catctctatt aaaaaataca
19261 aaattagcca ggcttgggtg tggcgccctg aatccacact acttgggagg ctgaggcagg
19321 agaatcgctt gaacctggga ggcagagggt gtggtgagcc aaggttgac cactgcactc
19381 caccctggca acagagcaag actccatctc aaaaaaaaaa aaaaaaaact tggcataacc
19441 accatgatgt ctaattgtat gtgtccactt gactgggcca caggataccc agatattatg
19501 ttaaacatta tctctagtgt gtccatgaag gcgtttctgg aggacattaa cgtttcgatt
19561 agtactatga gtaaagcaga ctgcccttcc caatgtgggt ggcttcatac aatctgttga
19621 aggcctgaat aaaataaaaag gctgagttag aaagaactgc ctctctatgc ctgacttcaa
19681 gctgagacat cagcttctcc tgcccttcca ctcagacttg gatattggaat ggaactgatg
19741 cctttttatc tcctgcttct cagctgtcca gactcagaca tgaactgtac cattggttgt
19801 cctgggtttc gatgtctcag tctctgtaat ttcatgagtc aattccttat ttaaaaatct
19861 ttatatatat ctttatacat atatacagaa aaatgtgtgt gtgtatgcac ttgtgtgttt
19921 atagatctat attgaactat atatacact attatacact gtattagtac acagtgtata
19981 gtacatacac tatagtgtgt atagtataac tctataact atagtgttta tatatattat
20041 ttagtacata taatgtatag atatagaaag acacacccat aggtgtgtat agatacagaa
20101 acacacaccc ataggtgtgt ataggtacag acagacacac ccataggtgt gtatagatac
20161 agacagacac acccataggt gtgtaaagat acagacagac acacccatcg gtgtgtatag
20221 atacagacag acacacccat aggtgtgtat agatatagat agacacaccc ataggtgtgt
20281 gtatagatat agacacaccc gtaggtgtgt atagatatag acacacccgt aggtgtgtat
20341 agatatgcat atatctctct ctatatatat aatagatata tgtgtgtatc tatatctata
20401 catagatata cacacacata tagtattagt tcaattttct cagagactcc tactacaacc
20461 atcagtatca ccaacaacca aatctttctc aaatgtttat caccagaaag caatttttagc
20521 cttgacttgg atattacaac cttgaataga aaacattaga ggcctggaaa catggtgtat
20581 ttaattttct ttgtgcttta cctatttcaa caattttctg actttttaag acagaaacta
20641 ttcaaccaac ttttgaaaaa tcaaaaagaag gaaatgagtt aaaggttttt acctggaatt
20701 caaacaact aatgaaagat gacatttata atatttagag aatgattgga aaaaatgggac
20761 ttcacttcat gatattaaat aatttgggt gttttgggt gtgatgatga tactgttaatt

```

20821 atcatttttt aaagagacct tacttttagt tactcaaat gtctatgaat aacaatatat
20881 aatgtcttgc gtttactttg gtaatttttc aggcattggg gaagtgggtg gagagagata
20941 aaacaacaat ggccacatgt aataattact gaactctgat ggtagactca tgggatttaa
21001 ttatactctc tgtcaacttc tgtaaatcat ttacattttt aaaaataataa gctggagcca
21061 aaaaataattt taaagccagt gtgaataagt taataggtgg ataggtggat ggatggatgc
21121 atggactggg agaagcctta cgtccagct tgaagttagg cagagggagt caattctttc
21181 ttactcagtc ttttatttta ttcaggcctt caacagagaa ggaaaaagg aaagaagcaa
21241 agagaggaag aaagagagag agggaggaaa ggcaggcagg cagacaggac ctctgaggct
21301 gtgcacagt gctcacacct ataattccaa cactttggga ggccaaggca agcacattgc
21361 ttgagcccag gagttcgaga caagcctagt aaacatggca aaacccatc tctacaaaaa
21421 aaaatacaaa aaattagttg cgagttacgg catgcgcctg tagtccagc tactcagggg
21481 gctgaagtgg gaggatcacc tgggctggg aggttgaggc cactgcactc tagcctgggt
21541 gacagagtga gaccctttct caaaaacaaa acaaaaacaaa cactctgggag agaaatcctc
21601 cctatagcct gagctaaagt ggcattttt aactccctaa ttttagctag tccccagaca
21661 tactcaagaa catccacaca ttttgacgtg cagcagagca ctaaagcgga tgttggcact
21721 gctaacagga agaactcttc tttttcacgc attatcatta cctgaactta tatgaagtat
21781 ttattttgtg tttgttgctt taccttctcc acgataatct aagatccacc aggataggga
21841 cttttctttt tcacagtatc tttccctctt agaacaatgt ctggcacatg ataagaggct
21901 ttttttttcc ttcttttttc ttttgatgtc aggcattttg cataaatgaa taaatcaaag
21961 tctagccaat tcatttgtat cttcattgac tgctactat atactaggct ttatgtgagg
22021 catcaagata gtgaatggga ggtgctcaga acagacgtta tatccaaagg gggccaagt
22081 tgggaattct tcaattacct tcacagaagt aggcactat tcattcatcc atccatttac
22141 tgattcaca aaatttatta agcatctact atagtggaa tgacaaatag tataaataat
22201 agcacagtat aagtaaatat ttggtaaaa ttctcaacta atacaatcta catttttagca
22261 tatggcgat ggaataagga tgggagctac ttcatattcc acaattccag ccaaagttt
22321 atgtgtttgt gcaataatgt aatatgcggc tagaaaaagg ttacaatttt tcttttgaga
22381 actaaaaagt ttactcgtga aaatgctatt tatctaagg attatagcta ttgtctatag
22441 ctatctggat atgtcaccaa atcacaaagt tcattatgct ttctcattca agcaagcaaa
22501 aaatatgtct acttggaac cactgttta taagtaagt aaaaaggag atgcaaataa
22561 tgtcttttaa aaaaaatcac tgttaaatca cattaaattt cctcttcatt ttcttctta
22621 aaacttaact atcgatgtcc atcttttga aataaccatc aatagctatt agtgttctgt
22681 ttgccagctg ttatctctc taaccagaa ggctatggag aaatttttga gtacattact
22741 cgccctgctc ttaaaccaag agaatacag aagatcatga gttttaggga ctgacacata
22801 aaatgctgaa catgaaggtt tttccctaa aaccaaatcc ataatagacag gaaaaatctg
22861 aagttttact aacagcaaca tgccctctgg aatgggtgct aatgataaaa atcgagctg
22921 aacacattcc atttttaatt aatttttaac actgtaaaaa aagcttttcc ttgcaatag
22981 tagaccagt tcttctggt aagattccca aaagtactgc aaggtacctc tgctcttttc
23041 tgggaaggcag agctcttcta atttattaga aattgcagga agggagtagg gagaagggga
23101 attcagcagg ggggaaaaat caattccatt cctgccttct ccacttccat ttcaggcagc
23161 tcagcccaag ttttatgctg ggaacaaaag ttgaaatcag ttgaactcat ttagggccc
23221 ttcatcctgc ttctctgcaa aggtggaggg ttctccccag tgtctcagat tgccccgaga
23281 acatcaagga gccacttcat cgattatagt tgtgcaactg aaatcgtttg tcttttttt
23341 catatatata tatatatata tatatatata tttttttttt tttttttttt taatttcaaa
23401 actagtagat attggccagc cgtggtggct cacacctgta atcccagcac ttggggaggc
23461 tgaggtggga gggtaacttg agcccaggag ttcaagacca gcctgggcaa catggtgaga
23521 ccccaactac aaaaaggctt aaaaatttag ccagatgtgg tgacacatgc cagtgggtccc
23581 agcaactgag gaggctgaga tgggagaatc acttaagcct agaagtttga ggctgcagt
23641 agctgtgatt gtgcctgca ctacagaatg ggtgatgaag taagacacta tctcaaaaaa
23701 ataaaaagga catgttgatg gaacacaatt caaacatgac aggtaaagaa aaaagaaaga
23761 aaattccctc ctcaaggcct tctcagctcc taagccacac tccgtgctgg tgatagaagt
23821 tatctaccac tatttataat taatgtttat cactcaacc ccaatcatt ttatgaaaa
23881 acacacaaaa acattcagct atgtgtatag ttttttttta aagacatgat aatacatgta
23941 ttattcttca atttgccttt tccaactcaa aattatatca tgtacagcca ttatacatat
24001 acagatacat acatatatat acatacacac acatatatat acatacacac acacacacac
24061 acatatatat atatgactac atattgggta cagcatatgc tgctcagatg ggtacactga
24121 aatctgataa atcgccacta aagaacttct ccatgtaatc aaaaaccact ttaccoccaa
24181 aacgattgaa ataaaaactt atatcatgca cagccaattt atacacacac acacacacac
24241 acacacacac acacacacaa acacacaatg tatgtatata gaggtatctt ttaattttct
24301 ttcatttttc ctttttttgc tatagagtat ttaaaacttt ggaaaaactg taactcaaat
24361 acctctttat taatatcaat ttagaatgta ataggtcaaa taactaaata aatatgtatg
24421 cacacaaaaa atgctaaaaa agcatttcat tcttctaatt ggggtgctctg gcacattcat
24481 tcaaatattt ctgtattttc tggtagagaa tggaaattgt tgatcaaaag gcatgtgttt
24541 aatttcggct aaaaatgcca acttgttctt caaaataacc aaaaacaatg tatgtctcta
24601 taaacagcag ctgttctttt ctctgttaaa ttggaaaact ttggaaaact gagttatgag
24661 catgagtcaa agttttatta taatgttact actagggaaa aggcctctag tgatcaattc
24721 aaagattcag ccttgggtgga ggcattttat aggaaaatga aatgacaaga tagtcaatgt
24781 taggctagat acaaaaggaa aataacattt ggtttaaggt cactagactc ttgaccgaca
24841 gtcagtttgg tgagtgggt gactgatttc tcagaacaag tcttaatcgc attaaagttt
24901 atcgaaaaat gtgttaagca atttatcagg aatgaggctg tgaattacat catgcatcat
24961 ggaaaaaaag gttctatttc agaccagatt caggacaact cttctttttt atacctttt
25021 atacttacat gctaccaaac atggaagtta tctgccttct taacttttgc caatgtcatg
25081 ttgaaaaaca gtatctcaat gttcaatttc catttttatg attaaaaata aagttgagaa
25141 gtttttcatg ttttccaatt cttttcattg aatttcttgt tcattatctt tgccatttt
25201 tctatttaga ggttcacatt tttcttttcc cttagccaaa actcttttga tatgtgagat
25261 aaattattta agcactgtca cacactgcat aatgacattt tgatcaacaa tgaaccacat

25321 atgcaatgggt gatcccagaa gattgtaata ccatatttta actgtacctt ttctatgttt
25381 gtatatgcaa atacttagca ttgtattaaa attgcctaca gtattcagga cagaaacatg
25441 ctgtacatgt ttgtgccag ggagcaatat gctctaccta gcctaggagt atggcagggt
25501 ataccatcta ggattgtata ggtatactct atgatgggtg cacaatgaca aaatggccta
25561 acgaagcatt tctcagaaca caacctcctc tctaagcaat gatgactgta tatgtaaag
25621 tgtatgttcg tgaatatgtg tgttaaatct atgtacatgt atatttctat ttcataagat
25681 agtacatttt tttaaagtac tgaattatat gccccttccc attgtactga aagagatcta
25741 ttccattttc ttctcttttc tgagacagag tcttgcctcg tcaccacgc tggagtgcag
25801 tggcatgatc tgggctcact gcaatctctg cctcctgggt tcaagggatt ctctgcctc
25861 agactcctga gtactgtcta ttacaggagt gtaccaccac aaccagctga tttttgtatt
25921 tttagcagaa atgagggttt gtgatgttg ccaggctgggt ctgcaactct tgacctcaag
25981 ctatccaccc gcctcagcca accaaagtgc tgcgattaca ggcgtgagcc actgtgccag
26041 gctagatcta ttcaacttct acttcgataa aagtcactac aagcctgtta ctccctgctt
26101 taaagctttc ggtgccctta cttgcctaca aacaacgtcc aggcctgttg caaggccctt
26161 tccaacgcag tctctgccta atctcttctc attttctctc gtcattctgt tctggccctt
26221 tatgcaccaa aaaaattatt tctagggacc agactgactc ttttcatccc tgaactcctt
26281 tcttatgtcg atcctctctg cagaaacatc ctccctggat actcatattt gtcttcccct
26341 gctcgaagga aactttgccc aattatttgc cttgccctgc aagtaaagtt agataaagtt
26401 agtcactccc gatctgggta ccttgtgcgc gcaccgactt ttctcgtaca aaactcattt
26461 tgattgattt gttcccaagt ctgtcttctg taaaagactt cgagttacat gagagtaagg
26521 actgggcctc aattttccct ggatccctcg ggcttcacac agaactctgac agacccaagg
26581 tggaggtcag gaaataagtg atgaatgaac aggcatactt ttctgatcca cacagcatga
26641 gggaagcaaa cacagaagtt aggagaggtg gtgcgtctct ctccacccca accaataaac
26701 aaaaacaacc ttaaaccctg aaaatgatta agtctataca ggctggaaac tgggagaaga
26761 caggttgtct tccctctttg gttagctcta gaactctgat ggctacagct ctgagcagga
26821 agtattaaaca caaacatcat caaagtgcct ggggaaattt tattgtctgc cacatttaca
26881 aattggaatc gatcttctt cagccagttt cgccaaagtt tctgcaaagt gaacatagca
26941 aaagataggt ggtgcctttc agatcacctg tgattaaact cactgcattt gtcttcaaac
27001 aaaagtgttt ttttttctc cccgcaacat acaatttttag tcagctaaca cttaaattaga
27061 caccactcca gatttattat gataagaaca ttcagtaagc taatttcaag aagatgactc
27121 ctataaattc ttataattta ttattttagt ctttgggttt taactattaa gtactggaag
27181 actttgtagg tcaaaccctg ataatgaag acagtaatct atttttcaaa ctcttctcct
27241 accacacttt caaattgtaa ataacagaa agagatttaa acacacttgt aagaacaaag
27301 gtaataaattg gggggtggtc cccactttcc taatctttct aggtagactg tcaatcatag
27361 tctctagttt atcatactga atcatactga tttttttaa taaataatg gagtgtaaat
27421 ttgagaagcc attacttcac taagaaaata aaacacataa cccattttaa agttttgtta
27481 aaaaaaaaaa aaaaagctgc tgttcaaaaa tcagcaaata gagctggcac ggtggctcag
27541 gcctctaata ccagcacttt gggaggccga ggagggcaga tcacctgagg tcgggggttc
27601 aacaccagcc tggccaaaag tggatgaaacc ccatctttac taaaataaca aaaagtagcc
27661 gggagtgggt gcatgtgcct gtaatcccaa ctacttggga ggctgaggca ggagaatcac
27721 ttgaacccgg gaggcggagg ttgcagtcag ctgagatcgc gccactgcac tccagtctgg
27781 gtgacaagc aacatgtctg ttcaaagaaa aaaaagaaac aaattagcaa atacaggtat
27841 cgttaggtgt taatctcaat agaggaattt ttattgtcca ggggtgttac aatttgaggg
27901 atgcataggt aaaagtaaaa tattaactgg ctacatattt tagaaagcta ttgatgttaa
27961 ctaaaggaca gtcttcatct cctgaactca ctgccaattt agaattgtgt tcatgataat
28021 ttcaaacatt tgggtgctaaa agacttaagc gtttcatatt gctgaaccaa ggaattctat
28081 ttgatacaat gcatgcaaat aataaataaa gttactgca tagtaacatc ttttcatatt
28141 atctaaaata aaatgaagtt ttattataat acaagctcat tataagcaac ctgagtattt
28201 agagtagaaa gaacaatgtt cacaattatt atttttaatt agaaaaata tcaagatgcg
28261 aaatgaaata actgttcggc aaagtcacta ctatgtaaaa acaatcgtgt aaatgctgag
28321 aaaaatatag aaagaaatat agcaaataga tagtagtggt tatcttcagg tgggtgtaca
28381 acagacaatt ttttttttca ttctctctgt tcatttttta atcgaacatt ctggaaattc
28441 cttcagaaat aaaaaggcat atgtttgtat ccatgatact acaagtattt taaattacat
28501 caatgtctga atcttcatat gacagataga cagtcagcat ccattttacc tgaagatcta
28561 ttgctgaggg ctctcgtatt aaattattac aacaaggact gcttatggca tctcttggtt
28621 cagtgaaaac ctccctggga tgtagatata tgcttacaag ctgggtttca taacaggaag
28681 cccactacac cccaccacg caggagagtg catactacat tactttagaa gtatttatcc
28741 gccctctctc tccaccaggg gaaaggcgaa gtactacagg tttttcagat aaaatccttg
28801 atgagaagaa aatacaaga ttctgcctca tggcaagaa gattcatgag taatggagag
28861 cagtgagggg gtttttagc acgggtttat ggaatgtttg ctgaaactgg atttctggat
28921 tttgatgatc aataactaaa taaataatga taaccacaa atgaaaaca ataccagcct
28981 ggttaacgtg gcaaaaccct gtctctacta aaaatacaaa aatcagtcgg gcttcgtggc
29041 atgcgcctgt aatcccagca ggctgaggca gaagaattgc ttgaaccag gagacagagg
29101 ttgcagtgag ccgagatcac gccactgcac tccagcctgg atgacagatc aagactgtct
29161 cagaaaaaac aaaaaagaaa aaaataataa taattatacc tgctatttac tatgcatttg
29221 ccatggctat acatggcaac atattaacat attgttataa cgtatagtac aacatattgt
29281 tatgcaacaa attaaacacc ttacagacat taaactccca cactaacccc atcaggtatt
29341 ctcattttgc agataagaaa actgagataa gacattacta attatctgta tgaccccggg
29401 caaatcaaca ctgggtgggg gcaagatata aattgcagtt catctgactg atctccagta
29461 tgtcatttaa tgatgagaag aaagaagcct gtcaccaaac tactttttga gaaagtgcta
29521 tatgcagagg gaacaaagaa tttattactg tataaaagtt tctgccaca aatgtgtaca
29581 ttttttaacct caagaaacag gtggaacctc tgaggaactc ctacattttc ttccatttta
29641 attgttatta agctattaca ttattttatc tgtaggcagc gcatatgggc tctgtattaa
29701 tattgggtgt tagcaaatta ctccaaaatg aagcatctta aaaattaata aatatttact
29761 cctcacata gattttctgg gtcaagaatt caggagcagc ttagctagct gatttgactt

29821 ggggtgtctcc taagtcaaga tgggtcatttc atctgttggtc atccaaaagt ttaaaggggg
29881 ttggagggaac tgcttccaac aaggctcgcg catgttggtc ggcaatctgg tctgactggt
29941 ggaagcctga ttccttgcta tgccgatctc cccatggtgc tgtttgagta tctcgcacac
30001 atgggtgtcta gcttctgcca caaggagtga tccaagagaa gcaaagcaga agtccaaatg
30061 tattttgtca cctagcttca gaggtcatgc gctatcactt cccctgtag gttacacagg
30121 acaatcctgt ccagataga agagaatgt actgcaatgt aaaaccagg aagtgaggg
30181 cactagaggc catcttgaga tctggctacc acagaagctc atctccctt ctctagacag
30241 tgccatgctc ttaagtattt aaggttgaac tctaacttt caacaacaaa atgacctcaa
30301 aatgaatgag atgagagaat gaaaagtcac cttgaagaaa tacaacatg tcccagttca
30361 agtcactctt gattgtgggg ccagtattat acaaggatcc caaaagtgtc gtgtttcaaa
30421 cagctgagga atgaatgaag attacaggtta cagaaaccaa gaggtcttag caatgatgct
30481 gaagatgggc atgaaggggt taaatgaat tatttcataa atgtaaggat atataaaaaac
30541 tccagctctt taaaataaat acattacttg tgaaaatgca ttagcaagtg aaatcctaca
30601 ataaaaactt tgaacagttc atctacagcc cctaaagttt ataaactggg cacaaaattt
30661 aggggtggtc cacttcattt gaaaataaaa aattgtttta tatttgaggt caccttgtat
30721 tttgaaacgt attgactcag ccaagattta ttgagcatct ctatgtgtcg gacactgtcc
30781 taggttggtc aaagtgggtg atgagacaga taaagtccct caccgtctag tgggaaagat
30841 ggaaaaataa caaacacaaa cgtgcaatac agcttctactg tgaaagtatc aggtcatta
30901 tcttctgagg caaccaagca ttttgatcat ataggcaatg accttctgtc taatcatttg
30961 ccaattaaat aacttaacaat gtcacttggc tcagtaccg tacttctgcc tataagtaaa
31021 ctctttttct gtagttccac ctataagaaa attctcatcc tctcttcta ctcagattaa
31081 caagagcatt tcaactatg tgataattat agctcctgtt gaaaattatt gtttatgacc
31141 ctgggtttac acatcagttt ctgtgaattt ggttattgta gactctgtac ctaacagaaa
31201 gacctactct tagtgggctc acaaagtcta atttctgaat gagcaagttt gagggtgaaa
31261 gccatattgt taatgaactc atcaaggtaa ataccacagg caagcttctg gaaattaagt
31321 cacctggcct cactgtccac acctaccctc tttcaataa ctcacatgta atacattaaa
31381 aaatttatct ctaggagctg caaaagaaac actacatgca gagagacca gaatactgag
31441 agagggtgtg gcacactccc gactgccatc ccgattcctt attcatgact gatcaataag
31501 tgatcacaga aatcttccat gttgagccaa tatggcacca agttctactc aatcaccaaa
31561 aatagacact aagaactcat tagtgtgaaa agacagtggg gctcaaagac caggggtatc
31621 aatatctggt tgtcccaata agattgggtt cttttttgaa ttgagccctg agtccacaca
31681 cccctgggtc acagcagtg actggcacag agacacaagt aggtcctgga tgaggctcgt
31741 cattacataa agcttcaaca atggtgaaca aggatggtga tggtaaatat gaagtagcag
31801 tggaactcca aggaatcgta aacaatggg gagaggggac taaacagcat tatatacaaa
31861 cgtttcattg caacattatt cttagcagta aaaaaactat aaacggtata aattccaggt
31921 tattgaagag tttatgagct ataaggactt tctatcactt gacagctttt atctagctga
31981 tatttgacat taataatcac tatgttaca caggggaaga cacttgtgct ataattgtta
32041 gtgaaacact cgggatgtag tatcaatgta ttataactaa tattatggag gcgaaaaaac
32101 tcattcatag gggaaaatct gaattgggtt accaaatact gacctgggtt gttgtctgga
32161 gtgatgacac attggctagt tattattatt ttctctattt ttttattggt ttctctttgg
32221 ttttttacac acacacactc acacacactc acacacacag aaactggtag tgaaaacttc
32281 tgtagactaa aagccaaatt ctactctat cactctattt tttttttta agaaggaatt
32341 tgcctctgtg tgcccaggct ggagtgcacat ggcattgtct cggctacca caacctccat
32401 tcctcagggt caagctatc tctgctcctc gcctcccaag tagctgggag tacaggcctg
32461 gtccatcaca cccgtctaatt tttgtatttt aagtagagac aggggttctg catgttggtc
32521 aggtctggtc cgaactccca accttaggtg atctgaccac ctggcctcc caaagtgtg
32581 ggattacagg catgagccac cagcccaagc ccagcctatc actctatttt ttatgggtcc
32641 tttggctcag gtaagaacaa tataaacctc gccctttgct cactgcatca agattagaaa
32701 tctagtctag ggaggaaac aaccatactg tgttttgc tcaaatacag aaacgaaatc
32761 aaagtttgcc aaggaaggcc tatctcaaaa tgtggttggt gttgttttct ttttttttt
32821 tttttttttg agagggattc aggtctgtgc acccaggccg gagtgcagtg tcacgatctc
32881 cgcctactgc aagctccgcc tcccgggttc acgccattct cctgctcag cctccccagt
32941 agctgggact acaggcgccc gccaccagg ctggctaatt tttttttgta ttttaatatg
33001 agatgggggt tcaccgtgtt agccaggata gtctcgatct cccgacctcg tgatcccccc
33061 cgcctcggcc tcccaaagtg ctgggattac aggcattgag caccgcgccc ggcctgtcgt
33121 tgtgtttttt gacaacttcg tgacttcgca atttctagga atgagtgcac ctgtagcaac
33181 acgccccaaag gtgagtgctc ccagagactt acattgactc ttgtatgttt gggcagaaca
33241 gtggccaaac gtagaccctg gggagctgtg gcaagattgt caacagtgat catgccatg
33301 gggacaccaa ggcaccctat cctactgctg ctcatggtta ctatgtcttt gcgagtcac
33361 gcagcaaatg attttcagca cctttacccc taaatagaaa tatgatcaca accagcagaa
33421 aaagaagcgt actaacttat ctgcaaggat aaaaactggg ctaaatagat ttttcggctc
33541 attaaaggaa tacagaatct cagaggaggt taaaaaaaat ctcaaggag gttaaaaaaa
33601 aaaaggtctc tgtgtaactc ccgtctattt tgggaatctc atgtatggca ttgagaactg
33661 gtgggttaac ctcactatta ccctgttggt agggaggag cagactgatc taggctttgc
33721 tttctgcttc atggctgccc ctggttaatta ggctaattt ggccacttag ggccacttag
33781 atactcctgc ccttccact ctgcacctg tttcctccca acaccaggcc aggttccccg
33841 tacccttagg caacaccaca taaaggactt tccattcccc agcattcaca gtgctcactc
33901 caccctcatg ccagtcgctc ctgagctctc tcttctctgg tgtgagctga taaactca
33961 gagccttaca ttttaacagt ggttctttct cgaggtgctg gtctagtcca aaagccaagt
34021 tccaacagtt agcaaatata gtgcatttag ttgactgtc tgggaaggctc tgtgggggca
34081 aacatgactt gaagattttt ttcaacatta acaacaacat caacaacgaa aagcagcact
34141 gattggggag ccacgggtga caaagttact cttacttgtt ttccgtatgt caactcta
34201 tcattggcat ttgctggata ttaaaccctc gcaaaaccca gtgagtaaca acagtgaaca
34261 tttttcttat atttagtttc tgagtcgcg aatgggctgt gctctttctc tgggtgtgtc

34321 ggggtcaggt ggtagcttgg ctagtagcta gatgactcta gagggacctc actcatatgc
34381 caggcaccga caggctatca gctggggcaa ccactctccc tttatgtggc caccatgctc
34441 cagcaggtca gctcaggggtt gttcgtgcag tggcacagg gttgtaagca acgaaacaga
34501 aagtcaccagt atctgaccgc ttgtcatgcc tctgctgcta agattccact gggcaatgcc
34561 agtcatacag gacaggtgtt gatgcggtga gggaaatact gttttccttt ttcttcttct
34621 tttttttttt aaacaagcta ccatttttcc aatttaccat accctcccca aatcctagcc
34681 tttagtgtgtt attattttcca tcttatagaa gaagaaactg agagttaaat aacatcccaa
34741 agaaagctca gaataatgaa ctcagttgtg gctagatgca gtggctcaag tctgtaatcc
34801 caacacttag ggaagctgag gcggggagaat cgcttgagcc caggactttg agactgagct
34861 gggcaacata gcaagaccct gctctccaca aaaagaaaaa aacaaagaaa caagtttgaa
34921 aaaacccagt tgttgtgttg gatttggatt aggtacaaac acacattaaa gtgtacatat
34981 atataattta taatagatac tgatatgtta taaatatatg aacaaataat ggaatgtgtc
35041 cagaagaaaa tataaatata ctaaaattat aatatacaca gagatacagg aataaatgga
35101 gataggtgta tgtgcatggg tttgtataat acacatattt ctaaaactctg ttgagaagtt
35161 ctttagaagaa tctgaagcaa gcaagcttga gcgcaactag cactagatc ttagtcttaa
35221 atatgattct ataataaaac gaaccaagcc tccatggaga atgagttaat tccaagactg
35281 aggcagggaa gtccaagatg acagtgtaaa gcctcttaca gtgccaaaaa ataagaaagt
35341 gctcaaaaaa gaacggggca tgtcaaaaagg gtgcaggaaac ctgcccgaac gacctctat
35401 gggccaaagc cggaacaatt tgagcaccac aatatatcac aatactgtcg tattatgacc
35461 ttcagaataa actaaattat cacttatcca taccataata aatggagaag aagaaacagc
35521 cttccatgta gaagaattcc caccaaaaaa tagaaggcat gacagaaaga caatatcagt
35581 catgagaata ccacagtatt aatcatttgc ggcaagatcc ccagagggat gctaaaatta
35641 attgatgaaa attagagaag tagtcccaaa gtacctcccc caatatattt attaattaca
35701 aaggaaaaaa ttgtactctt acagtggaga aatctggcag ataccacgtt aaccgagagg
35761 tcaaggctaa catcactagt aataagatat ttccacatta cacatctctc gacttgatgg
35821 ccgaagaatg gcacatcact tatgtatatt cctcccaaaa atgcaccacg tcatttctaat
35881 caagagaaca catcagacaa acccaaatat cgggcattct acaaaataac tgaccggaac
35941 cttcaaaaaa ttcaaggcc attaaaaaaa ataatgcatg agaaaactgtc ccagaccaga
36001 ggggactgga gagatatgat aataaatgcc aggtggtatc tggttgtaaa agaaggaaga
36061 ggacacaccg tcaaatccaa ataaagtctg ttggtcagtt atagtctgag tgtagttaat
36121 agcatcataa caagggttaac ttctcagtgc tgaaaaatgt atcatgttag tattagggga
36181 agctgacatg agagtcactg ggaatctttt gcagtatttt ttatggcttt tctgtaagcc
36241 aacattttat tcaaaattta aaaactggaa caaaccaacc aaccaacctt tcccaaggctc
36301 ccacagctcc tgatgactaa gtctgaattc aaatccactt gtgccagatt ccaaaactcca
36361 tgctttccat cctgtgcagt gcctcccgca tccacgttac catcttagaa ttggttcaga
36421 ctggattagg ccaccctctc caaatgaaat attttatggg aaaaactggg ggcacaatta
36481 ggcataaaac catctacctt aaatggggaa aatgaggcac aagggtcata aaatggacgt
36541 gcagaatatt cactctcata ttcactctca gctccatgtc ttaagtgtcc acataagcca
36601 gcttataatg tcattttcttg attccattaa attagtacag gattagtaca tatctcaacc
36661 ttcaaccatt ttgtcactta aaatgagtgt ctggaaggcc attcttccgg aaatattagt
36721 taccttgttc attacttact taatcatagc ttggagttaa tttttgcctt gggaggctg
36781 actataaatt atggactatt acgcagcaaa gccacactta gtaaattata tggcattgga
36841 aaacccctgc ttttggggga aaattacact ttctttaaaa atatgtttta taaaatatta
36901 tgctaagcct gtaaaagaga atccatgagc atacttttg gccataagga catatttgac
36961 agtctgactc agtttccagg ccgctcctaa aaagggtttg gaatggaaaa cttctcattt
37021 gatattcatg tcagaatggc cgtggtctgt gaatttctac atgcagacag ataggaggaa
37081 aggtcggaaa ccttgttggg cttcacctat gatgcagtaa ataaattagc catgtagtct
37141 taagtttcat tttgagccac aatagcagac taataggcag tattttttca cagttatgaa
37201 tggattcttt ttttttttta agaccagctc atagaagtac tttggtattt gatttaaaaa
37261 aaaaaaaaag acagcaagat aaaaaaaagt gcatgaatgc agggctatta aataggagga
37321 gacaacgacc ctttgggaat aaggttttcc atttgtctgt agcttttcca accgcttcac
37381 tgcgctgtgt ccgcactggt ggagacagcc ttccaggctg gccaaaggaag ttaagacttc
37441 ctgcctcaat aggcagctct ttgttgttct gtcagggcca aagatcctga gagtacgcaa
37501 ccactagctc acacggtgac actgttagac tgtgccccag ccaactctgg ccggggatac
37561 ataaatatac aagactaaaa aaggaggatg gcactggggt ttccagacgc atcttgaag
37681 ccagacagtt gcccagctta aaagtctgca aaatctttct ttaaaaaagt atgttttaat
37741 ttgaggatat taattgcacg gaaattattt gactgtatga tttataaacc cgccagaatt
37801 ctgcggtctt tccctccaca tgtgctgttg ccattttccc ttttgtacac ctatcatttc
37861 ccattgttta tcttccctga ttgatgttgc ggctcgggat gttttccatt atgagattca
37921 taattatcac tggtaataga gaaggcttcc ctattatctt cagtgaagact gccaaatta
37981 ttcactgtaa cctactggta ccacacggca ggaaaataag aatttatttc ccatccagg
38041 catatggtag ataagaggat gtatttattt ctccatgttt caaaaggatt aagctttgaa
38101 aaaaataata tcacttaggc tgtcagtaag cagaacttta tggttctggg ttttagagggc
38161 ctctcttggg ctaagaatag cacaactaaa ctctggtttc caaaagaggg gaaggtatgg
38221 agttggggaa tctcttacag ttttacttgg ctaaaataaac aaatacgata gatttcaacc
38281 acagtatcgg tctacaaggc acccagcgtc accttagacc tccacgttaa ataacgcacc
38341 agcttattta taaaaatgtt accaaattcc agcagtcttt aacctctggc tattctcaga
38401 gcatgttgaa tacatcatct gggttttgcc taattacaca taattaggaa atgtaattac
38461 gctttctcgt cttgtctgcg cattaggaac cgagtggaca gctgaaacgc taccaaggat
38521 gcagcgcttc agagaaaaca aattaaaaat atgagccaac ctctaaaaat agggattgtg
38581 ctgaagggtta gtaaatcaaa cttattttta aaaacataat aaattgcttt tggctctggc
38641 taaatatttg atgcaacagt tatgtctggc gtctttgttt tggggactta cttaagtata
38701 cattatttgc atccatgctg agccacggag agggaatgaa ttattttgct cctcgatgag
38761 tgtgatttgc tcacttccct attcatttat gcttttttat ttttatttcc tcttttacac

38821 cggaccctctg ctctggccaa ggaagtgtatt tccaaccatt ctgtgtcaaa gagtcaaaac
38881 atttcattttg tgggttttgtt gcatatggag ggtgtcaatg cccaaagctt aggcaaagct
38941 gacagtaatc tcatccctctg agctgggcat tgcgcatctta gcagcatagg aatgggagac
39001 tggcttttgtt aagtcaacaa aacaggcacc acaataatcg ttttccagat tgggttggac
39061 atggcactga cctaggtggc tttaccagcc caaaaagtaa gaattttgca ggtggagaaa
39121 tagaaaaatc gcattcttta gaggtacaag ctcatgaagg atctggaatt ggaagcttcc
39181 aacgttcttaa tctttgtctt tgtgtttatt gaattttcct ctccataggac agtggctgac
39241 agtaataaag taacacactc cattgaatgc actatttatg gaaacatttc tatggtgcca
39301 aaaaaaaatt aacaagagaa gtgattgcca aaagcaaaga cccaaacatt agtgcaatgt
39361 ttgcagcact taaagtaaaa tagccagccc tgttaacaaa catcctctcc acctgccagt
39421 cctgtgaagc gtgctgtgtg gtgctgtcat ttttctaaat tagatttctt tccatatttc
39481 ttactttttt cttagagagc ttttttaagt ctatctttat cccccctgtt attctatttt
39541 tatttttatt tgagataggg tctcactctg tcaccccggt ctggtgtgca gtggcgtgat
39601 cttggttgac tgcaacctcc gcctcctggg ctcaaatgaa tctactgcct cagcctcctg
39661 agtagctgag gctacaggtg tgagatgatt ttttttactt cttgtagaaa tggggtcaca
39721 ctatgtttcc ctggatgttc tcaaactcct gagctccagc aatccatccg ccttgacctc
39781 ccaaagtgtc gggattacag gcatgagcca gcatgcccaa ctctctctgt attctatgta
39841 cactgtttcc aatcatctta gatcctttcc cactcatttc caactttttg tttctttttt
39901 cttttttgaa acaggggtgc actttttcac ccaggttgaa gtaaaagtag gtgatcctag
39961 ctcaccatag cccacacatg ccagcctcaa gcaattctcc catcttggcc tcccgagcag
40021 ctcagcctac aggtgtgac caccaagccc agctaattta attttttttt tttttttttt
40081 tagagatggg gtctgcctat gttgcccaga ctggtctcaa attcttggcc tcaagcaatc
40141 ctctgcctc agcttctaaa agcgtgtgaa ttacaggaga gagccactgc acccaacca
40201 ttttgaattt ttacttctc ctcttcaagt gttccactgc tgaatcgggt gaaaatgaac
40261 tctcctctga ttaactttaag agatacattg ctgactcttc taatctcagt tcaaacaca
40321 cttccacaaa ggcacccagt acctttatag cagctcagat cctcctggtc ccttgaagg ggagatgccg
40381 attaccattc acctttatag tgtgtctctt atatccccct tcccttccag agaatagctg
40441 ggtgtccac acgtctgcca gctctgtcca gtgcattaat tagatcagga tactcaagcc
40501 caataatcga gacctctgtt tcaaaagaaa tattgtataa ccccttacca aggtcctgaa
40561 ataaaattca tgaataacat aatctacca cacacataat tagcaaaagt aatatgtcat
40621 aaattttttt taaagaaaac ataattgaca ataaaaatg acacattttc aaaggtaact
40681 tctcggacag gagtgtatca gaagcccaaa atgaaatcgt ctaatgtttg cacctactta
40741 taggttttga tctgaagaaac ataagacaaa aaattcgcca gagttttgtt aatgtattct
40801 cataatactt aacatttttga aagcagcatt acatatattt taatacagac atcatattgg
40861 taaaccaact ctgaaaatta caaaatgaaa actaaaaaaa tcatccttat tagtagcatt
40921 tgccactttc catggtgtta atattctcac caggtcagt ttcaagctac caacacgatg
40981 tccatgaaac cagatttttg aagaaacagg caaaatctgc tctcatgagc tgctcgctaa
41041 gggcatgtct agcacccaac tatttaatca ccatgaatac aaacagctac atatgtagac
41101 agatcacatt atggtgactc aaatattatg agcagtgtc catgatgttt caagatggta
41161 ttgagacctt ggtaaaagac tggaaacaaa caccacaaa tcttcccttg atttagaagg
41221 cccctgcatt cctggaagac ccagtgccag tttgttatct gtataagcac agggaaattct
41281 ggggtcagat caatggaaac aagtttttta ccgaaatgaa tgtctggggg cacaggtgta
41341 tgttacgggg acgagggcag ttctttgtta tattggactg cctatggcat cacaggatgg
41401 acccgtggac cccacctgct aagtgcctaa gggccacaaa atgcctttcc aaatttccaa
41461 agtgccacct tagtctact tagtctact attgagaact acgtctagat gtttgctact
41521 ccaagtgtgt tacctggacc aacaaggcag gcacccctg ggggatcacc aatttataag
41581 aaacacagac cacaagata tatataccta ctaagtgcct acaatttttt tgaaaaaacc
41641 acatatatat atacatatat atgtacatac acacctacta ggtaccacaa aaaattaaat
41701 aagaaaagga atcaaaagaa ctcgggcccc acctagacct actgaatcag aatccaaatt
41761 taacaagatc cctcgggtgat ttataggagc atcacatttg gagcaactac tagagtagat
41821 actgagtttt aagacttaca aactgtgtta gaataactgt taatgctgac ataaacaatg
41881 caaaataaac cactggctct gttagacta cataattagc ctccctaagt agtgggatca
41941 tgcctgccta tctgctctct tcattgtaac tgtgctgcag aggcaagagg acttttgcac
42001 tgactgtggg cctactgaat ttgtcaacca cagacgtacg gtggccttac catgcctcat
42061 gcctcctctc cctgaattca cacaagaatc gctcttcaaa actagaacaa gacgtgaaag
42121 aaatcaaggc acagagaggt tcaggatttt gctcagtgtc acagagtcaa gaatgtgcac
42181 agttaggatt agtgatgcta attattttat attaaaaaat tattccacaa gtacacactg
42241 aggttcaact gggaggcaat gtccacaaac agtttctccc atgccataat gataacttat
42301 tttgcataca actttgtttg tgcaaagcat gttctcatgt gctaactcat ttgatctttc
42361 aaacacccag taattttgtta actctactca aagacgaaga aactgtgggt cagaaaaggg
42421 aatggaggat caggaaaaatg aagcaacttg ctcaagtcac tagctaataa tatatgggta
42481 actgagaaaat gcaggatttg tgcgtttacc tgcctgaagg cttcgctagt tctcgggggt
42541 gggagggtcac tggaaacaaa agcacttgga gaaatatctc tagacgatga tgagacgggt
42601 ttaggagggtg ggttcttcaa gccttctcct aacccattcc tcagtcccaa tttagcatca
42661 ccaaccaagc ctgtgacttg gttagaacat caccagggat gtattttcca aatcagatat
42721 cctctccagc tctaccctat tctaccctct cccaccctc cataacagtg agaacctgga
42781 gaaactaaaa tgagaaaata aatatgtgct gacaggctgg gatgcagttc atttcataga
42841 cataagtaat atttatttga aagtattaac acctattagc atgaggagg ggaagaaaa
42901 agtcacagcc ctgtacataa aatgcatcca ttctgaatcc atagtaatcc acatgggttc
42961 ctagaaaggg gatcttgttg ctgtcttttg tcaaaatcaa tgccaaacca acaagtttca
43021 gcaaagcctt ttgacctctc tgaggacatg aaaaggttgg atattacca gccaggggat
43081 agttagatgt aattacattt taaaacctct ccattttata tctaggaaca gaagagagag
43141 actggaaggg aggaagagaa aatatatcaa aatagagcag gtgactctct ctgggtgggtg
43201 ggctcgtggg tgatttgaat ttacttgttg aatttttccc ccaaaatatt aagcagttat
43261 ttgatttttaa tgaaagtttt tttttttgag ataagttag attcacatgc agtcaagaaa

43321 taatacagca atctcatgca ccttggatcc agtttccccc ataggtgata tctcacaana
43381 ctctagtagc atttcacaa caggaaattg acattgagac agtcaagatg cagaacattt
43441 ccactctatac caggatccctc cagttgctgt tttatatcca ctctggttcc cactcaccctc
43501 ccactcctct ccagtcctctg gcaatcactt atctgttgtc tttccttttc tctccttttc
43561 ttctcttttg agatggagta ccactctgtt gccagggtg gactacaggg gcacgatctg
43621 ggctcactgc aacctctgac tcccgggttc aagcaattct cctgtctcag cctcccgagt
43681 tgctggggat tacagggtgt tgcttaccac gccggggtc actttttgta ttttttagta
43741 gagatggggt ttcacaatat tggcagggtt ggtctggaac tccagacctc aggtgaccca
43801 tctgctcttg cctcccaaa tgctgggatt acaggagtga gccaccgtgc ccagccatct
43861 gttttctatt tttataattt tctaatttca agaactattt gtaaatggaa tcctaccaat
43921 gtaattctttt gggattggct ttttactctt tttatagtag atttgagcc aaagaaaata
43981 ttcttattgt gtatacgtgt aagtctcaac attttaagat gcaactgtgt ctttagttct
44041 ctaagaatca acatgcagga gcgcctaaag cctcctctga agtcagctct tctggttctt
44101 ggttctactgt cactctgcaa cgccatggcc caactacctt gtctttttt gacgctcgct
44161 ttgttctctt ggaattgacca aggcacagcc ctccacgtac cctgctttgc atccctctgc
44221 ttcaccacca cccaccacaa cctgaaaagc taccttccaa tgtgcatgca gcctgacaga
44281 gttgaaggag gaggctctca agctaccagc ctcccccaca accccagaga caaagcagaa
44341 ggcacacagc caagatgggt tcttggcctc taactgtgcc agtctttctc aaaaagagaa
44401 tagccttggg aggtgcaaag accttggag aaacctttgg aacaacacaa agtaaattta
44461 ctcacttcaag ctttctctgc ccttgagcag gttaggtcctt gggactccat tttctcatct
44521 gtaaaatggg gacaataata cttaccttta tttttattga tttttctaca caggatgact
44581 atgaaaatta agtaaaaata taaatataag actcctaaca ccatgccccaa atctaggaag
44641 tatagataga tgggtggtat tgttattaca aattaccaag tcaaaataat aaatagaaat
44701 tcaattggat ttctaatcac tcaattcttg tcagcccttc tttcttggta taagatacaa
44761 aatatattgtt tcaccaataa acagtttcta ggtaagaacc acgcagacgc ctaagagggtc
44821 tgtattaaat cttcaatctt gcaactgtag aaaaataaaa ataataataa aaaaagtat
44881 ccactcctg agaagtgttc aggttttgag tgatgtcaa ggcctttgaa caagccttat
44941 aagtgacatc catatttctc catttttgac ttaaattgct tttggttcaa ccactgccgt
45001 gaattgcctt gatgcaatat cacacagaat gacacaaaac acagaggaaa aagcaagttg
45061 ctgggtgagg gttagggaat aaaggagtca ctgctctgtt cacttctcta agtgttggaa
45121 gaaatgaaaa tgaactcgc gttgaaaggt aatctctatg aaccgtgata agagcaagtg
45181 acattttttac atagctcaag tcttctggtt cagcctagca gttataataa aagccatcta
45241 catgcagcta aacatttttt taagtttcca cctgctcttt ttctttttct tctttttctc
45301 cttcttcttc tccccctcc ctaagcagca aagggccatc tgcaattctg gaacttctcg
45361 ttaataataat ctgggctctg gtttccattt tgtgggatga agaagcggct tctatgttct
45421 agagaacaac ctcgactctc cctgtttctc tcttctgctg cacttgacct tccatctctc
45481 atattttgct gccaacctct gactttgaaa aaagaaaaaa cttcttcgca aaagccatc
45541 tactgtctgg cccctatgc taagagattc tgtttcatct cagtcctgtg attaggaatc
45601 caaaccacag gggcttttgg tgtatagaat aattaaagag atcagaaatt aggtcagaaa
45661 tcttgggggtc cagcctcatc tctgccatt accatctgcc tgatattaag tgagctgcta
45721 cagtattttt gcatctcatt tctcacccc cgcaaatggc ctaatgccag ccacctcaag
45781 gatggtagca agaattaaat gaggtactgt attggcaagg cctggtgcag tgcaggaact
45841 gaggaatgct cattctcttt cctcccaaac aacatagatg acttactaaa catggcaagg
45901 ggcagaagt tctgaaaata ccaatgtgag atcctactag aagagtggat gccaccctc
45961 agctgggtcc acagtgtat gccttgcgg gaataagttt caggagacct caatcccagg
46021 gaaaccactg ccgaaatcac agagagggcc tctatctctt gctggggcca ctggctttgc
46081 aaatggagca taagggttta cctccttctg tggctctgac agttgtocct cctaggcca
46141 cagcagtaca acttgccaag gagccgtccc tggatcctac ctgagtggtc tattagtctg
46201 tgcagaaggaa agtgaataat aactgttaaa aaaaaaaaat gcatgttaac cactgtgtt
46261 atacccttac aaagaaggag ccaggcagta tatatagatc tctaaattct catgtgtgca
46321 tacaagggtc ctttctcaac gaaatcaata gaacaatgtg aatacacaat tttcatgtca
46381 ctatgtattt gggagtgaac atacattgaa gggaacaaga ataacgagga tttgaagaag
46441 tggcagctta ggtagtaca taattttata tttccttgtt gttagtctca aatatactg
46501 aggatacaac tcagagctct gtttacgtaa aaagtcagaa acaaaaaaat aaatatgttg
46561 aattcagatt tgaatttttc ctcttttctt accaaaagaa gttgaagaca ttttctaga
46621 tgtctgctag caattttttg gcaatacatt ttttgttgtt gttgttttct tttctcctg
46681 gagctagttt tgcctaattt cttcacaggc tcagattagc acagggtgag tttcagaact
46741 gctgtgtgtt cttaggcaag tcacgtcgca tctctgtttc ctactctata aaacacattc
46801 ataataactg atctagccaa taggactgct ataaggctct atataaatat gtttgtgaac
46861 aactgtgtga acattcttaa gtgctgattt tgtgatttta cggggtattc agtatcactc
46921 cacttctctt tttctcaaca cacaactgct ctactaacat gctcatggg gcttgaaca
46981 ttgaaggaat atttccccct taaagtcatt tttgtgtctg gcccttttaa gaggatttga
47041 ccattatcaa cgtgtggatt taaagcctct atttactact agaataattt gcacaacgct
47101 ttgaatgggt tagttaagg gataaaagct acagactaaa atagtaata atctcggaag
47161 gtgaataaat tttactagaa tgctggcact tgtttttagt gtggtagaa ggccactata
47221 ataaagacag ctaattgttg ataatgacaa aagcaaggct ttcggagcaa gatacactgg
47281 attcaagccc atatatacc ttaagatcct tgggcttcat ttttgagct tctcctcca
47341 cctctgtaaa atgggcacac taacgccttc caaacccctt taaaaatttg agtggaaatt
47401 gaacaaaaaa gaagactgga aatacagttt gtagaacact cagcacagtg tctggttctt
47461 gactgccttt caataattac gaactgctaa tatgattgct cagactaagg tggtaacgat
47521 gattattaca aacagtcatt atcataataa tgtcattacg aacaatcatg aaaaactaaa
47581 gcttcatatt tatatatgac ataatttttt tggttctggg taaactaatg taatgatttg
47641 acatacgcaa catcctgaag ttagcctttc tctttgtctg tatccctttt gtacctgtat
47701 ctataaatta tctctgcaat atacaaaatc tttattctgt taagaagtca gtggaatgtt
47761 caagaagat caagaattcc tggaacctg tctcatctg caacaaacta cgctgtactt

47821 tctgatcatc ggcaatgggg attctacatt gcagaccctg gtcctttctg ccagccttca
47881 gaccttggtt acagacctcc tgaggatata cttttctcac ttactatggt tctttggatg
47941 gcaacctata cacctctcaa taaatttttg tttacttagg agctgagggg cacagaaacc
48001 tagaaacctt gattcaattt gtgccgattt atgagacaca cgcacgacaa tcctggaaac
48061 tttcccgtag ctacttttat aaattaaccc cttattttaa tattctgcag actcagcaca
48121 gagcatgttg caatggggag atggtcccag atcagccttt tgggctctc catgtttgct
48181 atcagaacac acgggcccctg ttcggcaca acaatgcaaa tttacaagat ttatgagaag
48241 aagggatgtg tcctatcctg ttgttattca ggccacagca tctactggtc taacaggctc
48301 catactgctc agttccagac gttcgacagc tggacttggg atgcatgtgt gagcagtgtt
48361 ctgatttgac tgatggcttc actcattcac tcattcagtc attcagctga aatgttccaa
48421 atgcttaata aacgcaagac aatgaggctg aagccaaagg gatgcaacac agagtaagac
48481 acagtccttg gcctcaaaga acttatattc cactgggaga caaagtgcct gtatggtacc
48541 atagagaagg catgaacgc atgagccagc aaaccttggc tgggaagcctg cacttgcttg
48601 tgagctgtgt gactctgggt aatttatcgg atcctcttat gcctcagttt cctcatcagc
48661 aaaatgggtg tagtcatacc caatttcaca gaggatgctg aggtaacagc attcaatcaa
48721 ctgctgtgaa atctctaagc accatataga tattcaagat tcttaaacac atcagtaatg
48781 cacaagagaa aggaacatat gtgcagtaaa ttaacaagcg aaagactatg aaaaatcaga
48841 tacaagcacc ataagcctac tggggttatg ataaagagt gtcctcactg caggttgtag
48901 gtattgtaac ccaattttct gaactcgcag aagaggacaa tgatgaggaa ggagataga
48961 aagcaggagg aggattggga ggaggagatg gctgggcat taagtaaaaca tgagaacagc
49021 cacattagag aaacaagctg tatgcaggaa agagtgcagg ttgaggactg gtataaagaa
49081 agagcttgct atcccagtg tttgagagaa tgaggtgaga ggactgcttg aagccaggag
49141 ttcaagacca gactggagaa aaaagcaagc aagccccatc tctacaaaaa aatagtcaaa
49201 attaaccaag cacaggatg catgctttgta gtcccagata cttggcaggc agaggctgga
49261 ggatcgcttg agcctaggag ttggaggctg cagtgtatctc tgattgtacc actgcactgc
49321 agcctgggca aaagagcaag accctttctt aagaaggaa aaaaaaaaaa aaagatcgag
49381 agaaaaggct gagcctggcc actttgcttt tctatatccc accaactgat taacaccaat
49441 ggggacatag cacattgtcc aaatggcaga aatcctttaa agaaagtttc ttactttcag
49501 agagaaaaat aaatagaact gcatgagctc aaaagtcact ggtgaaataa ttataaatgg
49561 atgtcatctg tctttggggg aagtctctga atgaatatca cagaagaagc tcaaggtttc
49621 ctctgtaaaag gcgcctcccc aactcacgtg ctggcctgta tgctccacca tgacacatga
49681 ttcccttggg ttgtcattc tttaatcaca atcctcctg agaggccac cacaggacat
49741 ggattcacac tagcaggatg atgacttttc taatccagga aggagagagg gacgcatttt
49801 cccacactcc atgccactgc caatagccga accagtgaag cgagcagggtg ttaggagagt
49861 cagggtgtgt ggagtggcag agtggtgtgg tcttagaata tgcccacaag ttctttgata
49921 gacctccctt gcaattgtgg agccaggttc ccctctccta actatggtct ttactagtat
49981 tcttctaato aatagaatgt agctaaagtt acggtgcttg acagtgcatt atgtctaaga
50041 atggggctta aaaggccatg ccacatcttc ctcacactct ctctgagatc atcactctgt
50101 gggagaccag atgacatatt gtgaggctgc tctgaagct gtacagagag gcccccatgg
50161 tcaagaactg aggcctcctg ctaaaagcca catcagttag ccccttggac acgaaacctc
50221 cccctcagtc aaggattctg agactgcagc cccagccaac agcttgcttg caacttcaga
50281 aaagacctg agctagaatc accagctaa gccactccct aattcctgac ccacaaagac
50341 aatgagattc taagtgttta cattttgggg taatttgtaa ggcagcaatg gataactggt
50401 gcatatcct aggtgtgtgag ttagtggatc caggcaaaag tgacaagagc aacacaggta
50461 gttatccaca aagtgaggaa aagaggagg gtatttgaga aaattacgac gagatccaca
50521 atatgcgaac ctgccaagga tgtttctctc ccctgtgtct cctaagagac tgtactctag
50581 cttggcttga catgcagtgc tacagataga tgctcagcaa aagcttctgg aggtcatagt
50641 tataatcatt attttacta gtatttactg agtacttatt gaataccagg gattatgctt
50701 tgtgtcttac ataaattatt tcttctctc aatggaaata gtattatgat cactctttca
50761 cagatgaaaa aactcaagaa aagaaagact gagtgaacca cctaaggact tgcacccaat
50821 catcatgcag cctgcctcct ggtgtgcagg tcaactgatg tggctttgtg caccggggca
50881 tgggcaccgg ggtctccccc gtagggtacc agtgtatact caaagccaca ggataaactc
50941 actgcatctc cctagagcac ccattttatt cactgctaag catcttaaga catcattttt
51001 acattttacat gaacacagat attttgagtg aaatgtaaac ttccatagga gcttttagga
51061 tacatcttgg aggtcgttca ggggtactt caggggatat caatcctcca ggagcctaaa
51121 gatattcttt gctgaaagca ctagctaaga cacagcttat aaagggggaa atgagggtg
51181 gagggaaaac atgacctoga aagtcacaga gatggtgctc agacagccag ggtcttcagc
51241 ccccaaattc tgagtgggtc tcagctctgc aagccctcc accagccagg ctgtgatagc
51301 tgcaagctct ggagggttag gaacgcagtc ccttcttctc ttacagaatt cactcccaaa
51361 acatcacatt ctgcctctcc cttccactag cactgtgatt actgctgcat cattagtggc
51421 ctttaaaaga acatggtttc caaatcctcc taaacatggt tgcaatgatt gctatggccc
51481 ttttgataaa taatgaaga agacgcacct gacctgattg ctatagaggg taaggatggg
51541 gctgtaggag aaagaaaagg acactctgca aacgacagaa atagtcatct acagtggcaa
51601 ggaggagggg aacgctctga ctcccagggg gccctgagct gctcagatgt tccctccaat
51661 acaagctgat gccgtcctgc ttggccaaat cgacctgaac agccagaaa gctgcacggc
51721 cgtacctgtc agccccaatc ggtgctgcag aaattttggt aggaaaaatg aggtactgag
51781 attcaatttt tcgattgtct gaaggcttaa tttagtgaac ttggaaaata tctcctagag
51841 gtgaaagaag atgctgggaa tctgctggga ggaaggaggc ttccctggta atgggtaatt
51901 tgtttactct aattttgagg cctcttcagg cagccaagaa aatagtcaga taggtactac
51961 cacttcttag aaaaagtggg ggaggggaga gccatagaaa ccagtgaag agaccccgag
52021 ccatacggca ctacttttgc aagagcaggg aggcattatg ataatatgta catatatggt
52081 ttatgtgtat atatatataa atatgcttat tatgaaatt ttaacatac acaaggagg
52141 gacaataacc ccatataaat atcattcaga tgcaaatatt actagaatgt taacactgct
52201 tctttccttc atcctgtccc tcttttctt tcttctttaa ttgcggcagc tcttgctgct
52261 gctgttgacg aagtattttt tttatttttt ttcattgtaa ttttttatag agatgagggt

52321	ctccctatgt	tactatgtta	cccaggctgg	tcttgaactc	ctgacctcta	gtgatccctac
52381	cacttcagac	tcccaaagca	ctgggcttac	aggtgtgagc	cactgtgtct	ggcccaaaag
52441	tattttaaag	caagccccag	acctcacatc	atcttctctc	tgctgaatgt	atatgtcaga
52501	tggtatttag	aagaggcggg	gttgctctgg	tgctcaacag	cttttctcat	taataaaact
52561	actcaaagaa	aaatgcctagc	aggaggggag	agctctggaa	ttaggagttc	caattttggc
52621	tacaatctgc	aattcctgtg	ggatcttggg	atactctgaa	cctctgggtc	tcagtttctc
52681	taggttgggg	aggataatga	ctcctagacc	tgtaggggga	actgaatgag	acatgacttt
52741	ctaaaatcct	tgccacagaa	cctagtacag	gctaagggaa	aggtgtgatg	attgactata
52801	tgtgccttgg	acacaggatg	acaacaccaa	aaataaaaaa	aaggcaaaaa	aaaaattgta
52861	ggtgtcaact	tgactggggc	acacagtgcc	cagatatctg	actaaccatt	atctctgagt
52921	gtgtgtctgt	gagggtgatt	ctacatgaga	ctaacccttg	aatcagtaga	ctgagtaaaa
52981	ctgattgccc	tgccctgtag	gggtggatct	catctaactc	gttgaaggcc	cgaataaaac
53041	aaaagtctga	gtaagaaata	atcttctctc	tttgccctgac	tgctctcaac	ctgggatgct
53101	tgtcttctgc	ctttggatga	ggtttctacc	atgggcccct	ctggatctcc	agattgctgg
53161	ctgacttctc	tggtgactct	gggcttccat	aattgtgtga	gccaatctcg	cagttcctaa
53221	aaatctctat	ctgtccatct	gtctagctat	ctgtctgcct	atctgtctct	ctctctctcc
53281	atccatccat	ccatccatcc	atccatccat	ccatcttcca	gatggaccct	gacttatgat
53341	ggttctgctt	atgatgttta	gaatttatga	tggggtggaa	tggcaaggag	aagaagtcca
53401	agggttctaa	tctagctttt	gccattctatg	gctgtgtcgc	tttggaagt	cccttaaac
53461	tctataagtt	tgtattacct	tatctctaaa	agggggaaaa	ctacatctac	atcttaggat
53521	tacatacaag	aatgcaatgc	agaaaatgct	gctcaaaaga	cagtggcctg	agagtctcca
53581	ttacatagtt	tccaatccag	ctgaggctaa	atggcaattg	caatagagaa	ataataattg
53641	tggccacttt	atagggttgg	aggactagag	acgatattgc	taactacgat	taatacagtt
53701	ccctgcacat	aatgtggaca	cacataatta	ataaagggtc	gagtggtgaag	ttttgtaaat
53761	aatgatagat	tatatcacgt	ttattattag	gacatgtgtc	caatagaatt	tggtatatag
53821	taggacctta	ataaatgata	tagttataaa	ttaaattatt	attatatata	attatatact
53881	aatgataaatt	taaaaatgcc	cagtgcagtg	ctgaacttta	gatggtagac	accccatagg
53941	cagatggcag	ggaacagtaa	cactgatggg	gacgatgggt	gtagaatcct	gtacacggtc
54001	atattgccta	aatgttgggtc	ctaaccgtat	ccgttcttct	cactcacctc	cagcccaacc
54061	tcctattctg	catccccccag	tttttgccctg	gcccctgggt	taacaccocag	gtccatcgaa
54121	ggctcttctc	tctggagggt	gtgcttttat	tgctattgtc	tttgccactg	tgacagggag
54181	cagaagccag	ctcttgaagt	cctcagcccc	caactcctgt	ggggcgtaga	gattagatta
54241	gctggcctct	ctcattccta	ctgtcacttg	ctgcctctctg	taatgttggc	aggggtgtca
54301	ttaaggcctc	acagcctgag	gagctaatag	acacaccagg	gctcccagtt	gccaatgcct
54361	gcagcaatgt	gcacctcttg	acacccagca	gctaatttcc	cttcataacc	tgacaatttc
54421	aacagcaact	ctgtccccag	tcattgtcaac	cagcttagcc	cccttactct	gactcctaatt
54481	gaggagggtg	agtgcctggg	tcccactctg	aaataacaac	actggctgct	ggccatatgt
54541	tttgtgtgtg	ttgtttttct	ctgaaatggg	gtcttgcttg	ccgcccaggc	tagagtgcag
54601	tggcgccatc	tcggctcact	gcaaccgctg	cctcccaggt	tcaagtgtat	ctcctgcctt
54661	agcctcccaa	gtagctggga	taacagacat	gcaccaccat	gcctggctaa	tttttttttt
54721	ttttttat	tttagtagaga	tgcggtttca	ccatgttggc	caggctgggtc	tcgaagtctc
54781	gacctcaggt	gaccacacca	ccttggcctc	ccaaagtgtc	gggattacag	gcattagcta
54841	ccacacccag	cccttttttc	tcttagacct	cactcttcca	gctcctttca	gtcctggggt
54901	ctccctgcca	gaaaatgggg	ctggaaatgt	gttaaggaga	aacttgacga	acagaaaaca
54961	gccttcgaga	ctacacacct	gacctgggag	ccacagagac	tccagctcca	cttctctgt
55021	gagttgatga	caccgagcct	taccttctc	atctgtaaaa	tggtcaagat	catcgtgctt
55081	ccccacaca	tgggtgctttg	atgtcatctg	cgtgaagctc	ttatcacaga	gcccagcact
55141	tggacagtga	gcaattaaca	tctgctctca	ctgtctttaga	ggatcagcca	ttcaggtttt
55201	catcatctta	ccctttcact	tgatgcctat	gtactttgca	gttgggggaa	cagctaaatt
55261	tgatttagcc	cccacagaaa	ggcagcctgg	agttctggag	aggagagcag	gtttgtgacc
55321	agagaaacca	gggatcaaaag	ctctctgggt	cccttgcaac	atctttaaca	tgtgggggca
55381	ggaaagcgag	acggggaggga	aataatctaa	acccggctgg	ttagtctca	agaggcaaaag
55441	aaagaaacata	ttcaaaaaat	gtaaatgctt	gggtgcggc	atgtagtgtg	tgatcaatga
55501	ataccacttc	cacttacaga	gaaagggaga	tggaggcaga	ggacagctaa	ggaaatccag
55561	aattgtcaca	cagctgggtga	gaggggtggc	tgtgactgtg	acctcatacc	acccctcaaa
55621	cctcaccact	gtgctcttat	tgtgggttga	atgggtggcct	ccaaaaaggc	agttccatat
55681	ccaaatccct	gcaacttgtg	aaggcaagct	tattgggaat	caggtcttgg	cagatgtaat
55741	taagttacgg	atcttgacat	gagatcagcc	aggaagaccc	taaatccaaa	aacaagtgtc
55801	ttcatagcag	aaaggtagag	ggagatttga	ggcagacagg	aaaggaaacac	aggagaagag
55861	gagaaggcca	tgtggctgca	gagggcaggga	ttggagtgtat	atgggtcacag	cccacaatca
55921	cgagcagcca	ccagaaacga	aagatgcaag	gaacagattc	ttagctagag	cctccaaagt
55981	aagtatagcc	ctgccttgat	tctgaatgtc	tggcctccag	aactgtgaga	gaatacattt
56041	ctgttgctgt	tgttttgaga	ctgagtttta	ctctttttgc	ccaggctgga	gtgcaatggc
56101	acgatcttgg	ctcactgcaa	cctccacctc	ccgggttcaa	gcgattcacc	tgccctagcc
56161	ttcccaagtag	ctgtgattac	agggcacgcc	aggctaattc	ttgtattttt	agtagagaca
56221	gggtttcacc	atgtttggcca	gactggctct	gaactcttga	cctcaagtga	tcggcctgtc
56281	ttgactccca	cagtgtctggg	attacaggca	ttcccggttg	tctttgtaca	atattttatt
56341	aaatgtcttt	acaaagcaac	atccagactc	cgaatacaac	tgccaaggac	agcccggttat
56401	gctatgggga	ctggctgggg	catagcaggt	ggctctggct	tcccaccctt	ctgttctgag
56461	atgggagtgg	tgggcactac	ctcatcttgg	gggtccatga	tgctcacgtg	gtcaggcaga
56521	ggcttcttag	ggccagtctt	accagcgggg	tcccagggca	gcattgacct	caccttgatg
56581	cccagaaaac	cctatctgag	cagcacatgg	cacacaacag	catcaatgta	ctagttaacg
56641	tggtctccgc	tggggatcat	caggccatcc	acaaactcat	ggatttgacc	ctctgtcctc
56701	agagtctcct	agaaaccaca	gcttggcagc	ctatggcccc	cctattcatg	atgaaccaca
56761	gcccaccatc	gcaggccctc	cgcacagtaa	gcccctctag	gagttgttac	tgacagactcg

56821 acctggggcaa tggcacacag acctctgggg ccaccttttc agcataaagc tctacaatgc
56881 cctgtgggaa gccaaatctc ttctgaacta cagcagtcac tccagaatc cctggctgtt
56941 ctcaccagga acattttttg ttctgttggc taagatattt gttactgtcg tgatgggtgt
57001 aacttgaacc tgagcttcag agaagcgtct ttagccagct cggagtaag aaactgatcc
57061 cgttcggtt tgaagatgcc atcagcgacc aacatcctct tcttggaaat tcgcgcggcc
57121 atcatgtctg tgcacaccat caaaaggaaa gcagattgtg cctctcttat atctcactag
57181 agcaagtcag gcagtgacag taagaagacg ctgcccattg aacacacctg ggtgggagtc
57241 agccctgcca cttggttgct ctatgacctt atgaaactca cttgacctcc ccgagtgcgc
57301 gcatcctcat ttatgaagtg gagttgttca tgagtattac ctttttccc tagccttgta
57361 gggtttaggg gatggtgaga gagaaaccac agagcacttt gtttatggct ataacgctgc
57421 cattttctac tgttactatt actaccagga atgaaaacaa caaataaaaa caaaagcaac
57481 ccaaaaattg ctcccaaagg aaaggtgtgt cgcttctctc ctgttctgtt ctcacacaaa
57541 gttgctagg accctgatat gctttgggtg tgtctccacc caaatctcaa cttgaattat
57601 atctcccaga attcccacat gttgtgggag ggacccaggg cgaggttaact caatcatgtg
57661 ggccggtctt tctcgccta tctcgtgat agtgaataag tgtcacaga tctgatgggt
57721 ttaccagggg ttctcagctt cgcttcttcc tcattttctc ttgcccgtgc cgtgtaagaa
57781 gtgcctttca cctcctgcca tgattctgag gcctcccag ccgtgcagaa ctgtaagtc
57841 aattaaacct ctttttcttc ccagtctcgg gtgtgtcttt atcagcagcg tgaanaacaa
57901 actaataagt gccctgaagt actttgtctg tttctccca gcacctagga aagtatctga
57961 catgtacca caatgtatt catattgatt agaggaaatga atgaatgagg aaaacagagt
58021 tgtagagtca atgagctaac ctttgggagg agcttgact gaatacagta aatcaaccaa
58081 tcacacattt gatgcaataa aaatttcatc atcattggtc agtttatgt tagaaaaact
58141 ttctacaggc aaaaatgaagc atctaaatgt gtctacatgt aggagtggac tgtttataaa
58201 aagcaaaaatg ttaacattt ttaacatttca tatattttcta aagatcgttt aaaatcaaat
58261 agatttttaa aaactttatt tcaaggtttc aatcaataaa aagtaaaata aaataaagta
58321 ctgaaaaaat aaaatttggg ttcagaggct agaaacctac aatgaacacg tctatcaagg
58381 caggaggatt gctttgaggc cagaagtttg agaccaggct gggcaacata ggaagacccc
58441 atctcaataa aaaaacaaaa ttagccagat atggtggctc tcgcccgtag tcttagctac
58501 ttgggaggct gaggtggcag gatcacttaa acccaggcat tggaggttgt agtgagctat
58561 gatcatacca ttgtactcta gctcggagac agaacaagat tctgtcttaa aaaaaaaaaa
58621 aataacaagt ctgaaaagct cagggtagcc aatccttcca tccccttaga gaaacagcaa
58681 agttaagaca tctaatcag ctcaggctcg gggggcctta aatgcacaca tttgcacaga
58741 tacgtgtata cttttatata aactccctga caccagtgac tgggtctgtt ttatcaaaaa
58801 atgtccatta aacttcagat gaagccttta ttaaactatt gctgaatgaa tggaaactct
58861 ttagaatgct atatgcgatt acacagacag gtgacctctc tcgttttgca gcaccttag
58921 atgtgggtca ccatggtgaa cattcaggtg atgataagcg atgatgactt cccttacct
58981 tttctgtctt aggaagcacc tacctcttat tgaacctgga atgatgggat ggggtgggag
59041 tctgtccttc cttattcaca caggcggctg acacaataat gtgatcatca actcctctct
59101 tctgcagcc cccaacccgc cagccgcccc agctgcagaa tgcaaacatc tgccagcatc
59161 attaaagcat ttctatacag caccatccaa ggccctgacc tgtgaccgtt tccaccatta
59221 gatttgaatg gattctacag cagggtgaa aggttgaggt attaatcac agaaccacaa
59281 gctcaattta agatttaatt tgagataacg aagagctact gaaagtgtat tcaaaacttca
59341 aagcatgcaa taaaaggcct ttccctgttt tccaagtga atatgaatcc aatatttctt
59401 taacagattt attcacaatt ttacaaaacaa cacgaagcct cttttctctg tttctaattc
59461 ctcttttttt ttcttttagt ttttttgctt tatcaagccc ctttatgatg tttcttgcta
59521 ggaatctttt ttagctcttc ctccctaatt tacaaatgac tcttgtttag gaattacctt
59581 tcaatttgat agcattcttg aagagaaagt agacttctct aagaatctcc cctaccttta
59641 gtcccttgcc attccaacct aaatatgcta agcgtctgtt tattcaacaa tgatgatgtt
59701 gctcaaaaag ctctaaccca tcaatgtaac tctcatcatg gaaagattca aaataatatt
59761 ccaccattta ggaacacgtg accactgggt tctagtgaat atctaggctc tgaagacttt
59821 atttataaaa tatttagaat tctaggtggg gatgggaatt tttattgggt caagtagatt
59881 ttgttttgtt tttgtttttg tttttctttg agacagagtc tcgctctgtc tctcaggtct
59941 gagtacactg gcgcagcttc agctgactgc aacctctgcc tctgggttc aagccattct
60001 cctgcctcag cctcttgagt agctaagatt acaggcacat gccaccacac ctggctaatt
60061 tttgtgtttt tagtagagat ggcgtttcgt catgtcagcc aggtctgggt tgaactcctg
60121 acctcagatg acccaccac cttggcctcc taaagtgtg tgattacagg ggttaagccac
60181 cacacctggc ctcacataga ttttttgaca ctaaaagatt tatttaaggc tgggcatggt
60241 ggctcacacc tgtaattcca gcactttggg aggccaaagg aagaggatca cttgtagcca
60301 ggagttagg tcaagtctgg caatgcactg agaccccatc tctacaggaa attttaaaaa
60361 tagctgggca tgggtgtgca tgcctatagt cctacctact caggagactg aggcagaagg
60421 atcgcttgag cctggtaggt cgaggctgct gtgagctaag atgccacagc actctagcct
60481 gtcgaacaca gtctgattct gtctcttaaa aaaaaagttt attttaatat ttgaagatgg
60541 gaattggaga tgagaattgt tagcttttga ctcagaagcc tgaatctacg atggtatttg
60601 ctgactatth tgtgtctgac actatgctag gttactttgc attttctcaa agactcagtc
60661 cagcctcaga aatagacttg ggtttaaagc tcagcaacca actgagtccc ctgagcctct
60721 gtctttgtca cctgtgaacg accacatgcc tcaagtgttc ctgaaaacaa ctttaaaagt
60781 tataaacatt gacacatata tgggtataaa aataccacag gtcactctgag cttgacctg
60841 ggacactggt gggaatgggt gaacttccca ggaactgcaa acactctggt cactgtgaag
60901 attacacaa ggacaaaagg caggatcaca atattttgca atcctgaac tcactactt
60961 tattagccac cgggttttca aaatgagaag ccatgtggtg agcaggggga aagaaggata
61021 aaccagaggc cacatacacc tgttgtggg tgggggctgg ggggcgttg gcttccgacc
61081 caccctccat cataactagc tgtgtaacct ggggcaagcc tgtgcctcag tttctcact
61141 tttatcatcc ttctgtctct caggtaacag acgatgtcga acatgcaggg ataagtagat
61201 ggggtgtgaag ccacaatttc caacacagag aaggcaaata ggagaaaggc caagagaaag
61261 cacacccata cgtttgatgc agtgacgtg gttcaatagt gtccccctag aaacatgttc

61321 actcagaacc aacgaatgtg actttatttg gaaacagggt ctttgcaaat gtaattaaga
61381 taagggaatga gatgagatca tactcaatta ggtgggtcct aagtccaatg actgggtgtcc
61441 ttgtaagaga cagaaaggac acaaagccag aggagaaggat gatgtaaggg aggaagtaga
61501 gattagaatg tgggtgttcc aagccaaggg acatcaagaa ttgccagcag tcaccagaaa
61561 ccaggagaca ggcatggcat ggtttctccc tcatagcttc cagaaggaac gaacccaca
61621 aacgccttga ttttggactt ccggccacca aaaccatgaa acaatgaatg attctcaatc
61681 taccagttt gcgataattt gttatggcag gcccaggaaa cacatacacg tggcatgggt
61741 ggtattaaaa tgcaaggcac ttccctgaag ataggccctg tggctctgct ttcaccaagg
61801 ttgtcattat atctcaagga agggccacac taatcctaag ttcatccact aatcccaata
61861 aaaaccacct aaattttctt agtgggcaat ggccaactct actcatggaa atggggctta
61921 caagaagttc tcagatcatc agtaagaaag atttttattt aaggatggga aaatgaatta
61981 ggaatactga gatgtctcca aacaatactc ccagatcttc gttgactcca cgattatttc
62041 tggcgtattc agggcaccac ttccactggt ggagggcatg caacgtcttc agtagccaaa
62101 actttgggtc acacatggaa aggacattct ggtactgcaa atttggctct ttggcatcaa
62161 aacttagcag ttcccatgac tgttcttgct ttcttacaac acccagatgt cagtggctgg
62221 gggcttctct tatgtctcca gcaagcaggg acagggctcat tgtgcatcct gagagcctac
62281 tagagtgcga ggcccatgac aggtgctcac ggttatcaaa ggaatgataa cgatgacagt
62341 acagaggtaa atagtaagaa caatgccaga gttattttat ttctctccat atcaccacat
62401 taccattccc attttacata gtgtgatac aaactaagag tataaattaa tgaatagatg
62461 agtgaataca taaataagta aataatgagt ccatctagga aggaggagac tcagaatcga
62521 gttcaagtct cactcaaaaga agactgagtg caagtctcac tggcgcaaac acgtaagctc
62581 ttaaccatca gagatattgc caagctttgt ttacggatga aaatgctgtg agcttgtggc
62641 ctccactgt gctggtgatg cagggcaggc gaacccaga actgctgctt aggccaacag
62701 ggttcttggc tttggccagg aaagaattca agggcaagggt ggtgggtgta gcaactttta
62761 ttgaaggagc agtgtacaac aggagcagag gtgctgctcc ttgcaaaaca gggctacccc
62821 acatgcagag taccacagat ggcaattccg aggcagttct gccatcacat ttacacccat
62881 ttttaattat atccaaatta agtggtagat tatgcagaaa tttctagaaa aagggtggtg
62941 acttccaggt tgttgggtca ttgtcatgga aaggggcagt aacttctagg tgttggcatg
63001 gaaattgtaa actgacatga cacactggcg gacacagctc atggaaagggt gcaccacccc
63061 tatccctgtt ttagctagtc ctcaatttgg tccggtgtgt aagccctgtc tatggagttg
63121 agtcttgctt ccagaatcaa gtcccacctg ctgctcactt gggggtcact gaagacaact
63181 ggcctgctga gtcggggctc atttccactg ggaacctgat ggggctgaga agatccaaaa
63241 gaagtgaact gaacagcagt ggccaactga ctgagaaaga gtgcagaaga gtgaacgctt
63301 ttctgtggaa tgaacacctg agtactatgg gcctgctcat gtgctaagtg cttcgccgtt
63361 atcgtttcca ttaatttttc tcaacaagcc tccattctag agctaagcac aatgaggatt
63421 agagagatta agtggcttac cctggaacat tcaactcaga aatcagggtg caagtctagg
63481 ttctctgact ctgctcttaa gccgtacact taacctccac ttacattcc ctctctcagt
63541 gctaacgaat ttctgccaat atttctactt acgcttaaaa gcaacctttg gaattacgta
63601 tactggctcc aattcagaaa agacgaaact aaggcccgca atagttaatg acttgactgg
63661 caagctagtt acatggtaga ggcagcactc aaaactgccc aggcctatag cctgtggcat
63721 cttagttcac tgcagcctcg acctaccagg ctcaagtgat cctctgctc cagtctcctg
63781 agtagctagg actacaggca tgtaccacca tgccagccg atttttaaac tttttggaga
63841 gattgggtct cgctgtgttg gccagactga tctcaaactc ctggcttcaa gtgatcctct
63901 tgccgtggcc tcccgaagtg ctgggaattac aggcattgagc ctctgcaccc agcctcaaaa
63961 ctgggctgct cttgtcctag ggctttctac tgcacttcaa ggcttgagtc aatgaagggtg
64021 gtagaacagc tcaaccaaac ctaatcaaca gagaaggggt gtgtgtgctg gagaggggtg
64081 tgggtgtggc gggctggggc aggagctgga acttgtccac actggaaagt agatgggctc
64141 ttgtgtgcag cccaggtctc ccttcagggt taacctgtag ccttcaggca ttagcctttc
64201 cagggagtag ctgaacacag agactacctt ctgcaagggt acatccttc tggggcagcc
64261 caccacaatc cgagtcaagg caggtttata aaagcctggc cacattagcc caatagggat
64321 tagctctgat gggccctttt agcttcaata ggttgactga gaccctgtct ggactgcac
64381 tcagttagct tctcctctg cccactccat cttcgttttc ttcccttcca taggtgttaa
64441 ttccaaggca cgtgttcttc acaacaaact tgcactcaga gtctccttc tggaaagccc
64501 aatgagatgg tttctcattt ctaaagaaaa tgacctatga caataagaag gcttgacctc
64561 atcagaaaaa ttttctactg ggtgactgga ctgccttggg actctttcca tccaagacag
64621 aggtgtgagg ggcgcaact cagggggaca gaaagggctg ggaccgcaag aggtctctgg
64681 aatttttagg ggaagccaag cgaagacagg gcccgtttgc caccacacaa agactcatcc
64741 ccaataccca ggagtcagg acttaacagg ggcataaact gaactacttg ttgacataat
64801 tagtgctggc tccaagcgag aggttttcta gccacttgg catgggttctg tgaattttga
64861 ttggcaaat tgaagcaag ttccagcaag ctgtacactt attttgcatg gtgccttatg
64921 cacatccaga gaagccaact cttccgatag atctttcagt tttatgattg ttggtagctg
64981 aagatattag ctctttaagg aggcacatgc ttctggcagg ctggcctgca ctaggaatag
65041 gagaaatgcc ttctgggttc ttctaaaaat aatgtaataa gatgcattaa tcagaattct
65101 atcaagtcta cacactggc ccaggcttaa gaagcaatac ttgaaaactg cagttaggcta
65161 agcttcccta ttctttgtga atcagagctc ggggtgaaga aggaaaaaaa aaaaaaaa
65221 aaaaaaaaaa agaataagca ctaatgttta agaaaaactg gcaacaggaa aatgtttaag
65281 caacttttca ttcttagct ccaccaggga ttacagaggg ttagggggag gtttgacctt
65341 tgtatttcca caaacgtact tcagactgtg ggtatcaaaa cagttgggtc gaacccaagc
65401 caagttagga ctggtttgg caatagctca ggcccaagggt atttacttgt ttgtttctgt
65461 ctaataataa ctactctgg gacttgcaat ggaatcttgg ctattttctg cttcagatg
65521 tttgtaacca ggtgatgaaa aatttttgaa actgaaatag attacacaga tgagtacttg
65581 gcaattgcata acttttgact taaagatgat cttctcaaga aacaaaaaaa aactgagcca
65641 caaaatcaga gccaaaccca gtttctcac agcaattgct catttttaga tgataactta
65701 cattttaaag tgacataaaa gtgtctgaa cattgtacta caatttgggt gtgcttttaa
65761 tgtgacacag ctacatctgt atttactatt acaactcagt acccaaaaga tgaaaatttt

65821 taaagacaaa cggccaggct tttgtggaag aaacatttcc cctcattgta tcaaaaaaaa
65881 aaaaaaaaaa aaaaaaaaaa agagtggctc cttcttgtct ggtagatttc agtaattggc
65941 aggattttga gtaagctctt ttaaaagccc tccatttcta ttttcacatt aaacacactt
66001 gcaatatcta ttaaaagcac aaatactgaa gaacacacca agactatcaa tgaggttaca
66061 tctggagtcc tcgatatatc agggaaaaat gaagtgaaca ttcacagagt tttacttctt
66121 ttgggaactca aatgtctagaa aagaaaaagg tgccctcttt ctctggcttc ctggctctat
66181 ccagcgctccc aaattttaca tcaattcttt atcagagggt ttatcagagg ggggtccagt
66241 agggatttag tttaaacaac agatactgga ttctgccttc attttgggga gtatttattc
66301 acattaaggc agaggggatt ccatgctaga aaagcagaat agaagcagga atgtttctgc
66361 catgttctgg ctatgaccac ttggcccttac agttctaggg tgattgagca atatcccagg
66421 aaggacacac aaaggtcaccc agggagacttg ggaacatcga gagagagcag ggccagtga
66481 tgggttgggg agagaacctc tgagccctgt atatatcttg gaagtcactc tcaagtttat
66541 atttgggagc acagagccag atgtcagcat ggactcatag gcagccaagc agcaagagga
66601 gggctactga aacactggca gagaggtctg cgtacaactg tccttggcct cagacagatg
66661 cattgcagtt ctaaagctct tttgtccttt ttcagatttc cttaaaagaa caggaaggga
66721 aggaaggatt aaaaccagg ggaagcaaaa ggagccatgg ctacagacgaa gtttccttcc
66781 agagagactc cctctgcccc cataaatgtg tgttttggag gacagcttac gcattgggca
66841 aggaggtcat catgggtctga gatttcaaat tcttgggtcag ggtcctggca agaggcagat
66901 ggtgacacac aaacgggtaaa cgtaaaaagt gtttagtaaa ggcactgttt gtaaaagtcg
66961 gtgcagggtt taagggaaca gcaagggtttc atgcaatgta ctccagttag taacagcagg
67021 aacagctcct gcccttgtca gctaaaatgt atgaaacctt cttttttttt ttttttctcg
67081 agacagagtt tcattctctc agccaggctg gagtgcagtg gcacaatctt ggctcactgc
67141 aaacctccat tccgaggctt aaggaaatct cctgtctcaa cctcccaagt agctgggatt
67201 acagggtgtg gccaccatgc ctgggttaatt tttgtatttt tagtagagat ggggtttcac
67261 tatgttggcc aggtctgggtt caaactctct accctcagaca atctgccac ctccgctcc
67321 cgaagtgttg ggattacagg cgtgagccac tgtgcccggc ctggacgaaa ccttctacag
67381 aggaagggtg tgaagtgaac ccctgcaggg agcaagcctg aaaattaaat tgctaaatcc
67441 aaccagaaga agaaaaggga agagagccaa ctatggtcag ctccaggcc aggtggaaga
67501 atgtggggag cacaaaggta gctgggtgcac agaccgcacg cgagagagcc caagggtggt
67561 tttgcaaggg cagatgacag gactagtggg gacaacgccc acagttcccc aacttcaacc
67621 agaaggcctt ggctgtaatg tcttatacac tgccatgtca cattagtgtg tacatgaagg
67681 cagaactttt tccccaaaaa tacctgattg gaaaaccttg accctggatg tcacgctggt
67741 ttctcccagg tctaagggtg atgattccat agaaaagaac caatgtaatc cacaaaggat
67801 acatcttgaa attggatagg ttggaaaagt acacaggtgc ctttatccac gccatcactg
67861 caacctcttt tgttttgtac atatatgaaa agccaacatt ctaaagtaga ggttcaacta
67921 attttttttt tttcttcttg ggcttcttgg tagtttctac acacagtgtt tttattagg
67981 gatgtaagga ttacagaaac atcgtatttt ttaacatata gtattttttg aatatgattt
68041 gaattaatat agaaaagtgc atttttttcca gtttttttag gaaaaggaga tacttcacca
68101 ggaggataaa aaggaacaag aggggaaggg gaaataaaaa ttccagaaag atgaaaaatt
68161 gttgatgtaa actggaggca cattttttgc aaaattctct agaagaaaga attattatgg
68221 ctcccagta actgactccg cttgcccggc gcgggaggat ctggccgggt tctgtcttct
68281 cctgcaatga cacactgtcc tgcactgaaa acttgagcca cagcccattg gcctgggcag
68341 tattgctaag tgcagatatt cagcaaggaa agaaaagaaa actcctaaaa gaaacagcag
68401 ttgccttaaa ccagcggaga tataatagaa cctatagaat tgggggtggg gagacaagct
68461 tcagggaagt taacactggg gcctctcatat tttctaatat agattaatgg cttgtctcagg
68521 caagcagcta catgcttgct aaatgtgctg accgcctgaa attagcaaaag gtggtgacga
68581 aggaagggtg aaaaaaaata aaatgagctg aatctgtatg tgccccactc atcctggtct
68641 cacatatgac aaacaaaatt aacggcgaca aagagaaagc agtaagtatc aggtagtaga
68701 aaacaaacat cgaatgaatg tgattgatct caaaggaggc cttttgttgc tgttgataag
68761 accttgagga cacaatggat acgtgatgaa cacacacaca ggagctcaca catgcacaca
68821 cacacgcaca cacattcctg cccacatata catacatcaa agccagacca ccacagaatc
68881 agataggcat cattatata ctctctaacc aggacaaaa atgtgtcccc agaaaattaga
68941 atagatgata ttggactcta gcaaaactca gctcaagtat cctccattct ggtaaccacc
69001 tgacaaaaat gttattaatc tagcacttga aaggtatcaa gaaaagcagg cttcttggac
69061 ttaaatctct gaagtgtttt ttaaggctg tatattttata gcttaggagg gaaaaaaagg
69121 aaattaaggg gaaaaaaaat taaatgaaaa acacttatga cctaaaacat ctctgtgagg
69181 taggtaacgc tatgatagca aaacaacaaa aatcagaagc aatattaaag gtacatttga
69241 gatgctgaat ttttttttcc tgaaaaacaa tcaaccactt atagaacaac gtgtatacaa
69301 gttggaaaaa aaaaaaaaga aaacatctca caagtatctc agtattttcc tataactaga
69361 cggaaataag aaattacatg ggtttaccta ttaaggtaga ttccctaatt gtgtttcccc
69421 aaagattcat aacaaaattc ttatatttga ttttattttt ccattttaag acaaatccac
69481 cagtgaagtca aaacctcttt taaaaatata tgtgtttaag aagatgtgaa atgatagaaa
69541 ataagacagg ggaaatattt taaaaagttt gaaaacttat aacacaaaca tggggtcttt
69601 agtttatggg gcttgtaaat tagtgctgat tctgcattag tcaaggcctt tggatagatt
69661 ttttttttag ggggtgggag gatggagctc cattctgtca cccaggctgc agtgcagtgg
69721 cctcactctg gctcactgca accctgcctt cctgggttca agtgattctc gcgcgtcagc
69781 ctcccagaca gctgggatta cagggtgcct cgccatggtg tggcaatttt ttttttttat
69841 ttttagtaga gaaggagttt cgccatgttg gccaggctgg tctcgaactc ctgacctcag
69901 gtgatccgtc cacctcggcc tcccaaagtg tcaggattac aggcaggagc caccatgccc
69961 agtcagatat tttctgtttt ttgggttttt ttttaacaa attttcaaga agttgtttga
70021 cattacccaa gaacataaga cctgtcatgt taaatcgggt taccctgag ggtctcaaaa
70081 ccaatggca ccaagagatg gcctgtggct ggctgtgat gtcctctata atgtccacc
70141 tcacagaatg ggacattatc ctaaatatgc cccaatcttt gggatgtcat cttgtctttt
70201 aaaaaattgg cagatacagt gccaaagttag gacacctagt tccatgcat tgccatgcat
70261 tggtaacctac tgtatttggg ctctgtgtgt gctggggact ttggggttca aaagagaatg

70321 agacttgatc cttttcagaa agatcttact gtgtgagagg gtaaacaatg atgagggtaa
70381 gaaccacagc tttgatgggt ttataatagc tatagtttat caagtaatta ttacatgtct
70441 ggcacaattc tttaaaaatt ccattttatc ctcaaaagaa ccctaacagg tatatcttat
70501 tatcctcatg actcagtaag aagagagagg cttaccaagc ttaagtaact tgaccaagtg
70561 ttagggactg aatgtttgtg tccctctacc cctcattcat atgtcaaagc cctgaccatc
70621 agtgggactg tatctgggtg tgggaccctg gagagggttg taggtttaga tgaagtcttg
70681 aggatgggtc cctcatgag gggattagta gccttataag aagaggacaa gggggctggg
70741 catgatggct catgcctgta atcccagcac tttgggagac tgaggcaggt ggatcacctg
70801 aggtcaggag cttgagacca gcctggccaa catggtgaaa ccccgtttct cctagaaata
70861 caaaaagggg gaaagagaga gagaaaaagg aaaaagaaag aaaagaaaga gggagggaga
70921 gaaaaggac aggagaggag aaaggaaaag gaaaggaaaag gaagaaaagg aggaagaggg
70981 agatgaagaa agttaataga tacagtaaag gtacacagtg atagcttctc aaaggaattc
71041 tagtgacata aatatactag tagatataat tccccgaagt gatttatcca acccagagag
71101 cctatgaatc acagagagaa tgaaggatca tcaattactc agcaattgca gaataatata
71161 cctgtttctg tgtgtgacca tgtgtataca acataaggta gatcacactc aagaatgtca
71221 caaaacactg attgtttttc ggatactgaa ttaccaaagt cccttcagac tttttcatca
71281 tttgttcaact gcattcctct aaaatccaga cgagaagagg agttgtctta ctggcacact
71341 gctttcctgt cccttcctct tataaacctc tgaataacag tgcaagttac tgaacaccag
71401 agaagctctt tgatgcctcc tcggttccacc aaatatgctc tggccacgga atcccagct
71461 ctgcctgcaa tatgttctaa atgtctgaat gcatagtcca cacagcatta ctgtctcttc
71521 tggcattatg acaaaatgac tgagcacttg tctttttgga tcttgctgctg tcatttgtct
71581 tttttaggga gttttttttc cccctgcat aagatgattt gtctccaaa agaaagtctt
71641 catagagtta tctctacaga agggagcaaa tctagtttat attcccactc tcttcacccc
71701 ttgatcttat ggcocgcttc aatcagcatt aggcaggctt aacaattaga accaaaagtc
71761 ctgttcagcg gaagaaataa tgggaggtaa aatactccag cactgcagaa tttgtcaagg
71821 caatcatggt agcagggaaa tgctttaatc agttgttgac tattaattta tttgttaac
71881 agcaaatatg gatccaagaa tctcaagtga tacaggggtg tcccataata cttcctaggg
71941 atgttttctg agttgaccca taatatttga tagcttatat gaactgcaa tacgctgtca
72001 ttctcaaatg ttaaaaacaa gtgtggctgc atgtgtccac ataaatatac cggctgatca
72061 tatgaggcag ggtaggtgat tgggcagaac atgatatttc atagctaagc tgccatttaa
72121 catagccagg tggaaattgc agatcagctg agaataagac tgtgttctga tagaaatgtt
72181 ttgaaatttt ttgaaattgt ttgaaattgt ataggcaagg ggtaccgctc actctgaaga
72241 agaattattt aggaccattt aacagaactg tatgagggtc cctcttcccc atactcttaa
72301 ttcactgggt taggtctgga aatttccatc aagggtgaa ggattaccag gaagcataaa
72361 aatggaaact tcaacatttt tcctttgatg aatccatgtt ctgtgtgttt ctattggtgc
72421 tgagatttgc cagatgaaca ggataccaag ggtcccctaa gggagacttt gctttgagaa
72481 ggtgagtgtg gaacatgcta acccacggga ggagggaag ctcatatgca catgcaactg
72541 atctgccata gagggctcatc atcccctggg aacagtgacc caagagcttt taggagctca
72601 cacactgaac acaccgctat cctccccttc cttcttctctg tcccagctaa gctttgagaa
72661 attgtctatg caaccacagg gtcaaacaaa gccacatggt cctcattcac actccagtc
72721 ctctttctag aaggcatctg gaaacagggg tggggggccc ctgtgtacta ggttaaattt
72781 ctggagtttc tgaaaaactg ataggaggag ggaaagaaga catgacacca aaaataaagg
72841 ctaacttcta cctatttggg gcaagtggaa gttggaaaag aatactgcca gaggctggca
72901 gagtccctag ggtagaggga tgggcttcaa ctttaattat aacctgaaa ttaagaagtg
72961 atttactctc acttaacatc actaggggag ggaagcagaa tatatcaaat ataataaaaa
73021 gttttcattc gaaaaatgct tttttcttcc tagaatacca cggtggtttt tctttttttt
73081 ttttttttcc aagatctcta ttggctttgc tttggttctt tagaatacca cggtggtttt
73141 taacttctaa aaacattctg ctcagacaac catttcaagt tataggacac atgctctaa
73201 ggaaccatc actcaatcta atttgcacaa gttctcctat gacttgagat tgcattgag
73261 aagggtgcag ggggagaaca gacagaaaca gccactctg tgtgcagaac gccgtgtgtc
73321 ctcatgtgtt ctgggggccc atagctcatt agctgcagtt ggtatgaagc ctgcaacctg
73381 tgagccata aaattccgaa taataattca tcaggctctg agaattctcc taagtacatt
73441 tagatcaagc cagtgcacatt tcgcccctaa tagcagcatt ggcaaatggc ctaacggaat
73501 ttagatggct ccaccaagcc gcacaactat attttgtgtg ttcaaagag gggcagccgt
73561 agaggttgat ggttgacat aaaatagcag tttaggctag tggcaagat cacacaccac
73621 gacactgggc aaattagaac ctacgcactc caatttactc atctttgacg taggatatta
73681 atatggaacc actcaatcta gtgtgaggac tacatgaaat aaatgcttag ctgatgcagg
73741 aaattaaaga tgatggcatg tttttctgtt ggagtttatt ttaaaccaat gaagcagtga
73801 ggaagaggcc tctacttccc agaattgttg ctactgactt tccagttaa gaacaccctt
73861 ctatgacatc ggaaattcac aaaggtccac atttttagta atcatcaatt agtaaatatg
73921 taatgatcag gttagtatgg attcaataac gctttaaaat ggatttctac tttacacatc
73981 ccaatagcat ttaccatata ttgaaaatta tttgcaccta tatctaagac ctattattta
74041 ccctacctag tataaaatac ttgcagcata tacagggttg aagtgccat acagtagttg
74101 ttctgggtt gcaaagggat ccatagtcca aaggggtgaa tgactgctct tgaggactag
74161 aggttcaggg tccctatggg tatcacagga ggagcatatt cagagaggtt aaaagaggac
74221 atgatcttga ggtggaataa catgggtgcc aaaaattgag gagtggggtt gactacaggg
74281 agtctgtgtt gcttgggcct aggccctagg aagagtctca aatggggaag gggatgcctt
74341 tgagcacaata tctctgtggg gaaagatggg acatttgaac tggttgactt taattctgga
74401 gtgaacatgt aaaaagaaaa aggagaacca gtctccaaag cagttaaact gtccgatgaa
74461 atgaaaacgt tctgtaaccg tgctgtccaa tgtgttaggt acatgtagct actgagcact
74521 tgaaatgagg ctagttaatg aaaccgaaga agtgattttt acaaattgta tacaacttta
74581 attcatttca gtttaaatag ccacatgtgg ctaatggcta ccgtatcaga caaacaagca
74641 gctctacagt ttggtcaggc cactttggag aagcccaat tatgtaacag tacgttgttt
74701 cttctttctg agaatcagct gatgcccatc acaggctggc gcccttcaat ctaagagaat
74761 atttctttcc ataagccata aaatgctcct agatgaaatt gactggcttc atcccatggc

74821 actccacatt tgccacattt gaatcaggtt ttagccactg tcgttaatta gaatccatgt
74881 agaagcaaaa acattttaaaa taaaccggg cccttgatgt tatagctgtc atttttttac
74941 atggcctcat gattcagcga ttaatggacc ttaaaacaat cataaaacat caaggcctgt
75001 gttcaagctt agaagaacaa gaatagtttt acttctgctc tggctcctct gttttagatt
75061 cactgggtgt cactggcatc tgtaaacact ttttaagtatt ttgacattgt ggtatgagat
75121 gttgtttaac ttttccctgc ctgacctca ctggccagtgc gcatgtttgcg actcagtgga
75181 aaattctatga aaaacagcaa ggaagtactc agtgacatag attaggacac aataaaccta
75241 aataatggcc ataattgtgca gattccaatt caatacatgg acccaccaaa gacttattga
75301 gcatccagtc tgcaccaggc acttggtgga tgcttgcaaca aattacagat tttatttgca
75361 taatcctcag cacaaatgtg gggtcagcat tagtgtcccc catttcatag atgagcatgc
75421 taagacccag tcatgtggct agtaagaggc agaggtagga ttcaaaagca ggtttcctga
75481 ccccttgcca aataaccattc ttttcccaat atcccactgc aggacacgaa ctgtttgctt
75541 atgtgacaga ctgtatcttt caaaagtggc catggcagta tgtccagtc cactattctc
75601 tccagaagag gtgggtgtct tttcctctca ctgcaaacct ggttgggtgt ggtctgacag
75661 cctaaaaaat gtaaacagg aaaacctagg gctatgtaac tttatggaa ggccataaaa
75721 ggcaatgcag catctgcttg gttctttctc ttgggacgct cacccttggga acccagccgc
75781 catattgtga ggaagctcag ggtacatgga gacaatgtgt aggtgttcca gccaatagac
75841 cctccagcaa gggctccacc caccagtcag catcattcct cagactcatg agtgaacaac
75901 cttcagatga tctcagaccc tggctttcaa gctgcttcag ctgatgctgg agcagagaca
75961 agctgttctt gagagccctg ctgaaactac agattcctga acaaaataaa tgttgtgtt
76021 ttaagccact aaatttgggg gtggtttgtt atgcaacaat tgttactgga atatagtcaa
76081 actttaatga aactctaaag aatagggaaa tgcttcaatt cctcatcaa tgatatccaa
76141 atggccagaa aatgggttct catgaaagaa atcctgagag gaaaaagttc aaggtcttgg
76201 ttgtagaaaa acaccaagaa tttggaagcc ttattatctc agggaattaa gtgaaacatt
76261 tgaagaaaaa gaaaacagac agcctaata atataaccaca aagtttagat ttatgggatt
76321 atatatattat tgctttgact gctaagatct atctagagcc tcaagtggct ttggattaat
76381 tcattatttg gctttgaaag atttcttgtc ttaagaggat cctccacttc tgtctcgaga
76441 ttataggggt gcatgtgggt ttattcccta atgttcaaaa gatgagaaaa atgttgctgg
76501 catgctagaa agaagaccca acaaggcaga aaaaaactct taatctttct atattcgag
76561 atcttggcac tgtccttgac agtttggaga ggaactgaaa acagaaacaa aaacaaaaca
76621 aaaactggat atctattggag atatagccgt ataaagagtt aaaggaagtt ggcaagagt
76681 gacagtgaat tctatttgac atcccactgt ttcacccaaa taagaagctg ttaagtctt
76741 aacagtgaat aatctaaaaa tccaaagtag atcccactct tctgcatcta ccttcaagat
76801 gcctcaaatc tatgtctgtag gccgggagcg tcagctcagc cctgtaatcc cagcactttg
76861 ggaggtctag gccggcggtat cagcatgtca ggagatcgag accatcctgc ataacactgt
76921 gaaacccctga ctctacgaaa aacatgaaaa atacaaacaa tacaaaaaaa aaaattagcc
76981 aggcgaggtg gccgggtgct gtagtcccag ctactccgga ggctgagaca ggagaatggc
77041 atgaacccgg gagcgggagc ttgcagttag ccgagatcct gagatggcgc cactgcactc
77101 gagcctgggc gacaggggtga gactccgtct ctaaaaata tacatatata tgcgtttttg
77161 gatattgatt tccagaggca gtggtgaact catcaggtct ctctcaata cacttttctc
77221 ttcttgggta acaattcttt gcctacctta aacatttccac aatctagtcc ttaaattttg
77281 atattttggt agtgatattc ttaatttcat gtacaagacc acatgcagaa aagtactttt
77341 atttttaaga tgggttgcaa atatcaggag aaaggggcat ttgtctcatg caaagcttcc
77401 caaatacaaa tggaaacttc ccaaataatc atggaaccaa tccgtacaca ttggtagcaa
77461 tatttcaaat tttcaggaat tggttaattt gaggaatttt agattacttg ggtggctttt
77521 aaaacccgta atactgtcat ggctacatcc taaggatcac agaagccta aggtataaac
77581 aggatttttt tttcttttct attgatggct gtgaattttc tctgcacacc tgaactatca
77641 agttaacttt tgcatacaac agcattttta aattatcaca taaaaaacta tcaagcacta
77701 aattagaaaa ttgaaagaa tttgaaagt atagttaaat ttatgaagca attctgtac
77761 actcaaaggg tcattgcttg acatgtaaaa cattttgagc tacgtgtaag acctgggtat
77821 gaatttccct ccagtgggag aaaccacagt tctcatcagg ctccaaatga gagccacacg
77881 cagaacatat gcgcttcgca tgtgcgctgt tttgcatgac taatggagtt aatattaaaa
77941 gtcttttctc atcttttcaa ttctttcttt cttttttttt tttttaattt ggctgagcgc
78001 cttttttctc acctccaaga gctgttaatt ttgttcgctg ccgagcaaaa gtcaaagtca
78061 gagtctaaac agcttgtaat gagttttcaa tggcccatct caatgaaatt gagggcaaa
78121 accagccggc tcaggcagtg tcagccctca gaatttatta gtgagggcgc actgtgttca
78181 ggggaaggca ctgaggagg actgcagttc ctgggctctt caagaggacc cccagcctt
78241 attaaaaact tgtgacagg acaggacaca tgcatactga cccatctgcc acaatctcca
78301 ctgcggcggg gtcaaaactt gttgggaatg aaggagaggg aagtcagctg aaggaaagaa
78361 gggtttccat ctcatagtga tggggctgtt tctatctttc tatctcatca tcaatcagct
78421 aagaaggagg gccgccttcc ttcttccaag atcatgaagt accaccaggc cacctcccc
78481 acccacacac agacctgttt gtctgggtgat ggttatttgg gagaaacgaa gcagtaactca
78541 atttttgagc tctgactatt ttatttgttc aattctttta aaattcctcc atcatgccac
78601 ttccaacaga tccctctgtg ttttacttcc aagaatgcca tttaggctgg acacgatggg
78661 tcatgcctaa aatgcctgca ctttggggag ccagggtggg aagactgctt gagcctagga
78721 gttttgagac aacctgggga acatagggag acctcatctc tacaaaaata aaaattaaag
78781 ttaaaaacat gtccagggtat ggtggtatat gctgtgggt ctaagctact tgggaggctg
78841 aggcaggagg attgcttgag cccacaaggt caatgctgca gaaagctgtg atcgaccac
78901 tgcactccag catgggcaac acagcgagac cctgtctcaa aaaagaaaaa agagtacctt
78961 tgaacccac gtaatacttt tctgcacaaa tttaaaacct ccatataaaa cagaattctg
79021 catgagctgg agaaaataat actacacttg agaatgaaga gcaatttgac tatagacttt
79081 ctggccaaat aaatactctg cgaagccact acaataacac acaagagcac gtggtgggtt
79141 ggagaggaaa aaaaaaaaaa ctctcacttc ttcatagcca cagcttttta ttaaggaag
79201 aacctatgtg gtttgtgtta agaactgact tgttgtgtga gtggaataaa tcagaactgt
79261 tggatcctgc aagactaatt tatatataat tgatattaaa ctatgactga ttccaagaca

79321 ttttttataaa ataaagcacc tactagatac ttttgcacct actggccaca gtacaaggca
79381 ccatgaattc catggcaggg ctggtgatga aaatcatttc atctttcttg ccactcactc
79441 gttcattttt ctgttttttt tttttttttt tttttttttt tttttttttt
79501 ttttttttca gatgaagtct tgctctgtga cccaggctgg agtgcaatgg catcatcttg
79561 tctcactgca acctctccct cctgggttca agcaattctc ctgcttcggc ctcccatgta
79621 gctgggatta caggcgccca ccaccacacc tggctaactt ctctattttt agtagagacg
79681 gggcttcacc atattgcccc ggctgatctt gaactcctga cctcaagtaa tctgcctggc
79741 ttggcctctc aaagtgtctg gattacaggc atgaggcacg gtggccagcc attcaaccat
79801 taatgcatta ctttagtcac tcactatatt cacaaatatt tattaattag ttgttaagga
79861 caaaactagt gactaagttt tggggaaaaa ggttggctct tgtcctcaac tattaataat
79921 ttaagttctg gtaaaaattc ataaaatttc agattaatat agtggatttc caaagccttc
79981 cataaactac tgtttattta aatacacttg cttcctcggc atttatcttg ttcaacctac
80041 ctgttcaatt ccattcacag acctaccctc tttctctctg taacaattta tgttcctttc
80101 tgtgtcctat agcattgtct ggaaaatgaa acaccggtta aatatcttaa cacagagcct
80161 gtgacagaaa gccttgacg cattcagtaa acaccagcca aaaaaaaaaa aaaaaaaaaa
80221 ctaaaccaaac aaaaataaaa acaaacctcg ctctttgtgt tgtatatac tggatatttc
80281 aaaagcacgt ctgatctaag agtgagattc acgcacaggc acattccttg tcactttcac
80341 aatgacaata atgctaataa taataaccag cagagccagg agaagccacc atggtacacc
80401 agcctctggg atagggcctt tccacacatc atctcgggta attctctgca aggcagattc
80461 tgttcttacc ccaattttgt gaaaaaacat tgaaagaggt taagcgattt acaccaatc
80521 acaaaaccag ttaatttttag atcaggacaa tcggactcaa caatctataa aatatcaaca
80581 ttcagtttaa attgtatatc ttacacagct ttaatctcct aaaaaaatg aaatgtccct
80641 ttgtctgaaa ctgaaatgtc atcaatccat atacactaag gagagggaca atggcaggat
80701 ggggtgtcac ctgtcgggaa gagggtatcca caactcacca ctcactttaa aactctgttg
80761 ataacttcat tcagaaacaa agttaaggag agaaattgtt aatgtggggt gagagctcaa
80821 aaatttgccc agtaaggact ttggctgcat tcaaattgcta gaaggataaa tatcctcatc
80881 ggaagctaaa atagcaaggg tttgtttatt tttgagatag ggtctagcct tgtcaccag
80941 cttggagtgcc ggtgacatga tatcagctta ctgcaacctc tacctcctgg gttcaagtga
81001 gcttctgccc tcagcctcct gagtagctgg gattatagca catgccacca caccagcta
81061 atttttgtat ttttagtaga gatgggattt caccatgttg gccagggtgg tctcaaacctc
81121 ccaacctcag gggatctacc tgcgttggcc tcccaaagag ctgggattac aggcagagc
81181 cccatgccc accacaaaaa tgggtgagtgg tgtttgtttg tttgttttaa tgagtagaa
81241 accactttgag atgttatcca ctgaaacctg ggaggcagag gtggaggctg cagttagcca
81301 agattgcacc actgcactcc agcctgggca acagagttag actctgtctt taaaaaaaaa
81361 aaaagaggta gagagagaat gacaacaaaa ctgcccagaa aagtggagca tgaataaat
81421 aaactattac atgggggtgat agtttgcatt tatgtcact tttttctgtt tttcgaact
81481 tccattttgag agttttgatg ttaattgtta tattgggaa tgccctgcaa aagcittcta
81541 aactatcaga ctgagtgttg actgaccaca atctgtcaag tgagtgtctg ggaggagatg
81601 ctatctcaag agaagtttgc tgtggctgct acatgcctga cacagaccca gacacactga
81661 ccttagctaa gaatgcattt gggatttttag acaattccct cattctgaaa agaggcctga
81721 agtcttggaac ccctcaaaat gttttcagtt gaattcttgc tgttctcagc tcccccttg
81781 gccgtcagct gccactgcaa gccatttagc aaaggaagcg aatggcaaat tctatcacag
81841 tggggacaga tcttgcatat taattcacgt ttgcaggcta attatgacca tataggctta
81901 cccccgttcc tagacctcca aattcgtagg agaaagaaga agtgtggata ccactttatt
81961 tgggttgcca gtgactacag gtgactacag gcacctacac aatcatagcc tgcagatatt
82021 atataacgac agctgggtcac tctattccaa gcggaatttt aaagcaacat atttgtcttt
82081 gtgttaaaag cacacgggtac acatttacag aaaaacaggc cctggcattt gtctgaaata
82141 ctgtggctga aaagctcgac tttttttttt tgccattgaa caatgaacat ttacacaatc
82201 attaaaatcg atcttaccgc catatttttt ctcctttcca gttttaatac atttttataa
82261 ttgcattgaa gatattctaa ccctgttttt agtgcaaaga taaaatttat gaaccgtgac
82321 aaacgtatca tctcagagcc aacccgaagg ataacaatgt gcttgatgaa acccaagtgt
82381 tccttccctt ctgcccattt taatggggaa ggagagaaaa aagagttcat cggaacctca
82441 gacctcagc gccagacggt ggggaagttc ctaactagtg cctgagatgg aggacgtatt
82501 tcaggggaaa gtagtcattc acatagaaat ttttctaaag ctacataact ggaactttga
82561 ctaatatgca tttaaaattt gtatatggg tataattggg cagcttctgt caacacagcc
82621 aaagatatct aaataaattt gttctcccaa tggcatgtcc aattccccct ctctccattt
82681 gtgtactttc ttttagaag gtttttggac aatattagag agcaggcagg ataaaagagc
82741 agaaggttca gtatgcaaa gtcacacaga catgagctcc aaggttcagg ggggcccgtc
82801 aaagccatgt gaccttggcc aagtcctctg gcttctgaca gcctcacccc tctcaattc
82861 cataagcaga gattcggagt ggacttttgg ggtctaaaaat gacatgtgat gacgatatta
82921 tttaaaacaa cataaaatac ctccaacttt gagactctat ccctgggtgag taaaatcagt
82981 ttcataagaa aatctttaat gctggtaagt tcttaaaaat ccagcaagca cagacgtgtg
83041 agcatgtgtt tgctaaccga gatggacacc atacattttt taaaagtgat ttttgttagc
83101 atctaccctg gggttttcat tcttctcac agactgtacc ctgcccataga actctccgtt
83161 aaagagacag caagacacaa gcctaactcc agatgaactt ttctgcaccg tgtccctgtt
83221 tcttagaaa ggcagagttt taaatatttc ctaacttcac ataatagcct tgcataagac
83281 acaaatgcca ggaacagataa tgaagtggag gtaatctaca caatttaaaa acacttattg
83341 tgacaaaatg gattgacaag gtatagacga tacaagcaca tataaatgaa atgcatccca
83401 ccggaaaagc attttgctca cattgttgtt tacggctcct gaattaatag accaagaaag
83461 gcaccaccgg ccccaacaaa atgccataaa accactggca gcaagtgggtg tctcaaaact
83521 taattccccg ggacagtacc taactgttat taactctgta tcagtcctga cattggccgc
83581 atctgatatg gaacattagc ttctaagtct ctcaatagac cagtgtcctt cagtttatat
83641 tactttatgt taatagtaga aaaattacac acaacatcat ttatcattgt tatactctgc
83701 tgtacatccc atagcttatt ttaatatatt tatttaccoc tgagatgggtg agaaattaaa
83761 aatatatatg tttcgagaaa aacctatatg gaaagatcac tgtaaatctc ttaaaaaaaaa

83821 aaaaacaac ccaacaacaa ctaccttggg gggaggagg aatatattgc atagctaagc
83881 ttgtgaatga taagatgctt tctgtctaag gactcaagta caggctgtac aataatttct
83941 ggggcatgag tacataacaa aaaagcggca tattaatgat aaaatagctt ttgttccgc
84001 atcgaccag ttttttcatt tgcgatgac atccttgggt tgtgttatta gcttttttga
84061 catctgacct ctagctaggg aaaggcaaga tttttttctt tttttttctc tctcttgaaa
84121 agcgtcaact tttagagacag ttctactctt ttgacccag attctggaag cccaaagcat
84181 aacttcagtt tggattaaaa ataacaaggc tatcctttct tgctcacgtt gtggcaaagg
84241 tgccgtggct ttggtatcat gacctctgcg ctctgggtcca agctctgtcc tttgtccct
84301 atataacatg agcaagctac cccatctctc tgaacctcag cttccccaga aacaaaagga
84361 gaagactgga ttccatgggc taagatttct catagctcca gtgaattttt agtagacttt
84421 gcttttgttt tttagagacag ggtctcaccg ttgtacccag ggttgagggc agtggtgtga
84481 ccacgaatca ctaccgtctt gacctcttgg gctcaatcaa tcttcccatg tcagcctctt
84541 gagttagctag gactacaggc acgcgccacc acgcgagct aatttttgta tttttttag
84601 agacagagac ttgctatggt gccagactg ttctcgagct cctagctca agagatcctc
84661 ctgcctcgac gttgggatta gttgggatta caggcatgag ctaacgcacc tggcctccag
84721 tggatttttg actggagatt tttctgggat attgtttgct acttatcata gttccttgag
84781 actggacaaa tcttctattt ttcaaataa gcacatggaa gctcaggaa attgacatga
84841 ctaaagcccc aggttgaaaa agcagccaga ctggagtgg aacagtgcct caatcctggc
84901 tggcactctt gctctgactc caggctgcct cgagaacatc tctacaaatt agagcaattg
84961 gaatgggtct actttaggca ttgggggaaa tgactacaag ctctgacctg tcggggctgc
85021 ctttttatat ttgattttcc tttttttttt tttttttacc actttgacc ttaaaattgc
85081 ataccttgtg tcttgcataa ttatacaata cagtcttgta attatgtgtt cttatttggg
85141 tcagagggtg ctgacttgag atcatgtctt ccttttagca ggttctctt attcagaagc
85201 cactctcatg gattatgtca tttcttccac atccaatgag gcagacaggg caggtagcat
85261 ttccccactt ctattgataa agaaagtgg ggcccagcac agtggtctac gctgcaacc
85321 ccaacacttt aggaggctga ggtgggtgga tcaacttgaga tcaggtgttc cagaccagac
85381 tggccaacat ggtgaaaccc cggcactact aaaaatacaa aaattagcca ggcattggtg
85441 ctctctgcta taatccacag tacttggaag gctgaggcag gagaatcagt tgatcttagc
85501 aggcagaatt tgcagtgagc cgagatcgca ccactgcact ccagcctagg tgacagagtg
85561 agactatggc taaaaaaaaa aaaaaaaaga agaagataaa gaaacatggg atcaaagggt
85621 cttactgacc agccagagct cacacagcaa tgagtggctg gatggccgtt gggaaactgaa
85681 gaattgctct atctcctagc ccaggcaggg ccttttctaa tactttgcaa tgatgctgat
85741 aacagatat atctctaaca aatatggaca ataactcctt ccaaaaggca aaataaaact
85801 cgtatcattt gtacaagacc atgcaattta aaagcaatat tgtaagcaat ctacaataga
85861 aagcaagcct gagaaggcaa tgtgttctact gaaaacattt ctcttgctc ctcgaggcat
85921 caccagacta gatttcccag aatcctctgc agttggtgt gatcatgtga ctgaattctg
85981 gccaatggga agcagggtgga agtgacctca ctgcttccag gcttgacct taataactcc
86041 ttggaactt gtactttttc ttcccctgtc agatgtcttg acttaaagga tccagcagag
86101 gatttggagg ctccagggtg tggttgagcc caagatgtca aagtctgggt cagtgaatca
86161 cagtatggga ggccagttgc tgaatgtcta tactaattgt tacttcacca agcaatcaac
86221 gacagttcta ggagtttaaca gttaagtcaa tcttgattaa ggaagaaagt cctggaagga
86281 aggcaagggg cgtttctaaa tgtgatagct aggtagacat tcagagccat tctcttaacc
86341 agtctaagat atttattata tatactgtct ttgagcaaat attgccaaa acttccctag
86401 tgggtctttag gatatttaaa cattcacaaa atgttctttg ccttatctta gacatcatc
86461 gattttcttc tccaattatc ttccatttcg ttgcatttat tgggtactca ctatacgcta
86521 ccacttgaca gtaataaaaag ccaacatcta ttgcatttat tgggtactca ctatacgcta
86581 gccactctac tagatacttt atactcaata tctcattcca tctcaagga cattaggtag
86641 atgtcagtat tgtccccatt tacagatgaa aaacctgagg ttgagaaata tgagacttgc
86701 ccactagaat agtgcctcag agccacaccc aatgctgact gtgtatgtta ataaaaaaat
86761 aaaaattcaa aagccagaat tatacatgag tgttccatta gtgaggcgtg gtgctccaag
86821 aaagcactgt ccagaaatc tgtgtgagaa attataccct gaatcctttt tttcagaatt
86881 gggaagactc agcagtggac taagaagcca ggtttgatgt agaggatctt gtgagcactc
86941 cttctagatg aggttggaag acaagtacta gttgtagtcc atgggtagcc ttcccaattc
87001 aaggatctcc tttccatcct actcattcac aaaacagcca ggaagacaga agcatatggt
87061 gttaaagagt cagctttcag ggggttggac tgccctggact taaaatctac cctctactta
87121 aaatcctgag taaattatat aaagtattta tgcccttttt tctttacatg tagaaagaga
87181 atatctgtga agtgtgaata acataatgcc cgcaaagcac ttagcacaat atctggcacc
87241 ttttgaacac tctataaatg taagacattc ttgctgtcat tatcaatatc atcaccatca
87301 cctctccac caccaacacc accctcgaaa acaggatatg cttagcacc aacgtccaaa
87361 atgagttggc tggaaaaatc gccagctcaa agatcactgt taagcctcca actccatta
87421 ctacagact tccaagatg cttacgtgat gatgataaca ttaatttatc aaccatagat
87481 atttgcagta tgcaggcac agggctaaca tacaaaagga aagtcatttc tttgtcacta
87541 acccagtcaa agtcagacag gtgtcagcag ccacagtgg cagttctgtg ccctgtgtct
87601 acacttctg cattagaaag gatctgccta tgctcacagc ctgaacacat gggctcccat
87661 cttctccagc cacagcatca ctctgatagc agagctaata ataacagtaa gcgtaatgac
87721 aaagataaca gctgcaggaa tgacagcaac agctataact taccaagggtc ttgctatgtg
87781 tcagccattg tgctgaccac atgaagatgg tactttagtt aattctcaca gcaacactaa
87841 gaggtattag ggttattacc tcttagatat tattcaccca ttttttggga tgagaaaatt
87901 ggtattcaga gattttgggt attttgccta aggcacata gatagaagga tttgtcatag
87961 tcttttgggg ttttttgac aaaataactc aagctgggta gcttttattt attttgtttt
88021 ttgtttattt gtttgttaca aataaggcag cttcctgagc cagaacagac cgagagagac
88081 tcttggggag ctttgaaaaa aagaaattta ttgctcatgg ttctggaagc tgggaagtcc
88141 aagatcaagg aagcagcaaa ttcaatgtct ggccagagtc cgcctctc atagattcat
88201 ggatattctt cttgctgttt tctcacatgg tgaagaagc aaggcagctt ctgggggtcac
88261 ttttataagg gcaactatgc aattatgcag gctctgtct catgtccaaa tcatctccca

88321 aaagacccca tctcctaaca aatgaatgct ggggtgacac agacattctg accacagcaa
88381 gatttgaatc tagcctgctg taacccaaag cctgtgttac taagaacttt gctatatggc
88441 atgggtcctt ctgagcccta cctgccctac atcctcttct atatacaaaa tttcactttt
88501 ttttttcaaaa tatttttattt tttgtagaga tgaggagggtc ttgaactcct gccctcaaat
88561 gattctcctg cctcggcctc ccaacgtgct gggattacag acgtgagcca ccttgcccag
88621 ccagaaatcat ttaattcatta tgacctggtat tccctttcaa acccttctag gcaatgttta
88681 tcccactgca aggatgagtt gcatttgcaa catttctgaa tghtaattata agttatttcc
88741 ataattggctg aatagtctga aaaaaagttt tttttgctgt gtgctatgta ggcacattga
88801 ataattattta aacaataaag gttacctctt atgtactaca gctgtgtttt atgctaataa
88861 ccagaaatcat ttaattcatta tgagctaattg acctgcaaaa ttctatttaa aaaatgaagc
88921 catatctggg tctctggaaa gcaaaaactgg ataaaaaatg aggaaagtca atgttcaatt
88981 tgtattcttg agtgagagc agcgttatag tctgtgcagt tccataccaa gtttgagcat
89041 ttaaacagag gcaggggctc ggcatggtga ctacgcctg gaatcccagc actctgggag
89101 gctgaggcag gcagatctcc tgagcccagg agttccagac cagccagtgc aacatggcaa
89161 aacaccgtct ctacaaaaaa atataaaaaat tagctgggca ttgtgttccc agttacttgg
89221 gaggtgagg tgtgaagatc acttgatccc atgagacagc agttgcagtg acctgagatt
89281 gcatcacttc actccagcct gagcaacaga gtgagagcct ttctcaaaaa atagattaga
89341 tatagatata gatatataga taagatgaaa gaaagaaagg gggcagcggg ggcaaggaaa
89401 ttatgcactc aatgggtact aatgggtacta cttgagcacc aacgaaataa agagatttcc
89461 tattgcattg ccatggttat caaggttttg gtgtgctgt ttccttctgt ctgtacagca
89521 ctctgtcctt ctagtgtgga ttctgttact gctaaatccc cggggtgagc agagagcaga
89581 gctgtggaca atcagagctc cctgctggca atcttggtga ggatcctggc cttccttggc
89641 ttcccaacc tgaaccactc tttgcttttg ctaacctca tcttaagatt tctacaggtg
89701 agatgacctc atagacttgt atagtaagct ctatccattg tctgccccaa aggtatcctt
89761 cctcttctct tactaaaata attataattc tgtttgggcg acagagcaat gaatcaaat
89821 caatccaagc cagtgtgatg tgacaaattt gtattaaatg gccctaagtt ttacgaacc
89881 ccttatccat gccctctgac gtgcagactt gcagcacctt ttcagtctgt aagtgggaca
89941 tacttctcca ccttgagaca cgaccatatg atttgcctct gcccagaatg aagaagcaat
90001 aggaagccat ctccgagctt tttatgtttc tgctgtttt tttctgtttc tacctttaac
90061 catgaaaagg atacatgttg gaagtagagg agagagatcc aaggtggggc tgggttactc
90121 cagccaagtc cagcctagat cagcccatc ccagcccatc tgccagactc gtgagaaaga
90181 tgagcagagc agctcagggg agcttagcca aggtcacctc aaaccagag atggcgagaa
90241 tcgaatgttt attgctgagg gccactgagg tctaattggt gtttgtgat cagcaagcct
90301 gcggcaatga ctaagggata caggcaacag tctgtctccc ccgcaccagg gacagggcta
90361 agctgactat gggatgtgta gctcaagggt aaataaggga atgtccagta ctgacttctg
90421 aagaaatatt cctcccttaa aaaaacaaaa aacaataaga aaaacttgtg aagagaaggc
90481 ctcttttatg tattttttgt ttctgtttg tttgtttgt ttgtttgtg tgtttttgag
90541 acaaaagttt cactgtcgcc caggctgcag tgcatgtggc cgatctcgcc tcaactgcaac
90601 ctctgacctc ctggttcaag tgattctccc gcctcagcct tccaagtatg tgcaattata
90661 ggcagcgccc accaaatccc agctaatttt ttgcattttt agtagagacg gggtttcatc
90721 atgttggcca ggctggtctc gaacttctga cctcagggtg tccaccatc tcattatccc
90781 aaagtgtctg gattacaggt atgagccacc gcaccagcc cttctgtttg cctcagattc
90841 actaacttca gatggcctgc gaaggtatga tcccttagagc agtgaacccc atctggggaa
90901 caagaagaaa aggcacaagc cagcagaggg caaagtgtc acatcaagga gtcactcagc
90961 cagccctgga acagtctcct ccaaattatg tttcaggaga tgaatgatgt ctccactgcc
91021 catgccagtc tcagatcgcc tgctcctgcc tgctgaatgc ttctaatac ataaacctga
91081 gactgccgtt cagtccagat ccacaacacc cagcacatca ccagacacac aggaaacccg
91141 agtgccgtgt ggatcggagg gaggtgtgtt gtttgcctcc catgagttca tgaggccgc
91201 ctgtccgggc accttacgca gatacagccc acatccagat ggtagtcagg aaagcactga
91261 gtcacagagt tattctctcc actgacctcc aacccccctc ttccctgccc ttccttcagg
91321 ggccctgtgt ggaggcttct gatgaagaac aacgaagatt ttcctttttt tcaacttttt
91381 tttttttttt tttttttgag acagggtctg gatctgtcac ccagggtgga gtgcaatggt
91441 ttaattcttg tctactgcaa cctccatctc ctgggctcag gtgacctcc cactcagcc
91501 tctgagtag ctgggaccac aagcaagcac caaaacgccc ggctaatttt tgtattttt
91561 gtgaaatga ggtttcacca tgttgcacag gctgggtctc aaccctaggc ttaagtgatc
91621 ctcccacttc tgccctccaa agtgctaggg ttacaggcat gagtcactgt gccagccaa
91681 cagttagatg ttactagtac tacttatttg taaaccacag tcttgttttg attttctctg
91741 aacctttgta cttgtgtttc atgtccaagg catgggtgaa gaaagaaaga aaattaatct
91801 gccagagaga aaacaggctc ctcttttcag tttctgttta tctcctccat gttaaatagg
91861 gttgtccagc gtagtagata ctggtctctt ttggtgaac tcttaaagtt gtacgtagac
91921 cttctgactt tttcagagga gatttaagtt cactgtgtgt agactaaaaa taataatgct
91981 gagctgggca cgggtggtca cacctgtaat cccagcactt tgggaggctg gggcgggcaa
92041 atcacttgat gtcaggagtt tgagagcagc ctggccaaca tgatgaaacc ccatctctac
92101 tgaaaataca gaaatcagtc aggcgtgctg gcgtgcgcct gtaatcccag ctactaggga
92161 ggctgaggca ggacaatcac ctgaacccag gaagcaggtt gcagtgagct gagatcgcac
92221 caactgcact cagccgggac aacagagcaa gacctgtcc caaaaaata aaataaattt
92281 aaaaaaata ataactctga aacaataaca gtactcgatt ttaggtatta aatgcttctc
92341 atgtgcaagg tgttatacta agagccttac atgaataata ttaactctc ttgagtgtcc
92401 aataaggaaa gaacaactat ttttagcatt ttatagtcag ggaaactgag gcttggagag
92461 gtgaagtaac ttgtccaaag tgacacaata agtggcagaa ttggagttaa agtttacaac
92521 tgtctgattt agaagcccaa gatcctaacc atgtgccat atggtcacag gaattaacga
92581 aaatatatcc cctacagctg gaggggaaa aactggaaaa tgagcttttc ctgcaagttg
92641 tatgtcatgg tgtttgggag ctggccaacc gtggctcaca agagctgatg actgttcaa
92701 aaattagcaa gccagttatt gaacactgcc atgattaaaa ttaaatat attgatctta
92761 aaattcaaat ggaaatacaa ggaaccaga atacccaaaa caatcttgaa aatgaagaac

```
92821 aaagttggag aattcacaat tccaaatttc aaaacttaca cagagtacag taacccaaac
92881 agtgtggcaa tggcataagg acaggcatat agatcaatgg gatataattc agagtccaga
92941 aagaaatact tacatttatg gccatttgat ctctgataag ggtgcaaaga ccatttaata
93001 gagaagaat tatctttttt aatcaatgct tctgggacaa atggatattc acattcaaaa
93061 gaacaaagtt gaatgcctac cttaactat atagaaaaat tgacgtaaaa tggatcaaaa
93121 gtcttaacat aagtgtctaa actataaaag tctgagaaga aaatagagga gtggtttcag
93181 ggaaaaactc ttttctgaaa ccatgtttcc ctctgtctct cacaccacca tgacaatcaa
93241 cacagaagac tcctctcacc aaatgcgaga ggagggtgga caccacagag gtaaacgttc
93301 atgaccttgg tctacgtgga gttagttag atacaacacc caaacttttg ttgttaaaac
93361 ttttgtgcat cacgagatga tatcaaaaga ataaaaagac taccacaga atgagagaaa
93421 atgtttgcaa atcatttata tgataagggg ctagtttcca aaatatataa acaactttta
93481 caactcaact tccccacat actaagcagg ggacagcagc tgggagtcct ccaattcaat
93541 cctgacctgg tctacgtgga gttagttaga ggttgaggc tcagtcacca agactgcccc
93601 ccataccccc agacaccaat agcaagtcag agacttcaga atgtctggct gaggggcttc
93661 aggtggaagt tcccataacc ccctctttgg gtttgattaa tttgctggag cagatgacag
93721 aactcaggaa aacacttgct accacttact gctttattat aaaggacagt actaaggaca
93781 gagatgaaaa gacacatagg gcgaggtatg gggtaggggc atggagcttt ccagcccttc
93841 ctaggcagcc acgctccagg aacctccttg tcttcagcta tctggaagct cccaaacca
93901 gccctcttgg gtttttatgg gagcttcagt aggtcagcat tcctttcccc agggcataag
93961 gcaggactga ctctctgggg agggctctgaa gactcacaat caaaaagggt ggaaagatta
94021 gagtcttccc ttggggcagg tgaaagaagg acaggagaca aagagattct gtttctgat
94081 gcctaacaca cgcaatattg taacaatagg ctgcaacaag ggctatgaga gttatgagcc
94141 aggaacccta tatatatcat aacaccacag gagtaaatgt ttatgtcctt ggatttgga
94201 atggattctt agatacaaca ccaaaacag aagcaacaac atccaaaata gataaagtgg
94261 acttcatcaa gatttaaaat ctttgttcat caaaagacac tataaaaaga gtaaaaaagc
94321 tctaccttag atagagaaa aatgtttgca aaggatttat acgataaggg tctagtatcc
94381 aaaatatata aacaactttt acaactcaac acaaaaagcc agatgaccca gttaaaaact
94441 gggcaaagga cttgaatcaa catttctatt ttaaaaaaga taaaaataac caataaccac
94501 ataaaaatac tcaacatcat taatcatgag ggaaatgcaa atcaaaacca cgatacaatt
94561 ctataccttc aaagaaaaca gaaaaataag tgttgcgaag gatgtggaga aattggaacc
94621 ttcataact gcaagtgga atataaaatg gtgcagcctc cgtggaaaac aatttggtgg
94681 ctctctgaa agttaaatat aaaatgcca tattaccag caatgccact ccccaaaata
94741 tgcccaagaa tggaaaacag gagtttcgag aaaacataaa aacagtacat gtatgatcat
94801 agcagcataa ttctgaacag ccaacaagta gaaacacaat gaccaccac tggcaaatgg
94861 ataaacaaaa agtggatat ccatgtaaca gaatatcact caaccataaa aagaatgaag
94921 tactgatata ttctacaaca tggatgaacc ttgaaagcat gctaaaagca agaagccaga
94981 cacaaaaggc cacatattgt gtgattccat ttatatgaga tatccagaat agtcaaatct
95041 atagagacac aaagtagatg tggttatgag gggctggggg aaggaggaaa tggggaatga
95101 ccacttaatg gactatgtgt ttctttagcg ggggatggta aaaatgttct gaaatggctg
95161 ctgattgtgg cacgatattg tgaacgtatt aaaagtcact gaattttaca ctttaaaatg
95221 gtcaaagtgg tgaacttttt ttgttttgtt tgttttattt ttgtttttga gacacagtct
95281 cactctgtcg ccaggtctgg agtccagtgg tgcaatcttg gctcactgca acctccgcct
95341 ccaggttcca agcgaattct ctgcctcagc ctctgaata cctgggatta caggcaccca
95401 gcaccacacc tggctaattt gtgtattttt agtagagaca ggttttcac atgttgccca
95461 ggctcatctc taactcttca ccccaagtga tccaccacc tcagcctccc aaagtgttgg
95521 gattacaggc gtgagtcacc acgcccagcc ccaaagtggt aaattttaca ttatgtaaat
95581 cttaccacaa tttaaaaatc cataaagcat gtattagaaa cattcttggc atgtagaaga
95641 tgttgtgtaa ctgcctgctg tctttaatga taagctcttt aaaggaaaca gtgattgagt
95701 gatatgacaa actgccaact atgggcacag agttactttt agggggacaa aaagatactc
95761 taaaattaga ttttgatgaa aattacataa ccatgcgaat atactaaaaa aagttagaatg
95821 ttacacttca aatgggctta ttggaaagt tatgaaatac atctcaataa aacaattaaa
95881 agaaaaacat tatataaggt tactattaaa taaatcatac taaaaagtac taagtactca
95941 aaactcatga cttctaaatt gttttactac attttactgt tacctatgct cttgaagtca
96001 ttgactgtat cctgtgtgtg gtgaaaaatc tatataataa cgtgttcccc aactccactt
96061 tcagtgatct catatttata acttaaaat gctcagggtg ccactattta caccatggaa
96121 atagacatto gctacaaatc cagggtgcat ttattgcttt attgattgtc tcgacttaag
96181 aaagtgggg agaaaatatt aattcaggcc aggcgggtg gctcacgcct gtaatcccag
96241 caacttggga gcgggagaca ggcagatcac cggaggtcag gagttcaaaa ccagcctggc
96301 caccacggga aaatctcgcc tctactaaaa aattcaaaaa caattagcca ggcgtggtgg
96361 tgggtgcctg t
```

//

the above report in

format

THE MOLECULAR BASIS OF BREAST CARCINOGENESIS

April Charpentier, Ph.D. and C. Marcelo Aldaz, M.D.

Department of Carcinogenesis, The University of Texas M.D. Cancer Center,
Science Park - Research Division, Smithville, Texas 78957

Tele: (512) 237-9530

Fax: (512) 237-2475

Acknowledgment: The authors wish to thank contributing colleagues Andrzej Bednarek, Feng Jiang, Kathleen Hawkins, Kendra Laflin; Michelle Gardiner for her secretarial assistance and Chris Yone for art work. This work was supported by Grants DAMD 17-94-J-4078 and DAMD 17-96-1-6252 from the U.S. Army Breast Cancer Program; NIH Grant R01 CA59967; and Susan G. Komen Breast Cancer Foundation.

INTRODUCTION

Breast cancer is the most common malignancy affecting women today. This disease has reached epidemic proportions in the industrialized world afflicting as many as one in eight women (1), and causing approximately 45,000 deaths per year (2,3). In response to this major public health problem, research funding is being used to identify key steps in breast carcinogenesis with the goal of developing effective means for preventing, diagnosing and treating this devastating disease.

Overwhelming evidence has accumulated indicating that breast cancer is a genetically-based disease in which spontaneous mutation and/or hereditary genetic predisposition play primary roles. Environmental and epigenetic influences are also important, however their contribution to breast carcinogenesis is, at present, not well understood. The potential for developing breast cancer is most likely determined by the specific genetic makeup of an individual woman, however, this potential only becomes a threat by the interaction with specific endogenous as well as, perhaps, exogenous factors (Figure 1). For example, an important endogenous risk factor would include the extent of exposure to a woman's own ovarian hormones (4). Early age at menarche and nulliparity have been linked to an increased risk for developing breast cancer. It is likely that the extent of endogenous hormone exposure is genetically pre-determined or at least influenced by genetic factors. Examples of exogenous factors would include lifestyle choices such as, diet, alcohol intake and cigarette smoking (Figure 1). Physical environmental causes, such as ionizing radiation, have been shown to increase the likelihood of breast cancer development (5,6). Also, although

the topic is controversial and less understood, we should mention the potential role of environmental pollutants and hormone disrupters (7) (8). Taken together, it is then the combination of the genetic constitution, plus the influence of multiple endogenous and exogenous factors which, ultimately, will determine the overall risk of any particular woman for developing breast cancer.

Numerous mutated genes have been shown to be linked to breast cancer development although the assumption is that there are many more important breast cancer genes yet undiscovered. This overview focuses on the currently identified genes as well as genetic aberrations which may lead to the identification of as yet unknown genes key to breast carcinogenesis. In addition, other factors which also exercise significant influence in breast carcinogenesis, such as the hormonal regulation of cell proliferation, are discussed.

HISTOPATHOLOGY

Normal Breast Tissue

In order to correlate the genetics of breast cancer to the clinical manifestations, an overview of the histology of both normal and cancerous breast tissue is required. It should be mentioned, however, that it is beyond the scope of this chapter to perform a detailed analysis of breast tumor pathology.

The mammary glands are derived from modified sweat glands and basically represent downgrowths of the epidermis. In the adult woman the mammary gland is composed of approximately 15-20 lobes of branched

tubuloalveolar glands. Dense fibrous connective tissue separates the lobes. Each lobe in turn is subdivided into multiple lobules. Mammary lobules are located at the deepest end of the duct system. These lobules form clusters identified as blind-ending terminal ductules, or acini. These structures are embedded into a loose connective tissue rich in capillaries. Dense fibrocollagenous support mixed with abundant adipose tissue fills the interlobular spaces. The main collecting ducts (i.e. the lactiferous ducts) are lined by stratified squamous epithelium near their opening onto the nipple. A short distance from the surface each lactiferous duct presents a dilated portion known as the lactiferous sinus where the epithelial lining shows a transition to a two layer cuboidal epithelium. From there and throughout the rest of the duct system and acini the epithelium consists of one layer of luminal cuboidal cells and a basal layer of myoepithelial cells (Figure 2).

The development and differentiation of the mammary gland is hormonally regulated. The ovarian hormones estrogen and progesterone control breast development, especially during puberty. Full or complete differentiation of the mammary gland takes place during pregnancy and lactation, a time when the hormone prolactin plays a fundamental role. The explosive growth that the mammary epithelium undergoes during pregnancy causes the mammary tree to branch dramatically increasing the number of acini. This level of differentiation constitutes what Russo and Russo have described as lobule type 3 (9).

Wellings has suggested that the majority of breast carcinomas originate in what is known as the terminal ductal-lobular unit (TDLU) (10), also known as lobule type 1 (9). The TDLU has only 6-10 terminal ductules/lobule and is equivalent to the less differentiated state of

mammary gland development found predominantly in the breast of the nulliparous women (9).

Invasive Carcinoma

The most frequently observed invasive breast carcinoma is the infiltrating (invasive) ductal carcinoma (IDCA). IDCA represents approximately 75-80% of the total invasive breast cancer cases (11). Most invasive ductal carcinomas display the typical phenotype of well to poorly differentiated adenocarcinomas. Another type of invasive breast carcinoma, which accounts for approximately 10-15% of the total invasive breast cancer cases, is the infiltrating lobular carcinoma (ILCA) (Rosen, 1979). ILCA has a very distinctive infiltrating growth pattern, characterized by the pathognomonic presence of isolated cells or cord of cells (i.e. Indian files pattern) (11). This tumor type also presents a different clinical and metastatic pattern than the invasive ductal type (13). For example, patients with invasive lobular carcinoma have been reported to have a higher risk of developing multifocal and contralateral breast cancer than patients with invasive ductal carcinoma (14). It is important to remember, that the designation of ductal and lobular carcinomas does not imply that ductal carcinomas originate exclusively in ducts and lobular carcinomas in lobules. According to Wellings, both tumor types, ductal and lobular, appear to originate in the TDLU (10).

Preinvasive and Hyperplastic Lesions

In an attempt to clearly identify stages of breast cancer development, standardized terminology is used to refer to important changes in the morphology of the breast epithelium which have been noted by pathologists. This is shown schematically in Figure 3.

The identification and nomenclature of "potentially premalignant" lesions of the human breast have been a matter of controversy for many years. Among the non-invasive breast lesions, ductal carcinoma *in situ* (DCIS) is the most common and best characterized precursor to invasive carcinoma. Some researchers have also proposed models where there is a direct transition from normal to malignant epithelium, without any visible evidence of a preneoplastic stage (15). Nevertheless, evidence placing DCIS as a major precursor lesion of invasive carcinomas is substantial. For instance, the majority of IDCA's have an *in situ* component (16). Women with biopsy-proven DCIS have an increased risk for development of subsequent invasive breast cancer (17) and a high recurrence of invasive carcinoma occurs in women who have had breast-conserving treatment of DCIS (18). Taken together these findings strongly suggest *in situ* carcinomas are precursors to invasive carcinomas. A more insidious lesion is lobular carcinoma *in situ* (LCIS). LCIS is characterized by a uniform population of generally small and loosely cohesive cells growing in a solid occlusive fashion. Whereas the more common DCIS represents a highly heterogeneous group of lesions ranging from microscopic to grossly detectable intraductal carcinomas, as well as predominantly *in situ* carcinomas with areas of stromal microinvasion. When breast neoplastic cells begin proliferating outside their site of

origin, (i.e. beyond the containment of the basement membrane) and the microinvasion spreads further, the neoplasia is then termed invasive carcinoma. Invasive ductal carcinomas are not necessarily the result of DCIS nor are invasive lobular carcinomas the obligated direct result of LCIS. In fact, there is some evidence that LCIS may play an important role as a precursor of invasive ductal carcinoma as well (Figure 3) (19). It should be mentioned however that the relationship of LCIS as a precursor lesion of invasive breast cancer is a matter of controversy (19). It has been suggested that due to its morphologically diffuse and generalized nature, the presence of LCIS indicates that the whole breast epithelium is at risk of malignant transformation. It is possible that the distinction between DCIS or LCIS may be indicative of important differences in their genetic pathways during breast carcinogenesis.

Mammary epithelial hyperplastic lesions which demonstrate only some of the characteristics of *in situ* carcinoma are frequently identified in the clinic. These lesions are called atypical hyperplasias (AH) (20). Atypical hyperplasias can either be ductal (ADH) or lobular (ALH) in type. Finally, other less advanced hyperplastic lesions which are only associated with a slightly increased risk for breast cancer development, are known as proliferative disease without atypia (PDWA). PDWA lesions lack the qualitative and quantitative histologic features of AH (20) meaning that they comprise a variety of epithelial hyperplastic lesions from mild to florid but do not show signs of atypia.

FAMILIAL AND SPORADIC BREAST CANCER FORMS

Family history constitutes the strongest known risk factor for development of breast cancer. Women who have a family tree in which several blood relatives were afflicted with breast cancer have a far greater chance of developing breast cancer as compared to the general population. Because of this fact, in the last few years intense research has focused on identifying the breast cancer susceptibility genes, passed down from generation to generation. However, the inherited forms of breast cancer account for only 5-10% of total breast cancer incidence (Figure 4). The remaining 90-95% of women who develop breast cancer do not appear to segregate for an inherited susceptibility allele. Such cases are known as "sporadic" breast cancer (21). This label is somewhat misleading since "sporadic" breast cancer is actually the most frequent form of breast cancer. Nevertheless, approximately 25% of breast cancer cases diagnosed before age 30 are believed to be caused by genetic factors alone (22). Analysis of familial pedigrees suggested the existence of various types of inherited breast cancers, consistent with models of autosomal dominant transmission of a highly penetrant susceptibility allele (21). The major familial breast cancer forms include (23):

- 1.) site-specific breast cancer, which is the most frequent and occurs in families in the absence of any other familial occurring neoplasm;
- 2.) breast and ovarian cancer syndrome, which is characterized by early-onset and high rate of bilaterality;
- 3.) Li-Fraumeni cancer syndrome, which is characterized by early-onset of breast cancer, bilaterality, and association with other

familial neoplasias, such as leukemia, sarcomas, brain cancer and adrenocortical carcinoma;

- 4.) Cowden disease which is a rare condition also known as multiple hamartoma syndrome and is characterized by multiple mucocutaneous hamartomatous lesions, both benign and malignant.

In addition to the above forms the Muir Torre Syndrome which is a variant of Lynch II syndrome, also includes breast cancer, although it is a very rare syndrome. This syndrome is caused by mutations in DNA mismatch repair genes and is associated with microsatellite instability (24,25).

BREAST CANCER SUSCEPTIBILITY GENES

BRCA1

We have witnessed tremendous progress within recent years in the identification of genes responsible for several of the inherited breast cancer types. In 1990 genetic linkage analysis of affected families identified a gene predisposing individuals for early-onset breast cancer. This locus (i.e. Breast cancer 1 or BRCA1), was mapped to chromosome region 17q21 (26,27). Furthermore it was estimated that this tumor susceptibility allele, would account for 45% of families with high incidence of site-specific breast cancer and approximately 80% of families identified as carriers of the early-onset breast and ovarian cancer syndrome (28). After intense effort, the gene itself was cloned in

1994 by Miki and coworkers (29). Mutations in BRCA1 were found to co-segregate with the predisposing haplotype in affected kindred (29). Thus, a woman who has a mutation in the BRCA1 gene has a high risk of developing breast cancer and this risk increases over her lifetime reaching a peak by the age of 70 with a risk of 87% (28).

BRCA1 is a large protein with 22 exons and 1,863 amino acids and shows very little homology to other known genes and also has several alternative spliced forms. However, based on the fact that BRCA1 has a ring finger motif close to its amino-terminus and a leucine heptad repeat within its sequence, speculation was made that BRCA1 may function as a transcription factor (30). BRCA1 mutations are scattered throughout the entire coding region. Interestingly, a frequently found mutation (185delAG) is also found to be present in 1% of women from Ashkenazi Jewish descent (31). Most commonly the germinal mutations affecting BRCA1 are small insertions and deletions causing frameshifts, which produce stop codons, and result in truncation of the protein product.

The BRCA1 gene product appears to play a much smaller role, if any, in non-familial breast cancer. As with other tumor suppressor genes it was expected that mutations of BRCA1 would be frequent in sporadic breast cancer forms, particularly due to the common finding of 17q loss of heterozygosity in most breast tumors (32-35). However, no mutations in BRCA1 have been found in non-familial breast cancer cases. It has been suggested that subcellular mislocation of the BRCA protein may play a role in sporadic breast cancer. In normal breast epithelial cells, BRCA1 is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients and in some primary tumors it is localized, mainly in the cytoplasm (36).

Some groups have suggested that BRCA1 is a secreted protein since it contains certain homology regions to granins, a protein found in secretory granules (37). Conflicting with this suggestion, the nuclear localization originally reported in normal cells was later confirmed by other groups (38). Some evidence has also accumulated indicating that normal BRCA1 may act as a tumor suppressor gene inhibiting tumor growth (26,39). At present the function of BRCA1 is controversial and therefore requires further analysis. However, both BRCA1 and BRCA2 have been shown to bind and colocalize in the nucleus with the DNA repair protein RAD51 but further analysis is needed to define BRCA's role in this pathway (38,40,41). Furthermore, it was recently suggested that BRCA1 is required for transcription coupled repair of oxidative damage (42). These investigators showed that cells deficient in BRCA1 are impaired in their ability to carry out transcription coupled repair of oxidative damage (42). This would imply that BRCA1 may be playing an important role as guardian of genomic integrity.

BRCA2

A second breast cancer susceptibility gene was isolated in 1995, named BRCA2 (43). BRCA2 was originally mapped by linkage analysis to chromosome arm 13q12-13 (44). Similar to BRCA1, BRCA2 is a large gene encoding for 3,418 aminoacids and has several splice variants. Germinal mutations on this gene predispose a person to early-onset, site specific breast cancer and moderately predispose a woman to ovarian cancer. These families also present a higher incidence of male breast cancer and are associated with a higher predisposition to prostate, pancreatic, colon and

other cancers (43). As with BRCA1, the germinal mutations identified are spread throughout the coding sequence of BRCA2. Most of the mutations were frameshift mutations generating a truncated gene product as was the case with BRCA1. A particular BRCA2 germinal mutation, in this case 6174delT, is also frequently found (1%) in Ashkenazi Jewish women (45). Like BRCA1, BRCA2 appears to play no major role in sporadic breast cancer, since only very few somatic mutations were observed in these tumors. The function of the BRCA2 protein is uncertain as well.

Very recently the contribution of BRCA1 and BRCA2 to inherited breast cancer was assessed by linkage and mutation analysis in a series of 237 families with a history of breast cancer chosen at random without regard to the existence of other cancers (46). Linkage to BRCA1 was observed in 52% of the families, to BRCA2 in 32% and to neither in 16% of the families, indicating the existence of other predisposing genes. The vast majority (81%) of the breast/ovarian cancer families were associated with BRCA1 mutation, 14% due to BRCA2, while 76% of families with both female and male cancer cases were due to BRCA2. BRCA2 carriers appear to have a similar lifetime cancer risk as BRCA1 carriers but a lower risk before age 50 (46).

TP53

Germline TP53 mutations have been found in affected families and shown to be causative of the Li-Fraumeni cancer predisposition syndrome (47,48). Breast cancer is one of the neoplasms affecting patients with this syndrome. In tumors from patients with Li-Fraumeni syndrome, loss of the wild-type TP53 allele is observed with retention of the mutant

allele. As indicated above, this syndrome is characterized by early-onset breast cancer, bilaterality, and association with other familial neoplasias, such as leukemia, soft tissue sarcomas, osteosarcoma, brain cancer and adrenocortical carcinoma.

Contrary to the previously described tumor susceptibility genes, TP53, a known tumor suppressor gene, has been shown to play an important role in sporadic breast cancer progression as well. However, germline mutations of this gene in the general population are rare. TP53, located on chromosome arm 17p13, is known to harbor somatic mutation in 25-45% of primary breast carcinomas (49). All evidence indicates that TP53 is one of the most frequently affected genes in breast cancer. The role of TP53 in breast carcinogenesis will be further discussed in a following section.

PTEN/MMAC1

Recently, a new putative tumor suppressor gene, PTEN, has been identified on chromosome 10q23.3. PTEN is responsible for Cowden disease's familial predisposition (50-52). Breast cancer is a component of this rare syndrome as was described in a preceding section. The majority of the women who have this mutated gene develop breast neoplasia and approximately half of these cases develop into breast cancer. The amino acid sequence of PTEN resembles two different types of proteins: tyrosine phosphatases, enzymes that remove phosphate groups from the amino acid tyrosine in other proteins; and tensin, a protein that helps connect the cell's internal skeleton of protein filaments to its external environment (53). Homozygous deletions and mutations affecting

PTEN have been found in both prostate and glioblastoma cancer cell lines. Somatic inactivating mutations of PTEN were associated with numerous primary prostate and endometrial carcinomas (54,55). However, practically no somatic mutations affecting PTEN were found in sporadic forms of breast cancer (56,57).

ATM and HRAS (Putative breast cancer susceptibility genes)

Several years ago it was suggested that heterozygous carriers of a defective Ataxia-telangiectasia (ATM) gene are at increased risk (3-5 fold) of developing breast cancer (58). However, later studies concluded that there was no clear association between the ATM mutants and the risk of early onset or familial breast cancer in general (59,60). Nevertheless, it is an issue of importance since ATM heterozygous carriers represent a high percentage of the population (0.5% - 5%). At this point, the role of ATM as a factor for increasing breast cancer risk in the general population is unclear.

Other potential breast cancer susceptibility alleles are the polymorphic variants of the HRAS gene minisatellite sequence (61,62). These studies reported a positive association between rare HRAS alleles and breast cancer (61,62). However, controversial results have been reported by other research groups (63) and further confirmation of the positive association between these rare alleles with breast cancer is required.

Common Enzymes Allelic Variants that may Contribute to Breast Cancer Risk

Through molecular epidemiology studies, it is becoming apparent that the combination of a specific genetic makeup plus exposure to specific exogenous factors (e.g. environmental, chemical and physical carcinogens) play decisive roles in defining the risk for tumor development. The heterogeneity of the genetic background found in the general population would explain why certain individuals develop cancer while others do not even when exposed to a similar dose of a particular carcinogen (e.g. cigarette smoke and lung cancer risk).

Therefore, as previously suggested, breast cancer etiology may be explained by inherited predisposition to develop cancer, inherited predisposition to accumulate new mutations, and exogenous exposures (64) (Figure 1). This would be the basis for the expected etiologic heterogeneity found in the general population. Thus, although breast cancers are classified as a single disease, not all are caused by the same set of etiologic agents. Most likely, different population subgroups will respond differently to the same set of carcinogens.

Numerous studies have focused on a series of allelic variants that would confer increased tumor susceptibility. Several of these genes are enzymes involved in detoxification pathways that the organism utilizes to eliminate xenobiotics. In most cases, a phenotypic polymorphism in the metabolic rate of specific chemicals correlated with the finding of genotypic polymorphisms (i.e. allelic variants). The genotypic polymorphisms were detectable as restriction fragment length polymorphism (RFLP's) variants or as gene deletions. A good example of

such polymorphism affecting breast cancer is seen with the Cytochrome P-450 (CYP) superfamily of enzymes. These "Phase I" enzymes are responsible for the oxidative metabolism of diverse endogenous and exogenous substrates, such as steroids, prostaglandins, fatty acids, foreign chemicals and drugs. CYP enzymes are responsible for the biotransformation of xenobiotics to toxic intermediate metabolites (i.e. phase I). The level of CYP expression and CYP's catalytic activity can vary dramatically among the general population due to the highly polymorphic nature of these enzymes. The "Phase II" group of detoxification enzymes are also usually polymorphic and are responsible for the conjugation reaction necessary for the efficient excretion of toxic compounds. These enzymes transform toxic compounds into more hydrophilic forms for excretion. Ambrosone and Shields (65) have suggested that women who have genetic polymorphisms that could result in greater activation, or impaired detoxification of; aromatic and heterocyclic amines, (e. g. NAT1, NAT2, CYP1A2 enzymes); polycyclic aromatic hydrocarbons (e. g. GSTM1, CYP1A1 enzymes); and nitroso compounds (e. g. CYP2E1 enzyme) may be at greater risk for developing breast cancer. Recently it was reported that the GSTM1 homozygous null phenotype was associated with increased risk of developing breast cancer, similar associations were also observed with polymorphic variants of the enzymes GSTT1 and GSTP1 (66). On the other hand, it was very recently shown that cigarette smokers who are carriers of BRCA1 or BRCA2 mutations were found to have a lower breast cancer risk than subjects with mutations who never smoked indicating that somehow smoking appears to reduce breast cancer risk in these patients (67). This confuses the significance of published observations in the field and indicates the amount of work which lies ahead in order to clarify our

understanding of the interaction of environmental carcinogens and breast cancer genetic predisposition.

SOMATIC CHROMOSOMAL AND GENETIC ABNORMALITIES IN BREAST CANCER

Cytogenetics of Breast Cancer

Numerous studies have been performed in order to characterize the role of chromosomal abnormalities in breast cancer. However, as is the case with other solid tumors of epithelial origin, it has been difficult to identify any primary cytogenetic changes among the large number of apparently random alterations. This is due to the clonal heterogeneity characteristic of breast cancer as well as to the inherent difficulties in obtaining high-quality metaphases from solid tumors. Nevertheless, the prevalence of several specific chromosomal aberrations have been noted. The most frequent tend to be numerical alterations of whole chromosome copy number including trisomies of chromosomes 7 and 18 and monosomies of 6, 8, 11, 13, 16, 17, 22, and X (68). The most common aberrations in non-metastatic near-diploid tumors are, loss of chromosomes 17 and 19, trisomy of chromosome 7, and overrepresentation of chromosome arms 1q, 3q, and 6p (69). Structural alterations include terminal deletions and unbalanced nonreciprocal translocations, most frequently involving chromosomes 1, 6, and 16q. Breakpoints for structural abnormalities cluster to several chromosomal segments, including 1p22-q11, 3p11, 6p11-13, 7p11-q11, 8p11-q11, 16q, and 19q13 (69). In particular, 16q was shown to participate systematically in

translocations with chromosome 1q and to display frequent deletions. In fact, some investigators have suggested that specific abnormalities affecting chromosome 16q could be considered primary cytogenetic aberrations since they were observed in the absence of other anomalies (70,71).

A recently developed molecular cytogenetic technique called comparative genomic hybridization (CGH), allows for the analysis of chromosome copy number abnormalities involving segments of at least 10 Mb (72). Since CGH involves hybridizing differentially labeled genomic DNA from a tumor and a normal cell population to the same normal metaphase, it circumvents some of the difficulties encountered in conventional karyotyping. Through such analyses, nearly every tumor analyzed revealed increased or decreased DNA sequence copy number (73).

The most common regions of increased copy number in breast cancer as determined by CGH include 1q, 8q, 17q22-24, and 20q13. Regions of decreased DNA copy number were also observed and include 3p, 6q, 8p, 11p, 12q, 13q, 16q, and 17p (74). For some of these regional losses, candidate genes exist that may be the target of deletion in the progression to a malignant phenotype (Table 1). These genes and their corresponding regions will be discussed in more detail in the following sections. Interestingly, when both loss and gain of DNA copy number as determined by CGH were compared with survival data in a series of node negative breast tumors, only copy number losses were significant for recurrence and for overall survival (75). However, as is the case with conventional cytogenetics, CGH studies failed to reveal any characteristic abnormalities that occur in the majority of breast tumors or to identify any abnormalities which could be considered "primary".

Oncogenes and Gene Amplification

In human breast cancer as in other solid tumors, the most common aberration affecting oncogenes appears to be gene amplification. Abundant evidence demonstrates that huge regions of DNA, up to entire chromosome arms, can be amplified as a contiguous unit. The importance of this to breast cancer development is still unclear although it suggests that genes within these regions are overexpressed, due to their high representation. Chromosomal regions overrepresented in tumor cells suggest the presence of activated oncogenes. Proto-oncogenes encode proteins involved in cascade of events leading to growth in response to mitogenic factors. Alteration in the normal function of proto-oncogenes, through mutation or increased expression, can result in a constant growth stimulus and a constitutive mitogenic response. Aberration of a single allele of an oncogene can be sufficient to lead to altered signal and as such is dominant. Current data suggest that of the numerous oncogenes described to date, only a few may have a role in breast tumorigenesis.

Regions Affected by Gene Amplification

Region 17q12 (ERBB2)

In 1987, ERBB2 was demonstrated to be overexpressed and amplified in 20-40% percentage of breast cancers (76,77). Amplification was shown to be consistently accompanied by increases in mRNA and protein levels (76,77). In later studies, increased copy number of the long arm of

chromosome 17 (17q) which contains the ERBB2 gene, demonstrated a 50 to 100 fold amplification in some cases as determined by gene fluorescence in situ hybridization analysis (72).

The fact that ERBB2 is overexpressed in a high percentage of breast cancers implicates its involvement in breast tumorigenesis (78,79). Therefore in recent years the diagnostic and possible treatment value of ERBB2 detection has been extensively studied. Early studies reported a prognostic value of ERBB2 overexpression in node negative breast cancer. However, more recent studies using larger data sets did not support these early observations and question the prognostic role for ERBB2 expression in node positive breast cancer. Expression of ERBB2 may have value in predicting response to specific therapies, additional studies are underway to confirm these observations (reviewed by Ravdin & Chamness 1995). For instance, ERBB2 overexpression has been associated with increased resistance to chemotherapy (82) and estrogen receptor positive patients who overexpress ERBB2 are less likely to respond to hormone therapy (83).

Studies have also shown that activation or overexpression of ERBB2 in transgenic mice results in the genesis of mammary tumors (84). Whereas neutralizing antibodies against ERBB2 lead to tumor regression (85). The possibility of using antibodies against ERBB2 as a means of treating breast cancer is presently under investigation (86,87).

The ERBB2 proto-oncogene is a member of the epidermal growth factor receptor family. All of the family members which include EGFR, ERBB2 (Her-2/neu) ERBB3 and ERBB4, have demonstrated overexpression in breast cancer. In addition, overexpression of ligands for these receptors, such as TGF-alpha, have been associated with neoplastic transformation in transgenic mouse models (88). This family of receptors encodes

transmembrane glycoproteins with tyrosine activity. However, although the family members share high homology their ligand specificity is distinct. It has been suggested distinct biochemical and biological responses of the individual receptors such as ERBB3 and ERBB4 (89). Therefore although these receptors may show similarity in their ability to regulate cell proliferation their mechanism of action is most likely diverse.

Region 8q (c-Myc)

Amplifications at region 8q including the oncogene *c-myc*, a gene known to be overexpressed, either by amplification or regulatory means, in breast cancers (90). *c-myc* is a member of a small family of related proteins that function as sequence specific transcription factors (91). Activation of the *c-myc*, *Nmyc* and *Lmyc* genes has been described in many human cancers (92). In normal cells, *c-myc* expression is rapidly induced following mitogenic stimulation, and its activity is absolutely dependent upon the presence of growth factors (93). The *c-myc* protein is commonly implicated in mediating the transition of cells from quiescence to proliferation (94). Therefore, *c-myc* is considered to be a positive regulator of cell growth and its activation is thought to confer a growth advantage upon a tumor cell. Conversely, *c-myc* has also been demonstrated to induce apoptosis a function more consistent with a negative regulator of cell growth (95,96). A possible explanation for this bifunctional activity lies in the fact that in order for *c-myc* to act as a promoter of cell proliferation appropriate serum growth factors, stimulating growth via a separate pathway, must be present (92). In the

absence of growth regulators, over expression of c-myc is sending conflicting signals to the nucleus, which in turn initiates programmed cell death (i.e. apoptosis).

The *myc* gene has been shown to be amplified in approximately 25% of breast carcinomas (90). Overexpression of *c-myc* in transgenic mice results in mammary tumors (97), and amplification of *c-myc* has been associated with high grade tumors in humans (98). Of additional interest, *c-myc* expression is modulated by the presence of estrogen in estrogen-responsive cell lines, and constitutively high *c-myc* expression is observed in hormone-dependent lines, probably because of increased stability of the transcript (99).

Region 11q13 (cyclin D)

Chromosome region 11q13 has also been reported to be amplified in 15-20% of breast cancers and is associated with poor prognosis (100). The *cyclin D1* gene, located in this region, is thought to be the target of such amplification. Cyclin D1 is overexpressed in 45% of breast carcinomas, most of which are both estrogen and progesterone receptor positive (101,102). Studies show that transgenic mice homozygous null for *cyclin D1* fail to undergo proliferative changes of the mammary epithelium associated with pregnancy, thereby indicating a role for *cyclin D1* in steroid-induced proliferation of the mammary epithelium (103). Transgenic mice overexpressed *cyclin D1* have been shown to develop mammary carcinomas (104). Analysis of *cyclin D1* expression by mRNA *in situ* hybridization has shown a dramatic increase of *cyclin D1* expression

in 76% of low grade carcinoma *in situ*, further suggesting a role for cyclin D1 in the tumorigenesis of the breast (105).

Mapped within this same region is the *int-2* gene. Transgenic mice strains containing the *int-2* transgene develop multifocal preneoplastic hyperplasia of the mammary gland which can give rise to focal mammary tumors (106). The possibility that an additional gene responsible for breast tumorigenesis within this amplified region is *int-2* is controversial since corresponding increases in mRNA and protein levels for *int-2* rarely correspond to amplification status. Thus, the possibility remains that a yet unknown gene located close to *int-2* might have a biological effect, whether *int-2* itself is merely co-amplified remains to be seen.

Region 20q13 (AIB1)

The gene (AIB1), amplified in breast cancer, was very recently identified as a leading candidate for the amplification of region 20q13 (region described to be amplified in 15-30% of cases) (107). AIB1 was found amplified in all estrogen receptor positive cell lines and it has been identified as a nuclear steroid receptor coactivator (107). AIB1 amplification may contribute to the development of steroid-dependent breast cancers by interacting with the estrogen receptor to enhance the effects of estrogen on tumor cells.

Tumor Suppressors and Loss of Heterozygosity

Knudson, on the basis of statistical analysis of clinical observations, was the first to suggest that retinoblastoma was a cancer caused by two mutational events (108). In the hereditary form of retinoblastoma one mutation is germinal; thus only a single additional somatic mutation is required. This resulted in early onset and a tendency toward bilateral tumorigenesis. In the sporadic form, both mutations are somatic, resulting in a tendency toward unilaterally and late onset. It was later suggested that these two mutational events could occur within separate alleles of a regulatory gene (109). Supporting this, cytogenetic analysis of retinoblastoma revealed characteristic deletions of the long arm of chromosome 13. Subsequent analysis of the same chromosome region led to the cloning of *RB1* and identification of aberrant transcripts encoded from the remaining allele (110). As a consequence of these studies, a precedent emerged where inactivation of one allele of a tumor suppressor is accomplished by mutation, leading to the eventual deletion of the remaining normal allele through chromosomal aberrations and thus loss of heterozygosity (LOH) is thereby observed in the suppressor locus. This precedent is now considered the convention for tumor suppressor gene inactivation and similar observations have been made for several other putative tumor suppressor genes (e.g., *APC*, *DCC*, *VHL*, *TP53*; reviewed by (111). Therefore, LOH is considered indirect evidence for the existence of a suppressor gene within the affected chromosomal region.

Breast Cancer Allelotype

The chromosomal mechanisms by which loss of heterozygosity occurs tend to involve large segments of DNA, thus it is possible to utilize adjacent genes or known noncoding sequences as markers to identify deleted regions harboring putative suppressor genes whose loss may be important in the genesis or progression of a tumor. One such genetic marker is the naturally occurring simple sequence length polymorphisms (SSLPs). SSLPs consist mainly of dinucleotide repeats, primarily (CA)_n, which are repeated in tandem at variable number interspersed throughout the genome (112). These polymorphic microsatellites have a mean heterozygosity of 70% and recent mapping efforts reported an average spacing of 199 Kb (113). Through known linkage maps and comparison to physical maps, it is possible to select highly polymorphic microsatellites at any position within the genome. Further, through PCR amplification of these microsatellites and comparison with normal DNA from the same patient, it is possible to generate a comprehensive map of allelic imbalances and losses (allelotype) occurring in a neoplasm.

Numerous studies have analyzed the breast cancer allelotype, and numerous regions of allelic imbalance have been described using microsatellites as well as the older restriction fragment length polymorphism analysis. Deville and Cornelisse, reviewed data from more than 30 studies revealing a consensus of imbalances affecting 12 chromosome arms at a frequency of more than 25% (Table 1). Chromosome arms 1p, 1q, 3p, 6q, 8p, 11p, 13q, 17q, 18q, and 22q were affected at a frequency of 25-40%, whereas chromosome arms 16q and 17p were affected in more than 50% of tumors (68). In addition, chromosome arm

9p, has recently been reported to be affected by allelic imbalances and losses in numerous breast carcinomas (114). In general, the loss of genetic material in many of these regions has been corroborated by either CGH or classic cytogenetic data (68,115). Some of these regions are known to harbor tumor suppressive genes whose loss has been demonstrated through a variety of techniques, including Southern blot analysis and FISH using gene-specific single-copy probes (111).

Although there is overwhelming evidence that these genetic losses occur, inherent difficulties exist in determining the relevance of such losses to breast carcinogenesis. In most cases, the tumors analyzed were of the invasive type and/or advanced stages of progression, leading to the question of whether these losses are causative factors of tumorigenesis or consequences of the general genomic instability inherent to tumors. It is possible that certain losses may be selected for in the progression or clonal evolution of a tumor to a more advanced type but not strictly necessary for the genesis of the tumor. Some of these questions could be addressed in part through comparative allelotyping of both noninvasive and invasive tumors.

The relative timing and frequency of allelic losses of commonly affected regions in breast cancer was estimated by comparing the allelotype of preinvasive ductal carcinomas (DCIS) and invasive carcinomas (81). The allelotypic analysis of DCIS samples revealed that chromosomal regions 3p, 3q, 6p, 11p, 16p, 18p, 18q, and 22q were not affected by a high frequency of loss, on the other hand analyses of these same regions of invasive tumors showed them to be affected in 10-40% of cases (81) (Table 1). These findings are in agreement with those of Radford et. al. who examined 61 DCIS samples (116). Since allelic losses

affecting these regions were not frequently observed at the noninvasive (DCIS) stage it can be concluded that alterations of these regions are late events in breast cancer progression. More importantly, allelic imbalances observed on chromosome arms 7p, 7q, 16q, 17p, and 17q (81), as well as 9p as reported by others (117), appear to be early abnormalities because they occur frequently in DCIS (Table 1).

Targets of Allelic Loss

Chromosome Region 17p13

The short arm of chromosome 17, is subject to allelic loss in more than 50% of invasive ductal carcinomas, and approximately 30% of noninvasive ductal carcinomas (81,116,118). This high frequency of allelic loss suggested that a tumor suppressor of relevance to breast tumorigenesis resides in this region. Indeed, tumor suppressor *p53* maps to chromosome band 17p13 and is known to harbor somatic mutation in 25-45% of primary breast carcinomas (49). Recently *p53* mutations were identified in mammary ductal carcinoma *in situ* but not in epithelial hyperplasia (119). It has been suggested that *p53* mutation analysis may serve as a marker for identifying preinvasive lesions at increased risk of developing invasive carcinoma.

We have already discussed the relevance of germinal *p53* mutations as the cancer predisposing alteration in the Li-Fraumeni syndrome (47,48). In tumors from patients with Li-Fraumeni syndrome, loss of the wild-type allele is observed in conjunction with retention of the mutant *p53* allele. Functional studies of cells with mutant *p53* indicate a change

of phenotypes, including cellular immortalization, loss of growth suppression, and fourfold increase in protein half-life which leads to *p53* accumulation. Accumulation of *p53* protein, observed by immunohistochemical analysis in roughly 30-50% of sporadic breast carcinomas, was proposed to be an indicator of higher risk of recurrence in patients with tumors positive for *p53* expression (reviewed by (120)). It appears that *p53* inactivation through mutation and LOH is intrinsically linked to the development of subsequent further genomic instability as suggested by *in vitro* findings, as discussed in a separate chapter, and as demonstrated in experimental models of mammary cancer (121).

Although *p53* is most likely the driving force for allelic loss on 17p, some reports indicate that there may exist another distinct locus that may be a target of allelic loss. In an analysis of 141 breast tumors, Cornelis et al. observed a strong association between *p53* mutation and allelic loss of the *p53* locus (122). However, in cases where *p53* mutation was not observed, allelic loss of distal region 17p13.3 was always observed, sometimes without *p53* allele loss. Similar findings of distal deletion of 17p were also observed in DCIS (116). While these findings support the existence of a second gene as target of allelic loss, further studies are needed to address this issue.

Chromosome Region 17q21-22

The long arm of chromosome 17, also frequently affected by allelic imbalance in both familial and sporadic breast cancers, has recently been subjected to extensive analysis because 17q has been linked to familial breast cancer (123). As a result, the *BRCA1* gene was isolated by

positional cloning as discussed in preceding sections (29). However, when sporadic breast tumors with allelic loss of 17q were examined for *BRCA1* coding sequence alterations, only about 10% of those with LOH revealed any change of sequence, and those mutations were found to be germinal (124).

Another known putative suppressor gene localized in this region, nm23 or *NME1*, has been shown to undergo allelic loss in as much as 60% of breast carcinomas (125). However, analysis of *NME1* has not revealed evidence of mutations (126). An additional possible explanation for allele loss in 17q is the existence of a yet-unidentified gene within this region as the target for LOH (122).

Chromosome Region 13q14

Loss of the *RB1* region 13q14 has been reported for numerous neoplasms including small cell lung carcinoma, bladder carcinoma, osteosarcoma, and breast carcinoma (reviewed by (111)). These losses appear to be relatively early losses in some tumors since 15-20% of tumors at the DCIS stage reveal allelic loss of 13q (81,116). However, when allelic loss and expression are examined in the same breast tumors, no correlation between the two is observed, suggesting that Rb inactivation is not acquired by allelic loss and that another gene may be the target of such inactivation (127). As discussed in a previous section, a second breast cancer susceptibility gene, *BRCA2*, was mapped to chromosome 13q12-13 (43). This suggested that the *BRCA2* gene may be involved in sporadic breast cancer as well. However, similar to the findings with *BRCA1* on 17q, when sporadic breast tumors were analyzed

for mutation of *BRCA2*, mutations were infrequent, indicating that *BRCA2* is not the gene being targeted by loss (128-130). *Brush-1* is another gene that has been mapped to 13q12-13, proximal to *RB1*. Analysis of *Brush-1* expression showed it to be low to absent in 6 of 13 breast cancer lines and decreased in four of four tumors showing LOH of 13q12-13 (131). However, no sequence analysis has yet been reported, and the question of whether decreased expression of *Brush-1* results from allelic loss involving large regions of another gene has yet to be addressed.

Chromosome Region 16q

Chromosome 16q has been suggested as a site for the occurrence of primary cytogenetic structural abnormalities in the development of breast cancer (70,71). In particular the long arm of chromosome 16 was shown to systematically participate in nonrandom translocations with chromosome 1. Breast cancer allelotypic studies have also shown the common occurrence of allelic losses affecting the long arm of chromosome 16 (132-134). Several studies have reported the occurrence of frequent allelic losses affecting chromosome 16q in DCIS (81,116,133).

It has been suggested that more than one putative tumor suppressor resides in the chromosome region 16q. At least two regions of chromosome 16q have consistently been reported to show LOH: 16q21 and 16q24.2-qter (132-134). In most recent studies, high-resolution allelotyping of chromosome 16 in DCIS lesions have identified three distinct regions with a very high incidence (about 70% or more) of allelic losses (41). Two of the three regions agree with previously described areas: 16q21 at locus D16S400 and 16q24.2 at locus D16S402 (41).

However, the region with the highest incidence of LOH observed, lies within 16q23.3-q24.1 close to marker D16S518 (41).

E-cadherin (CDH1), a cell adhesion molecule implicated as an invasion suppressor protein, is one possible candidate target of the LOH at chromosome 16q21. Interestingly, this gene was demonstrated to be mutated at a high frequency in invasive lobular carcinomas of the breast. The lack of E-cadherin expression is believed to be the cause behind the infiltrative growth pattern characteristic of lobular carcinomas (135). However, the more common, invasive ductal carcinomas do not show high incidence of E-cadherin mutations. In addition to mutation E-cadherin may be inactivated by CpG methylation within the gene's promoter region (136,137). Expression of a second cadherin gene, H-cadherin, map to region 16q24 (138) was reported to be absent or reduced in several breast cancer cell lines. Further studies are necessary to identify additional possible targets for the common allelic losses observed to affect this autosome in breast cancer.

Chromosomal Region 9p

Chromosomal region 9p21, as previously discussed, has been shown to be affected by allelic loss or imbalance in more than 58% of invasive ductal carcinomas and 30% of DCIS, suggesting it may be involved in breast tumorigenesis (114,117). Previously, the p16 tumor suppressor gene was identified within this region by positional cloning and shown to be affected by homozygous deletions in 60% of breast carcinoma lines (139). However, when primary breast tumors were analyzed for mutation of the *CDKN2* coding region, few mutations were found (114). More recent

analysis, including FISH determination of gene copy number, methylation of the 5' region, and analysis of expression, indicate that *p16* appears to be a target of abnormalities in approximately 40% of breast tumors (140). These observations substantiate a role for *p16* inactivation in the tumorigenesis of the breast and as a target of 9p allelic loss. Interestingly, however some breast tumors show overexpression of *p16* indicating that involvement of this gene as well as that of *p14^{ARF}* (homolog of mouse *p19^{ARF}*), encoded at the same locus in an alternative reading frame is more complex than previously thought, as will be discussed in the following section.

CELL CYCLE IN BREAST CANCER

Cell replication in eukaryotes proceeds through an orderly cascade of events manifested as the cell cycle. The machinery responsible for such progress includes a hierarchy of proteins and complexes each exerting an effect on the next. At the top of this hierarchy are the cyclin subunits, whose expression and stability oscillate in a phase-dependent manner. The expression of certain cyclin genes can be upregulated by different mitogenic stimuli, for example, the upregulation of cyclin D1 by estrogen (141). Each of these cyclins can associate in a specific manner with corresponding cyclin-dependent kinases (CDKs). Cyclins are in competition with CDK inhibitors, which have the ability to displace the cyclin and form an inactive complex with the CDKs. When CDKs are active, they phosphorylate, and hence inactivate, other proteins with transcription-repressing activity (Reviewed by Sherr, 1996) (Figure 5).

Of the restriction points, G1 to S is best characterized in breast cancer. Key players in early G1 and after the passage of cells from G0 to G1, include cyclins D1-D3, CDKs 4 and 6, the specific inhibitors of these CDKs, p15, p16, p18 and p19 and the substrates of CDKs, Rb and Rb-like proteins. Later in G1 and fueled by E2F1 transcriptional activation, cyclin E and its partner CDK2, become important players in the G1-S transition. Collectively, these proteins are known elements responsible for regulating progression through G1 and as a consequence loss of function or abnormalities in the expression of an individual protein can lead to cell cycle dysregulation and altered cell proliferation.

An additional family of CDK inhibitory proteins also exists which includes, p21^{cip1}, p27^{kip1} and p57^{kip2}. Of the proteins mentioned, the Rb protein, cyclin D1, cyclin E, p16 and p27 have all been observed to be affected in breast carcinogenesis. As previously mentioned, cyclin D1 has been shown to be both amplified in 10-20% of breast tumors and overexpressed in the majority of breast tumors (101,102,105). Cyclin D1 competes with *p16* for heterodimerization with the CDKs. When cyclin D1 is more abundant than p16, it binds to and activates CDK4 and CDK6 (Figure 5). Recently cyclin D1 mRNA and estrogen receptor expression were found to be positively correlated in primary breast cancer (144). There is no conclusive evidence however demonstrating that estrogen receptor directly up regulates cyclin D1 transcription.

Recent studies have suggested that overexpression of cyclin E, which is often found in breast tumors, is functionally redundant to cyclin D (145). In cells overexpressing both cyclin E and p16, cyclin E can functionally replace cyclin D providing tumor cells with a growth advantage (145). They do this by activating CDK's which in turn

phosphorylate *Rb*, releasing E2F and initiating gene transcription, leading to cell cycle progression and a self-perpetuating positive regulatory loop (Figure 5). Interestingly, it was recently reported a bad prognosis and very high mortality rate in women with breast cancers showing high cyclin E expression concomitant with low expression of the CDK inhibitor p27^{kip1} (146).

Inactivation of *Rb* itself has been described in breast cancer as a means of enhancing cell cycle progression. Although, when multiple modes of inactivation are accounted for, *Rb* is inactivated in less than 20% of breast cancers (127,147). In the vast majority of tumor lines there is an inverse relationship between *Rb* and *p16* expression (148,149). (i.e., breast tumor cell lines which retain *Rb* expression have no expression of *p16*. Whereas, cell lines retaining *p16* expression often lack expression of *Rb*.) When primary breast tumors were analyzed for *p16* expression, approximately 50% showed loss or reduced expression (140). This loss of expression may be due to homozygous deletion, methylation or in rare instances mutations (140).

The CDK inhibitor *p21* CIP1 as indicated, is a universal inhibitor of CDKs, inducing cell cycle arrest at both the G1/S and G2/M restriction points (150). Inhibition of DNA replication occurs when *p21* complexes with the proliferating cell nuclear antigen, PCNA (151). Because *p21* gene transcription is regulated by *p53*, it has been suggested that *p53*-dependent cell cycle arrest is mediated by *p21*. Indeed, *p21* nullizygous mice fibroblasts fail to undergo G1 arrest when *p53* is activated following DNA damage, although apoptosis is unaffected and occurs when *p53* is activated in these same cells (152).

As previously mentioned, positive detection of the p53 protein accumulation has been shown to be associated with p53 mutations and a higher risk of breast cancer recurrence (reviewed by Ozbun and Butel, 1995). Therefore, p53 inactivation appears to be a critical event in the tumorigenesis of the breast. This also suggests that an additional consequence of p53 inactivation would be abrogation of cell cycle arrest through loss of transcriptional activation of p21.

Interestingly, very recently it was demonstrated an important regulatory link between both the P53 and Rb pathways. At the center of this link is the recently described p14^{ARF} (previously called p19^{ARF} because of the mouse homolog). As mentioned in a preceding section, this gene is encoded at the INK4a locus in chromosome 9p21, as an alternative reading frame of the cyclin dependent kinase inhibitor p16^{ink4a}. It was demonstrated that the putative tumor suppressor ARF gene physically interacts with MDM2 and as a consequence basically blocks MDM2-induced p53 degradation and transcriptional inactivation (153,154). Thus, this interaction leads to increase p53 stability and accumulation (Figure 5). Further strengthening the connection between the p53 and Rb pathways, it was very recently reported that ARF is transcriptionally upregulated by E2F1 (155). This allowed to speculate that perhaps abnormal cell proliferation, which results in E2F1 increase (Figure 5), in turn would result in increase of ARF which would lead to cell arrest or apoptosis via p53. This would not happen if an additional abnormality takes place such as p53 mutation or ARF inactivation (155). In studies from our laboratory we have demonstrated that both ARF and p16 expression levels are highly variable in breast cancer (140). We observed subsets of tumors that lack expression of both genes (p16 and ARF) due to common inactivation events

such as homozygous deletion. On the other hand we have also observed numerous tumors that dramatically overexpressed ARF. We are currently addressing the p53 status in the same tumors.

APOPTOSIS AND BREAST CANCER

Closely linked to the deregulation of the cell cycle are the molecular pathways leading to programmed cell death (i.e. apoptosis). When DNA is altered during replication, control checkpoints stop the mitotic cycle in order to repair the damage. If the DNA cannot be repaired, apoptosis is induced. At first much of cancer research focused on uncontrolled cell proliferation, now researchers are aware of the important role cell death has in maintaining homeostasis.

Much remains to be done in terms of understanding the sequence of events that occur during apoptosis, which of them are essential of the process and their role in carcinogenesis. As already mentioned, p53 plays an important role in directing cells into apoptosis when DNA damage occurs. Other key players include the family of Bcl proteins and ICE (interleukin 1 β converting enzyme).

Bcl2 is a potent repressor of apoptosis conferring survival advantage to cells expressing it. On the other hand, Bax, another Bcl2 family member, is capable of countering the death repressor activity of Bcl2. Bax has been found to exist as a homodimer and is also capable of forming heterodimers with Bcl2 *in vivo* (156). Therefore the ratio of Bax to Bcl2 in a given cell may dictate whether the cell survives upon receiving apoptotic stimuli. This type of homeostatic control by the ratio of homo and heterodimers can be expanded to include several members of

the Bcl2 family. Some Bcl2 members acts as promoters of apoptosis (i.e. Bax) while other members inhibit apoptosis (i.e. Bcl2). Although not a member of the Bcl2 family, cMyc has been shown to cooperate with Bcl2 to achieve immortalization of tumor cells (92). Bcl2 protein expression is highly variable in breast cancer and it was suggested that high expression associated with favorable clinicopathological features (157,158). Recently a study analyzed Bcl2, Bax, Bcl-x and Bak expression and loss of apoptosis in small, non-metastatic breast carcinomas (159). Bcl-2 expression but not Bclx expression was associated with loss of apoptosis. Expression of Bax and Bak was found significantly associated with increased apoptosis in the breast carcinomas. These large gene families form complex set of interactions which may balance the scale either towards or away from apoptosis. It is still premature however to determine whether alterations in pathways of apoptosis play a relevant role in breast carcinogenesis.

ESTROGEN AND BREAST CANCER

The role of estrogen as an important factor in the etiology and progression of human breast cancer has been well documented. It was already observed 100 years ago that ovariectomy could lead to breast cancer regression in premenopausal patients (160). The extent of exposure to ovulatory cycles is one of the most important endogenous causes associated with a higher risk for development of sporadic breast cancer (4). However, while the association of estrogen in the development of breast cancer is well established, the fundamental mechanism(s) by

which this hormone modulates cell growth and tumor development are not yet clear.

It is known from *in vitro* and *in vivo* studies that estrogen's mechanism of action is via its ability to bind the estrogen receptor (ER) which in turn binds specific enhancer regions on the DNA and regulates gene transcription (161). The interaction of estrogen with its receptor and the recruitment of accessory cofactor proteins to bind DNA and activate gene transcription has been the focus of intense recent research (162). However we understand very little downstream from these events. Important questions still remain such as; What are the main gene targets upon which estrogen acts to exert a growth response? What is the chronology of such events?

Estrogen has been shown to increase the pool of cells synthesizing DNA by recruiting non-cycling cells into the cell cycle and by reducing the length of the G1 phase (163). The ability of estrogen to regulate the transcription of c-Myc and c-Fos is believed to be, in part, responsible for estrogen's stimulatory effects on the cell cycle (164). Entry into S phase was found to be preceded by increased activity of both Cdk4 and cyclin E-Cdk2 and hyperphosphorylation of pRB, all within the first 3-6 hours of estradiol treatment (165). The increase in Cdk4 activity was accompanied by increases in cyclin D1 mRNA and protein, indicating that an initiating event in the activation of Cdk4 was increased cyclin D1 gene expression. In addition to cyclin D1's ability to activate cdk4, cyclin D1 has recently been shown to directly enhance transcription of estrogen receptor related genes (166). Cyclin D1 does this without binding cdk4 and in the absence of estrogen, thereby identifying an additional role for cyclin D1 in promoting cell growth.

However the effects of estrogen on cyclin D1 expression may not be a direct effect of the estrogen receptor on the cyclin D1 gene promoter. The ability of protein synthesis inhibitors to abolish cyclin D mRNA induction by estrogen, suggests intermediary proteins could be involved (165). Clearly our understanding of how estrogen exerts its effects on breast tissue requires further analysis.

NEW TECHNOLOGIES AND FUTURE DIRECTIONS

It is estimated that within the next few years we will have compiled gene sequence information for the entire human genome. However if we are to use the tremendous amount of information gained to improve the treatment of breast cancer patients, it is imperative that we bridge the gap between genes and their relationship to a particular physiopathological outcome. To date the majority of molecular biology research has focused on abnormalities of the genome such as mutation, gene amplification and loss of heterozygosity as discussed in preceding sections. Identifying defects in the genome associated with breast cancer is the first level of genomic complexity. The next level of complexity is characterizing the changes in gene expression as a cell progresses from normal to malignant.

Present day advances in gene expression technology are allowing researchers to study this next level of genomic complexity by defining global changes in gene expression. Technologies such as SAGE (Serial Analysis of Gene Expression) and Microarray technologies are at the cutting edge of cancer research. Ultimately, the ability to understand the detailed mechanisms of tumor progression, from the very early stages of

carcinogenesis through metastasis will allow researchers to identify key components and interactions of the malignant pathway. Recently, the feasibility of SAGE was demonstrated by analyzing more than 300,000 transcripts derived from at least 45,000 different genes in both normal and neoplastic cells (167).

The knowledge found by defining global and specific alterations in the transcription of premalignant and malignant cells, would allow researchers to concentrate on gene targets that will better serve as diagnostic and prognostic tools. Ultimately it would be ideal to achieve a very precise matching of treatment to individual tumors profiles. A logical additional consequence will be the designing of more rationale therapeutic approaches.

REFERENCES

1. Feuer, E., Wun L., Boring C., Flanders W., Timmel M. and Tong T. (1993) The lifetime risk of developing breast cancer. *J Natl Cancer Inst*, **85**, 892-897.
2. Kelsey, J. and Horn-Ross P. (1993) Breast Cancer: Magnitude of the problem and descriptive epidemiology. *Epidemiol Rev*, **15**, 7-16.
3. Wingo, P.A., Tong R. and Bolden S. (1995) Cancer Statistics, 1995. *CA-A Cancer Journal for Clinicians*, **45**, 8-30.
4. Pike, M., Spicer D., Dahmouch L. and Press M. (1993) Estrogens, progesterones, normal breast cell proliferation, and breast cancer risk. *Epidemiol Rev*, **15**, 17.

5. McGregor, H., Land C., Choi K., Tokuoka S., Liu P., Wakabayashi T. and Beebe C. (1977) Breast cancer incidence among atomic bomb survivors, Hiroshima and Nagasaki, 1960-1969. *J Natl Cancer Inst*, **59**, 799.
6. Bhatia, S., Robison L., Oberlin O., Greenberg M., Bunin G., Fossati-Bellani F. and Meadows A. (1996) Breast cancer and other second neoplasms after childhood Hodgkin's disease. *N Engl J Med*, **334**, 745-751.
7. el-Bayoumy, K. (1992) Environmental carcinogens that may be involved in human breast cancer etiology. *Chem Res Toxicol*, **5**, 585-590.
8. Wolff, M. and Weston A. (1997) Breast cancer risk and environmental exposures. *Env Health Perspect*, **4**, 891-896.
9. Russo, J., Rivera R. and Russo I. (1992) Influence of age and parity on the development of the human breast. *Breast Cancer Res Treat*, **23**, 211-218.
10. Wellings, S., Jensen H. and Marcum R. (1975) An atlas of subgross pathology of 16 human breasts with special reference to possible precancerous lesions. *J Natl Cancer Inst*, **55**, 231-275.
11. Rosen, P.P. (1979) The pathological classification of human mammary carcinoma: Past, present and future. *Ann Clin Lab Sci*, **9**, 144-156.
12. Tavassoli, F. (1992) *Pathology of the Breast*. Appleton & Lange, Norwalk, CT.
13. Silverstein, M., Lewinsky B., Waisman J., Gierson E., Colburn W., Senofsky G. and Gamagami P. (1994) Infiltrating lobular carcinoma.

It is different from infiltrating duct carcinoma? *Cancer*, **73**, 1673-1677.

14. Dixon, J.M., Anderson T.J., Page D.L., Lee D., Duffy S.W. and Stewart H.J. (1983) Infiltrating lobular carcinoma of the breast: an evaluation of the incidence and consequence of bilateral disease. *Br J Surg*, **70**, 513-516.
15. Ponten, J., Holmberg L., Trichopoulos D., Kallioniemi O., Kvale G., Wallgren A. and Taylor-Papadimitriou J. (1990) Biology and natural history of breast cancer. *Interntl J Cancer*, **5**, 5-21.
16. Alpers, C. and Wellings S. (1985) The prevalence of carcinoma in situ in normal and cancer-associated breasts. *Human Pathology*, **16**, 796-807.
17. Dupont, W. and Page D. (1985) Risk factors for breast cancer in women with proliferative breast disease. *N Engl J Med*, **312**, 146-151.
18. Solin, L., Recht A., A F., Kurtz J., Kuske R., McNeese M., McCormick B., Cross M., Schultz D., Bornstein B. and al e. (1991) Ten-year results of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast. *Cancer*, **68**, 2337-2344.
19. Lakhani, S.R., Collins N., Sloane J.P. and Stratton M.R. (1995) Loss of heterozygosity in lobular carcinoma in situ of the breast. *J Clin Pathol: Mol Pathol*, **48**, M74-M78.
20. Page, D. and Dupont W. (1992) Benign breast disease: indicators of increased breast cancer risk. *Cancer Detection & Prevention*, **16**, 93-97.

21. Newman, B., Austin M., Lee M. and King M.-C. (1988) Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. *Proc. Natl. Acad. Sci. USA*, **85**, 3044-3048.
22. Claus, E.B., Risch N. and Thompson W.D. (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. *Am J Hum Genet*, **48**, 232-242.
23. Anderson, D. (1991) Familial versus sporadic breast cancer. *Cancer*, **70**, 1740-1746.
24. Liu, B., Parsons R., Papadopoulos N., Nicolaides N.C., Lynch H.T., Watson P., Jass J.R., Dunlop M., Wyllie A., Peltomaki P., de la Chapelle A., Hamilton S.R., Vogelstein B. and Kinzler K.W. (1996) Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients [see comments]. *Nat Med*, **2**, 169-74.
25. Kolodner, R., Hall N., Lipford J., Kane M., Rao M., Morrison P., Wirth L. and al e. (1994) Structure of the human MHS2 locus and analysis of two Muir-Torre kindreds for MSH2 mutations. *Genomics*, **24**, 516.
26. Bowcock, A.M., Anderson L.A., Friedman L.S., Black D.M., Osborne-Lawrence S., Rowell S.E., Hall J.M., Solomon E. and King M.C. (1993) THRA1 and D17S183 flank an interval of <4cM for the breast-ovarian cancer gene (BRCA1) on chromosome 17q21. *Am J Hum Genet*, **52**, 718-722.
27. Chamberlain, J., Boehnke M., Frank T., Kiouisis S., Xu J., Guo S., Hauser E., Norum R., Helmbold E., Markel D., Keshavari S., Jackson C., Calzone K., Garber J., Collins F. and Weber B. (1993) BRCA1 maps proximal to D17S579 on chromosome 17q21 by genetic analysis. *Am J Hum Genet*, **52**, 792-798.

28. Easton, D., Bishop D., Ford D. and Crockford G. (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. *Am J Hum Gene*, **52**, 678-701.
29. Miki, Y., Swensen J., Shattuck-Eidens D., Futreal P., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L., Ding W. and al e. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science*, **266**, 66-71.
30. Chapman, M. and Verma I. (1996) Transcriptional activation by BRCA1. *Nature*, **382**, 678-679.
31. Cornelisse, C., Cornelis R. and Devilee P. (1996) Genes responsible for familial breast cancer. *Pathology, Research & Practice*, **192**, 684-693.
32. Futreal, P., Söderkvist P., Marks J., Iglehart J., Cochran C., Barrett J. and Wiseman R. (1992) Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite lenght polymorphisms. *Cancer Res*, **52**, 2624-2627.
33. Cropp, C., Champeme M.-H., Lidereau R. and Callahan R. (1993) Identification of three regions on chromosome 17q in primary human breast carcinoms which are frequently deleted. *Cancer Res*, **53**, 5617-5619.
34. Saito, H., Inazawa J., Saito S., Kasumi F., Koi S., Sagae S., Kudo R., Saito J., Noda K. and Nakamura Y. (1993) Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. *Cancer Res*, **53**, 3382-3385.

35. Devilee, P. and Cornelisse C. (1990) Genetics of human breast cancer. *Cancer Surv*, **9**, 605-630.
36. Chen, Y., Chen C., Riley D., Allred D., Chen P., Von Hoff D., Osborne C. and Lee W. (1995) Aberrant subcellular localization of BRCA1 in breast cancer. *Science*, **270**, 789-791.
37. Jensen, R., Thompson M., Jetton T., Szabo C., van der Meer R., Helou B., Tonick S., Page D., King M. and Holt J. (1996) BRCA1 is secreted and exhibits properties of a granin. *Nat Genet*, **12**, 303-308.
38. Scully, R., Ganesan S., Brown M., DeCaprio J., Cannistra S., Feunteun J., Schnitt S. and Livingston D. (1996) Localization of BRCA1 in human breast and ovarian cancer cells. *Science*, **272**, 122.
39. Smith, S., Easton D., Evans D. and Ponder B. (1992) Allele losses in the region 17q12-q21 in familial breast and ovarian cancer involve the wild-type chromosome. *Nat Genet*, **2**, 128.
40. Scully, R., Chen J., Plug A., Xiao Y., Weaver D., J F., Ashely T. and Livingston D. (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. *Cell*, **88**, 265-275.
41. Chen, T., Sahin A. and Aldaz C. (1996) Deletion map of chromosome 16q in ductal carcinoma *in situ* of the breast: refining a putative tumor suppressor gene region. *Cancer Res*, **56**, 5605-5609.
42. Gowen, L., Avrutskaya A., Latour A., Koller B. and Leadon S. (1998) BRCA1 required for transcription-coupled repair of oxidative DNA damage. *Science*, **281**, 1009-1012.
43. Wooster, R., Neuhausen S., Mangion J., Quirk Y., Ford D., Collins N., Nguyen K., Seal S., Tran T., Averill D., Fields P., Marshall G., Narod S. and al e. (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. *Science*, **265**, 2088-2090.

44. Wooster, R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C. and Micklem G. (1995) Identification of the breast cancer susceptibility gene BRCA2. *Nature*, **378**, 789-792.
45. Struewing, J., Abeliovich D., Peretz T., Avishai N., Kaback M., Collins F. and Brody L. (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. *Nature Genet*, **11**, 198-200.
46. Ford, D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D.T., Weber B., Lenoir G., Chang-Claude J., Sobol H., Teare M.D., Struewing J., Arason A., Scherneck S., Peto J., Rebbeck T.R., Tonin P., Neuhausen S., Barkardottir R., Eyfjord J., Lynch H., Ponder B.A., Gayther S.A., Zelada-Hedman M. and et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. *American J. Human Genetics*, **62**, 676-689.
47. Malkin, D., Li F., Strong L., Fraumeni J.J., Nelson C., Kim D., Kassel J., Gryka M., Bischoff F., Tainsky M. and al e. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science*, **250**, 1233-1238.
48. Srivastava, S., Zou Z., Pirollo K., Blattner W. and Chang E. (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-fraumeni syndrome. *Nature*, **348**, 747-749.
49. Osborne, R., Merlo G., Mitsudomi T., Venesio T., Liscia D., Cappa A., Chiba I., Takahashi T., Nau M., Callahan R. and Minna J. (1991) Mutations in the p53 gene in primary human breast cancers. *Cancer Res*, **51**, 6194-6198.

50. Nelen, M., Padberg G., Peeters E., Lin A., van den Helm B., Frants R., Coulon V., Goldstein A., van Reen M., Easton D., Eeles R., Hodgson S., Mulvihill J., Murday V., Tucker M., Mariman E., Starink T., Ponder B., Ropers H., Kremer H., Longy M. and Eng C. (1996) Localization of the gene for Cowden disease to chromosome 10q22-23. *Nature Genetics*, **13**, 114-116.
51. Liaw, D., Marsh D., Li J., Dahia P., Wang S., Zheng Z., Bose S., Cell K., Tsou H., Peacocke M., Eng C. and Parsons R. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. *Nature Genetics*, **16**, 64-67.
52. Steck, P., Pershouse M., Jasser S., Yung W., Lin H., Ligon A., Langford L., Baumgard M., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D. and Tavtigian S. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. *Nature Genet*, **15**, 356-362.
53. Li, J., Yen C., Liaw D., Podsypania K., Bose S., Wang S., Puc J., Miliareis C., Rodgers L., McCombie R., Bigner S., Giovanella B., Ittmann M., Tycko B., Hibshoosh H., Wigler M. and Parsons R. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science*, **275**, 1876-1878.
54. Cairns, P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J., Jen J., Isaacs W., Bova G. and Sidransky D. (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. *Cancer Res*, **57**, 4997-5000.
55. Risinger, J., Hayes A., Berchuck A. and Barrett J. (1997) PTEN/MMAC1 mutations in endometrial cancers. *Cancer Res*, **57**, 4736-4738.

56. Rhei, E., Kang L., Bogomolnii F., Federici M., Borgen P. and Boyd J. (1997) Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinoma. *Cancer Res*, **57**, 3657-3659.
57. Ueda, K., Nishijima M., Inui H., Watatani M., Yayoi E., Okamura J., Yasutomi M., Nakamura Y. and Miyoshi Y. (1998) Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers. *Japanese J Cancer Res*, **89**, 17-21.
58. Gatti, R., Berkel I., Boder E., Braedt G., Charmley P., Concannon P., Ersoy F., Foroud T., Jaspers N., Lange K., Lathrop G., Leppert M., Nakamura Y., O'Connell P., Paterson M., Salser W., Sanal W., Silver J., Sparkes R., Susi E., Weeks D., Wei S., White R. and Yoder F. (1988) Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. *Nature*, **336**, 577-580.
59. FitzGerald, M., Bean J., Hegde S., Unsal H., MacDonald D., Harkin D., Finkelstein D., Isselbacher K. and Haber D. (1997) Heterozygous ATM mutations do not contribute to early onset of breast cancer. *Nature Genetics*, **15**, 307-310.
60. Chen, J., Birkholtz G., Lindblom P., Rubio C. and Lindblom A. (1998) The role of ataxia-telangiectasia heterozygotes in familial breast cancer. *Cancer Res*, **58**, 1376-1379.
61. Krontiris, T., Devlin B., Karp D., Robert N. and Risch N. (1993) An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. *N Engl. J. Med.*, **329**, 517-523.
62. Garrett, P., Hulka B., Kim Y. and Farber R. (1993) HRAS protooncogene polymorphism and breast cancer. *Cancer Epidemiology, Biomarkers & Prevention*, **2**, 131-138.

63. Hall, J., Huey B., Morrow J., Newman B., Lee M., Jones E., Carter C., Buehring G. and King M. (1990) Rare HRAS alleles and susceptibility to human breast cancer. *Genomics*, **6**, 188-191.
64. Rebbeck, T., Couch F., Kant J., Calzone K., Deshano M., Peng Y., Chen K., Garber J. and Weber B. (1996) Genetic heterogeneity in hereditary breast cancer - role of BRCA1 and BRCA2. *Am J Human Genet*, **59**, 547-553.
65. Ambrosone, C.B. and Shields P.G. (1997) Molecular Epidemiology of Breast Cancer. In Aldaz, C.M., Gould, M.N., McLachlan, J. and Slaga, T.J. (eds), *Etiology of Breast and Gynecological Cancers*. Vol. 396. Wiley-Liss, New York, pp. 83-99.
66. Helzlsouer, K., Selmin O., Huang H., Strickland P., Hoffman S., Alberg A., Watson M., Comstock G. and Bell D. (1998) Associate between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. *J Natl Cancer Inst*, **90**, 512-518.
67. Brunet, J., Ghadirian P., Rebbeck T., Lerman C., Garber J., Tonin P., Abrahamson J., Foulkes W., Daly M., Wagnercostalas J., Godwin A., Olopade O., Moslehi R., Liede A., Futreal P., Weber B., Lenoir G., Lynch H. and Narod S. (1998) Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. *J Natl Cancer Inst*, **90**, 761-766.
68. Devilee, P. and Cornelisse C. (1994) Somatic genetic changes in human breast cancer. *Biochimica et Biophysica Acta*, **1198**, 113-130.
69. Thompson, F., Emerson J., Dalton W., Yang J.-M., McGee D., Villar H., Knox S., Massey K., Weinstein R., Bhattacharyya A. and Trent J. (1993) Clonal chromosome abnormalities in human breast carcinomas I.

- Twenty-eight cases with primary disease. *Genes, Chromo Cancer*, **7**, 185-193.
70. Dutrillaux, B., Gerbault-Seureau M. and Zafrani B. (1990)
Characterization of chromosomal anomalies in human breast cancer.
A comparison of 30 paradiploid cases with few chromosome changes.
Cancer Genet Cytogenet, **49**, 203-217.
 71. Pandis, N., Heim S., Bardi G., Idvall I., Mandahl N. and Mitelman F.
(1992) Whole-arm t(1;16) and i(1q) as sole anomalies identify gain
of 1q as a primary chromosomal abnormality in breast cancer. *Genes
Chromosomes Cancer*, **5**, 235-238.
 72. Kallioniemi, A., Kallioniemi O.-P., Sudar D., Rutovitz D., Gray J.,
Waldman F. and Pinkel D. (1992) Comparative genomic hybridization
for molecular cytogenetic analysis of solid tumors. *Science*, **258**,
818-820.
 73. Kallioniemi, A., Kallioniemi O.-P., Piper J., Tanner M., Stokke T., Chen
L., Smith H., Pinkel D., Gray J. and Waldman F. (1994) Detection and
mapping of amplified DNA sequences in breast cancer by comparative
genomic hybridization. *Proc Natl Acad Sci USA*, **91**, 2156-2160.
 74. Gray, J., Collins C., Henderson I., Isola J., Kallioniemi A., Kallioniemi
O.-P., Nakamura H., Pinkel D., Stokke T., Tanner M. and Waldman F.
(1994) Molecular Cytogenetics of Human Breast Cancer. .
 75. Isola, J., Kallioniemi O., Chu L., Fuqua S., Hilsenbeck S., Osborne C.
and Waldman F. (1995) Genetic aberrations detected by comparative
genomic hybridization predict outcome in node-negative breast
cancer. *Am J Path*, **147**, 905-911.
 76. Venter, D.J., Tuzi N.L., Kumar S. and Gullick W.J. (1987)
Overexpression of the c-erbB-2 oncoprotein in human breast

- carcinomas: immunohistological assessment correlates with gene amplification. *Lancet*, **2**, 69-72.
77. Slamon, D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A. and et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science*, **244**, 707-712.
 78. Berger, M., Locher G., Saurer S., Gullick W., Waterfield M., Groner B. and Hynes N. (1988) Correlation of C-ERBB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. *Cancer Res*, **48**, 1238-1243.
 79. Zhou, D., Battifora H., Yokota J., Yamamoto T. and Cline M. (1987) Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. *Cancer Res*, **47**, 6123-6125.
 80. Ravdin, P. and Chamness G. (1995) The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. *Gene*, **159**, 19-27.
 81. Aldaz, C., Chen T., Sahin A., Cunningham J. and Bondy M. (1995) Comparative allelotype of in situ and invasive human breast cancer: High frequency of microsatellite instability in lobular breast carcinomas. *Cancer Res*, **55**, 3976-3981.
 82. Muss, H.B., Thor A.D., Berry D.A., Kute T., Liu E.T., Koerner F., Cirrincione C.T., Budman D.R., Wood W.C., Barcos M. and et al. (1994) c-erbB-2 expression and response to adjuvant therapy in women with node- positive early breast cancer [see comments] [published erratum appears in N Engl J Med 1994 Jul 21;331(3):211]. *N Engl J Med*, **330**, 1260-6.

83. Leitzel, K., Teramoto Y., Konrad K., Chinchilli V.M., Volas G., Grossberg H., Harvey H., Demers L. and Lipton A. (1995) Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. *J Clin Oncol*, **13**, 1129-1135.
84. Muller, W., Sinn E., Pattengale P., Wallace R. and Leder P. (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. *Cell*, **54**, 105-115.
85. Petit, A., Rak J., Hung M., Rockwell P., Goldstein N., Fendly B. and Kerbel R. (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. *Am J Pathol*, **151**, 1523-1530.
86. Wright, M., Grim J., Deshane J., Kim M., Strong T., Siegal G. and Curiel D. (1997) An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. *Gene Ther*, **4**, 317-322.
87. Eccles, S., Court W., Box G., Dean C., Melton R. and Springer C. (1994) Regression of established breast carcinoma xenografts with antibody- directed enzyme prodrug therapy against c-erbB2 p185. *Cancer Res*, **54**, 5171-5177.
88. Sandgren, E.P., Luetkeke N.C., Palmiter R.D., Brinster R.L. and Lee D.C. (1990) Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. *Cell*, **61**, 1121-1135.
89. Cohen, B.D., Siegall C.B., Bacus S., Foy L., Green J.M., Hellstrom I., Hellstrom K.E. and Fell H.P. (1998) Role of epidermal growth factor

- receptor family members in growth and differentiation of breast carcinoma. *Biochem Soc Symp*, **63**, 199-210.
90. Visscher, D., Wallis T., Awussah S., Mohamed A. and Crissman J. (1997) Evaluation of MYC and chromosome 8 copy number in breast carcinoma by interphase cytogenetics. *Genes Chromosomes Cancer*, **18**, 1-7.
 91. Chin, L., Liegeois N., DePinho R. and Schreiber-Agus N. (1996) Functional interactions among members of the Myc superfamily and potential relevance to cutaneous growth and development. *J Invest Dermatol Symp Proc*, **1**, 128-135.
 92. White, E. (1996) Life, death and the pursuit of apoptosis. *Genes Dev*, **10**, 1-15.
 93. Alexandrow, M.G., Kawabata M., Aakre M. and Moses H.L. (1995) Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1. *Proc Natl Acad Sci U S A*, **92**, 3239-3243.
 94. Evan, G. and Littlewood T. (1993) The role of c-myc in cell growth. *Curr Opin Genet Dev*, **3**, 44-49.
 95. Shi, Y., Glynn J., Guilbert L., Cotter T., Bissonnette R. and Green D. (1992) Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. *Science*, **257**, 212-214.
 96. Steiner, P., Rudolph B., Muller D. and Eilers M. (1996) The functions of Myc in cell cycle progression and apoptosis. *Prog Cell Cycle Res*, **2**, 73-82.
 97. Leder, A., Pattengale P., Kuo A., Stewart T. and Leder P. (1986) Consequences of widespread deregulation of the c-myc gene in

transgenic mice: multiple neoplasms and normal development. *Cell*, **45**, 485-495.

98. Varley, J., Swallow J., Brammar W., Whittaker J. and Walker R. (1987) Alterations to either C-ERBB-2 (NEU) or C-MYC proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. *Oncogene*, **1**, 423-430.
99. Shiu, R., Watson P. and Dubik (1993) c-myc oncogene expression in estrogen-dependent and independent breast cancer. *Clin Chem*, **39**, 353-355.
100. Lammie, G. and Peters G. (1991) Chromosome 11q13 abnormalities in human cancer. *Cancer Cells*, **3**, 413-420.
101. Gillett, C., Fantl V., Smith R., Fisher C., Bartek J., Dickson C., Barnes D. and Peters G. (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. *Cancer Res*, **54**, 1812-1817.
102. Bartkova, J., Lukas J., Muller H., Lutzht D., Strauss M. and Bartek J. (1994) Cyclin D1 protein expression and function in human breast cancer. *Intl J Cancer*, **57**, 353-361.
103. Sicinski, P., JL D., Parker S., Li T., Fazeli A., Gardner H., Haslam S., Bronson R., Elledge S. and Weinberg R. (1995) Cyclin D1 provides a link between development and oncogenes in the retina and breast. *Cell*, **82**, 621-630.
104. Wang, T., Cardiff R., Zukerberg L., Lees E., Arnold A. and Schmidt E. (1994) Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. *Nature*, **369**, 669-671.
105. Weinstat-Saslow, D., Merino M., Manrow R., Lawrence J., Bluth R., Wittenbel K., Simpson J., Page D. and Steeg P. (1995) Overexpression

- of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. *Nature Med*, **1**, 1257-1260.
106. Muller, W., Lee F., Dickson C., Peters G., Pattengale P. and Leder P. (1990) The int-2 gene product acts as an epithelial growth factor in transgenic mice. *EMBO J*, **9**, 907-913.
107. Anzick, S.L., Kononen J., Walker R.L., Azorsa D.O., Tanner M.M., Guan X.Y., Sauter G., Kallioniemi O.P., Trent J.M. and Meltzer P.S. (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. *Science*, **277**, 965-968.
108. Knudson, A. (1971) Mutation and Cancer: Statistical study of retinoblastoma. *Proc Natl Acad Sci USA*, **68**, 820-823.
109. Comings, D. (1973) A general theory of carcinogenesis. *Proc Natl Acad Sci USA*, **70**, 3324-3328.
110. Goodrich, D. and Lee W.-H. (1993) Molecular characterization of the retinoblastoma susceptibility gene. *Biochim Biophys Acta*, **1155**, 43-61.
111. Cox, L., Chen G. and Lee E.Y.-H.P. (1994) Tumor suppressor genes and their roles in breast cancer. *Breast Cancer Res Treat*, **32**, 19-38.
112. Weber, J. and May P. (1989) Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. *Am J Hum Genet*, **44**, 388-396.
113. Hudson, T.J., Stein L.D., Gerety S.S., Ma J., Castle A.B., Silva J., Slonim D.K., Baptista R., Kruglyak L., Xu S.-H., Hu X., Colbert A.M.E., Rosenberg C., Reeve-Daly M.P. and al e. (1995) An STS-based map of the human genome. *Science*, **270**, 1945-1954.

114. Brenner, A. and Aldaz C. (1995) Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. *Cancer Res*, **55**, 2892-2895.
115. Trent, J., Yang J.-M., Emerson J., Dalton W., McGee D., Massey K., Thompson F. and Villar H. (1993) Clonal chromosome abnormalities in human breast carcinomas II. Thirty-four cases with metastatic disease. *Genes, Chromo Cancer*, **7**, 194-203.
116. Radford, D., Fair K., Phillips N., Ritter J., Steinbrueck T., Holt M. and Donis-Keller H. (1995) Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. *Cancer Res*, **55**, 3399-3405.
117. Fujii, H., Marsh C., Cairns P., Sidransky D. and Gabrielson E. (1996) Genetic divergence in the clonal evolution of breast cancer. *Cancer Res*, **56**, 1493-1497.
118. Radford, D., Fair K., Thompson A., Ritter J., Holt M., Steinbrueck T., Wallace M., Wells S.J. and Donis-Keller H. (1993) Allelic loss on a chromosome 17 in ductal carcinoma in situ of the breast. *Cancer Res*, **53**, 2947-2949.
119. Done, S., Arneson N., Ozcelik H., Redston M. and Andrulis I. (1998) p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. *Cancer Res*, **58**, 785-789.
120. Ozbun, M. and Butel J. (1995) Tumor suppressor p53 mutations and breast cancer: a critical analysis. *Adv Cancer Res*, **66**, 71-141.
121. Donehower, L., Godley L., Aldaz C., Pyle R., Shi Y., Pinkel D., Gray J., Bradley A., Medina D. and Varmus H. (1995) Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. *Genes Dev*, **9**, 882-895.

122. Cornelis, R., van Vliet M., Vos C., Cleton-Jansen A.-M., van de Vijver M., Peterse J., Khan P., Borresen A.-L., Cornelisse C. and Devilee P. (1994) Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. *Cancer Res*, **54**, 4200-4206.
123. Hall, J., Lee M., Newman B., Morrow J., Anderson L., Huey B. and King M. (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. *Science*, **250**, 1684-1689.
124. Futreal, P., Liu Q., Shattuck-Eidens D., Cochran C., Harshman K., Tavtigian S., Bennett L., Haugen-Strano A., Swensen J., Miki Y., Eddington K., McClure M., Frye C. and al e. (1994) BRCA1 mutations in primary breast and ovarian carcinomas. *Science*, **266**, 120-122.
125. Leone, A., McBride O., Weston A., Wang M., Anglard P., Cropp C., Goepel J., Lidereau R., Callahan R., Linehan W., Rees R., Harris C., Liotta L. and Steeg P. (1991) Somatic allelic deletion of nm23 in human cancer. *Cancer Res*, **51**, 2490-2493.
126. Cropp, C., Lidereau R., Leone A., Liscia D., Cappa A., Campbell G., Barker E., Le Doussal V., Steeg P. and Callahan R. (1994) NME1 protein expression and loss of heterozygosity mutations in primary human breast tumors. *J Natl Cancer Inst*, **86**, 1167-1169.
127. Borg, A., Zhang Q.-X., Alm P., Olsson H. and Sellberg G. (1992) The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression. *Cancer Res*, **52**, 2991-2994.
128. Miki, Y., Katagiri T., Kasumi F., Yoshimoto T. and Nakamura Y. (1996) Mutation analysis in the BRCA2 gene in primary breast cancers. *Nature Genetics*, **13**, 245-247.

129. Teng, D., Bogden R., Mitchell J., Baumgard M., Bell R., Berry S., Davis T., Ha P., Kehrer R., Jammulapati S., Chen Q., Offit K., Skolnick M., Tavtigian S., Jhanwar S., Swedlund B., Wong A. and Kamb A. (1996) Low incidence of BRCA2 mutations in breast carcinoma and other cancers. *Nature Genet*, **13**, 241-244.
130. Lancaster, J.M., Wooster R., Mangion J., Phelan C.M., Cochran C., Gumbs C., Seal S., Barfoot R., Collins N., Bignell G., Patel S., Hamoudi R., Larsson C., Wiseman R.W., Berchuck A., Iglehart J.D., Marks J.R., Ashworth A., Stratton M.R. and Futreal P.A. (1996) BRCA2 mutations in primary breast and ovarian cancers. *Nature Genetics*, **13**, 238-240.
131. Schott, D., Chang J., Deng G., Kurisu W., Kuo W., Gray J. and Smith H. (1994) A candidate tumor suppressor gene in human breast cancers. *Cancer Res*, **54**, 1393-1396.
132. Sato, T., Tanigami A., Yamakawa K., Akiyama F., Kasumi F., Sakamoto G. and Nakamura Y. (1990) Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. *Cancer Res*, **50**, 7184-7189.
133. Tsuda, H., Callen D., Fukutomi T., Nakamura Y. and Hirohashi S. (1994) Allele loss on chromosome 16q24..2-qter occurs frequently in breast cancer irrespectively of differences in phenotype and extent of spread. *Cancer Res*, **54**, 513-517.
134. Cleton-Jansen, A., Moerland E., Kuipers-Dijkshoorn N., Callen D., Sutherland G., Hansen B., Devilee P. and Cornelisse C. (1994) At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. *Genes, Chromos & Cancer*, **9**, 101-107.

135. Berx, G., Cleton-Jansen A., Nollet F., de Leeuw W., van de Vijver M., Cornelisse C. and van Roy F. (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. *Embo J*, **14**, 6107-6115.
136. Yoshiura, K., Kanai Y., Ochiai A., Shimoyama Y., Sugimura T. and Hirohashi S. (1995) Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. *Proc Natl Acad Sci USA*, **92**, 7416-7419.
137. Rimm, D., Sinard J. and Morrow J. (1995) Reduced α -catenin and E-cadherin expression in breast cancer. *Lab Invest*, **72**, 506-512.
138. Lee, S. (1996) H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. *Nature Medicine*, **2**, 776-782.
139. Kamb, A., Gruis N., Weaver-Feldhaus J., Qingyun L., Harshman K., Tavitigian S., Stockert E., Day R., Johnson B. and Skolnick M. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. *Science*, **264**, 436-440.
140. Brenner, A., Paladugu A., Wang H., Olopade O., Dreyling M. and Aldaz C. (1996) Preferential loss of expression of p16^{INK4a} rather than p19^{ARF} in breast cancer. *Clinical Cancer Res*, **2**, 1993-1998.
141. Altucci, L., Addeo R. and Cicatiello L. (1996) 17 β -estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. *Oncogene*, **12**, 2315-2324.
142. Sherr, C. (1994) G1 phase progression: cycling on cue. *Cell*, **79**, 551-555.
143. Sherr, C. (1996) Cancer cell cycles. *Science*, **274**, 1672-1677.

144. Hui, R., Cornish A., McClelland R., Robertson J., Blamey R., Musgrove E., Nicholson R. and Sutherland R. (1996) Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. *Clin Cancer Res*, **2**, 923-928.
145. Graybabin, J., Zalvide J., Fox M., Kinckerbocker C., Decaprio J. and Keyomarsi K. (1996) Cyclin E, a redundant cyclin in breast cancer. *Proc Natl Acad Sci USA*, **93**, 15215-15220.
146. Porter, P., Malone K., Heagerty P., Alexander G., Gatti L., Firpo E., Daling J. and Roberts J. (1997) Expression of cell-cycle regulators p27^{Kip1} and cyclin E, alone and in combination, correlate with survival in young breast cancer patients [see comments]. *Nat Med*, **3**, 222-225.
147. Varley, J., Armour J., Swallow J., Jeffreys A., Ponder B., T'Ang A., Fung Y., Brammar W. and Walker R. (1989) The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. *Oncogene*, **4**, 725-729.
148. Okamoto, A., Demetrick D., Spillare E., Hagiwara K., Hussain S., Bennett W., Forrester K., Gerwin B., Serrano M., Beach D. and Harris C. (1994) Mutations and altered expression of p16^{INK4} in human cancer. *Proc Natl Acad*, **91**, 11045-11049.
149. Parry, D., Bates S., Mann D. and Peters G. (1995) Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16^{INK4}/MTS1 tumour suppressor product. *EMBO J*, **14**, 503-511.
150. Xiong, Y., Hannon G., Zhang H., Casso D., Kobayashi R. and Beach D. (1993) p21 is a universal inhibitor of cyclin kinases. *Nature*, **366**, 701-704.

151. Waga, S., Hannon G., Beach D. and Stillman B. (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. *Nature*, **369**, 574-578.
152. Brugarolas, J., Chandrasekaran C., Gordon J., Beach D., Jacks T. and Hannon G. (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. *Nature*, **377**, 552-557.
153. Pomerantz, J., Schreiber-Agus N., Liegeois N., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H.-W., Cordon-Cardo C. and DePinho R. (1998) The Ink4a tumor suppressor gene product, p19^{Arf}, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell*, **92**, 713-723.
154. Zhang, Y., Xiong Y. and Yarbrough W.G. (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. *Cell*, **92**, 725-734.
155. Bates, S., Phillips A.C., Clark P.A., Stott F., Peters G., Ludwig R.L. and Vousden K.H. (1998) p14ARF links the tumour suppressors RB and p53. *Nature*, **395**, 124-125.
156. Oltvai, Z., Millman C. and Korsmeyer S. (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, accelerates programmed cell death. *Cell*, **74**, 609-619.
157. Joensuu, H., Pylkkanen L. and Toikkanen S. (1994) Bcl-2 protein expression and long-term survival in breast cancer. *Am J Pathol*, **145**, 1191-1198.
158. Barbareschi, M., Caffo O., Veronese S., Leek R., Fina P., Fox S., Bonzanini M., Girlando S., Morelli L., Eccher C., Pezzella F., Doglioni C., Dalla Palma P. and Harris A. (1996) Bcl-2 and p53 expression in

node-negative breast carcinoma: a study with long-term follow-up. *Human Pathol.*, **27**, 1149-1155.

159. Sierra, A., Castellsague X., Coll T., Manas S., Escobedo A., Moreno A. and Fabra A. (1998) Expression of death-related genes and their relationship to loss of apoptosis in T1 ductal breast carcinomas. *Intrnl. J. Cancer*, **79**, 103-110.
160. Beatson, G. (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. *Lancet*, **ii**, 104-107.
161. Fishman, J., Osborne M. and Telang N. (1995) The role of estrogen in mammary carcinogenesis. *Annals NY Academy of Sciences*, **768**, 91-100.
162. Tsai, M. and O'Malley B. (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. *Ann Rev Biochem*, **63**, 451-486.
163. Leung, B. and Potter A. (1987) Mode of estrogen action on cell proliferation in CAMA-1 cells: II. Sensitivity of G1 phase population. *J Cellular Biochem*, **34**, 213-225.
164. Davidson, N., Prestigiacomo L. and Hahm H. (1993) Induction of jun gene family members by transforming growth factor alpha but not 17 beta-estradiol in human breast cancer cells. *Cancer Research*, **53**, 291-297.
165. Prall, O., Sarcevic B., Musgrove E., Watts C. and Sutherland R. (1997) Estrogen-induced activation of Cdk4 and Cdk2 during G1-Sphase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. *J Biol Chem*, **272**, 10882-10894.

166. Zwijsen, R., Wientjens E., Klompaker R., van der Sman J., Bernards R. and Michalides R. (1997) CDK-independent activation of estrogen receptor by cyclin D1. *Cell*, **88**, 405-415.
167. Zhang, L., Zhou W., Velculescu V., Kern S., Hruban R., Hamilton S., Vogelstein B. and Kinzler K. (1997) Gene expression profiles in normal and cancer cells. *Science*, **276**, 1268-1272.

Figure Legend

Figure 1. Diagrammatic depiction of the multiple endogenous and exogenous factors which contribute to breast cancer risk. Ultimately, it is the combination of multiple factors along with the unique genetic composition of each individual woman that plays a decisive role in defining the risk for tumor development. This etiologic complexity is also responsible for the characteristic heterogeneity of breast cancer.

Figure 2. A diagrammatic representation of the normal breast structure and histology (modified from Tavassoli 1992).


Figure 3. A graphic depiction of the 'sporadic' breast cancer incidence as compared to hereditary breast cancer incidence.


Figure 4. Schematic putative model of breast cancer histopathological progression and corresponding estimated breast cancer risk based on studies by Page and Dupont (Page DL, Dupont WD, 1992). A woman with PDWA (proliferative disease without atypia) has a 1.5 to 2 times greater risk for developing breast cancer as compared to the general population. Whereas, a women with atypical hyperplasia (AH) has 4-5 times greater risk. Women with DCIS (ductal carcinoma in situ) and LCIS (lobular carcinoma in situ) are at a much higher risk of progressing to invasive cancer. LNG is low nuclear grade and HNG is high nuclear grade

Figure 5. Schematic representation of cell cycle's G1/S key restriction point controls many of which are known to be altered in breast cancer (see text).

Genetic Region	Cytogenetic ¹ Finding	CGH ² Finding	Invasive ³ LOH (%)	DCIS ³ LOH (%)	Possible Targets	Possible Consequence
1p	-1p		32	8		
1q	+1q	+1q	30	16		
3p		-3p	22	0		
3q			25	0		
4p	-4p		2 ¹	0 [†]		
5p			18 ¹	0 [†]		
5q			13 ¹	0 [†]		
6p	-6	+6p	30	0		
6q	-6, -6q	-6q, +6q	26	8		
7p	+7	+7p	32	32	<i>EGFR</i>	overexpression
7q	+7		25	24		
8p	-8, -8p	-8p	18	10		
8q	-8, +8q	+8q	20	22	<i>MYC</i>	overexpression
9p	-9p		58	30	<i>p16^{INK4a}</i>	↓ expression/ dysregulation
9q			24 ¹	0 [†]		
10p			11 ¹	0 [†]		
10q			15 ¹	0 [†]		
11p	-11, -11p	-11p	28	0		
11q	-11, -11q	+11q	30	12	<i>CCND1 (cyclin D1)</i>	overexpression
12p			8 ¹	0 [†]		
12q		+12q	4 ¹	0 [†]		
13q	-13	-13q	30	18	<i>RB1, BRCA2, Brush</i>	↓ expression
16p	-16		40	0		
16q	-16, -16q		48	27	<i>CDH1 (E. cadherin)</i>	↓ expression
17p	-17, -17p	-17p	57	33	<i>TP53</i>	inactivation
17q	-17		36	31	<i>BRCA1, NME1</i>	↓ expression
		+17q			<i>ERBB2</i>	overexpression
18p			25	0		
18q			48	12	<i>BCL2</i>	dysregulation
19p			18 ¹	0 [†]		
19q		+19q	14 ¹	0 [†]	<i>CCNE (cyclin E)</i>	overexpression
20q		+20q13	17 ¹	6 [†]	<i>AIB1</i>	overexpression
21q			17 ¹	5 [†]		
22q	-22		36	0		
Xp	-X		22 ¹			
Xq	-X		8 ¹			

Table 1. Summary of genetic aberrations affecting sporadic breast cancer (¹ Devilee and Cornelisse [1994], Thompson et. al. [1993]; ² Gray et. al. [1994]; ³ Aldaz et. al. [1995]; [†] Radford et. al. [1995]).






Risk for Breast
Cancer Development


1.5 - 2


4 - 5

9 - 10

Committed
to Invasion







CHROMOSOME 9P LOH AND ANALYSIS OF MTS1 (P16) IN BREAST CANCER. Brenner AJ* and Aldaz CM. The University of Texas M.D. Anderson Cancer Center, Science Park - Research Division, Smithville, Texas 78957

In order to define the extent of involvement of chromosome 9p in breast carcinogenesis, we performed microsatellite length polymorphism analysis of markers spanning this region. Of 24 primary breast carcinomas analyzed, we observed a high frequency (58%) of loss of heterozygosity (LOH) or allelic imbalance affecting subregion 9p21-22. Mutational analysis of the CDKN2 (p16) tumor suppressor gene was performed to determine whether this gene was the target of such alterations. Of 21 tumors analyzed, only 1 showed a mutation of probable consequence, suggesting that CDKN2 appears not to be the target of LOH. However, gene inactivation *in vivo* has not yet been explored, and we are currently investigating this prospect. Additionally, since it has been suggested that some CDKN2 deletions and mutations could be due to an *in vitro* phenomenon, 4 immortal breast cell lines derived from normal epithelium, MCF10F, MCF12F, 184A1, and 184B5, were examined for loss or mutation of CDKN2. Two lines (MCF10F and MCF12F) showed homozygous deletions of CDKN2, and one (184A1) revealed a hemizygous deletion and a nonsense mutation in the remaining allele. This could imply an important role of CDKN2 in the control of immortalization or *in vitro* adaptation, and is the first evidence of such in non-tumor derived cell lines. Additionally, this is the first report of frequent LOH in the 9p21-22 chromosome subregion of uncultured primary breast tumors. We are currently investigating the growth suppression potential of p16 in the aforementioned lines as well as the expression of p16 *in vivo*. Supported by U.S. Army Breast Cancer Program, DAMD 17-94-J-4078 (CMA) and NIH R01 CA59967 (CMA).

702

Allelotype of breast carcinoma in situ from paraffin sections, correlation with chromosome copy number. Chen, T., Dhingra, K., Brenner, A., Sahin, A., Snieg, N., Vogel, V., Hortobagyi, G.N., & Aldaz, C.M. Dept. of Carcinogenesis, Dept. of Breast and Gynecologic Oncology, Dept. of Pathology, Dept. of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Smithville, TX 78957 and Houston, TX, 77030.

We have optimized a technique that allows the analysis of numerous chromosomal loci from single 8 µm sections of paraffin embedded tissues. DNA samples from normal and breast CIS tissue can be obtained from the same section by means of microdissection. Further improvement was achieved by the use of a short PCR round with a universal primer followed by the use of the specific microsatellite primers. Numerous markers were analyzed spanning the 17 p and q arms. Higher incidence of losses was observed affecting the p arm, close to the TP53 locus. The same samples were analyzed for ch 17 copy number by means of in situ hybridization. Analysis of the same samples is being extended to all the chromosome areas of interest in breast cancer and correlations will be performed with multiple diagnostic/prognostic indicators. Supported by NIH grant CA58186.

703

Microsatellite instability in Muir-Torre syndrome.

Halling, K.C., Honchel, R., Pittelkow, M., and Thibodeau, S.N. Mayo Clinic and Foundation, Rochester, MN 55905

Muir-Torre syndrome (MTS) is characterized by at least one sebaceous gland tumor and at least one visceral malignancy. Although a wide range of internal malignancies have been reported, the most frequently observed internal neoplasm is colorectal carcinoma. MTS and hereditary non-polyposis colorectal carcinoma (HNPCC) share many clinical and pathologic characteristics, and thus may share similar genetic mechanisms of tumorigenesis. Microsatellite instability (MI) has recently been reported in tumor tissue from HNPCC patients. In order to determine if tumors from MTS patients might also show MI, we examined DNA extracted from paraffin-embedded tissues for the presence of MI at (CA)_n repeats on chromosomes 5q, 15q, 17p, and 18q. Data was obtained on 12 patients diagnosed with MTS, 9 of which had at least one colorectal tumor. Of the 12 MTS patients, six had widespread MI in all sebaceous and colorectal tumors examined, as well as in a prostatic adenocarcinoma, a transitional cell carcinoma of the bladder and two keratoacanthomas. These patients were characterized by: 1) uniform presence and early onset of colorectal cancer (average age of 39.7 yrs; range 23-53); and 2) prolonged survival following diagnosis of colorectal cancer (average survival of 30.5 yrs; range 23-37). These results indicate that MTS and HNPCC may share similar genetic mechanisms of tumorigenesis, and supports the notion that these syndromes are allelic.

704

(CA)_n repeat alterations in human gastric adenocarcinomas and hepatocellular carcinomas (HCC).

Mironov, N.M., Aguelon, A.-M., Potapova, G.I., Krutovskikh, V.A., Mazzoleni, G., Omori, Y., Gorbunov, O.V., Klimenkov, A.A. & Yamasaki, H. International Agency for Research on Cancer, Lyon, France, and Cancer Research Center, Moscow, Russia.

The human genome contains approximately 50,000-100,000 loci of (CA)_n repeats. Ten of these were chosen at random and two distinct patterns of alteration were identified in human tumors: loss of heterozygosity (LOH) and gain of new (shorter or longer) repeats. Among 15 gastric adenocarcinomas, one tumor had LOH at 5 loci out of the 10 studied, 3 gained a new sequence at 1 locus and one showed gains at 5 loci. Three tumors out of 15 carried mutations in the p53 gene, but only one showed (CA)_n repeat alterations (LOH) and no mutation was found in the connexin 32 gene. This indicates that genomic instability at (CA)_n sites does not confer an ability to produce abundant point mutations. In contrast, among 11 human HCCs studied, only one had LOH at 1 locus and no gain of new repeats. Our results suggest that different mechanisms exist for LOH and gain of new (CA)_n repeats, and their prevalence differs between human gastric and liver cancer.

705

Chromosomal changes during the acquisition of doxorubicin resistance in human leukemia HL-60 cells. R. Ganapathi, G. Hoeltge, D. Grabowski, R. Neelon, and J. Ford. Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195.

Tumor cell resistance to doxorubicin (DOX) is usually associated with the overexpression of P-glycoprotein (PGP) in model systems. We have characterized the karyotypic changes in two sublines of HL-60 cells designated HL-60/A and HL-60/Y, selected in increasing concentrations of 0.025-0.1 µg/ml DOX. Monosomy 8 in HL-60/Y was the only karyotypic difference prior to DOX exposure. Both sublines acquired 7q+ markers upon exposure to DOX. In HL-60/Y, an add(7)(q21) replaced one homologue at 0.025 µg/ml DOX, and an add(7)(q32) appeared which replaced the other normal 7 at 0.05 µg/ml DOX. The HL-60/A cells acquired an add(7)(q31) at 0.025 µg/ml DOX. Exact mechanisms of these 7q+ abnormalities could not be determined, but all involved breakpoints in the midregion of 7q. The overexpression of PGP in immunoprecipitates with C-219 antibody in both sublines of DOX-resistant HL-60 cells with 7q+ abnormalities is consistent with the location of MDR1 sequences to 7q21.1. (Supported by USPHS CA35531).

706

Hodgkin and Reed-Sternberg cells do not show lymphoid differentiation: Results of single cell analysis at the DNA level

Daus, H., Trümper, L., Roth, J., Jacobs, G., v. Bonin, F., Gause, A., Pfreundschuh, M. Dep. Internal Medicine I, University of Saarland at 66421 Homburg/Saar, Germany

Investigations on the nature of Hodgkin's disease have been hampered by the fact that the neoplastic Hodgkin and Reed-Sternberg (H&RS) cells represent only a minority of the cells in affected tissue. Since a lymphoid origin of H&RS cells has been proposed, and IgH and Tcell receptor gamma chain rearrangements can serve as markers for origin and clonality in B and T lymphocytes, we developed a PCR based assay to detect IgH or TCR rearrangements in single H&RS cells. Single cells were isolated by micromanipulation from cytopins prepared from fresh HD lymph nodes. Primers were constructed corresponding to the variable and joining regions of the IgH and TCR-gamma genes and for detection of N-RAS codon 12/13 or 61 mutations. Oligo hybridization and SSCP/direct sequencing were used to confirm the presence of rearrangements or mutations. These methods were established on single cells of different lymphoid cell lines and Non Hodgkin's lymphomas. Immunoglobulin rearrangements were not detected in H&RS cells of 15/15 patients, T cell receptor gamma rearrangements were absent in 15/15 patients. N-ras codon 12/13 or 61 mutations could not be detected in one case examined so far. These results suggest that H&RS cells are not derived from T or B lineage cells that have initiated DNA rearrangements. The role of N-ras mutations in the pathogenesis of HD remains uncertain.

707

Microsatellite-based high resolution deletion mapping of chromosome 8p in prostate cancer

L.Schmidt, R.Leibowitz¹, K.Tory, M.-H.Wei, H.Li, Peter Scardino¹, M.Linehan² and B.Zbar³; PRI/DynCorp, FCRCDC, Frederick, MD 21702; ¹Baylor College of Medicine, Dept. of Pathology, Houston, TX 77030; ²Surgery Br., NCI, Bethesda, MD 20892; ³LIB, NCI-FCRDC, Frederick, MD 21702

Previous studies by a number of laboratories show frequent allelic loss on chromosome 8p in several cancer types including bladder, liver, lung, colorectal and prostate (Bova, S. et al, Cancer Res. 53:1-5, 1993). Frequent loss of heterozygosity (LOH) at a chromosomal locus in a particular tumor may indicate the presence of a tumor suppressor gene (TSG). In an effort to localize the site of a putative TSG for prostate cancer, we have examined LOH on chromosome 8p in paired prostate tumor and normal tissue samples. To date twenty pairs have been analysed using eleven chromosome 8 microsatellite markers mainly from Genethon, (Weissenbach, J. et al, Nature 359:794-801, 1992) several RFLP markers and a newly characterized microsatellite marker from our laboratory, located near the MSR gene. These microsatellite markers have heterozygosities >70% and therefore are informative with more than two-thirds of the samples. LOH was observed in 25% of the prostate tumor samples, with the region of minimal deletion lying between D8S265 and D8S261. The high density of the ordered microsatellite markers will allow fine resolution mapping of deletions in prostate tumor samples and more narrowly define the localization of a putative TSG.

3226

Defective Mismatch Repair and Microsatellite Instability in Human Cancer Cell Lines. Boyer, J.C., Umar, A., Risinger, J., and Kunkel, T.A., Natl. Inst. of Environ. Health Sci., RTP, NC 27709.

Microsatellite instability has been shown to be associated with several types of cancer, both hereditary and sporadic. Although this phenotype has been designated RER⁺ (for Replication Error), it has not yet been demonstrated to result from a defect in the fidelity of DNA replication. Rather, extracts of several RER⁺ colon and endometrial cancer lines have been shown to be defective in mismatch repair (MMR). Some of these lines contain mutations in the human homologs of *E. coli* MMR genes, *mutS* (*hMSH2*) or *mutL* (*hMLH1*). Here we have measured MMR activity and RER status of human cell lines derived from tumors of the colon, cervix, endometrium, uterus, and ovary. All that are MMR⁺ are RER⁻ and all that are MMR⁻ are RER⁺. This strengthens the correlation between microsatellite instability and defective MMR and suggests that the loss of MMR activity is a step in carcinogenesis common to many types of cancer. Additionally, we have found that human cell extracts are proficient in repair of heteroduplexes containing loops of five to 16 bases, a repair activity not seen in *E. coli*. This activity is present in an extract of a colon cancer line defective in the *hMLH1* gene product, suggesting that repair of heteroduplexes containing a large loop may have different protein requirements than does repair of mismatches.

3227

Allelotypic profile and replication error phenotype in lobular vs. ductal and in situ breast cancers. Chen, T., Sahin, A., Aldaz, C.M. UT MD Anderson Cancer Center, Smithville, Texas 78957

We are currently analyzing for specific allelic losses or imbalances and replication error phenotypes (RER) a series of early breast cancer samples from paraffin embedded tissues by means of microsatellite (SSRs) length polymorphisms. In our series of 58 breast cancer samples we analyzed 25 invasive ductal carcinomas, 19 in situ ductal carcinomas and 14 invasive lobular carcinomas. The SSRs markers used were representative of the chromosome subregions more commonly involved in abnormalities in breast cancer. We observed allelic imbalances affecting the p and q arms of chr. 1 in approximately 40% of invasive ductal tumors but only in 10-14% of lobular tumors. However these abnormalities appear to be a late event in ductal tumors carcinogenesis since they were not observed at the in situ stage. On the other hand abnormalities affecting ch. 11p15.5 appear more common in lobular tumors than in ductal carcinomas. Abnormalities affecting 16q, 17p, 17q appear to be early events since were observed in ~ 30% of carcinomas in situ. Interestingly the RER⁺ phenotype was more frequent in lobular tumors since we observed microsatellite instability affecting various SSRs in 5 out 14 tumors (36%) vs. 12% and 16% for invasive and in situ ductal tumors respectively. Our data suggests that lobular breast carcinomas appear as a different entity when compare with ductal tumors possibly involving different mechanisms of carcinogenesis. (U.S. Army Grant DAMD17-94-J-4078)

3228

Genomic instability in mouse mammary tumors with p53 deficiency or mutation. Aldaz, C.M.¹, Paladugu, A.¹, Medina, D.², Donehower, L.A.²
¹University of Texas M.D. Anderson Cancer Center, Smithville, Texas 78957;
²Baylor College of Medicine, Houston, Texas 77030

We analyzed the karyotypes of mammary tumors generated in *Wnt-1* transgenic mice lacking one or both p53 germline alleles. Tumors from p53^{+/+} animals were mostly diploid while tumors from p53^{-/-} animals presented highly abnormal karyotypes. As a cytogenetic measure of gene amplification and instability we quantified the percentage of metaphases per tumor with homogeneously staining regions (HSR), dicentric chromosomes or double minutes. All mammary tumors (n = 6) from p53^{-/-} animals showed these abnormalities, ranging from 17% to 62% metaphases/tumor with these anomalies; \bar{x} for this group = 40% vs. 3% for the tumors from p53^{+/+} mice (n = 5). Using a different mouse model we analyzed the karyotypes of tumors derived from transplantable mammary (TM) hyperplastic outgrowth lines (Kittrell et al. Cancer Res. 52:1924, 1992). TM lines and derived tumors were shown to have p53 inactivating mutations or mutations leading to p53 overexpression (Jerry et al. Cancer Res. 53:3374, 1993). Seven tumors were analyzed from 3 different TM lines. All the tumors showed highly abnormal and unstable karyotypes, six of the tumors showed multiple chromosomes with HSRs. The only consistent feature observed in 5 of 7 tumors was overrepresentation of chromosome 6. These studies with two *in vivo* tumorigenesis models support the hypothesis of p53 as a major player in maintaining genomic stability. Supported by NIH CA59967.

3229

4-nitroquinoline-1-oxide (4NQO) induced oral cavity Ha-ras mutations lead to loss of heterozygosity (LOH), gene amplification, and genomic instability during neoplastic transformation. L. Hu, B. Yuan, F. Hendler. Depts of Biochemistry & Medicine, Henry Vogt Cancer Institute, University of Louisville, and Louisville VAMC, Louisville, KY 40292.

To study the molecular events involved in human head and neck squamous cell carcinoma (HNSCC), we have developed a murine model using 4NQO induced carcinogenesis. In 13 of 25 HNSCC 4NQO induced Ha-ras mutations at codon 12 (Yuan et al. Cancer Res., 1994). Seven HNSCC had lost both normal Ha-ras alleles. Microsatellite markers identified LOH which always occurred on chromosome (chr) 7 telomeric to the tyrosinase gene. There was no evidence of trisomy. Quantitative PCR demonstrated that 3 of 5 tumors with LOH had evidence of up to 5 fold *int-2* amplification. Genomic instability was determined by comparing DNA fingerprints of germline and tumor tissue amplified by PCR with arbitrary primers having less than 50% homology with any known gene. All 3 tumors with *int-2* amplification had widespread genomic instability. FISH analysis demonstrated that the genomic instability involved chromosomes in addition to chr 7. No *int-2* amplification or genomic instability was detected in tumors without LOH at the Ha-ras locus on chr 7. Since these molecular events occurred at least 5 months after 4NQO had ceased, this suggests that the initial Ha-ras mutation is associated with a cascade of molecular events during tumorigenesis that eventuates in LOH and genomic instability in the absence of further carcinogenic pressure.

3230

Early apoptotic cell death and regenerative proliferation in livers of folate/methyl deficient rats is accompanied by nucleotide depletion and increased DNA repair activity. James, S.J., Pogribny, I., Basnakian, A.G., Miller, B.J., and Muskhelishvili, L. FDA-National Center for Toxicological Research, Division of Nutritional Toxicology, Jefferson, AR 72079

Two days after initiating a folate/methyl deficient diet in weanling F344 rats, the incidence of hepatic apoptotic bodies (without necrosis or inflammation) was significantly increased. Apoptosis was confirmed biochemically by an increase in Ca/Mg-dependent endonuclease activity in nuclear extracts. DNA strand breaks were also detectable in genomic DNA two days after initiating the deficient diet and the activity of the DNA repair-associated enzyme poly(ADP-ribose)polymerase was simultaneously stimulated. The hepatic deoxynucleotide pools were severely depressed after 5 days of deficiency and were associated with major decreases in the nucleotides NAD, ATP and GTP. These changes in nucleotide pools are consistent with an acute energy crisis and an arrest or delay in DNA synthesis and cell cycle progression. These indications of acute biochemical and molecular stress were followed by a transient recovery toward control levels after 5-7 days on the deficient diet. However, after 3-9 weeks of folate/methyl deficiency, significant increases were maintained in hepatic DNA strand break accumulation, DNA repair activity, nucleotide imbalance, apoptotic cell death and regenerative proliferation.

3231

Molecular pathogenesis of basal cell carcinoma: p53 mutations and instability of chromosome 9.

D'Errico M.¹, Sciò M.¹, Baliva G.¹, Corona R.¹, Signoretti S.¹, Dogliotti E.²

¹ Istituto Dermopatico dell'Immacolata (IDI - IRCCS), 00167 Rome, Italy. ² Istituto Superiore di Sanità, 00161 Rome, Italy.

Basal cell carcinoma (BCC) is the most common skin cancer and the most common malignancy in humans. Its occurrence is clearly correlated with exposure to sunlight. To investigate whether a prolonged exposure to UV light is responsible for the accumulation of mutations in genes critical for tumor development, we analyzed genomic DNA from BCC biopsies for the presence of p53 mutations. Additionally, loss of heterozygosity of chromosome 9q has been found in sporadic and hereditary BCCs. To further define the genetic events occurring during the tumorigenesis, alterations in microsatellite sequences and allele loss in chromosome 9 were also examined. Preliminary results obtained for 12 BCCs show that 3 tumors (25%) present heterozygous mutations in exons 5 to 8 of the p53 gene. All mutations were targeted at dipyrimidine sites and both transitions (C→T) and transversions (C→A and T→G) were identified. Interestingly, one sample showed multiple mutations likely localized on separate alleles. 4/5 mutations were targeted at mutation hotspots specific for skin cancers. The type and distribution of mutations detected in this study strongly support the hypothesis that p53 mutations are caused by exposure to UV light. 3/3 BCCs examined for genetic alterations of chromosome 9 showed major allelic rearrangements of more than one 2-base pair repeat by using a microsatellite marker that maps at 9p22-21, suggesting that microsatellite instability is also associated with BCC.

#3768 Wednesday, April 24, 1996, 8:00-12:00, Poster Section 12
Deletion mapping of benign, borderline, and neoplastic sporadic ovarian tumors. Muller C.Y., Vu T., Sharma D.S., Miller D.S., Mathis J.M., and Orth K. *Univ. Texas Southwestern Med. Ctr., Dallas, TX 75235.*

Heterozygosity studies comparing allelic alterations in DNA samples from tumor and normal tissue using polymorphic microsatellite (CA), repeat markers at the p53, the BRCA1, and the BRCA2 gene loci were performed with sporadic ovarian tumors. Matched normal and tumor DNA of 94 ovarian cancer patients (including 4 benign, 30 borderline, 47 malignant epithelial, 6 sex cord, and 7 germ cell cases) was isolated from paraffin embedded tissue by proteinase K digestion and phenol-chloroform extraction. The incidence of allelic loss in tumor DNA was screened using markers linked to the p53 gene on 17p13, the BRCA1 gene on 17q21, the BRCA2 gene on 13q12-13, and control markers on chromosomes 5 and 6. PCR analysis showed LOH at the p53 locus in 4% of informative borderline tumors, 44% of informative malignant epithelial tumors, 17% of informative germ cell tumors. LOH was observed at the BRCA1 locus only in the informative malignant epithelial tumors (54%) and germ cell tumors (33%). Only 2 of 47 malignant epithelial cases (4%) showed alterations in allelic markers demonstrating the replication error (RER+) phenotype described in HNPCC. No LOH was observed in benign tumors at any loci screened. These results indicate that LOH on chromosome 17 is rare in benign and borderline ovarian tumors compared to malignant tumors. LOH at the BRCA2 locus was low in malignant tumors and was not detected in benign or borderline tumors. Thus, allelic loss at the BRCA2 locus is not a significant event in sporadic ovarian cancer.

#3769 Tuesday, April 23, 1996, 1:00-5:00, Poster Section 5
Carcinogen and rat strain specificity of an allelic imbalance on chromosome 1 in rat mammary carcinomas. Haag, J.D., Hsu, L.-C., and Gould, M.N. *University of Wisconsin, Department of Human Oncology, Madison, WI 53792.*

In order to better understand the genetic components controlling individual rat strain susceptibilities to mammary carcinogenesis, we induced mammary carcinomas in (WxFxCo)F1 rats using either DMBA or radiation. Tumors were screened for allelic imbalances using 64 polymorphic microsatellite markers spanning the genome. While random allelic imbalances were observed in both the radiation- and DMBA-induced tumors, a non-random loss of heterozygosity (LOH) was also observed on chromosome 1 in the DMBA-induced tumors. This region spans approximately 40 cM from microsatellite markers R511 to R272 with a maximum frequency of LOH of 54% (6/11 tumors) occurring at the R27 locus. We then screened 3 other subsets of DMBA- and radiation induced mammary tumors for allelic imbalance on Chromosome 1 and found this imbalance only in the DMBA-induced tumors from the (F344xCo)F1. Thus far, only DMBA-induced F1 mammary tumors with a Cop parental strain have shown the chromosome 1 imbalance; however, the imbalance does not favor the Cop parental allele. These results suggest that: 1) rat mammary tumorigenesis occurs via different molecular mechanisms for the two carcinogens, DMBA and radiation, and 2) the genetic background of the F1 rat appears to influence the types of molecular lesions identified in the mammary tumors.

#3770 Monday, April 22, 1996, 1:00-5:00, Poster Section 14
No microsatellite instability or consistent loss of heterozygosity in B precursor cell acute lymphoblastic leukemias of children. Hua-Fang Yi and Geoffrey R. Kitchingman. *Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38101.*

We used 51 microsatellite markers to study all of the chromosome arms from at least 20 patients with childhood B precursor cell acute lymphoblastic leukemia. DNA from diagnosis and remission were studied, as was relapse DNA when it was available. We have found that only the short arm of chromosome 12 is consistently involved in loss of heterozygosity (LOH). Sporadic LOH was found in other chromosomes, but no other microsatellite marker was reduced to homogeneity in more than 10% of the cases studied. This contrasts with what has been found in solid tumors. We are currently expanding the number of markers used genome wide, and we are saturating 12p to define the smallest region of loss. We found no evidence for microsatellite instability. To partially confirm this, six exons of the MSH2 gene were examined for mutations by PCR and SSCP; no alterations were found. Thus, despite the presence of multiple chromosomal abnormalities in the majority of acute leukemias, LOH is infrequent and there are no changes in the microsatellite repeats.

#3771 Sunday, April 21, 1996, 1:00-5:00, Poster Section 2
Frequent loss of heterozygosity on chromosome 16q in "in situ" breast cancer. Chen, T.¹, Paladugu, A.¹, Sahin, A.², and Aldaz, C.M.¹. ¹Dept. of Carcinogenesis, UT MD Anderson Cancer Center, Science Park—Research Division, Smithville, TX 78957; ²Dept. of Pathology, UT MD Anderson Cancer Center, Houston, TX 77030

In our recent study of comparative allelotyping of *in situ* and invasive breast cancer lesions from paraffin embedded samples we determined that allelic losses affecting chromosome arms 16q, 17p, 17q and chromosome 7 appear to be early abnormalities since they were observed in a significant number of ductal carcinoma *in situ* (DCIS) lesions. In this study we performed a high resolution allelotyping of chromosome 16 in DCIS in order to further define the minimal target region for loss of heterozygosity (LOH). We observed a very high frequency (9 of 12 tumors) of LOH affecting the long

arm of this autosome. By overlapping LOH the most commonly affected marker was D16S398 at q22.1 chromosome band. Interestingly the E-cadherin gene (CDH1), a calcium dependent cell adhesion molecule, maps to this same chromosome band. The most common mechanisms for 16q allelic losses in DCIS appear to be mitotic recombination or terminal deletion. In order to better understand the chromosomal events leading to LOH we are analyzing adjacent tissue sections by means of chromosome 16 fluorescence *in situ* hybridization. These studies will assist in the elucidation of the mechanisms and extent of chromosome 16 involvement at preinvasive stages of breast carcinogenesis. (U.S. Army Grant DAMD17-94-J-4078)

#3772 Wednesday, April 24, 1996, 8:00-12:00, Poster Section 12
Involvement of a locus which escapes X chromosome inactivation in ovarian tumors of low malignant potential. Dubeau, L., Cheng, P., Kim, T.M., Velicescu, M., Wan, M., Zheng, J., Felix, J.C., Luo, P. *Univ. of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90033.*

Ovarian tumors of low malignant potential (LMP) are a subtype of ovarian epithelial tumors with reduced invasive and metastatic abilities. They are regarded as intermediate between benign (cystadenomas) and malignant (carcinomas) ovarian neoplasms. Allelotyping analyses of 24 LMP tumors showed that losses of heterozygosity in somatic chromosomes are rare in these tumors. Such losses were present in only 6 of the 24 tumors and involved a single somatic chromosome in five cases. In contrast, 8 of 16 (50%) LMP tumors informative for the androgen receptor locus in chromosome Xq showed losses of heterozygosity involving this locus. The losses were interstitial in 6 of the 8 cases. Examination of the methylation status of the retained androgen receptor alleles showed that the losses always affected the inactive copy of the X chromosome. By comparison, allelic losses on chromosome Xq were not seen in 15 low grade ovarian carcinomas. We conclude that a locus which escapes X chromosome inactivation in chromosome Xq is important for LMP tumor development. The results also suggest that low grade ovarian carcinomas do not usually evolve from pre-existing LMP tumors.

#3773 Tuesday, April 23, 1996, 8:00-12:00, Poster Section 6
High resolution allelotyping in hepatocellular carcinoma (HCC). Boige V^{1,3}, Laurent-Puig P^{1,3}, Schmitz A⁷, Flejou JF², Bedossa P³, Bioulac-Sage P⁴, Monges G⁵, Capron F⁶, Olschwang S¹, Thomas G¹. ¹Institut Curie, ²Hôpital Beaujon, ³Bicêtre, ⁴Béllevue, ⁵CHU Bordeaux, ⁶Centre Paoli-Calmettes, Marseille; ⁷CEA Fontenay-aux-Roses.

HCC is one of the most common malignancies in the world. Despite this, the molecular events involved in the development of this neoplasm are not well understood. In order to achieve a broader perspective on the prevalence of allelic deletions in HCC and to analyze the relationship between these alterations, we studied all non acrocentric chromosome arms in a group of 48 HCC. We used for this purpose 275 highly polymorphic microsatellite genetic markers with a mean heterozygosity of 0.75. In total, 1853 of the 1872 chromosome arms (99%) studied were informative for at least one microsatellite loci. Nine chromosome arms were deleted in more than 30% of the tumors (1p, 1q, 4q, 6q, 8p, 9p, 16p, 16q, 17p). The most frequent chromosome arm deletion was observed for 8p (60.4%). The mean of the Fractional Allelic Loss was 0.21. We demonstrated a significant association between LOH occurring on the short and long arms of chromosomes 1 and 16 and between chromosomes 16p and 4q. Furthermore, the high resolution of the allelotyping allowed us to point out some of the smallest common region of deletion among the most frequent arms lost.

#3774 Tuesday, April 23, 1996, 1:00-5:00, Poster Section 5
Allelic loss on chromosome 8p12-21 in BRCA1 mutation positive familial breast/ovarian cancer. RA Weiss, E DiFranco, S Aznavoorian, WM Linehan, C Vocke, R Chuaqui, MJ Merino, LA Liotta, Z Zhuang, JP Struwing¹, and MR Emmert-Buck, *Lab of Path, NCI, and ¹NCHGR, Bethesda, MD 20892.*

Frequent loss of heterozygosity (LOH) at specific genetic loci in DNA of tumor cells suggests the presence of a tumor suppressor gene within the deleted region. LOH on the short arm of chromosome 8 has been identified in several carcinomas including colorectal, bladder, hepatocellular, prostatic, and sporadic breast cancer. We studied LOH on 8p in tumors of 21 BRCA1 mutation positive familial breast/ovarian cancer patients. DNA was extracted from microdissected normal and invasive tumor cells obtained from formalin-fixed, paraffin-embedded tissue sections, and analyzed with 7 polymorphic DNA markers on 8p, 1 marker on 8q, and 1 marker on 17q at the BRCA1 gene. Extracted DNA was amplified by the polymerase chain reaction (PCR) and studied for LOH by denaturing gel electrophoresis and autoradiography. LOH was identified with at least 1 marker on 8p in 71% (12/17) of informative cases. The highest rate of deletion was 89% (8 of 9 informative cases) at marker D8S137 on 8p12-21. LOH was not observed on 8q. Seven of 8 (88%) informative cases showed deletion of 17q at BRCA1. Both breast and ovarian cancers demonstrated high rates of 8p LOH. These results suggest that a tumor suppressor gene located at 8p12-21 may be important in the development of BRCA1 mutation positive familial breast/ovarian cancer. Additionally, 8p LOH may represent a convergence of genetic alterations between sporadic and familial breast cancer.

MOLECULAR BIOLOGY/BIOCHEMISTRY

We have analyzed 150 frozen breast tumors using the TRAP assay to determine the level of activity and processivity of telomerase in these specimens. 91 of 150 tumors (61%) were positive for telomerase activity. Correlative analyses indicated that there were statistically significant correlations between telomerase activity and S-phase fraction (SPF, $r = 0.23$, $p = 0.004$), and EGFR ($r = 0.20$, $p = 0.013$). There was also weak correlation between telomerase activity and Cathepsin D levels ($p = 0.066$), but no statistically significant correlation of telomerase with ploidy, estrogen receptor (ER), and progesterone receptor (PGR) status. Correlative analyses of the processivity of telomerase with each prognostic marker showed statistically significant correlations with SPF ($p = 0.008$) and EGFR ($p = 0.035$), probably due to the strong correlation between processivity and telomerase activity (corr. coef. $= 0.75$, $p = 0.0001$). We have further analyzed retrospectively another 400 node-positive stage I breast tumors. Result indicated that 323 of 400 (81%) breast cancer samples were positive for telomerase activity. There were statistically significant correlations between telomerase activity and SPF ($r = 0.26$, $p = 0.0001$), ploidy ($r = 0.17$, $p = 0.0007$), and age ($r = -0.12$, $p = 0.02$). Weak or no correlations were observed between telomerase activity and the number of positive nodes, tumor size, ER, and PGR. Processivity was again very strongly correlated to telomerase activity ($r = 0.69$, $p = 0.0001$), but correlated only with ploidy ($r = 0.15$, $p = 0.009$) and SPF ($r = 0.14$, $p = 0.01$). Conclusion: Telomerase is a novel marker that may serve as an important prognostic indicator in human breast cancer.

#3853

Tuesday, April 23, 1996, 8:00–12:00, Poster Section 5

Cytokine regulation of telomerase activity in bone marrow primitive progenitors. Yui, J., Dragowska, V., Thornbury, G., Lansdorp, P. *Terry Fox Lab, Vancouver, BC, Canada.*

Telomerase is a ribonucleoprotein polymerase which synthesizes telomeric repeats onto the 3' ends of eukaryotic chromosomes. Activation of telomerase prevents telomeric shortening and may confer upon cells an extended lifespan as found in germ cells, immortalized cell lines and tumor tissues. As normal hematopoietic cells express low levels of telomerase, we are interested in examining cytokines that may upregulate functional telomerase activity in stem cell candidates (SCC) so as to potentially enhance their proliferative potential. Human SCC with the CD34⁺ CD45RA⁺ CD71^{lo} phenotype were purified from adult bone marrow and cultured for four days in stem cell factor (SCF), IL-3 and flt3 ligand (flt3-L). Functional telomerase was detected in SCC on day 0 using the telomeric repeat amplification protocol (TRAP). After 4 days in culture, activity was detected in total cell extracts from SCF + IL-3 and SCF + IL-3 + flt3-L cultures, but not from cells cultured in SCF or SCF + flt3-L. Within the CD34⁺ fraction, cells expressing low levels of CD45RA and CD71 had undetectable activity whereas considerable activity was found in the CD34⁺CD71⁺ fraction. In addition, cells that have undergone proliferation as determined by loss of PKH26 staining showed positive telomerase activity whereas PKH26^{bright} cells lack telomerase activity. These results suggest that in adult bone marrow, telomerase activity is associated with proliferating and differentiating hematopoietic progenitors but may not be expressed in quiescent stem cells.

#3854

Tuesday, April 23, 1996, 8:00–12:00, Poster Section 5

Inhibitory effects of telomere-mimic phosphorothioate oligonucleotides on various human tumor cells in vitro. Ohnuma, T., Li, F.-L., Zon, J., Zon, G., Pogo, B. and Holland, J.F. *Mount Sinai Medical Center, New York, NY 10029 and Lynx, Hayward, CA.*

Telomerase, a ribonucleoprotein that synthesizes telomeric DNA onto chromosomal ends, is known to be expressed in malignant tumor cells. We tested the cell growth inhibitory effects of telomere-mimic oligomers, 5'-d(TTAGGG)_n-3' where $n = 1, 2, 3$ or 4 in the following 9 human tumor cell lines: 2780 ovarian carcinoma, Hep-2 squamous cell carcinoma, VAMT-1 mesothelioma, DND-1A melanoma, MOLT-3 ALL, Jurkat lymphoma, Daudi Burkitt lymphoma, JAR choriocarcinoma and SK-LMS sarcoma. As controls, 2 scrambled 24-mers were tested. Among the compounds tested, 6-mer was not active in any of the cell lines studied. Increases in the length of oligonucleotides from 12- to 18- and 24-mer resulted in increased cell growth inhibitory activity in sensitive cell lines. Cells in suspension cultures, MOLT-3 ALL and Daudi Burkitt lymphoma were generally more sensitive than the monolayers (24-mer ID₅₀ = ~3 μ M). While inhibitory effects of authentic 24-mer oligomer were more pronounced than the scrambled oligomers, both of the scrambled 24-mers also showed some degree of inhibitory activity. Except for modest activity of the 24-mer in 2 cell lines, DNA-1A and 2780, none of the compounds tested were active against solid tumor cell lines. These data indicate that further study of the telomere-mimic 24-mer is warranted as a candidate compound for the treatment of leukemia/lymphoma.

#3855

Sunday, April 21, 1996, 04:25–04:40, Room 33

Telomerase in human breast cancer. Bednarek, A.¹, Sahin, A.², and Aldaz, C.M.¹ ¹Dept. of Carcinogenesis, Univ. of Texas M.D. Anderson Cancer Center, Science Park-Research Division, Smithville, TX 78957; ²Dept. of Pathology, Univ. of Texas M.D. Anderson Cancer Center, Houston, TX 77030

Telomerase is a ribonucleoprotein enzyme which contains RNA template complementary to telomeric repeats (TTAGGG) that permits the *de novo* synthesis of telomeric DNA. It has been postulated that malignant tumors must express telomerase activity to maintain their immortality. Unlike tumors, in most human adult tissues, telomerase

activity is not detected. To investigate the role of telomerase in breast cancer and to analyze its putative association with parameters of diagnostic-prognostic significance we assayed the activity levels of this enzyme in a set of 94 primary breast cancers. These studies were performed by means of the very sensitive telomeric repeat amplification protocol. To compare the level of telomerase activity in the different tumor samples we used a semiquantitative analysis based on the use of an internal standard. Telomerase activity was detected in 91 (96.8%) tumors, only in 3 (3.2%) activity was undetected. Telomerase activity was detected in 3 of 3 ductal carcinomas *in situ* which constitute a preinvasive stage. Most tumors negative for lymph node metastasis were also positive for telomerase activity. On the other hand 10 of 10 examined adjacent normal tissues showed no telomerase activity. The data obtained showed no apparent association between telomerase activity levels and estrogen receptor status, s-phase, ploidy or lymph node metastasis status. These data indicate that telomerase activation could constitute a relative early event in breast carcinogenesis. Therefore telomerase may be a useful target for therapeutic intervention at early breast cancer stages. (US Army Grant DAMD17-94-J-4078)

#3856

Tuesday, April 23, 1996, 8:00–12:00, Poster Section 5

Telomerase activity distinguishes different subtypes of epithelial ovarian tumors. Wan, M., Duggan, B.D., Li, W., Felix, J.C., Zhao, Y., Dubeau, L. *Univ. of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90033.*

Telomerase is a RNA-dependent DNA polymerase that directs the synthesis of telomeric DNA repeats onto the ends of eukaryotic chromosomes. It compensates for the telomeric losses that occur with each round of DNA replication. Telomerase is repressed in most normal cells after fetal life but its reactivation is thought to be essential for continuous cell division such as occurs in malignant tumor cells. We examined telomerase activity in 53 ovarian epithelial tumors, subdivided into cystadenomas (benign), tumors of low malignant potential (LMP), and carcinomas (malignant) in order to further examine the role of this enzyme in ovarian tumor development. Telomerase activity was detected in 20 (100%) of 20 carcinomas and in 17 (100%) of 17 LMPs. In contrast, telomerase expression was present on only 4 (25%) of 16 cystadenomas. Most of the positive cystadenomas belonged to a rare subtype called papillary. These results suggest that telomerase may be a useful marker for the detection of ovarian LMP tumors and carcinomas in clinical samples such as ascitic fluids. The data also suggest that the underlying mechanisms leading to ovarian papillary cystadenoma development may be different than for typical cystadenomas and that the papillary tumors may best be reclassified as LMP tumors.

#3857

Sunday, April 21, 1996, 03:25–03:40, Room 33

The effect of 7-deaza-2'-deoxynucleoside triphosphates on telomeres and telomerase. Fletcher, T. M. & Chen, S. F. *Cancer Therapy and Research Center Institute for Drug Development, San Antonio, TX 78245.*

Telomeres play an important role in chromosome organization and stability. Human telomerase is a terminal transferase that adds TTAGGG units onto the telomere end. In general, telomerase activity is not detected in normal somatic cells but is present in immortalized cells. Consequently, telomerase might be a selective target for cancer chemotherapy. Using an *in vitro* telomerase assay, we have found that 7-Deaza-2'-Deoxyguanosine-5'-Triphosphate (7-Deaza-dGTP) and 7-Deaza-2'-Deoxyadenosine-5'-Triphosphate (7-Deaza-dATP) were potent telomerase inhibitors. The concentration of inhibitors in which 50% of the telomerase activity was inhibited (IC₅₀ values) were 6–8 μ M for both nucleotides. Additional studies show that 7-Deaza-dGTP and 7-Deaza-dATP are also incorporated into telomeric DNA by telomerase. However, incorporation of 7-Deaza-dGTP results in a telomeric ladder that is prematurely shortened. It is possible that the telomerase translocation step is inhibited because 7-Deaza-dGTP lacks the 7 nitrogen which is essential for the formation of G-quartets or hairpins. This may be a novel approach in the design of new telomerase inhibitors. (Supported in part by Sanofi Winthrop Research and in part by a NIH-sponsored NCDDG grant.)

#3858

Tuesday, April 23, 1996, 8:00–12:00, Poster Section 5

Telomerase activity in hematopoietic cells. Leteurtre F (1), Gluckman E (2), Carosella E (1). *Service de Recherches en Hématologie, DRM, CEA (1) & Bone marrow Transplantation Unit (2); Hôpital Saint-Louis, 75745 Paris cedex 10, France.*

Telomeric DNA protects chromosome ends from recombination events and its length may serve as a mitotic clock that signals cell senescence and exit from cell cycle. Telomerase synthesizes *de novo* telomeric DNA and, authorizes unlimited cell proliferation. An hematopoietic dogma proposes an unlimited self renewal of hematopoietic stem cell (HSC). Using a recently described PCR-based measure of telomerase activity, we looked for the enzyme activity in hematopoietic cells. In agreement with the dogma, telomerase activity was found in mononuclear fractions containing HSC: adult bone marrow and cord blood cells. However, normal leukocytes also expressed the enzyme activity. Thus, telomerase activity is not a marker of HSC. Large variation in the intensity of telomerase activity was observed in normal leukocytes from healthy volunteers. This observation and that of telomerase activity in the leg bud of a 30 day fetus and in its trophoblast suggest that telomerase might be activated in some proliferating tissues. Therefore, telomerase activity is currently under investigation in leukocytes from patients with inflammatory response, in advanced aplasia and in hemato-

p21 monoclonal antibody. The protein expression peaked at day 5 after infection. A high level of expression of exogenous p21 was achieved in the H1299 cells and H460 cells infected by Ad5CMV-p21 (200 MOI), but expression in H322 cells was lower. Ad5CMV-poly A infected cells and mock-infected cells failed to show p21 staining. The growth of the Ad5CMV-p21-infected cells was greatly suppressed as evidenced by a decrease of both [3H]thymidine incorporation and cell counts. Ad5CMV-p53 was compared with Ad5CMV-p21. The MOIs for 50% inhibition (IC50) by [3H]thymidine incorporation assay for H1299, H322 and H460 were 64.8, 49.7 and 60.5 for Ad5CMV-p21, and 19.2, 26.9 and 78.7 for Ad5CMV-Ad5CMV-p53.

These data suggest that transduction of wildtype p21 can mediate inhibition of non-small cell lung cancer growth.

#4049 Wednesday, April 24, 1996, 8:00-12:00, Poster Section 12
The role of p16, p15, and p18 in ovarian cancer. Emilce Marioli¹, Gerardo Arroyo¹, Jeffrey Struwing², Robert Taylor³, Joseph Geradts⁴, Michael Birrer¹. ¹BPRB, DCS, NCI, Rockville MD 20850; ²DCEG, NCI, Bethesda MD 20892; ³Walter Reed Army Medical Center, Washington DC 20307; ⁴University of North Carolina, Chapel Hill NC 27599.

We characterized the p15, p16, and p18 genes in 30 matched tumor and normal samples from patients with sporadic ovarian cancer (SOC), and the p16 gene in 8 patients with familial ovarian cancer (FOC). PCR amplification and agarose gel electrophoresis demonstrated the presence of all exons of these genes in the tumor samples. 1/30 (3%) of the SOC, and 1/8 (12%) of the FOC specimens had an abnormal SSCP pattern in the p16 analysis. Cloning and sequencing revealed an A->C transversion at the first base of codon 140, resulting in the substitution of the amino acid thr for ala. Normal DNA from these two patients showed the same base substitution, suggesting the presence of a polymorphism. 1/30 (3%) of the SOC specimens revealed an abnormal pattern in the SSCP analysis of the p15 gene in normal and tumor DNA. SSCP analysis of p18 revealed no abnormality in any of the samples analyzed. Because point mutations are not the only mechanism for inactivation of p16, protein expression was analyzed by immunohistochemistry, in the SOC cases. 1/30 (3%) of the SOC specimens revealed no staining for p16 in the tumor, and 1/30 (3%) of the SOC specimens (a tumor with biphenotypic histology) stained only in the squamous area but not in the region with adeno differentiation. The 2 samples with the p16 substitution had normal protein expression. We conclude that p16, p15 and p18 genes appear to have a minor role in ovarian cancer.

#4050 Tuesday, April 23, 1996, 1:00-5:00, Poster Section 7
Von Hippel-Lindau (VHL) gene expression in renal cell carcinoma. Vasavada, S.P., Ye, Y., Stackhouse, T., Kuzmin, I., Lerman, M., Zbar, B., Williams, B.R.G. Cleveland Clinic Foundation, Cleveland, OH 44195 and the National Cancer Institute, Frederick, MD 21702

The Von Hippel-Lindau (VHL) tumor suppressor gene has a critical role in the pathogenesis of renal cell carcinoma. We have previously demonstrated elevated levels of VHL mRNA in the proximal convoluted tubules of the kidney, the site of origin of renal cell carcinoma. We have now examined the cellular expression pattern for VHL in several renal cell carcinoma cell lines to further localize the protein and help determine its ultimate function. Four characterized renal cell carcinoma cell lines were examined with polyclonal antibodies to N and C-terminal ends of the VHL gene with immunofluorescent cytochemistry. Subsequent nuclear stains were performed with anti-spliceosome antibody to determine nuclear colocalization. Cells were also examined at differing degrees of confluency on culture plates. Both immunofluorescence and confocal microscopy demonstrated a fine speckled nuclear staining pattern. Subconfluent cells exhibited moderate cytoplasmic staining and subsequent colocalization with antisplisosome antibody revealed a pattern distinct from that of nuclear chromatin. Confluent cells exhibit almost exclusive nuclear staining. These findings are consistent with the transcriptional role postulated for VHL and suggest that nuclear translocation of the protein may occur, subject to cell density.

#4051 Sunday, April 21, 1996, 8:00-12:00, Room 20
Comprehensive analysis of the p16^{INK4A} gene and transcripts in breast cancer. Brenner, A.J.¹, Paladugu, A.¹, Dreyling, M.H.², Olopade, O.I.², Wang, H.¹, Aldaz, C.M.¹. ¹University of Texas M.D. Anderson Cancer Center, Science Park¹, Smithville, Texas 78957; ²Department of Medicine², University of Chicago, Chicago, Ill. 60637

Homozygous deletion and loss of heterozygosity (LOH) of chromosomal subregion 9p21 are a frequent occurrence in a variety of primary tumor types. We have recently reported a high rate (58%) of LOH of this region in breast cancer as well. The p16^{INK4A} tumor suppressor gene has been localized in this region, and thus has been implicated in the genesis or progression of these tumors. However, when mutational analysis by sequencing and SSCP was conducted in these same tumors, we found aberrations to be infrequent, thus contradicting the involvement of this gene as postulated by Knudson's two hit hypothesis. Recent reports have suggested the primary means of p16^{INK4A} inactivation may alternatively be through homozygous loss or methylation of CpG islands in the 5' region of this gene. To address this issue, we have performed interphase cytogenetics fluorescence *in situ* hybridization (IC-FISH) with a 250Kb p16^{INK4A} cosmid contig as well as methylation sensitive restriction endonuclease Southern analysis in these tumors. Additionally, through reverse transcription coupled PCR we have analyzed the level of expression of the p16^{INK4A} transcript and the recently

reported beta transcript which is encoded from a separate promoter and first exon but with the same exon 2. In initial analyses utilizing this comprehensive approach, we have observed p16 to be affected in greater than 50% of human breast cancer samples analyzed thus far. (U.S. Army Grant DAMD17-94-J-4078)

#4052 Wednesday, April 24, 1996, 8:00-12:00, Poster Section 12
Introduction of a normal human chromosome 6 into ovarian carcinoma cell lines controls their tumorigenic expression. Wan, M., Vyas, R., Zheng, J., Dubeau, L. Univ. of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90033.

Structural abnormalities involving chromosome 6 are among the earliest and most consistent chromosomal alterations described in human ovarian carcinomas. We and others previously demonstrated that three distinct regions of chromosome 6 are frequently affected by losses of heterozygosity in primary human ovarian carcinomas. One of these regions involves the middle portion of chromosome 6q, a region also deleted in the ovarian carcinoma cell lines SK-OV3 and HEY. The role of this deletion in malignant transformation was investigated by introducing a normal human chromosome 6 into the SK-OV3 and HEY cell lines using microcell-mediated chromosome transfer techniques. The normal chromosome 6 was stably propagated in some hybrids as shown by fluorescence *in situ* hybridization (FISH). Tumorigenicity and anchorage-independent growth of SK-OV3 and HEY cells were completely suppressed or reduced after such transfer. In contrast, transfer of chromosome 11q in the same cell lines showed no measurable phenotypic changes. These results strongly support the hypothesis that the middle portion of chromosome 6q contains a tumor suppressor gene important for ovarian carcinoma development.

#4053 Wednesday, April 24, 1996, 8:00-12:00, Poster Section 12
Potential tumor suppressor loci on chromosome 14q in invasive epithelial ovarian cancer. Bandera, C., Takahashi, H., Rubin, S., and Boyd, J. Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104.

Chromosome 14 was screened for possible tumor suppressor loci in invasive epithelial ovarian cancer. DNA samples from 73 ovarian carcinoma specimens and matched normal tissues were evaluated using 12 polymorphic microsatellite markers. Loss of heterozygosity (LOH) was identified at one or more loci in 44 cases (60%). In 18 of these 44 cases (41%), at least 50% of informative sites exhibited LOH. In 8 of these 44 cases (18%) all informative sites exhibited allelic loss suggesting loss of the entire long arm of chromosome 14. An increased rate of LOH (34%-37%) was noted at three loci on 14q including D14S70, D14S290 and D14S267 mapping to 14q12-13, 14q21-23 and 14q32.1-32.2. LOH on chromosome 14 was seen at all stages of disease; however 4 borderline ovarian tumors also screened showed no LOH on chromosome 14. These data show that LOH on chromosome 14 is common in ovarian cancer, and suggest that tumor suppressor genes contributing to the disease process may exist in the regions 14q12-13, 14q21-23 and 14q32.1-32.2.

#4054 Tuesday, April 23, 1996, 1:00-5:00, Poster Section 7
Molecular cloning and TNF- α mediated expression of the human doc-1 oral tumor suppressor gene. Tsuji, T., McBride, J., Todd, R., Nagata, E., Donoff, R.B., Liao, P.H., Chou, M.Y. and Wong, D.T.W. Harvard School of Dental Medicine, Boston, MA.

We have recently identified and cloned a novel cellular gene doc-1 from normal hamster oral keratinocytes which exhibits tumor suppressor function when expressed in transformed hamster oral keratinocytes (FASEB J. 9, 1362-1370, 1995). Using hamster doc-1 specific primers, the human doc-1 cDNA homologue has been cloned from total RNA isolated from 2 normal human oral keratinocyte cultures (OKB2 and OKF4). Amino acid analysis of the coding region demonstrated complete identity to that of the hamster doc-1 amino acid coding sequence. Subjecting doc-1 sequence for a FASTA search revealed a significant match to a novel mouse gene TU-166, induced in mouse fibroblasts by TNF- α . These data suggested that doc-1 might be a downstream event in the signaling pathway mediating the cytostatic effects of TNF- α . To address this hypothesis, three human oral (SCC 15, 25, 66) and one cervical (A431) cancer cell lines were phenotyped for TNF- α inducibility of doc-1. All four cell lines were found to express TNF- α Type I and II receptor mRNAs by RT-PCR. Incubation of these human cancer cell lines with human recombinant TNF- α at 400U/ml for 4 hours led to the expression of doc-1 mRNA in all four cell lines. These results link TNF- α to the expression of doc-1, implicating doc-1 as a potential downstream mediator in the tumoricidal pathway of TNF- α . We hypothesize that TNF- α induced specific cellular factors which bind to TNF- α responsive elements in the promoter regulatory region of the human doc-1 gene lead to the induction of doc-1 expression. These results allow us to conclude that TNF- α induces doc-1 expression in human oral keratinocytes, linking the signaling pathway of a tumoricidal cytokine to an oral cancer suppressor gene. (Supported by DE-08680, DE-00275, DE-00318.)

expanding tumor margins (44% vs 24%), Crohn's-like lymphoid reaction (67% vs 24%), intratumoral (85% vs 44%) and peritumoral (100% vs 52%) lymphocytic infiltrates. Survival of patients with localized CRC (Dukes B) was similar regardless of tumor RER status. However, the Kaplan Meier survival curve for patients with RER+ CRC and nodal metastases (Dukes C) was significantly improved compared to similarly staged RER- patients. The ability to better identify HNPCC cases based on pathologic and molecular criteria will greatly aid clinical decision-making with respect to treatment and genetic counselling. * $p < 0.05$ by χ^2

#1002 Microsatellite instability at 11p15 markers in Wilms tumor is associated with the loss of heterozygosity in the same region. Perotti, D., Toffolo, E., Mondini, P., Pilotti, S., Luksch, R., Pession, A., Pierotti, M.A., Fossati-Bellani, F., and Radice, P. *Istituto Nazionale Tumori, Milano, Italy, University of Bologna, Italy*

A molecular study performed on 34 sporadic Wilms' tumors revealed microsatellite instability (MSI) at chromosome 11p15 in five cases (15%). The phenomenon occurred at D11S988 and D11S909 loci, and was specific of this particular chromosomal region since no MSI was detected in 25 additional microsatellite markers mapped to 9 different chromosomes. We did not find any correlation between clinical-pathological data and presence of MSI, but comparing loss of heterozygosity (LOH) and MSI results, it appeared that all the cases with MSI presented a concomitant LOH for 11p15 markers. Conversely, MSI occurred in roughly 40% of tumors bearing LOH for the 11p15 region. In our opinion, noteworthy findings are the site specificity of MSI, the involvement of 11p15 band, and the possibility of considering the loss of one allele and the concomitant instability of the remaining one as a "two hits" inactivation mechanism of putative tumor suppressor gene(s). Partially supported by "Associazione Bianca Garavaglia" and "Associazione Italiana per la Ricerca sul Cancro (AIRC)".

#1003 p53 nuclear accumulation (p53NA), Bcl-2 expression and clinicopathological characteristics of primary colorectal adenocarcinomas (CAC) with microsatellite instability (MSI). Manne, U., Shibata, D., Tsao, J., Srivastava, S., and Grizzle, W.E. *University of Alabama at Birmingham, Birmingham, AL 35294, University of Southern California, Los Angeles, CA 90033, National Cancer Institute, Bethesda, MD 20892*

Mutations in mismatch repair genes result in MSI in 10-20% of sporadic colorectal cancers. We have examined 103 archival tissue samples of sporadic primary CAC to evaluate MSI and to determine its association with p53NA, Bcl-2 expression and clinicopathological characteristics. The MSI at four loci (Mfd 27, Mfd 41, Mfd 47, Mfd 57) was analyzed by polymerase chain reaction and p53NA and Bcl-2 expression were detected by immunohistochemistry. MSI was detected in 15% tumors and p53NA was observed in 13% of MSI+ tumors as compared to 47% of MSI- tumors ($p = 0.004$). A similar incidence of Bcl-2 positivity was observed in both MSI+ and MSI- tumors (58% versus 56%). The majority of MSI+ tumors arose in proximal to the splenic flexure (80%), however, no significant difference was found in the distribution of MSI+ tumors between the proximal and the distal colorectum (39 and 49 respectively). The incidence of MSI+ tumors were higher among female patients (27% of 33) as compared to tumors from male patients (9% of 70) ($p < 0.04$). Eighteen percent of 51 mucinous tumors and 12% of 52 non-mucinous tumors have demonstrated MSI. These preliminary data suggest that a subset of tumors negative for p53NA that arise in the proximal colon and from female patients are most likely to exhibit MSI.

#1004 Frequent deletion in the DNA mismatch repair gene hMSH3 in endometrial cancers with microsatellite instability. Swisher, E., Mutch, D., Kowalski, L., Herzog, T., Rader, J., and Goodfellow, P. *Washington University, St Louis, MO 63110*

The genetic basis for microsatellite instability (MI) or the replication error phenotype (RER+) exhibited by a subset of endometrial cancers has not been identified. The DNA mismatch repair genes important in colorectal tumorigenesis (hMLH1 and hMSH2) are not involved in endometrial tumorigenesis. In an attempt to clarify the origin of MI in sporadic endometrial cancers, 28 RER+ endometrial cancers were screened for mutations of the human DNA mismatch repair gene hMSH3 using single strand conformation variant analysis of all 24 exons. All variants were sequenced. An identical single base deletion resulting in a truncated protein was discovered in 6 tumors (21.4%). This deletion occurred in a run of 8 consecutive A/T base pairs. Because simple repeat sequences are unstable in cells with defective mismatch repair, the mutation may be an effect of RER rather than a cause. Of 5 informative cases with this mutation, none exhibited loss of heterozygosity at intragenic markers as might be expected if the RER phenotype was due to loss of hMSH3 function. Additionally, 3 novel polymorphisms within this gene were identified, and a difference from the published sequence at codon 620 was confirmed in our population. Because of the inherent instability of simple nucleotide repeats in RER+ cancers, it is important to clarify the causality of any mutations identified in candidate DNA mismatch repair genes.

#1005 Microsatellite instability in intestinal type gastric cancer. Hamamoto, T., Yokozaki, H., Yasui, W., Semba, S., Yunotani, S., Miyazaki, K., and Tahara, E. *Hiroshima University School of Medicine, Hiroshima, Japan, Saga Medical School, Saga, Japan*

To elucidate the presence of genetic instability in the gastric precancerous lesions, we searched for the microsatellite alterations in 15 cases of intestinal type gastric cancer at 9 microsatellite loci of (CA) $_n$ or (A) $_n$ repeats. Alterations at one or more loci were observed in 40.0% of cancers and 26.7% of intestinal metaplasias. Altered metaplastic mucosae were microdissected and reexamined to analyze topographically. All the microsatellite alterations in metaplastic mucosae were detected in adjacent mucosa to the respective cancers. Moreover, in one case, an identical and sequential microsatellite alteration was found in the cancer tissue as well as in the adjacent metaplastic mucosa, suggesting sequential development of gastric cancer from intestinal metaplasia. Frequent alteration was found at the microsatellite locus D1S191, indicating this locus might be altered early in the development of intestinal type gastric cancer. No significant association between microsatellite instability and p53 immunoreactivity was observed in the cases examined. These results overall indicate that microsatellite instability may occur as an early event of stomach carcinogenesis of the intestinal type cancer.

#1006 Characterization of breast tumor DNA by multiplex microsatellite PCR. Beckmann, A., Zänker, K.S., and Brandt, B. *Institute of Clinical Chemistry and Laboratory Medicine, Muenster, D-48129, Germany, Institute of Immunology, Witten, D-58453, Germany*

Genomic instability detectable by polymorphic microsatellite markers is a common characteristic of human malignancy. In the case of breast tumors several microsatellite marker analyses are published. The articles showed only frequencies of loss of heterozygosity (LOH) or replication error (RER) less than 50%. For a screening of breast tumors with a high probability of LOH or RER and for the need of only small amounts of DNA we developed a multiplex polymerase chain reaction method consisting of several simple sequence repeats that have a heterozygosity over 80% and a frequency of LOH over 20%. In two multiplex PCRs 3 different microsatellites were amplified (D11S907, D6S261, D6S300 and D11S925, D8S272, D11S927). Primers were developed to generate fragments of different length to allow a simultaneous separation by gel electrophoresis on an automated sequencer. We showed that 63% of 70 analyzed breast tumors had a RER in at least one loci and an additional 28% had a LOH. 50% of the tumors showed multiple alterations. The method provides the basis for the detection and characterization of tumor cells in body fluids and tissue.

#1007 Microsatellite instability as a predictor of second breast cancer. Cunningham, J.E., Wang, H., Sahin, A., Mastromarino, C.L., Bondy, M.L., and Aldaz, C.M. *Dept. of Carcinogenesis [C.M.A., H.W.], UT MD Anderson Cancer Center, Science Park-Res. Div., Smithville, TX 78957, Depts. of Epidemiology [J.E.C., C.L.M., M.L.B.] and Pathology [A.S.], UT MDACC, Houston, TX 77030*

We recently (Aldaz et al., *Cancer Res.* 55: 3967-81, 1995) found microsatellite instability (MI) in breast cancers (BC's) from patients with bilateral breast primaries, and hypothesized MI may predict risk for a second breast primary. In an ongoing molecular epidemiologic case-control study we are examining the prevalence of MI in tumors from women with bilateral vs unilateral BC. Five loci are being used: DM (CTG), D3S1298 (CA), D8S322 (GAAA), D18S51 (GAAA) and D21S1245 (GAAA). To date, 27 tumors from 17 bilateral BC patients have been analyzed. MI, defined as 3 or more altered loci, was found in 46% (6/13) of first and 36% (5/14) of second BC's. This prevalence is in agreement with our earlier observations of bilateral patients, and significantly higher than our previous findings in unilateral cases. Where both primary tumors were available from the same patient (9 cases) there was 89% concordance in MI. None of the patients appears to be from an HNPCC, BRCA-1 or BRCA-2 kindred. There was no association with nodal status. These preliminary data support our hypothesis. We are continuing to study additional bilateral patients of various histologies, and matched unilateral controls. (Supported by US Army Grant DAMD17-94-J-4078, MDACC PRS, and Estee Lauder Breast Cancer Research Program.)

#1008 Use of mononucleotide repeat microsatellites to determine the replication error status of colorectal carcinomas. Hamelin, R., Hoang, J.M., Zhou, X.P., Cottu, P., Salmon, R.J., and Thomas, G. *Institut Curie, Paris, 75005, France*

Microsatellite instability (MI) is the consequence of the inactivation of mismatch repair genes characterizing a replication error phenotype (RER+). MI was first described in colorectal tumors from hereditary non-polyposis colorectal cancer (HNPCC) and sporadic patients. Colorectal tumorigenesis in RER+ and RER- tumors probably follow alternative pathways, and differences in prognosis have been shown between these two types of tumors. The study of the RER status of a tumor may thus be important in the future in order to determine biological prognosis factors and investigate therapeutic strategies. We have already shown that PCR amplification of Bat-26, a quasi-monomorphic mononucleotide repeat microsatellite (MRMS), was able to confirm the RER status of 159 out of 160 colorectal tumors and cell lines. We analyzed other MRMS localized in coding and non-coding sequences. All of them show a higher degree of instability in RER+ tumors than the more commonly used dinucleotide repeats. Some are quasi-monomorphic like Bat-26, while others show polymorphic alleles in normal DNA samples. Moreover, the average size variation between normal alleles and unstable alleles in RER+ tumors is different according to the analyzed MRMS. We compared these properties for all MRMS and showed that Bat-26 was the most useful for establishing the RER status of colorectal tumors.

these genes, we created a BAC and P1 map of the region defined by YAC 928F9. The breakpoints cluster into two distinct regions within the contig suggesting a very large gene or 2 or more different genes may be involved. We have tested 32 ESTs (between D8S279 and D8S286) for position in the contig and ruled them out as candidate genes. In addition, we have identified the chromosomal partner on the rearranged chromosome in MDA-MB-361 to be chromosome 17 by chromosome painting. FISH with cosmid mapping to chromosome 17 on metaphase chromosomes suggests that the breakpoint is distal to ERBB2 on chromosome 17q. Our molecular analysis of the marker chromosome in MDA-361 also suggest the rearranged chromosome is highly complex containing duplications and deletions of some chromosome 8 and chromosome 17 probes used in this study. Further fine mapping of breakpoints and candidate gene analysis may allow cloning of an oncogene commonly rearranged or amplified in breast cancer.

#871 Genetic Characterization and Expression of Uridine Phosphorylase. Deliang Gao, Meng-Ping Liu, R. E. Handschumacher and G. Pizzorno. Dept. of Internal Medicine, Yale Univ School of Medicine, New Haven, CT.

Inhibition of uridine phosphorylase (UPase) by benzylacyclouridine (BAU) results in the elevation of plasma uridine concentration leading, in animal models, to the reduction of the toxic effects of 5-fluorouracil (5-FU). Currently the clinical value of this observation is being evaluated in a trial of 5-FU followed by oral BAU administration. More interestingly, in human breast cancer tissues it was found an increased UPase activity combined with a lower sensitivity to BAU inhibition. Total RNA from human breast cancer tissue specimens was screened, using normal human UPase cDNA as a probe, and it was found that an extra band appeared at lower stringency. This band was not seen in normal tissues, colon tumors and human cell lines in which UPase is BAU-sensitive. These data might suggest that a UPase-similar, but with different enzyme kinetic properties, gene or UPase mutant being present in human breast tumors. Presently, the partial sensitivity to BAU is explored for a possible clinical therapeutic utilization. In order to have a deeper insight in its biological functions, expression regulation, and possibly its origin in evolution, we have characterized the mouse UPase gene. This gene consists of 9 exons ranging in length from 60 to 211 bp, separated by 8 introns with typical donor and acceptor sites. The regulatory elements in its promoter region and its chromosomal localization are now under investigation.

#872 Characterization of transcripts from a commonly deleted area of chromosome 16 (q23.3-q24.1) in human breast cancer. Bednarek, A.K. and Aldaz, C.M. Department of Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Science Park-Research Division, Smithville, TX 78957.

We have previously determined that the region q23.3-q24.1 from the long arm of chromosome 16 is frequently affected by allelic losses in human breast cancer. LOH in the region spanning from marker D16S515 to D16S504, was found in a majority (77%) of *in situ* breast carcinomas (Cancer Research 56: 5605, 1996). This suggests that a candidate tumor suppressor gene or genes at this location may play an important role in breast carcinogenesis. To identify areas of hemi or homozygous loss, we performed a high resolution allelotyping of the chromosome 16q area in a panel of 23 human breast cancer lines. In agreement with our previous findings, most breast cancer lines showed evidence of hemizygosity affecting all or almost all the chromosome 16q arm. One breast cancer line showed a homozygous loss affecting markers from this area, indicating that a likely target gene for inactivation may reside within this region. In order to identify candidate genes, we built a contig of YAC and BAC clones spanning the target region. Using a high density STS map we determined that the deletion is approximately 300 kb in size. Using BAC clones from this region, as selector DNA, we have isolated numerous cDNA clones from a human breast cDNA library. Partial sequencing and sequence comparison with GenBank databases indicate that these transcripts represent novel genes. We are currently characterizing the cDNA clones mapping to this region. (Supported by US Army Grant DAMD 17-94-J-4078)

#873 Localization Of 1p36 Breakpoints In Hematological Malignancy. Varga, Andrea E., Webb, Graham C., Hutchinson, Rhonda, Weith, Andreas, Dobrovic, Alexander. Departments of Haematology-Oncology, Medicine and Obstetrics & Gynaecology, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia, Research Institute of Molecular Pathology, Vienna, A-1030, Austria.

We used P1 artificial chromosomes (PACs) with inserts at intervals along chromosome band 1p36 to study patients with diverse chromosome rearrangements involving 1p36 as a first step to identifying new genes involved in leukaemia pathogenesis. Three patients with 1p36 abnormalities were studied: an AML patient with inv ins (12;1)(p12;p21p36), an MDS patient with t(1;3)(p36;q21) and a NHL patient with dup ins(1)(p36;q21 q44). The breakpoints were mapped relative to the PAC inserts by fluorescence *in situ* hybridisation (FISH). All three breakpoints mapped to the distal portion of 1p36. As at least one gene in this region is imprinted, it may be possible that the rearrangements might act as the second hit to disrupt an imprinted tumour suppressor gene.

#874 An improved PEP-PCR variant for multiple microsatellite and sequence analysis of DNA from microdissected single or few tumor cells. Dietmaier, W., Hartmann, A., Heinmöller, E., Kerner, T., Wallinger, S., Jauch, K.W., and Rüschhoff, J. Institute of Pathology, Department of Surgery, University of Regensburg, D-93042 Regensburg, F.R.G.

Whole genome amplification is a very useful tool for analysis of single or few cells, allowing multiple rather than single DNA analyses. We have tested the efficiency of *Primer-Extension-Preamplification*-PCR (PEP; Zhang et al., Proc. Natl. Acad. Sci., Vol. 89: 5847-5851, 1992), *Degenerate Oligonucleotide Primer*-PCR (DOP) and our new PEP-variant (I-PEP, improved PEP) on FACS sorted and microdissected tumor cells by subsequent single-round PCR. The highest amplification efficiency and specificity was found by I-PEP, especially when microdissected cells were investigated. I-PEP-PCR was successful in preamplification of DNA from 30 formalin-fixed paraffin-embedded cells. In contrast, unmodified PEP-PCR failed to preamplify DNA of 100 or less cells and showed reproducible results only with more than 500 cells. Furthermore, I-PEP-PCR is also more efficient in amplification of fragments greater than 500 bp as compared to unmodified PEP-PCR (100% vs. 20% amplification rate in multiple samples of five SW480 cells, sorted by flow cytometry). In addition, I-PEP-PCR enables mutation analysis by conventional sequencing as we have not found any artificial I-PEP-induced mutation in more than 4000 sequenced bases of p53 exon 7 and 8 in 10 breast cancers. I-PEP revealed the same mutations as detected in non-preamplified samples. Applications of I-PEP in LOH and sequencing analyses of microdissected preneoplastic lesions in the pancreas and urinary bladder as well as in disseminated tumor cells of the bone marrow will be presented.

#875 A molecular cytogenetic analysis of 7q31 in prostate cancer. Qian, J., Lee, H.K., Huang, H., Hirasawa, K., Bostwick, D.G., Proffitt, J., Wilber, K., Lieber, M.M., Liu, W., Smith, D.L., and Jenkins, R.B. Mayo Clinic, Rochester, MN 55905; Vysis Inc., Downers Grove, IL 60515.

To better understand the chromosome 7 alterations in prostate cancer, we undertook a molecular cytogenetic study of 25 prostate specimens using fluorescence *in situ* hybridization (FISH) with DNA probes for the chromosome 7 centromere and for 5 loci mapped to 7q31 (D7S523, D7S486, D7S522, D7S480, D7S490) and 1 locus at 7q11.23 (ELN). Six tumors had no apparent anomaly for any chromosome 7 probe. Nine tumors showed apparent simple gain of a whole chromosome 7, whereas one tumor had apparent simple loss of a whole chromosome 7. Four tumors had gain of the chromosome 7 centromere and additional overrepresentation of the 7 q-arm. One tumor had overrepresentation of 7q31 without any apparent anomaly of the chromosome 7 centromere, and one tumor had apparent loss of the chromosome 7 centromere with no apparent anomaly of the 7 q-arm. Three tumors had gain of the chromosome 7 centromere and loss of the 7q31 region. Gain of 7q31 was strongly correlated with tumor Gleason score. Multiplex PCR studies of these specimens supported these FISH observations. Mutation screening and DNA sequencing of the MET gene, which is mapped to 7q31, revealed only the presence of simple sequence polymorphisms but no apparent acquired disease-associated mutations. FISH analysis of metaphases from an aphidicolin-induced, chromosome 7 only, somatic cell hybrid demonstrated that the DNA probe for D7S522 spans the common fragile site FRA7G at 7q31. Our data indicate that the 7 q-arm, and particularly the 7q31 region, is genetically unstable in prostate cancer, and some of the gene dosage differences observed may be due to fragility at FRA7G.

#876 Altered expression of the suppressor gene PML in human liver and lung cancer. John YH Chan¹, Wai Chin¹, Louis Chow², Choong-Tsek Liew², Sing-Fai Leung¹, Anthony Yim³, Kun-Sang Chang⁴ and Philip J Johnson¹. ¹Clinical Oncology, ²A and C Pathology, ³Surgery, YK Pao Centre for Cancer, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, ⁴Laboratory Medicine, UT MD Anderson Cancer Center, Houston TX, 77030.

The promyelocytic leukemia (PML) gene, which encodes a growth suppressor, was first identified at the chromosomal t(15;17) translocation break point of acute promyelocytic leukemia. To elucidate if PML may be involved in other neoplasias, the expression of PML was analyzed by immunohistochemical staining in small cell lung cancer (SCLC), adenocarcinoma (ADC), squamous cell carcinoma (SCC) and hepatocellular carcinoma (HCC). PML expression was completely suppressed in all of the SCLC examined, whilst enhanced and/or moderate expressions were found in HCC, ADC and SCC. In HCC and SCC, PML was expressed most strongly in the cancer cells at the periphery of the tumors and in the surrounding non-tumor cells, while the expression was progressively decrease towards the tumor-center. Double staining with Ki67 and Kp1 showed that this decrease is not necessarily associated with decreased proliferation but may be related to altered transformed phenotypes. The specific inactivation of PML in SCLC indicate that this alteration may be an obligatory step in the tumorigenesis of SCLC.

#877 Computer assisted cytogenetic analysis reveals differences between malignant schwannomas of patients with and without neurofibromatosis. Plaet, B.E.C., Mastik, M.F., Molenaar, W.M., Van den Berg, E. Depts. of Pathology and Medical Genetics, University of Groningen, Groningen, The Netherlands.

Introduction: Cytogenetic studies of malignant schwannomas in small groups of patients with and without neurofibromatosis (NF1) revealed complex karyotypes in which no consistent chromosomal changes were detected. To allow direct comparison of the complex karyotypes of 28 malignant schwannomas (16 NF1 and 12 non-NF1 patients) obtained from the literature and own data (9 cases), a database was constructed using Dbase V-Windows. The breakpoints,